<?xml version="1.0" encoding="UTF-8"?>
<documents>
<document id="DBMI.pac1" origId="pac1">
	<sentence id="DBMI.pac1.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Established Drug Interactions\n\nClinical recommendations based on the results of drug interaction studies are listed in Table 5."/>
	<sentence id="DBMI.pac1.s1" origId="s1" text="Pharmacokinetic results of drug interaction studies are shown in Tables 9 to 12 [see Contraindications (4.1 and 4.2) and Clinical Pharmacology (12.3)]."/>
	<sentence id="DBMI.pac1.s2" origId="s2" text="Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].">
		<entity charOffset="367-376" id="DBMI.pac1.s2.e0" origId="s2.e0" text="tenofovir" type="Active ingredient"/>
		<entity charOffset="318-328" id="DBMI.pac1.s2.e1" origId="s2.e1" text="didanosine" type="Active ingredient"/>
		<pair e1="DBMI.pac1.s2.e0" e2="DBMI.pac1.s2.e1" id="DBMI.pac1.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="didanosine" precipitant="tenofovir"/>
		<pair e1="DBMI.pac1.s2.e1" e2="DBMI.pac1.s2.e0" id="DBMI.pac1.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac1.s3" origId="s3" text="Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy."/>
	<sentence id="DBMI.pac1.s4" origId="s4" text="Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response."/>
	<sentence id="DBMI.pac1.s5" origId="s5" text="Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)]."/>
	<sentence id="DBMI.pac1.s6" origId="s6" text="Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily."/>
	<sentence id="DBMI.pac1.s7" origId="s7" text="7.2 Predicted Drug Interactions\n\nPredicted drug interactions with didanosine delayed-release are listed in Table 6."/>
	<sentencespan id="DBMI.pac1.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Established Drug Interactions\n\nClinical recommendations based on the results of drug interaction studies are listed in Table 5. Pharmacokinetic results of drug interaction studies are shown in Tables 9 to 12 [see Contraindications (4.1 and 4.2) and Clinical Pharmacology (12.3)]. Exposure to didanosine is increased when coadministered with tenofovir disoproxil fumarate [Table 5 and see Clinical Pharmacokinetics (12.3, Tables 9 and 10)].">
		<entity charOffset="367-376" id="DBMI.pac1.sp0.e0" origId="sp0.e0" text="tenofovir" type="Active ingredient"/>
		<entity charOffset="318-328" id="DBMI.pac1.sp0.e1" origId="sp0.e1" text="didanosine" type="Active ingredient"/>
		<pair e1="DBMI.pac1.sp0.e0" e2="DBMI.pac1.sp0.e1" id="DBMI.pac1.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="didanosine" precipitant="tenofovir"/>
		<pair e1="DBMI.pac1.sp0.e1" e2="DBMI.pac1.sp0.e0" id="DBMI.pac1.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac1.sp1" origId="sp1" text="Increased exposure may cause or worsen didanosine-related clinical toxicities, including pancreatitis, symptomatic hyperlactatemia/lactic acidosis, and peripheral neuropathy. Coadministration of tenofovir disoproxil fumarate with didanosine delayed-release should be undertaken with caution, and patients should be monitored closely for didanosine-related toxicities and clinical response. Didanosine delayed-release should be suspended if signs or symptoms of pancreatitis, symptomatic hyperlactatemia, or lactic acidosis develop [see Dosage and Administration (2.3), Warnings and Precautions (5)]."/>
	<sentencespan id="DBMI.pac1.sp2" origId="sp2" text="Suppression of CD4 cell counts has been observed in patients receiving tenofovir disoproxil fumarate with didanosine at a dose of 400 mg daily. 7.2 Predicted Drug Interactions\n\nPredicted drug interactions with didanosine delayed-release are listed in Table 6."/>
</document>

<document id="DBMI.pac100" origId="pac100">
	<sentence id="DBMI.pac100.s0" origId="s0" text="Drugs demonstrated to be inducers of CYP3A\n\n Carbamazepine can increase alprazolam metabolism and therefore can decrease plasma levels of alprazolam. ">
		<entity charOffset="45-58" id="DBMI.pac100.s0.e0" origId="s0.e0" text="Carbamazepine" type="Active ingredient"/>
		<entity charOffset="138-148" id="DBMI.pac100.s0.e1" origId="s0.e1" text="alprazolam" type="Active ingredient"/>
		<pair e1="DBMI.pac100.s0.e0" e2="DBMI.pac100.s0.e1" id="DBMI.pac100.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="alprazolam" precipitant="Carbamazepine"/>
		<pair e1="DBMI.pac100.s0.e1" e2="DBMI.pac100.s0.e0" id="DBMI.pac100.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac102" origId="pac102">
	<sentence id="DBMI.pac102.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nThe effects of metoclopramide on gastrointestinal motility can impact the absorption of other drugs."/>
	<sentence id="DBMI.pac102.s1" origId="s1" text="The known drug-drug interactions are listed below."/>
	<sentence id="DBMI.pac102.s2" origId="s2" text="7.1 Anticholinergic and Narcotic Analgesic Drugs\n\nThe effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics."/>
	<sentence id="DBMI.pac102.s3" origId="s3" text="Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers."/>
	<sentence id="DBMI.pac102.s4" origId="s4" text="7.2 Monoamine Oxidase Inhibitors\n\nMetoclopramide has been shown to release catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients taking monoamine oxidase (MAO) inhibitors."/>
	<sentence id="DBMI.pac102.s5" origId="s5" text="7.3 Drug Absorption\n\nAbsorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).">
		<entity charOffset="802-816" id="DBMI.pac102.s5.e0" origId="s5.e0" text="metoclopramide" type="Active ingredient"/>
		<entity charOffset="824-831" id="DBMI.pac102.s5.e1" origId="s5.e1" text="digoxin" type="Active ingredient"/>
		<entity charOffset="962-970" id="DBMI.pac102.s5.e2" origId="s5.e2" text="levodopa" type="Active ingredient"/>
		<entity charOffset="972-979" id="DBMI.pac102.s5.e3" origId="s5.e3" text="ethanol" type="Active ingredient"/>
		<entity charOffset="981-993" id="DBMI.pac102.s5.e4" origId="s5.e4" text="cyclosporine" type="Active ingredient"/>
		<entity charOffset="948-960" id="DBMI.pac102.s5.e5" origId="s5.e5" text="tetracycline" type="Active ingredient"/>
		<entity charOffset="933-946" id="DBMI.pac102.s5.e6" origId="s5.e6" text="acetaminophen" type="Active ingredient"/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="levodopa" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethanol" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p4" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tetracycline" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.s5.e0" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="acetaminophen" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e1" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e2" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e3" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e4" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e5" e2="DBMI.pac102.s5.e6" id="DBMI.pac102.s5.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e0" id="DBMI.pac102.s5.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e1" id="DBMI.pac102.s5.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e2" id="DBMI.pac102.s5.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e3" id="DBMI.pac102.s5.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e4" id="DBMI.pac102.s5.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.s5.e6" e2="DBMI.pac102.s5.e5" id="DBMI.pac102.s5.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac102.s6" origId="s6" text="7.4 Insulin\n\nBecause the action of metoclopramide will hasten the movement of food to the intestines and therefore the rate of absorption, insulin dosage or timing of dosage may require adjustment."/>
	<sentence id="DBMI.pac102.s7" origId="s7" text="Increasing movement of food to the intestines may lead to absorption of less glucose from a meal, hence less glucose in the circulation for a particular dose of administered insulin to act upon, resulting in hypoglycemia."/>
	<sentence id="DBMI.pac102.s8" origId="s8" text="7.5 Antidepressants, Antipsychotics, and Neuroleptics\n\nConcomitant use of metoclopramide should be avoided in patients taking antidepressants, antipsychotics, and/or neuroleptics that have been associated with  extrapyramidal reactions such as tardive dyskinesia or Neuroleptic Malignant Syndrome (NMS) that have occurred in association with metoclopramide [see Warnings and Precautions (5.2), (5.3) and Adverse Reactions (6.2)]. "/>
	<sentencespan id="DBMI.pac102.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nThe effects of metoclopramide on gastrointestinal motility can impact the absorption of other drugs. The known drug-drug interactions are listed below. 7.1 Anticholinergic and Narcotic Analgesic Drugs\n\nThe effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics."/>
	<sentencespan id="DBMI.pac102.sp1" origId="sp1" text="Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. 7.2 Monoamine Oxidase Inhibitors\n\nMetoclopramide has been shown to release catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients taking monoamine oxidase (MAO) inhibitors. 7.3 Drug Absorption\n\nAbsorption of drugs from the stomach may be diminished by metoclopramide (e.g., digoxin), whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).">
		<entity charOffset="802-816" id="DBMI.pac102.sp1.e0" origId="sp1.e0" text="metoclopramide" type="Active ingredient"/>
		<entity charOffset="824-831" id="DBMI.pac102.sp1.e1" origId="sp1.e1" text="digoxin" type="Active ingredient"/>
		<entity charOffset="962-970" id="DBMI.pac102.sp1.e2" origId="sp1.e2" text="levodopa" type="Active ingredient"/>
		<entity charOffset="972-979" id="DBMI.pac102.sp1.e3" origId="sp1.e3" text="ethanol" type="Active ingredient"/>
		<entity charOffset="981-993" id="DBMI.pac102.sp1.e4" origId="sp1.e4" text="cyclosporine" type="Active ingredient"/>
		<entity charOffset="948-960" id="DBMI.pac102.sp1.e5" origId="sp1.e5" text="tetracycline" type="Active ingredient"/>
		<entity charOffset="933-946" id="DBMI.pac102.sp1.e6" origId="sp1.e6" text="acetaminophen" type="Active ingredient"/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="levodopa" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethanol" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p4" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tetracycline" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.sp1.e0" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="acetaminophen" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e1" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e2" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e3" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e4" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e5" e2="DBMI.pac102.sp1.e6" id="DBMI.pac102.sp1.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e0" id="DBMI.pac102.sp1.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e1" id="DBMI.pac102.sp1.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e2" id="DBMI.pac102.sp1.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e3" id="DBMI.pac102.sp1.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e4" id="DBMI.pac102.sp1.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac102.sp1.e6" e2="DBMI.pac102.sp1.e5" id="DBMI.pac102.sp1.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac102.sp2" origId="sp2" text="7.4 Insulin\n\nBecause the action of metoclopramide will hasten the movement of food to the intestines and therefore the rate of absorption, insulin dosage or timing of dosage may require adjustment. Increasing movement of food to the intestines may lead to absorption of less glucose from a meal, hence less glucose in the circulation for a particular dose of administered insulin to act upon, resulting in hypoglycemia. 7.5 Antidepressants, Antipsychotics, and Neuroleptics\n\nConcomitant use of metoclopramide should be avoided in patients taking antidepressants, antipsychotics, and/or neuroleptics that have been associated with  extrapyramidal reactions such as tardive dyskinesia or Neuroleptic Malignant Syndrome (NMS) that have occurred in association with metoclopramide [see Warnings and Precautions (5.2), (5.3) and Adverse Reactions (6.2)]. "/>
</document>

<document id="DBMI.pac104" origId="pac104">
	<sentence id="DBMI.pac104.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A\n\nConivaptan is a sensitive substrate of CYP3A."/>
	<sentence id="DBMI.pac104.s1" origId="s1" text="The effect of ketoconazole, a potent CYP3A inhibitor, on the pharmacokinetics of intravenous conivaptan has not been evaluated."/>
	<sentence id="DBMI.pac104.s2" origId="s2" text="Coadministration of oral conivaptan hydrochloride 10 mg with ketoconazole 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of conivaptan, respectively [see Contraindications (4.2)].">
		<entity charOffset="267-279" id="DBMI.pac104.s2.e0" origId="s2.e0" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="231-241" id="DBMI.pac104.s2.e1" origId="s2.e1" text="conivaptan" type="Active ingredient"/>
		<pair e1="DBMI.pac104.s2.e0" e2="DBMI.pac104.s2.e1" id="DBMI.pac104.s2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="conivaptan" precipitant="ketoconazole"/>
		<pair e1="DBMI.pac104.s2.e1" e2="DBMI.pac104.s2.e0" id="DBMI.pac104.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s3" origId="s3" text="Conivaptan is a potent mechanism-based inhibitor of CYP3A."/>
	<sentence id="DBMI.pac104.s4" origId="s4" text="The effect of conivaptan on the pharmacokinetics of co-administered CYP3A substrates has been evaluated with the coadministration of conivaptan with midazolam, simvastatin, and amlodipine."/>
	<sentence id="DBMI.pac104.s5" origId="s5" text="VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively.">
		<entity charOffset="648-656" id="DBMI.pac104.s5.e0" origId="s5.e0" text="VAPRISOL" type="Drug product"/>
		<entity charOffset="771-780" id="DBMI.pac104.s5.e1" origId="s5.e1" text="midazolam" type="Active ingredient"/>
		<pair e1="DBMI.pac104.s5.e0" e2="DBMI.pac104.s5.e1" id="DBMI.pac104.s5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam" precipitant="VAPRISOL"/>
		<pair e1="DBMI.pac104.s5.e1" e2="DBMI.pac104.s5.e0" id="DBMI.pac104.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s6" origId="s6" text="VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin.">
		<entity charOffset="796-804" id="DBMI.pac104.s6.e0" origId="s6.e0" text="VAPRISOL" type="Drug product"/>
		<entity charOffset="859-870" id="DBMI.pac104.s6.e1" origId="s6.e1" text="simvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac104.s6.e0" e2="DBMI.pac104.s6.e1" id="DBMI.pac104.s6.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="simvastatin" precipitant="VAPRISOL"/>
		<pair e1="DBMI.pac104.s6.e1" e2="DBMI.pac104.s6.e0" id="DBMI.pac104.s6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s7" origId="s7" text="Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)].">
		<entity charOffset="877-887" id="DBMI.pac104.s7.e0" origId="s7.e0" text="conivaptan" type="Active ingredient"/>
		<entity charOffset="978-988" id="DBMI.pac104.s7.e1" origId="s7.e1" text="amlodipine" type="Active ingredient"/>
		<pair e1="DBMI.pac104.s7.e0" e2="DBMI.pac104.s7.e1" id="DBMI.pac104.s7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="amlodipine" precipitant="conivaptan"/>
		<pair e1="DBMI.pac104.s7.e1" e2="DBMI.pac104.s7.e0" id="DBMI.pac104.s7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s8" origId="s8" text="7.2 Digoxin\n\nCoadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].">
		<entity charOffset="1125-1135" id="DBMI.pac104.s8.e0" origId="s8.e0" text="conivaptan" type="Active ingredient"/>
		<entity charOffset="1078-1085" id="DBMI.pac104.s8.e1" origId="s8.e1" text="digoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac104.s8.e0" e2="DBMI.pac104.s8.e1" id="DBMI.pac104.s8.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin" precipitant="conivaptan"/>
		<pair e1="DBMI.pac104.s8.e1" e2="DBMI.pac104.s8.e0" id="DBMI.pac104.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s9" origId="s9" text="7.3 Warfarin\n\nVAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively.">
		<entity charOffset="1333-1341" id="DBMI.pac104.s9.e0" origId="s9.e0" text="VAPRISOL" type="Drug product"/>
		<entity charOffset="1406-1414" id="DBMI.pac104.s9.e1" origId="s9.e1" text="warfarin" type="Active ingredient"/>
		<pair e1="DBMI.pac104.s9.e0" e2="DBMI.pac104.s9.e1" id="DBMI.pac104.s9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="warfarin" precipitant="VAPRISOL"/>
		<pair e1="DBMI.pac104.s9.e1" e2="DBMI.pac104.s9.e0" id="DBMI.pac104.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac104.s10" origId="s10" text="The corresponding prothrombin time and international normalized ratio values were unchanged."/>
	<sentence id="DBMI.pac104.s11" origId="s11" text="7.4 Captopril and Furosemide\n\nThe pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.">
		<entity charOffset="1802-1811" id="DBMI.pac104.s11.e0" origId="s11.e0" text="captopril" type="Active ingredient"/>
		<entity charOffset="1727-1737" id="DBMI.pac104.s11.e1" origId="s11.e1" text="conivaptan" type="Active ingredient"/>
		<entity charOffset="1821-1831" id="DBMI.pac104.s11.e2" origId="s11.e2" text="furosemide" type="Active ingredient"/>
		<pair e1="DBMI.pac104.s11.e0" e2="DBMI.pac104.s11.e1" id="DBMI.pac104.s11.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="conivaptan" precipitant="captopril"/>
		<pair e1="DBMI.pac104.s11.e0" e2="DBMI.pac104.s11.e2" id="DBMI.pac104.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.s11.e1" e2="DBMI.pac104.s11.e0" id="DBMI.pac104.s11.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.s11.e1" e2="DBMI.pac104.s11.e2" id="DBMI.pac104.s11.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.s11.e2" e2="DBMI.pac104.s11.e0" id="DBMI.pac104.s11.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.s11.e2" e2="DBMI.pac104.s11.e1" id="DBMI.pac104.s11.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="conivaptan" precipitant="furosemide"/>
	</sentence>
	<sentencespan id="DBMI.pac104.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A\n\nConivaptan is a sensitive substrate of CYP3A. The effect of ketoconazole, a potent CYP3A inhibitor, on the pharmacokinetics of intravenous conivaptan has not been evaluated. Coadministration of oral conivaptan hydrochloride 10 mg with ketoconazole 200 mg resulted in 4- and 11-fold increases in Cmax and AUC of conivaptan, respectively [see Contraindications (4.2)].">
		<entity charOffset="267-279" id="DBMI.pac104.sp0.e0" origId="sp0.e0" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="231-241" id="DBMI.pac104.sp0.e1" origId="sp0.e1" text="conivaptan" type="Active ingredient"/>
		<pair e1="DBMI.pac104.sp0.e0" e2="DBMI.pac104.sp0.e1" id="DBMI.pac104.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="conivaptan" precipitant="ketoconazole"/>
		<pair e1="DBMI.pac104.sp0.e1" e2="DBMI.pac104.sp0.e0" id="DBMI.pac104.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac104.sp1" origId="sp1" text="Conivaptan is a potent mechanism-based inhibitor of CYP3A. The effect of conivaptan on the pharmacokinetics of co-administered CYP3A substrates has been evaluated with the coadministration of conivaptan with midazolam, simvastatin, and amlodipine. VAPRISOL 40 mg/day increased the mean AUC values by approximately 2- and 3-fold for 1 mg intravenous or 2 mg oral doses of midazolam, respectively.">
		<entity charOffset="648-656" id="DBMI.pac104.sp1.e0" origId="sp1.e0" text="VAPRISOL" type="Drug product"/>
		<entity charOffset="771-780" id="DBMI.pac104.sp1.e1" origId="sp1.e1" text="midazolam" type="Active ingredient"/>
		<pair e1="DBMI.pac104.sp1.e0" e2="DBMI.pac104.sp1.e1" id="DBMI.pac104.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam" precipitant="VAPRISOL"/>
		<pair e1="DBMI.pac104.sp1.e1" e2="DBMI.pac104.sp1.e0" id="DBMI.pac104.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac104.sp2" origId="sp2" text="VAPRISOL 30 mg/day resulted in a 3-fold increase in the AUC of simvastatin. Oral conivaptan hydrochloride 40 mg twice daily resulted in a 2-fold increase in the AUC and half-life of amlodipine [see Warnings and Precautions (5.3)]. 7.2 Digoxin\n\nCoadministration of a 0.5 mg dose of digoxin, a P-glycoprotein substrate, with oral conivaptan hydrochloride 40 mg twice daily resulted in a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC values, respectively [see Warnings and Precautions (5.4)].">
		<entity charOffset="1125-1135" id="DBMI.pac104.sp2.e0" origId="sp2.e0" text="conivaptan" type="Active ingredient"/>
		<entity charOffset="1078-1085" id="DBMI.pac104.sp2.e1" origId="sp2.e1" text="digoxin" type="Active ingredient"/>
		<entity charOffset="859-870" id="DBMI.pac104.sp2.e2" origId="sp2.e2" text="simvastatin" type="Active ingredient"/>
		<entity charOffset="978-988" id="DBMI.pac104.sp2.e3" origId="sp2.e3" text="amlodipine" type="Active ingredient"/>
		<pair e1="DBMI.pac104.sp2.e0" e2="DBMI.pac104.sp2.e1" id="DBMI.pac104.sp2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin" precipitant="conivaptan"/>
		<pair e1="DBMI.pac104.sp2.e0" e2="DBMI.pac104.sp2.e2" id="DBMI.pac104.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e0" e2="DBMI.pac104.sp2.e3" id="DBMI.pac104.sp2.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="amlodipine" precipitant="conivaptan"/>
		<pair e1="DBMI.pac104.sp2.e1" e2="DBMI.pac104.sp2.e0" id="DBMI.pac104.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e1" e2="DBMI.pac104.sp2.e2" id="DBMI.pac104.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e1" e2="DBMI.pac104.sp2.e3" id="DBMI.pac104.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e2" e2="DBMI.pac104.sp2.e0" id="DBMI.pac104.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e2" e2="DBMI.pac104.sp2.e1" id="DBMI.pac104.sp2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e2" e2="DBMI.pac104.sp2.e3" id="DBMI.pac104.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e3" e2="DBMI.pac104.sp2.e0" id="DBMI.pac104.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e3" e2="DBMI.pac104.sp2.e1" id="DBMI.pac104.sp2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp2.e3" e2="DBMI.pac104.sp2.e2" id="DBMI.pac104.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac104.sp3" origId="sp3" text="7.3 Warfarin\n\nVAPRISOL (40 mg/day for 4 days) administered with a single 25 mg dose of warfarin, which undergoes major metabolism by CYP2C9 and minor metabolism by CYP3A, increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively. The corresponding prothrombin time and international normalized ratio values were unchanged. 7.4 Captopril and Furosemide\n\nThe pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged with coadministration of either captopril 25 mg or furosemide up to 80 mg/day.">
		<entity charOffset="1333-1341" id="DBMI.pac104.sp3.e0" origId="sp3.e0" text="VAPRISOL" type="Drug product"/>
		<entity charOffset="1406-1414" id="DBMI.pac104.sp3.e1" origId="sp3.e1" text="warfarin" type="Active ingredient"/>
		<entity charOffset="1802-1811" id="DBMI.pac104.sp3.e2" origId="sp3.e2" text="captopril" type="Active ingredient"/>
		<entity charOffset="1727-1737" id="DBMI.pac104.sp3.e3" origId="sp3.e3" text="conivaptan" type="Active ingredient"/>
		<entity charOffset="1821-1831" id="DBMI.pac104.sp3.e4" origId="sp3.e4" text="furosemide" type="Active ingredient"/>
		<pair e1="DBMI.pac104.sp3.e0" e2="DBMI.pac104.sp3.e1" id="DBMI.pac104.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="warfarin" precipitant="VAPRISOL"/>
		<pair e1="DBMI.pac104.sp3.e0" e2="DBMI.pac104.sp3.e2" id="DBMI.pac104.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e0" e2="DBMI.pac104.sp3.e3" id="DBMI.pac104.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e0" e2="DBMI.pac104.sp3.e4" id="DBMI.pac104.sp3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e1" e2="DBMI.pac104.sp3.e0" id="DBMI.pac104.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e1" e2="DBMI.pac104.sp3.e2" id="DBMI.pac104.sp3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e1" e2="DBMI.pac104.sp3.e3" id="DBMI.pac104.sp3.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e1" e2="DBMI.pac104.sp3.e4" id="DBMI.pac104.sp3.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e2" e2="DBMI.pac104.sp3.e0" id="DBMI.pac104.sp3.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e2" e2="DBMI.pac104.sp3.e1" id="DBMI.pac104.sp3.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e2" e2="DBMI.pac104.sp3.e3" id="DBMI.pac104.sp3.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="conivaptan" precipitant="captopril"/>
		<pair e1="DBMI.pac104.sp3.e2" e2="DBMI.pac104.sp3.e4" id="DBMI.pac104.sp3.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e3" e2="DBMI.pac104.sp3.e0" id="DBMI.pac104.sp3.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e3" e2="DBMI.pac104.sp3.e1" id="DBMI.pac104.sp3.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e3" e2="DBMI.pac104.sp3.e2" id="DBMI.pac104.sp3.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e3" e2="DBMI.pac104.sp3.e4" id="DBMI.pac104.sp3.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e4" e2="DBMI.pac104.sp3.e0" id="DBMI.pac104.sp3.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e4" e2="DBMI.pac104.sp3.e1" id="DBMI.pac104.sp3.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e4" e2="DBMI.pac104.sp3.e2" id="DBMI.pac104.sp3.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac104.sp3.e4" e2="DBMI.pac104.sp3.e3" id="DBMI.pac104.sp3.p19" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="conivaptan" precipitant="furosemide"/>
	</sentencespan>
</document>

<document id="DBMI.pac106" origId="pac106">
	<sentence id="DBMI.pac106.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Catecholamine Depleting Drugs\n\nCatecholamine depleting drugs (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents."/>
	<sentence id="DBMI.pac106.s1" origId="s1" text="Observe patients treated with TOPROL-XL plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension."/>
	<sentence id="DBMI.pac106.s2" origId="s2" text="7.2 CYP2D6 Inhibitors\n\nDrugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration.">
		<entity charOffset="444-453" id="DBMI.pac106.s2.e0" origId="s2.e0" text="quinidine" type="Active ingredient"/>
		<entity charOffset="518-528" id="DBMI.pac106.s2.e1" origId="s2.e1" text="metoprolol" type="Active ingredient"/>
		<entity charOffset="455-465" id="DBMI.pac106.s2.e2" origId="s2.e2" text="fluoxetine" type="Active ingredient"/>
		<entity charOffset="467-477" id="DBMI.pac106.s2.e3" origId="s2.e3" text="paroxetine" type="Active ingredient"/>
		<entity charOffset="483-494" id="DBMI.pac106.s2.e4" origId="s2.e4" text="propafenone" type="Active ingredient"/>
		<pair e1="DBMI.pac106.s2.e0" e2="DBMI.pac106.s2.e1" id="DBMI.pac106.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="quinidine"/>
		<pair e1="DBMI.pac106.s2.e0" e2="DBMI.pac106.s2.e2" id="DBMI.pac106.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e0" e2="DBMI.pac106.s2.e3" id="DBMI.pac106.s2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e0" e2="DBMI.pac106.s2.e4" id="DBMI.pac106.s2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e1" e2="DBMI.pac106.s2.e0" id="DBMI.pac106.s2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e1" e2="DBMI.pac106.s2.e2" id="DBMI.pac106.s2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e1" e2="DBMI.pac106.s2.e3" id="DBMI.pac106.s2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e1" e2="DBMI.pac106.s2.e4" id="DBMI.pac106.s2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e2" e2="DBMI.pac106.s2.e0" id="DBMI.pac106.s2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e2" e2="DBMI.pac106.s2.e1" id="DBMI.pac106.s2.p9" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="fluoxetine"/>
		<pair e1="DBMI.pac106.s2.e2" e2="DBMI.pac106.s2.e3" id="DBMI.pac106.s2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e2" e2="DBMI.pac106.s2.e4" id="DBMI.pac106.s2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e3" e2="DBMI.pac106.s2.e0" id="DBMI.pac106.s2.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e3" e2="DBMI.pac106.s2.e1" id="DBMI.pac106.s2.p13" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="paroxetine"/>
		<pair e1="DBMI.pac106.s2.e3" e2="DBMI.pac106.s2.e2" id="DBMI.pac106.s2.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e3" e2="DBMI.pac106.s2.e4" id="DBMI.pac106.s2.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e4" e2="DBMI.pac106.s2.e0" id="DBMI.pac106.s2.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e4" e2="DBMI.pac106.s2.e1" id="DBMI.pac106.s2.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="propafenone"/>
		<pair e1="DBMI.pac106.s2.e4" e2="DBMI.pac106.s2.e2" id="DBMI.pac106.s2.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.s2.e4" e2="DBMI.pac106.s2.e3" id="DBMI.pac106.s2.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac106.s3" origId="s3" text="In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life.">
		<entity charOffset="629-638" id="DBMI.pac106.s3.e0" origId="s3.e0" text="quinidine" type="Active ingredient"/>
		<entity charOffset="668-678" id="DBMI.pac106.s3.e1" origId="s3.e1" text="metoprolol" type="Active ingredient"/>
		<pair e1="DBMI.pac106.s3.e0" e2="DBMI.pac106.s3.e1" id="DBMI.pac106.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol" precipitant="quinidine"/>
		<pair e1="DBMI.pac106.s3.e1" e2="DBMI.pac106.s3.e0" id="DBMI.pac106.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac106.s4" origId="s4" text="In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate-release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of metoprolol.">
		<entity charOffset="844-855" id="DBMI.pac106.s4.e0" origId="s4.e0" text="propafenone" type="Active ingredient"/>
		<entity charOffset="893-903" id="DBMI.pac106.s4.e1" origId="s4.e1" text="metoprolol" type="Active ingredient"/>
		<pair e1="DBMI.pac106.s4.e0" e2="DBMI.pac106.s4.e1" id="DBMI.pac106.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol" precipitant="propafenone"/>
		<pair e1="DBMI.pac106.s4.e1" e2="DBMI.pac106.s4.e0" id="DBMI.pac106.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac106.s5" origId="s5" text="These increases in plasma concentration would decrease the cardioselectivity of metoprolol."/>
	<sentence id="DBMI.pac106.s6" origId="s6" text="7.3 Digitalis, Clonidine, and Calcium Channel Blockers\n\nDigitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate."/>
	<sentence id="DBMI.pac106.s7" origId="s7" text="Concomitant use with beta blockers can increase the risk of bradycardia."/>
	<sentence id="DBMI.pac106.s8" origId="s8" text="If clonidine and a beta blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine."/>
	<sentence id="DBMI.pac106.s9" origId="s9" text="If replacing clonidine by beta-blocker therapy, delay the introduction of beta-blockers for several days after clonidine administration has stopped [see Warnings and Precautions(5.11)]. "/>
	<sentencespan id="DBMI.pac106.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Catecholamine Depleting Drugs\n\nCatecholamine depleting drugs (eg, reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with TOPROL-XL plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7.2 CYP2D6 Inhibitors\n\nDrugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration.">
		<entity charOffset="444-453" id="DBMI.pac106.sp0.e0" origId="sp0.e0" text="quinidine" type="Active ingredient"/>
		<entity charOffset="518-528" id="DBMI.pac106.sp0.e1" origId="sp0.e1" text="metoprolol" type="Active ingredient"/>
		<entity charOffset="455-465" id="DBMI.pac106.sp0.e2" origId="sp0.e2" text="fluoxetine" type="Active ingredient"/>
		<entity charOffset="467-477" id="DBMI.pac106.sp0.e3" origId="sp0.e3" text="paroxetine" type="Active ingredient"/>
		<entity charOffset="483-494" id="DBMI.pac106.sp0.e4" origId="sp0.e4" text="propafenone" type="Active ingredient"/>
		<pair e1="DBMI.pac106.sp0.e0" e2="DBMI.pac106.sp0.e1" id="DBMI.pac106.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="quinidine"/>
		<pair e1="DBMI.pac106.sp0.e0" e2="DBMI.pac106.sp0.e2" id="DBMI.pac106.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e0" e2="DBMI.pac106.sp0.e3" id="DBMI.pac106.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e0" e2="DBMI.pac106.sp0.e4" id="DBMI.pac106.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e1" e2="DBMI.pac106.sp0.e0" id="DBMI.pac106.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e1" e2="DBMI.pac106.sp0.e2" id="DBMI.pac106.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e1" e2="DBMI.pac106.sp0.e3" id="DBMI.pac106.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e1" e2="DBMI.pac106.sp0.e4" id="DBMI.pac106.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e2" e2="DBMI.pac106.sp0.e0" id="DBMI.pac106.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e2" e2="DBMI.pac106.sp0.e1" id="DBMI.pac106.sp0.p9" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="fluoxetine"/>
		<pair e1="DBMI.pac106.sp0.e2" e2="DBMI.pac106.sp0.e3" id="DBMI.pac106.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e2" e2="DBMI.pac106.sp0.e4" id="DBMI.pac106.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e3" e2="DBMI.pac106.sp0.e0" id="DBMI.pac106.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e3" e2="DBMI.pac106.sp0.e1" id="DBMI.pac106.sp0.p13" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="paroxetine"/>
		<pair e1="DBMI.pac106.sp0.e3" e2="DBMI.pac106.sp0.e2" id="DBMI.pac106.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e3" e2="DBMI.pac106.sp0.e4" id="DBMI.pac106.sp0.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e4" e2="DBMI.pac106.sp0.e0" id="DBMI.pac106.sp0.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e4" e2="DBMI.pac106.sp0.e1" id="DBMI.pac106.sp0.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="propafenone"/>
		<pair e1="DBMI.pac106.sp0.e4" e2="DBMI.pac106.sp0.e2" id="DBMI.pac106.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp0.e4" e2="DBMI.pac106.sp0.e3" id="DBMI.pac106.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac106.sp1" origId="sp1" text="In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate-release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life. In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate-release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of metoprolol. These increases in plasma concentration would decrease the cardioselectivity of metoprolol.">
		<entity charOffset="629-638" id="DBMI.pac106.sp1.e0" origId="sp1.e0" text="quinidine" type="Active ingredient"/>
		<entity charOffset="668-678" id="DBMI.pac106.sp1.e1" origId="sp1.e1" text="metoprolol" type="Active ingredient"/>
		<entity charOffset="844-855" id="DBMI.pac106.sp1.e2" origId="sp1.e2" text="propafenone" type="Active ingredient"/>
		<pair e1="DBMI.pac106.sp1.e0" e2="DBMI.pac106.sp1.e1" id="DBMI.pac106.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol" precipitant="quinidine"/>
		<pair e1="DBMI.pac106.sp1.e0" e2="DBMI.pac106.sp1.e2" id="DBMI.pac106.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp1.e1" e2="DBMI.pac106.sp1.e0" id="DBMI.pac106.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp1.e1" e2="DBMI.pac106.sp1.e2" id="DBMI.pac106.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp1.e2" e2="DBMI.pac106.sp1.e0" id="DBMI.pac106.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac106.sp1.e2" e2="DBMI.pac106.sp1.e1" id="DBMI.pac106.sp1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="metoprolol" precipitant="propafenone"/>
	</sentencespan>
	<sentencespan id="DBMI.pac106.sp2" origId="sp2" text="7.3 Digitalis, Clonidine, and Calcium Channel Blockers\n\nDigitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. Concomitant use with beta blockers can increase the risk of bradycardia. If clonidine and a beta blocker, such as metoprolol are coadministered, withdraw the beta-blocker several days before the gradual withdrawal of clonidine because beta-blockers may exacerbate the rebound hypertension that can follow the withdrawal of clonidine."/>
	<sentencespan id="DBMI.pac106.sp3" origId="sp3" text="If replacing clonidine by beta-blocker therapy, delay the introduction of beta-blockers for several days after clonidine administration has stopped [see Warnings and Precautions(5.11)]. "/>
</document>

<document id="DBMI.pac108" origId="pac108">
	<sentence id="DBMI.pac108.s0" origId="s0" text="Quinidine:  Quinidine is a substrate of CYP3A and has been shown to inhibit CYP3A in vitro."/>
	<sentence id="DBMI.pac108.s1" origId="s1" text="Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively.">
		<entity charOffset="130-139" id="DBMI.pac108.s1.e0" origId="s1.e0" text="quinidine" type="Active ingredient"/>
		<entity charOffset="168-178" id="DBMI.pac108.s1.e1" origId="s1.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac108.s1.e0" e2="DBMI.pac108.s1.e1" id="DBMI.pac108.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="quinidine"/>
		<pair e1="DBMI.pac108.s1.e1" e2="DBMI.pac108.s1.e0" id="DBMI.pac108.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac108.s2" origId="s2" text="The heart rate in the initial interval after drug administration was increased by up to 17.9 beats/minute."/>
	<sentence id="DBMI.pac108.s3" origId="s3" text="The exposure to quinidine was not importantly changed in the presence of nifedipine.">
		<entity charOffset="476-486" id="DBMI.pac108.s3.e0" origId="s3.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="419-428" id="DBMI.pac108.s3.e1" origId="s3.e1" text="quinidine" type="Active ingredient"/>
		<pair e1="DBMI.pac108.s3.e0" e2="DBMI.pac108.s3.e1" id="DBMI.pac108.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="quinidine" precipitant="nifedipine"/>
		<pair e1="DBMI.pac108.s3.e1" e2="DBMI.pac108.s3.e0" id="DBMI.pac108.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac108.s4" origId="s4" text="Monitoring of heart rate and adjustment of the nifedipine dose, if necessary, are recommended when quinidine is added to a treatment with nifedipine."/>
	<sentencespan id="DBMI.pac108.sp0" origId="sp0" text="Quinidine:  Quinidine is a substrate of CYP3A and has been shown to inhibit CYP3A in vitro. Coadministration of multiple doses of quinidine sulfate, 200 mg t.i.d., and nifedipine, 20 mg t.i.d., increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37, respectively. The heart rate in the initial interval after drug administration was increased by up to 17.9 beats/minute.">
		<entity charOffset="130-139" id="DBMI.pac108.sp0.e0" origId="sp0.e0" text="quinidine" type="Active ingredient"/>
		<entity charOffset="168-178" id="DBMI.pac108.sp0.e1" origId="sp0.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac108.sp0.e0" e2="DBMI.pac108.sp0.e1" id="DBMI.pac108.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="quinidine"/>
		<pair e1="DBMI.pac108.sp0.e1" e2="DBMI.pac108.sp0.e0" id="DBMI.pac108.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac108.sp1" origId="sp1" text="The exposure to quinidine was not importantly changed in the presence of nifedipine. Monitoring of heart rate and adjustment of the nifedipine dose, if necessary, are recommended when quinidine is added to a treatment with nifedipine.">
		<entity charOffset="476-486" id="DBMI.pac108.sp1.e0" origId="sp1.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="419-428" id="DBMI.pac108.sp1.e1" origId="sp1.e1" text="quinidine" type="Active ingredient"/>
		<pair e1="DBMI.pac108.sp1.e0" e2="DBMI.pac108.sp1.e1" id="DBMI.pac108.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="quinidine" precipitant="nifedipine"/>
		<pair e1="DBMI.pac108.sp1.e1" e2="DBMI.pac108.sp1.e0" id="DBMI.pac108.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac109" origId="pac109">
	<sentence id="DBMI.pac109.s0" origId="s0" text="Diltiazem:  Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively.">
		<entity charOffset="74-83" id="DBMI.pac109.s0.e0" origId="s0.e0" text="diltiazem" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac109.s1" origId="s1" text="The corresponding Cmax values of nifedipine increased by factors of 2.0 and 1.7, respectively.">
		<entity charOffset="235-245" id="DBMI.pac109.s1.e0" origId="s1.e0" text="nifedipine" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac109.s2" origId="s2" text="Caution should be exercised when coadministering diltiazem and nifedipine and a reduction of the dose of nifedipine should be considered."/>
	<sentencespan id="DBMI.pac109.sp0" origId="sp0" text="Diltiazem:  Pretreatment of healthy volunteers with 30 mg or 90 mg t.i.d. diltiazem p.o. increased the AUC of nifedipine after a single dose of 20 mg nifedipine by factors of 2.2 and 3.1, respectively. The corresponding Cmax values of nifedipine increased by factors of 2.0 and 1.7, respectively. Caution should be exercised when coadministering diltiazem and nifedipine and a reduction of the dose of nifedipine should be considered.">
		<entity charOffset="74-83" id="DBMI.pac109.sp0.e0" origId="sp0.e0" text="diltiazem" type="Active ingredient"/>
		<entity charOffset="235-245" id="DBMI.pac109.sp0.e1" origId="sp0.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac109.sp0.e0" e2="DBMI.pac109.sp0.e1" id="DBMI.pac109.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="diltiazem"/>
		<pair e1="DBMI.pac109.sp0.e1" e2="DBMI.pac109.sp0.e0" id="DBMI.pac109.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac11" origId="pac11">
	<sentence id="DBMI.pac11.s0" origId="s0" text="In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group.">
		<entity charOffset="83-93" id="DBMI.pac11.s0.e0" origId="s0.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="161-171" id="DBMI.pac11.s0.e1" origId="s0.e1" text="sertraline" type="Active ingredient"/>
		<pair e1="DBMI.pac11.s0.e0" e2="DBMI.pac11.s0.e1" id="DBMI.pac11.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sertraline" precipitant="cimetidine"/>
		<pair e1="DBMI.pac11.s0.e1" e2="DBMI.pac11.s0.e0" id="DBMI.pac11.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac11.s1" origId="s1" text="The clinical significance of these changes is unknown."/>
	<sentencespan id="DBMI.pac11.sp0" origId="sp0" text="In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), C max (24%) and half-life (26%) compared to the placebo group. The clinical significance of these changes is unknown.">
		<entity charOffset="83-93" id="DBMI.pac11.sp0.e0" origId="sp0.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="161-171" id="DBMI.pac11.sp0.e1" origId="sp0.e1" text="sertraline" type="Active ingredient"/>
		<pair e1="DBMI.pac11.sp0.e0" e2="DBMI.pac11.sp0.e1" id="DBMI.pac11.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sertraline" precipitant="cimetidine"/>
		<pair e1="DBMI.pac11.sp0.e1" e2="DBMI.pac11.sp0.e0" id="DBMI.pac11.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac110" origId="pac110">
	<sentence id="DBMI.pac110.s0" origId="s0" text="Irbesartan: In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites by nifedipine."/>
	<sentence id="DBMI.pac110.s1" origId="s1" text="However, in clinical studies, concomitant nifedipine had no effect on irbesartan pharmacokinetics.">
		<entity charOffset="166-176" id="DBMI.pac110.s1.e0" origId="s1.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="194-204" id="DBMI.pac110.s1.e1" origId="s1.e1" text="irbesartan" type="Active ingredient"/>
		<pair e1="DBMI.pac110.s1.e0" e2="DBMI.pac110.s1.e1" id="DBMI.pac110.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan" precipitant="nifedipine"/>
		<pair e1="DBMI.pac110.s1.e1" e2="DBMI.pac110.s1.e0" id="DBMI.pac110.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac110.sp0" origId="sp0" text="Irbesartan: In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites by nifedipine. However, in clinical studies, concomitant nifedipine had no effect on irbesartan pharmacokinetics.">
		<entity charOffset="166-176" id="DBMI.pac110.sp0.e0" origId="sp0.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="194-204" id="DBMI.pac110.sp0.e1" origId="sp0.e1" text="irbesartan" type="Active ingredient"/>
		<pair e1="DBMI.pac110.sp0.e0" e2="DBMI.pac110.sp0.e1" id="DBMI.pac110.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan" precipitant="nifedipine"/>
		<pair e1="DBMI.pac110.sp0.e1" e2="DBMI.pac110.sp0.e0" id="DBMI.pac110.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac111" origId="pac111">
	<sentence id="DBMI.pac111.s0" origId="s0" text="Doxazosin:  Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d."/>
	<sentence id="DBMI.pac111.s1" origId="s1" text="Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively.">
		<entity charOffset="202-212" id="DBMI.pac111.s1.e0" origId="s1.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="255-264" id="DBMI.pac111.s1.e1" origId="s1.e1" text="doxazosin" type="Active ingredient"/>
		<pair e1="DBMI.pac111.s1.e0" e2="DBMI.pac111.s1.e1" id="DBMI.pac111.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="doxazosin" precipitant="nifedipine"/>
		<pair e1="DBMI.pac111.s1.e1" e2="DBMI.pac111.s1.e0" id="DBMI.pac111.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac111.s2" origId="s2" text="In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively.">
		<entity charOffset="357-366" id="DBMI.pac111.s2.e0" origId="s2.e0" text="doxazosin" type="Active ingredient"/>
		<entity charOffset="384-394" id="DBMI.pac111.s2.e1" origId="s2.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac111.s2.e0" e2="DBMI.pac111.s2.e1" id="DBMI.pac111.s2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="doxazosin"/>
		<pair e1="DBMI.pac111.s2.e1" e2="DBMI.pac111.s2.e0" id="DBMI.pac111.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac111.s3" origId="s3" text="Compared to nifedipine monotherapy, blood pressure was lower in the presence of doxazosin."/>
	<sentence id="DBMI.pac111.s4" origId="s4" text="Blood pressure should be monitored when doxazosin is coadministered with nifedipine and dose reduction of nifedipine considered."/>
	<sentencespan id="DBMI.pac111.sp0" origId="sp0" text="Doxazosin:  Healthy volunteers participating in a multiple dose doxazosin-nifedipine interaction study received 2 mg doxazosin q.d. alone or combined with 20 mg nifedipine ER b.i.d. Coadministration of nifedipine resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% of the values in the absence of nifedipine, respectively. In the presence of doxazosin, AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23, respectively.">
		<entity charOffset="202-212" id="DBMI.pac111.sp0.e0" origId="sp0.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="255-264" id="DBMI.pac111.sp0.e1" origId="sp0.e1" text="doxazosin" type="Active ingredient"/>
		<pair e1="DBMI.pac111.sp0.e0" e2="DBMI.pac111.sp0.e1" id="DBMI.pac111.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="doxazosin" precipitant="nifedipine"/>
		<pair e1="DBMI.pac111.sp0.e1" e2="DBMI.pac111.sp0.e0" id="DBMI.pac111.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="doxazosin"/>
	</sentencespan>
	<sentencespan id="DBMI.pac111.sp1" origId="sp1" text="Compared to nifedipine monotherapy, blood pressure was lower in the presence of doxazosin. Blood pressure should be monitored when doxazosin is coadministered with nifedipine and dose reduction of nifedipine considered."/>
</document>

<document id="DBMI.pac113" origId="pac113">
	<sentence id="DBMI.pac113.s0" origId="s0" text="Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine."/>
	<sentence id="DBMI.pac113.s1" origId="s1" text="Two studies investigated the impact of coadministered cimetidine on blood pressure in hypertensive subjects on nifedipine."/>
	<sentence id="DBMI.pac113.s2" origId="s2" text="In normotensive subjects receiving single doses of 10 mg or multiple doses of up to 20 mg nifedipine t.i.d. alone or together with cimetidine up to 1000 mg/day, the AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence of cimetidine.">
		<entity charOffset="417-427" id="DBMI.pac113.s2.e0" origId="s2.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="465-475" id="DBMI.pac113.s2.e1" origId="s2.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac113.s2.e0" e2="DBMI.pac113.s2.e1" id="DBMI.pac113.s2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="cimetidine"/>
		<pair e1="DBMI.pac113.s2.e1" e2="DBMI.pac113.s2.e0" id="DBMI.pac113.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac113.s3" origId="s3" text="The Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02.">
		<entity charOffset="624-634" id="DBMI.pac113.s3.e0" origId="s3.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="594-604" id="DBMI.pac113.s3.e1" origId="s3.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac113.s3.e0" e2="DBMI.pac113.s3.e1" id="DBMI.pac113.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="cimetidine"/>
		<pair e1="DBMI.pac113.s3.e1" e2="DBMI.pac113.s3.e0" id="DBMI.pac113.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac113.s4" origId="s4" text="The increase in exposure to nifedipine by cimetidine was accompanied by relevant changes in blood pressure or heart rate in normotensive subjects."/>
	<sentence id="DBMI.pac113.s5" origId="s5" text="Hypertensive subjects receiving 10 mg q.d. nifedipine alone or in combination with cimetidine 1000 mg q.d. also experienced relevant changes in blood pressure when cimetidine was added to nifedipine."/>
	<sentence id="DBMI.pac113.s6" origId="s6" text="The interaction between cimetidine and nifedipine is of clinical relevance and blood pressure should be monitored and a reduction of the dose of nifedipine considered."/>
	<sentencespan id="DBMI.pac113.sp0" origId="sp0" text="Cimetidine: Five studies in healthy volunteers investigated the impact of multiple cimetidine doses on the single or multiple dose pharmacokinetics of nifedipine. Two studies investigated the impact of coadministered cimetidine on blood pressure in hypertensive subjects on nifedipine. In normotensive subjects receiving single doses of 10 mg or multiple doses of up to 20 mg nifedipine t.i.d. alone or together with cimetidine up to 1000 mg/day, the AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence of cimetidine.">
		<entity charOffset="417-427" id="DBMI.pac113.sp0.e0" origId="sp0.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="465-475" id="DBMI.pac113.sp0.e1" origId="sp0.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac113.sp0.e0" e2="DBMI.pac113.sp0.e1" id="DBMI.pac113.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="cimetidine"/>
		<pair e1="DBMI.pac113.sp0.e1" e2="DBMI.pac113.sp0.e0" id="DBMI.pac113.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac113.sp1" origId="sp1" text="The Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02. The increase in exposure to nifedipine by cimetidine was accompanied by relevant changes in blood pressure or heart rate in normotensive subjects. Hypertensive subjects receiving 10 mg q.d. nifedipine alone or in combination with cimetidine 1000 mg q.d. also experienced relevant changes in blood pressure when cimetidine was added to nifedipine.">
		<entity charOffset="624-634" id="DBMI.pac113.sp1.e0" origId="sp1.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="594-604" id="DBMI.pac113.sp1.e1" origId="sp1.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac113.sp1.e0" e2="DBMI.pac113.sp1.e1" id="DBMI.pac113.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="cimetidine"/>
		<pair e1="DBMI.pac113.sp1.e1" e2="DBMI.pac113.sp1.e0" id="DBMI.pac113.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac113.sp2" origId="sp2" text="The interaction between cimetidine and nifedipine is of clinical relevance and blood pressure should be monitored and a reduction of the dose of nifedipine considered."/>
</document>

<document id="DBMI.pac114" origId="pac114">
	<sentence id="DBMI.pac114.s0" origId="s0" text="Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine."/>
	<sentence id="DBMI.pac114.s1" origId="s1" text="Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy.">
		<entity charOffset="198-210" id="DBMI.pac114.s1.e0" origId="s1.e0" text="quinupristin" type="Active ingredient"/>
		<entity charOffset="228-238" id="DBMI.pac114.s1.e1" origId="s1.e1" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="211-223" id="DBMI.pac114.s1.e2" origId="s1.e2" text="dalfopristin" type="Active ingredient"/>
		<pair e1="DBMI.pac114.s1.e0" e2="DBMI.pac114.s1.e1" id="DBMI.pac114.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="quinupristin"/>
		<pair e1="DBMI.pac114.s1.e0" e2="DBMI.pac114.s1.e2" id="DBMI.pac114.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.s1.e1" e2="DBMI.pac114.s1.e0" id="DBMI.pac114.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.s1.e1" e2="DBMI.pac114.s1.e2" id="DBMI.pac114.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.s1.e2" e2="DBMI.pac114.s1.e0" id="DBMI.pac114.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.s1.e2" e2="DBMI.pac114.s1.e1" id="DBMI.pac114.s1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="dalfopristin"/>
	</sentence>
	<sentence id="DBMI.pac114.s2" origId="s2" text="Upon coadministration of quinupristin/dalfopristin with nifedipine, blood pressure should be monitored and a reduction of the dose of nifedipine considered."/>
	<sentencespan id="DBMI.pac114.sp0" origId="sp0" text="Quinupristin/Dalfopristin:In vitro drug interaction studies have demonstrated that quinupristin/dalfopristin significantly inhibits the CYP3A metabolism of nifedipine. Concomitant administration of quinupristin/dalfopristin and nifedipine (repeated oral dose) in healthy volunteers increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18, respectively, compared to nifedipine monotherapy. Upon coadministration of quinupristin/dalfopristin with nifedipine, blood pressure should be monitored and a reduction of the dose of nifedipine considered.">
		<entity charOffset="198-210" id="DBMI.pac114.sp0.e0" origId="sp0.e0" text="quinupristin" type="Active ingredient"/>
		<entity charOffset="228-238" id="DBMI.pac114.sp0.e1" origId="sp0.e1" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="211-223" id="DBMI.pac114.sp0.e2" origId="sp0.e2" text="dalfopristin" type="Active ingredient"/>
		<pair e1="DBMI.pac114.sp0.e0" e2="DBMI.pac114.sp0.e1" id="DBMI.pac114.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="quinupristin"/>
		<pair e1="DBMI.pac114.sp0.e0" e2="DBMI.pac114.sp0.e2" id="DBMI.pac114.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.sp0.e1" e2="DBMI.pac114.sp0.e0" id="DBMI.pac114.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.sp0.e1" e2="DBMI.pac114.sp0.e2" id="DBMI.pac114.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.sp0.e2" e2="DBMI.pac114.sp0.e0" id="DBMI.pac114.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac114.sp0.e2" e2="DBMI.pac114.sp0.e1" id="DBMI.pac114.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="dalfopristin"/>
	</sentencespan>
</document>

<document id="DBMI.pac115" origId="pac115">
	<sentence id="DBMI.pac115.s0" origId="s0" text="Phenytoin: Nifedipine is metabolized by CYP3A4."/>
	<sentence id="DBMI.pac115.s1" origId="s1" text="Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%.">
		<entity charOffset="136-145" id="DBMI.pac115.s1.e0" origId="s1.e0" text="phenytoin" type="Active ingredient"/>
		<entity charOffset="68-78" id="DBMI.pac115.s1.e1" origId="s1.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac115.s1.e0" e2="DBMI.pac115.s1.e1" id="DBMI.pac115.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="phenytoin"/>
		<pair e1="DBMI.pac115.s1.e1" e2="DBMI.pac115.s1.e0" id="DBMI.pac115.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac115.s2" origId="s2" text="When using nifedipine with phenytoin, the clinical response to nifedipine should be monitored and its dose adjusted if necessary."/>
	<sentencespan id="DBMI.pac115.sp0" origId="sp0" text="Phenytoin: Nifedipine is metabolized by CYP3A4. Coadministration of nifedipine 10 mg capsule and 60 mg nifedipine coat-core tablet with phenytoin, an inducer of CYP3A4, lowered the AUC and Cmax of nifedipine by approximately 70%. When using nifedipine with phenytoin, the clinical response to nifedipine should be monitored and its dose adjusted if necessary.">
		<entity charOffset="136-145" id="DBMI.pac115.sp0.e0" origId="sp0.e0" text="phenytoin" type="Active ingredient"/>
		<entity charOffset="68-78" id="DBMI.pac115.sp0.e1" origId="sp0.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac115.sp0.e0" e2="DBMI.pac115.sp0.e1" id="DBMI.pac115.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="phenytoin"/>
		<pair e1="DBMI.pac115.sp0.e1" e2="DBMI.pac115.sp0.e0" id="DBMI.pac115.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac116" origId="pac116">
	<sentence id="DBMI.pac116.s0" origId="s0" text="Rosiglitazone:  Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.">
		<entity charOffset="36-49" id="DBMI.pac116.s0.e0" origId="s0.e0" text="rosiglitazone" type="Active ingredient"/>
		<entity charOffset="139-149" id="DBMI.pac116.s0.e1" origId="s0.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac116.s0.e0" e2="DBMI.pac116.s0.e1" id="DBMI.pac116.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine" precipitant="rosiglitazone"/>
		<pair e1="DBMI.pac116.s0.e1" e2="DBMI.pac116.s0.e0" id="DBMI.pac116.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac118" origId="pac118">
	<sentence id="DBMI.pac118.s0" origId="s0" text="Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs.">
		<entity charOffset="30-38" id="DBMI.pac118.s0.e0" origId="s0.e0" text="Synercid" type="Drug product"/>
	</sentence>
	<sentence id="DBMI.pac118.s1" origId="s1" text="The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.">
		<entity charOffset="282-292" id="DBMI.pac118.s1.e0" origId="s1.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="297-306" id="DBMI.pac118.s1.e1" origId="s1.e1" text="midazolam" type="Active ingredient"/>
		<pair e1="DBMI.pac118.s1.e0" e2="DBMI.pac118.s1.e1" id="DBMI.pac118.s1.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.s1.e1" e2="DBMI.pac118.s1.e0" id="DBMI.pac118.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac118.sp0" origId="sp0" text="Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.">
		<entity charOffset="30-38" id="DBMI.pac118.sp0.e0" origId="sp0.e0" text="Synercid" type="Drug product"/>
		<entity charOffset="282-292" id="DBMI.pac118.sp0.e1" origId="sp0.e1" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="297-306" id="DBMI.pac118.sp0.e2" origId="sp0.e2" text="midazolam" type="Active ingredient"/>
		<pair e1="DBMI.pac118.sp0.e0" e2="DBMI.pac118.sp0.e1" id="DBMI.pac118.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="Synercid"/>
		<pair e1="DBMI.pac118.sp0.e0" e2="DBMI.pac118.sp0.e2" id="DBMI.pac118.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="midazolam" precipitant="Synercid"/>
		<pair e1="DBMI.pac118.sp0.e1" e2="DBMI.pac118.sp0.e0" id="DBMI.pac118.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.sp0.e1" e2="DBMI.pac118.sp0.e2" id="DBMI.pac118.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.sp0.e2" e2="DBMI.pac118.sp0.e0" id="DBMI.pac118.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac118.sp0.e2" e2="DBMI.pac118.sp0.e1" id="DBMI.pac118.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac12" origId="pac12">
	<sentence id="DBMI.pac12.s0" origId="s0" text="In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03).">
		<entity charOffset="123-133" id="DBMI.pac12.s0.e0" origId="s0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="230-238" id="DBMI.pac12.s0.e1" origId="s0.e1" text="diazepam" type="Active ingredient"/>
		<pair e1="DBMI.pac12.s0.e0" e2="DBMI.pac12.s0.e1" id="DBMI.pac12.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="diazepam" precipitant="sertraline"/>
		<pair e1="DBMI.pac12.s0.e1" e2="DBMI.pac12.s0.e0" id="DBMI.pac12.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac12.s1" origId="s1" text="There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p &lt; 0.03).">
		<entity charOffset="419-429" id="DBMI.pac12.s1.e0" origId="s1.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="394-411" id="DBMI.pac12.s1.e1" origId="s1.e1" text="desmethyldiazepam" type="Metabolite"/>
		<pair e1="DBMI.pac12.s1.e0" e2="DBMI.pac12.s1.e1" id="DBMI.pac12.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desmethyldiazepam" precipitant="sertraline"/>
		<pair e1="DBMI.pac12.s1.e1" e2="DBMI.pac12.s1.e0" id="DBMI.pac12.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac12.s2" origId="s2" text="The clinical significance of these changes is unknown."/>
	<sentencespan id="DBMI.pac12.sp0" origId="sp0" text="In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03). There was a 23% increase in T max for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p &lt; 0.03). The clinical significance of these changes is unknown.">
		<entity charOffset="123-133" id="DBMI.pac12.sp0.e0" origId="sp0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="230-238" id="DBMI.pac12.sp0.e1" origId="sp0.e1" text="diazepam" type="Active ingredient"/>
		<entity charOffset="394-411" id="DBMI.pac12.sp0.e2" origId="sp0.e2" text="desmethyldiazepam" type="Metabolite"/>
		<pair e1="DBMI.pac12.sp0.e0" e2="DBMI.pac12.sp0.e1" id="DBMI.pac12.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="diazepam" precipitant="sertraline"/>
		<pair e1="DBMI.pac12.sp0.e0" e2="DBMI.pac12.sp0.e2" id="DBMI.pac12.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="desmethyldiazepam" precipitant="sertraline"/>
		<pair e1="DBMI.pac12.sp0.e1" e2="DBMI.pac12.sp0.e0" id="DBMI.pac12.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac12.sp0.e1" e2="DBMI.pac12.sp0.e2" id="DBMI.pac12.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac12.sp0.e2" e2="DBMI.pac12.sp0.e0" id="DBMI.pac12.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac12.sp0.e2" e2="DBMI.pac12.sp0.e1" id="DBMI.pac12.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac122" origId="pac122">
	<sentence id="DBMI.pac122.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP2C8 Inhibitors and Inducers\n\nAn inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone.">
		<entity charOffset="170-178" id="DBMI.pac122.s0.e0" origId="s0.e0" text="rifampin" type="Active ingredient"/>
		<entity charOffset="204-217" id="DBMI.pac122.s0.e1" origId="s0.e1" text="rosiglitazone" type="Active ingredient"/>
		<entity charOffset="87-98" id="DBMI.pac122.s0.e2" origId="s0.e2" text="gemfibrozil" type="Active ingredient"/>
		<pair e1="DBMI.pac122.s0.e0" e2="DBMI.pac122.s0.e1" id="DBMI.pac122.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="rosiglitazone" precipitant="rifampin"/>
		<pair e1="DBMI.pac122.s0.e0" e2="DBMI.pac122.s0.e2" id="DBMI.pac122.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.s0.e1" e2="DBMI.pac122.s0.e0" id="DBMI.pac122.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.s0.e1" e2="DBMI.pac122.s0.e2" id="DBMI.pac122.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.s0.e2" e2="DBMI.pac122.s0.e0" id="DBMI.pac122.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.s0.e2" e2="DBMI.pac122.s0.e1" id="DBMI.pac122.s0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="rosiglitazone" precipitant="gemfibrozil"/>
	</sentence>
	<sentence id="DBMI.pac122.s1" origId="s1" text="Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response."/>
	<sentence id="DBMI.pac122.s2" origId="s2" text="[See Clinical Pharmacology (12.4).]"/>
	<sentencespan id="DBMI.pac122.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP2C8 Inhibitors and Inducers\n\nAn inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response. [See Clinical Pharmacology (12.4).]">
		<entity charOffset="170-178" id="DBMI.pac122.sp0.e0" origId="sp0.e0" text="rifampin" type="Active ingredient"/>
		<entity charOffset="204-217" id="DBMI.pac122.sp0.e1" origId="sp0.e1" text="rosiglitazone" type="Active ingredient"/>
		<entity charOffset="87-98" id="DBMI.pac122.sp0.e2" origId="sp0.e2" text="gemfibrozil" type="Active ingredient"/>
		<pair e1="DBMI.pac122.sp0.e0" e2="DBMI.pac122.sp0.e1" id="DBMI.pac122.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="rosiglitazone" precipitant="rifampin"/>
		<pair e1="DBMI.pac122.sp0.e0" e2="DBMI.pac122.sp0.e2" id="DBMI.pac122.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.sp0.e1" e2="DBMI.pac122.sp0.e0" id="DBMI.pac122.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.sp0.e1" e2="DBMI.pac122.sp0.e2" id="DBMI.pac122.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.sp0.e2" e2="DBMI.pac122.sp0.e0" id="DBMI.pac122.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac122.sp0.e2" e2="DBMI.pac122.sp0.e1" id="DBMI.pac122.sp0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="rosiglitazone" precipitant="gemfibrozil"/>
	</sentencespan>
</document>

<document id="DBMI.pac123" origId="pac123">
	<sentence id="DBMI.pac123.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nRosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity."/>
	<sentence id="DBMI.pac123.s1" origId="s1" text="Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPAR)."/>
	<sentence id="DBMI.pac123.s2" origId="s2" text="In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver."/>
	<sentence id="DBMI.pac123.s3" origId="s3" text="Activation of PPAR nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization."/>
	<sentence id="DBMI.pac123.s4" origId="s4" text="In addition, PPAR-responsive genes also participate in the regulation of fatty acid metabolism."/>
	<sentence id="DBMI.pac123.s5" origId="s5" text="Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes."/>
	<sentence id="DBMI.pac123.s6" origId="s6" text="The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues."/>
	<sentence id="DBMI.pac123.s7" origId="s7" text="Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat."/>
	<sentence id="DBMI.pac123.s8" origId="s8" text="In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulins action in the liver, muscle, and adipose tissues."/>
	<sentence id="DBMI.pac123.s9" origId="s9" text="Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis."/>
	<sentence id="DBMI.pac123.s10" origId="s10" text="The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue."/>
	<sentence id="DBMI.pac123.s11" origId="s11" text="Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance."/>
	<sentence id="DBMI.pac123.s12" origId="s12" text="12.2 Pharmacodynamics\n\nPatients with lipid abnormalities were not excluded from clinical trials of AVANDIA."/>
	<sentence id="DBMI.pac123.s13" origId="s13" text="In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids."/>
	<sentence id="DBMI.pac123.s14" origId="s14" text="These changes were statistically significantly different from placebo or glyburide controls (Table 7)."/>
	<sentence id="DBMI.pac123.s15" origId="s15" text="Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials."/>
	<sentence id="DBMI.pac123.s16" origId="s16" text="In contrast, HDL continued to rise over time."/>
	<sentence id="DBMI.pac123.s17" origId="s17" text="As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time."/>
	<sentence id="DBMI.pac123.s18" origId="s18" text="Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids."/>
	<sentence id="DBMI.pac123.s19" origId="s19" text="At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily."/>
	<sentence id="DBMI.pac123.s20" origId="s20" text="The corresponding values for glyburide were 3.2, 3.1, and 2.9."/>
	<sentence id="DBMI.pac123.s21" origId="s21" text="The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant."/>
	<sentence id="DBMI.pac123.s22" origId="s22" text="The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy."/>
	<sentence id="DBMI.pac123.s23" origId="s23" text="The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls."/>
	<sentence id="DBMI.pac123.s24" origId="s24" text="12.3 Pharmacokinetics\n\nMaximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8)."/>
	<sentence id="DBMI.pac123.s25" origId="s25" text="The elimination half-life is 3 to 4 hours and is independent of dose."/>
	<sentence id="DBMI.pac123.s26" origId="s26" text="Absorption\n\nThe absolute bioavailability of rosiglitazone is 99%."/>
	<sentence id="DBMI.pac123.s27" origId="s27" text="Peak plasma concentrations are observed about 1 hour after dosing."/>
	<sentence id="DBMI.pac123.s28" origId="s28" text="Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours)."/>
	<sentence id="DBMI.pac123.s29" origId="s29" text="These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food."/>
	<sentence id="DBMI.pac123.s30" origId="s30" text="Distribution\n\nThe mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis."/>
	<sentence id="DBMI.pac123.s31" origId="s31" text="Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin."/>
	<sentence id="DBMI.pac123.s32" origId="s32" text="Metabolism\n\nRosiglitazone is extensively metabolized with no unchanged drug excreted in the urine."/>
	<sentence id="DBMI.pac123.s33" origId="s33" text="The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid."/>
	<sentence id="DBMI.pac123.s34" origId="s34" text="All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone."/>
	<sentence id="DBMI.pac123.s35" origId="s35" text="In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway."/>
	<sentence id="DBMI.pac123.s36" origId="s36" text="Excretion\n\nFollowing oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively."/>
	<sentence id="DBMI.pac123.s37" origId="s37" text="The plasma half-life of [14C]related material ranged from 103 to 158 hours."/>
	<sentence id="DBMI.pac123.s38" origId="s38" text="Population Pharmacokinetics in Patients With Type 2 Diabetes\n\nPopulation pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption."/>
	<sentence id="DBMI.pac123.s39" origId="s39" text="Both oral clearance (CL/F) and oral steady-state volume of distribution (Vss/F) were shown to increase with increases in body weight."/>
	<sentence id="DBMI.pac123.s40" origId="s40" text="Over the weight range observed in these analyses (50 to 150 kg), the range of predicted CL/F and Vss/F values varied by &lt;1.7-fold and &lt;2.3-fold, respectively."/>
	<sentence id="DBMI.pac123.s41" origId="s41" text="Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients."/>
	<sentence id="DBMI.pac123.s42" origId="s42" text="Special Populations\n\nGeriatric\n\nResults of the population pharmacokinetic analysis (n = 716 &lt;65 years; n = 331 65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone."/>
	<sentence id="DBMI.pac123.s43" origId="s43" text="Gender\n\nResults of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642)."/>
	<sentence id="DBMI.pac123.s44" origId="s44" text="As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females."/>
	<sentence id="DBMI.pac123.s45" origId="s45" text="In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response."/>
	<sentence id="DBMI.pac123.s46" origId="s46" text="In monotherapy studies, a greater therapeutic response was observed in females; however, in more obese patients, gender differences were less evident."/>
	<sentence id="DBMI.pac123.s47" origId="s47" text="For a given body mass index (BMI), females tend to have a greater fat mass than males."/>
	<sentence id="DBMI.pac123.s48" origId="s48" text="Since the molecular target PPAR is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to AVANDIA in females."/>
	<sentence id="DBMI.pac123.s49" origId="s49" text="Since therapy should be individualized, no dose adjustments are necessary based on gender alone."/>
	<sentence id="DBMI.pac123.s50" origId="s50" text="Hepatic Impairment\n\nUnbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects."/>
	<sentence id="DBMI.pac123.s51" origId="s51" text="As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively."/>
	<sentence id="DBMI.pac123.s52" origId="s52" text="Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects."/>
	<sentence id="DBMI.pac123.s53" origId="s53" text="Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT &gt;2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)]."/>
	<sentence id="DBMI.pac123.s54" origId="s54" text="Pediatric\n\nPharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg)."/>
	<sentence id="DBMI.pac123.s55" origId="s55" text="Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively."/>
	<sentence id="DBMI.pac123.s56" origId="s56" text="These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis."/>
	<sentence id="DBMI.pac123.s57" origId="s57" text="Renal Impairment\n\nThere are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function."/>
	<sentence id="DBMI.pac123.s58" origId="s58" text="No dosage adjustment is therefore required in such patients receiving AVANDIA."/>
	<sentence id="DBMI.pac123.s59" origId="s59" text="Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients."/>
	<sentence id="DBMI.pac123.s60" origId="s60" text="Race\n\nResults of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone."/>
	<sentence id="DBMI.pac123.s61" origId="s61" text="12.4 Drug-Drug Interactions\n\nDrugs That Inhibit, Induce, or are Metabolized by Cytochrome P450\n\nIn vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations."/>
	<sentence id="DBMI.pac123.s62" origId="s62" text="In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9."/>
	<sentence id="DBMI.pac123.s63" origId="s63" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.">
		<entity charOffset="9050-9057" id="DBMI.pac123.s63.e0" origId="s63.e0" text="AVANDIA" type="Drug product"/>
		<entity charOffset="9152-9162" id="DBMI.pac123.s63.e1" origId="s63.e1" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="9210-9223" id="DBMI.pac123.s63.e2" origId="s63.e2" text="norethindrone" type="Active ingredient"/>
		<entity charOffset="9188-9205" id="DBMI.pac123.s63.e3" origId="s63.e3" text="ethinyl estradiol" type="Active ingredient"/>
		<pair e1="DBMI.pac123.s63.e0" e2="DBMI.pac123.s63.e1" id="DBMI.pac123.s63.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.s63.e0" e2="DBMI.pac123.s63.e1" id="DBMI.pac123.s63.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.s63.e0" e2="DBMI.pac123.s63.e2" id="DBMI.pac123.s63.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="norethindrone" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.s63.e0" e2="DBMI.pac123.s63.e3" id="DBMI.pac123.s63.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.s63.e1" e2="DBMI.pac123.s63.e0" id="DBMI.pac123.s63.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e1" e2="DBMI.pac123.s63.e2" id="DBMI.pac123.s63.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e1" e2="DBMI.pac123.s63.e3" id="DBMI.pac123.s63.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e2" e2="DBMI.pac123.s63.e0" id="DBMI.pac123.s63.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e2" e2="DBMI.pac123.s63.e1" id="DBMI.pac123.s63.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e2" e2="DBMI.pac123.s63.e3" id="DBMI.pac123.s63.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e3" e2="DBMI.pac123.s63.e0" id="DBMI.pac123.s63.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e3" e2="DBMI.pac123.s63.e1" id="DBMI.pac123.s63.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s63.e3" e2="DBMI.pac123.s63.e2" id="DBMI.pac123.s63.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s64" origId="s64" text="Gemfibrozil\n\nConcomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone.">
		<entity charOffset="9317-9328" id="DBMI.pac123.s64.e0" origId="s64.e0" text="gemfibrozil" type="Active ingredient"/>
		<entity charOffset="9379-9392" id="DBMI.pac123.s64.e1" origId="s64.e1" text="rosiglitazone" type="Active ingredient"/>
		<pair e1="DBMI.pac123.s64.e0" e2="DBMI.pac123.s64.e1" id="DBMI.pac123.s64.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="rosiglitazone" precipitant="gemfibrozil"/>
		<pair e1="DBMI.pac123.s64.e1" e2="DBMI.pac123.s64.e0" id="DBMI.pac123.s64.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s65" origId="s65" text="Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)]."/>
	<sentence id="DBMI.pac123.s66" origId="s66" text="Rifampin\n\nRifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4\n\nGlyburide\n\nAVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy.">
		<entity charOffset="9731-9739" id="DBMI.pac123.s66.e0" origId="s66.e0" text="Rifampin" type="Active ingredient"/>
		<entity charOffset="9833-9846" id="DBMI.pac123.s66.e1" origId="s66.e1" text="rosiglitazone" type="Active ingredient"/>
		<pair e1="DBMI.pac123.s66.e0" e2="DBMI.pac123.s66.e1" id="DBMI.pac123.s66.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="rosiglitazone" precipitant="Rifampin"/>
		<pair e1="DBMI.pac123.s66.e1" e2="DBMI.pac123.s66.e0" id="DBMI.pac123.s66.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s67" origId="s67" text="Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%.">
		<entity charOffset="10201-10208" id="DBMI.pac123.s67.e0" origId="s67.e0" text="AVANDIA" type="Drug product"/>
		<entity charOffset="10295-10304" id="DBMI.pac123.s67.e1" origId="s67.e1" text="glyburide" type="Active ingredient"/>
		<pair e1="DBMI.pac123.s67.e0" e2="DBMI.pac123.s67.e1" id="DBMI.pac123.s67.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="glyburide" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.s67.e1" e2="DBMI.pac123.s67.e0" id="DBMI.pac123.s67.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s68" origId="s68" text="In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.">
		<entity charOffset="10362-10371" id="DBMI.pac123.s68.e0" origId="s68.e0" text="glyburide" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac123.s69" origId="s69" text="Glimepiride\n\nSingle oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA.">
		<entity charOffset="10434-10441" id="DBMI.pac123.s69.e0" origId="s69.e0" text="AVANDIA" type="Drug product"/>
		<entity charOffset="10478-10489" id="DBMI.pac123.s69.e1" origId="s69.e1" text="glimepiride" type="Active ingredient"/>
		<pair e1="DBMI.pac123.s69.e0" e2="DBMI.pac123.s69.e1" id="DBMI.pac123.s69.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.s69.e1" e2="DBMI.pac123.s69.e0" id="DBMI.pac123.s69.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA" precipitant="glimepiride"/>
	</sentence>
	<sentence id="DBMI.pac123.s70" origId="s70" text="No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.">
		<entity charOffset="10596-10603" id="DBMI.pac123.s70.e0" origId="s70.e0" text="AVANDIA" type="Drug product"/>
		<entity charOffset="10645-10656" id="DBMI.pac123.s70.e1" origId="s70.e1" text="glimepiride" type="Active ingredient"/>
		<pair e1="DBMI.pac123.s70.e0" e2="DBMI.pac123.s70.e1" id="DBMI.pac123.s70.p0" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="glimepiride" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.s70.e1" e2="DBMI.pac123.s70.e0" id="DBMI.pac123.s70.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s71" origId="s71" text="Metformin\n\nConcurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.">
		<entity charOffset="10811-10818" id="DBMI.pac123.s71.e0" origId="s71.e0" text="AVANDIA" type="Drug product"/>
		<entity charOffset="10842-10851" id="DBMI.pac123.s71.e1" origId="s71.e1" text="metformin" type="Active ingredient"/>
		<pair e1="DBMI.pac123.s71.e0" e2="DBMI.pac123.s71.e1" id="DBMI.pac123.s71.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="metformin" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.s71.e1" e2="DBMI.pac123.s71.e0" id="DBMI.pac123.s71.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA" precipitant="metformin"/>
	</sentence>
	<sentence id="DBMI.pac123.s72" origId="s72" text="Acarbose\n\nCoadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.">
		<entity charOffset="11026-11034" id="DBMI.pac123.s72.e0" origId="s72.e0" text="acarbose" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac123.s73" origId="s73" text="Digoxin\n\nRepeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers.">
		<entity charOffset="11178-11185" id="DBMI.pac123.s73.e0" origId="s73.e0" text="AVANDIA" type="Drug product"/>
		<entity charOffset="11308-11315" id="DBMI.pac123.s73.e1" origId="s73.e1" text="digoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac123.s73.e0" e2="DBMI.pac123.s73.e1" id="DBMI.pac123.s73.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.s73.e1" e2="DBMI.pac123.s73.e0" id="DBMI.pac123.s73.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac123.s74" origId="s74" text="Warfarin\n\nRepeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.">
		<entity charOffset="11391-11398" id="DBMI.pac123.s74.e0" origId="s74.e0" text="AVANDIA" type="Drug product"/>
	</sentence>
	<sentence id="DBMI.pac123.s75" origId="s75" text="Ethanol\n\nA single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA.">
		<entity charOffset="11473-11481" id="DBMI.pac123.s75.e0" origId="s75.e0" text="warfarin" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac123.s76" origId="s76" text="Ranitidine\n\nPretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers.">
		<entity charOffset="11699-11709" id="DBMI.pac123.s76.e0" origId="s76.e0" text="ranitidine" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac123.s77" origId="s77" text="These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.\n">
		<entity charOffset="11823-11836" id="DBMI.pac123.s77.e0" origId="s77.e0" text="rosiglitazone" type="Active ingredient"/>
	</sentence>
	<sentencespan id="DBMI.pac123.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nRosiglitazone, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPAR). In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver."/>
	<sentencespan id="DBMI.pac123.sp1" origId="sp1" text="Activation of PPAR nuclear receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In addition, PPAR-responsive genes also participate in the regulation of fatty acid metabolism. Insulin resistance is a common feature characterizing the pathogenesis of type 2 diabetes."/>
	<sentencespan id="DBMI.pac123.sp2" origId="sp2" text="The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues. Rosiglitazone reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat. In animal models, the antidiabetic activity of rosiglitazone was shown to be mediated by increased sensitivity to insulins action in the liver, muscle, and adipose tissues."/>
	<sentencespan id="DBMI.pac123.sp3" origId="sp3" text="Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis. The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue. Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance."/>
	<sentencespan id="DBMI.pac123.sp4" origId="sp4" text="12.2 Pharmacodynamics\n\nPatients with lipid abnormalities were not excluded from clinical trials of AVANDIA. In all 26-week controlled trials, across the recommended dose range, AVANDIA as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids. These changes were statistically significantly different from placebo or glyburide controls (Table 7)."/>
	<sentencespan id="DBMI.pac123.sp5" origId="sp5" text="Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time."/>
	<sentencespan id="DBMI.pac123.sp6" origId="sp6" text="Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids. At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily. The corresponding values for glyburide were 3.2, 3.1, and 2.9."/>
	<sentencespan id="DBMI.pac123.sp7" origId="sp7" text="The differences in change from baseline between AVANDIA and glyburide at week 52 were statistically significant. The pattern of LDL and HDL changes following therapy with AVANDIA in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy. The changes in triglycerides during therapy with AVANDIA were variable and were generally not statistically different from placebo or glyburide controls."/>
	<sentencespan id="DBMI.pac123.sp8" origId="sp8" text="12.3 Pharmacokinetics\n\nMaximum plasma concentration (Cmax) and the area under the curve (AUC) of rosiglitazone increase in a dose-proportional manner over the therapeutic dose range (Table 8). The elimination half-life is 3 to 4 hours and is independent of dose. Absorption\n\nThe absolute bioavailability of rosiglitazone is 99%."/>
	<sentencespan id="DBMI.pac123.sp9" origId="sp9" text="Peak plasma concentrations are observed about 1 hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours). These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or without food."/>
	<sentencespan id="DBMI.pac123.sp10" origId="sp10" text="Distribution\n\nThe mean (CV%) oral volume of distribution (Vss/F) of rosiglitazone is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis. Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin. Metabolism\n\nRosiglitazone is extensively metabolized with no unchanged drug excreted in the urine."/>
	<sentencespan id="DBMI.pac123.sp11" origId="sp11" text="The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid. All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of rosiglitazone. In vitro data demonstrate that rosiglitazone is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway."/>
	<sentencespan id="DBMI.pac123.sp12" origId="sp12" text="Excretion\n\nFollowing oral or intravenous administration of [14C]rosiglitazone maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively. The plasma half-life of [14C]related material ranged from 103 to 158 hours. Population Pharmacokinetics in Patients With Type 2 Diabetes\n\nPopulation pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of rosiglitazone are not influenced by age, race, smoking, or alcohol consumption."/>
	<sentencespan id="DBMI.pac123.sp13" origId="sp13" text="Both oral clearance (CL/F) and oral steady-state volume of distribution (Vss/F) were shown to increase with increases in body weight. Over the weight range observed in these analyses (50 to 150 kg), the range of predicted CL/F and Vss/F values varied by &lt;1.7-fold and &lt;2.3-fold, respectively. Additionally, rosiglitazone CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients."/>
	<sentencespan id="DBMI.pac123.sp14" origId="sp14" text="Special Populations\n\nGeriatric\n\nResults of the population pharmacokinetic analysis (n = 716 &lt;65 years; n = 331 65 years) showed that age does not significantly affect the pharmacokinetics of rosiglitazone. Gender\n\nResults of the population pharmacokinetics analysis showed that the mean oral clearance of rosiglitazone in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642). As monotherapy and in combination with metformin, AVANDIA improved glycemic control in both males and females."/>
	<sentencespan id="DBMI.pac123.sp15" origId="sp15" text="In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response. In monotherapy studies, a greater therapeutic response was observed in females; however, in more obese patients, gender differences were less evident. For a given body mass index (BMI), females tend to have a greater fat mass than males."/>
	<sentencespan id="DBMI.pac123.sp16" origId="sp16" text="Since the molecular target PPAR is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to AVANDIA in females. Since therapy should be individualized, no dose adjustments are necessary based on gender alone. Hepatic Impairment\n\nUnbound oral clearance of rosiglitazone was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects."/>
	<sentencespan id="DBMI.pac123.sp17" origId="sp17" text="As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively. Elimination half-life for rosiglitazone was about 2 hours longer in patients with liver disease, compared to healthy subjects. Therapy with AVANDIA should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT &gt;2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)]."/>
	<sentencespan id="DBMI.pac123.sp18" origId="sp18" text="Pediatric\n\nPharmacokinetic parameters of rosiglitazone in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg). Population mean CL/F and V/F of rosiglitazone were 3.15 L/hr and 13.5 L, respectively. These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis."/>
	<sentencespan id="DBMI.pac123.sp19" origId="sp19" text="Renal Impairment\n\nThere are no clinically relevant differences in the pharmacokinetics of rosiglitazone in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function. No dosage adjustment is therefore required in such patients receiving AVANDIA. Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients."/>
	<sentencespan id="DBMI.pac123.sp20" origId="sp20" text="Race\n\nResults of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of rosiglitazone. 12.4 Drug-Drug Interactions\n\nDrugs That Inhibit, Induce, or are Metabolized by Cytochrome P450\n\nIn vitro drug metabolism studies suggest that rosiglitazone does not inhibit any of the major P450 enzymes at clinically relevant concentrations. In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9."/>
	<sentencespan id="DBMI.pac123.sp21" origId="sp21" text="AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4. Gemfibrozil\n\nConcomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].">
		<entity charOffset="9050-9057" id="DBMI.pac123.sp21.e0" origId="sp21.e0" text="AVANDIA" type="Drug product"/>
		<entity charOffset="9152-9162" id="DBMI.pac123.sp21.e1" origId="sp21.e1" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="9210-9223" id="DBMI.pac123.sp21.e2" origId="sp21.e2" text="norethindrone" type="Active ingredient"/>
		<entity charOffset="9188-9205" id="DBMI.pac123.sp21.e3" origId="sp21.e3" text="ethinyl estradiol" type="Active ingredient"/>
		<entity charOffset="9317-9328" id="DBMI.pac123.sp21.e4" origId="sp21.e4" text="gemfibrozil" type="Active ingredient"/>
		<entity charOffset="9379-9392" id="DBMI.pac123.sp21.e5" origId="sp21.e5" text="rosiglitazone" type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="nifedipine" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="norethindrone" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e0" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e1" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e2" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e3" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e4" e2="DBMI.pac123.sp21.e5" id="DBMI.pac123.sp21.p25" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="rosiglitazone" precipitant="gemfibrozil"/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e0" id="DBMI.pac123.sp21.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e1" id="DBMI.pac123.sp21.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e2" id="DBMI.pac123.sp21.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e3" id="DBMI.pac123.sp21.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp21.e5" e2="DBMI.pac123.sp21.e4" id="DBMI.pac123.sp21.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac123.sp22" origId="sp22" text="Rifampin\n\nRifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4\n\nGlyburide\n\nAVANDIA (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy. Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%. In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.">
		<entity charOffset="10201-10208" id="DBMI.pac123.sp22.e0" origId="sp22.e0" text="AVANDIA" type="Drug product"/>
		<entity charOffset="10295-10304" id="DBMI.pac123.sp22.e1" origId="sp22.e1" text="glyburide" type="Active ingredient"/>
		<entity charOffset="9731-9739" id="DBMI.pac123.sp22.e2" origId="sp22.e2" text="Rifampin" type="Active ingredient"/>
		<entity charOffset="9833-9846" id="DBMI.pac123.sp22.e3" origId="sp22.e3" text="rosiglitazone" type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp22.e0" e2="DBMI.pac123.sp22.e1" id="DBMI.pac123.sp22.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="glyburide" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp22.e0" e2="DBMI.pac123.sp22.e1" id="DBMI.pac123.sp22.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="glyburide" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp22.e0" e2="DBMI.pac123.sp22.e2" id="DBMI.pac123.sp22.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e0" e2="DBMI.pac123.sp22.e3" id="DBMI.pac123.sp22.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e1" e2="DBMI.pac123.sp22.e0" id="DBMI.pac123.sp22.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e1" e2="DBMI.pac123.sp22.e2" id="DBMI.pac123.sp22.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e1" e2="DBMI.pac123.sp22.e3" id="DBMI.pac123.sp22.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e2" e2="DBMI.pac123.sp22.e0" id="DBMI.pac123.sp22.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e2" e2="DBMI.pac123.sp22.e1" id="DBMI.pac123.sp22.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e2" e2="DBMI.pac123.sp22.e3" id="DBMI.pac123.sp22.p9" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="rosiglitazone" precipitant="Rifampin"/>
		<pair e1="DBMI.pac123.sp22.e3" e2="DBMI.pac123.sp22.e0" id="DBMI.pac123.sp22.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e3" e2="DBMI.pac123.sp22.e1" id="DBMI.pac123.sp22.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp22.e3" e2="DBMI.pac123.sp22.e2" id="DBMI.pac123.sp22.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac123.sp23" origId="sp23" text="Glimepiride\n\nSingle oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA. No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects. Metformin\n\nConcurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.">
		<entity charOffset="10478-10489" id="DBMI.pac123.sp23.e0" origId="sp23.e0" text="glimepiride" type="Active ingredient"/>
		<entity charOffset="10596-10603" id="DBMI.pac123.sp23.e1" origId="sp23.e1" text="AVANDIA" type="Drug product"/>
		<entity charOffset="10842-10851" id="DBMI.pac123.sp23.e2" origId="sp23.e2" text="metformin" type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp23.e0" e2="DBMI.pac123.sp23.e1" id="DBMI.pac123.sp23.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA" precipitant="glimepiride"/>
		<pair e1="DBMI.pac123.sp23.e0" e2="DBMI.pac123.sp23.e2" id="DBMI.pac123.sp23.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp23.e1" e2="DBMI.pac123.sp23.e0" id="DBMI.pac123.sp23.p2" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="glimepiride" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp23.e1" e2="DBMI.pac123.sp23.e2" id="DBMI.pac123.sp23.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="metformin" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp23.e2" e2="DBMI.pac123.sp23.e0" id="DBMI.pac123.sp23.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp23.e2" e2="DBMI.pac123.sp23.e1" id="DBMI.pac123.sp23.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA" precipitant="metformin"/>
	</sentencespan>
	<sentencespan id="DBMI.pac123.sp24" origId="sp24" text="Acarbose\n\nCoadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA. Digoxin\n\nRepeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers. Warfarin\n\nRepeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.">
		<entity charOffset="11026-11034" id="DBMI.pac123.sp24.e0" origId="sp24.e0" text="acarbose" type="Active ingredient"/>
		<entity charOffset="11178-11185" id="DBMI.pac123.sp24.e1" origId="sp24.e1" text="AVANDIA" type="Drug product"/>
		<entity charOffset="11308-11315" id="DBMI.pac123.sp24.e2" origId="sp24.e2" text="digoxin" type="Active ingredient"/>
		<entity charOffset="11473-11481" id="DBMI.pac123.sp24.e3" origId="sp24.e3" text="warfarin" type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp24.e0" e2="DBMI.pac123.sp24.e1" id="DBMI.pac123.sp24.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="AVANDIA" precipitant="acarbose"/>
		<pair e1="DBMI.pac123.sp24.e0" e2="DBMI.pac123.sp24.e2" id="DBMI.pac123.sp24.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e0" e2="DBMI.pac123.sp24.e3" id="DBMI.pac123.sp24.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e1" e2="DBMI.pac123.sp24.e0" id="DBMI.pac123.sp24.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e1" e2="DBMI.pac123.sp24.e2" id="DBMI.pac123.sp24.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp24.e1" e2="DBMI.pac123.sp24.e3" id="DBMI.pac123.sp24.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="AVANDIA"/>
		<pair e1="DBMI.pac123.sp24.e2" e2="DBMI.pac123.sp24.e0" id="DBMI.pac123.sp24.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e2" e2="DBMI.pac123.sp24.e1" id="DBMI.pac123.sp24.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e2" e2="DBMI.pac123.sp24.e3" id="DBMI.pac123.sp24.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e3" e2="DBMI.pac123.sp24.e0" id="DBMI.pac123.sp24.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e3" e2="DBMI.pac123.sp24.e1" id="DBMI.pac123.sp24.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac123.sp24.e3" e2="DBMI.pac123.sp24.e2" id="DBMI.pac123.sp24.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac123.sp25" origId="sp25" text="Ethanol\n\nA single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with AVANDIA. Ranitidine\n\nPretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers. These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.\n">
		<entity charOffset="11699-11709" id="DBMI.pac123.sp25.e0" origId="sp25.e0" text="ranitidine" type="Active ingredient"/>
		<entity charOffset="11823-11836" id="DBMI.pac123.sp25.e1" origId="sp25.e1" text="rosiglitazone" type="Active ingredient"/>
		<pair e1="DBMI.pac123.sp25.e0" e2="DBMI.pac123.sp25.e1" id="DBMI.pac123.sp25.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="rosiglitazone" precipitant="ranitidine"/>
		<pair e1="DBMI.pac123.sp25.e1" e2="DBMI.pac123.sp25.e0" id="DBMI.pac123.sp25.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac124" origId="pac124">
	<sentence id="DBMI.pac124.s0" origId="s0" text="The AUC of propafenone is increased by more than 200% by co-administration of propranolol.">
		<entity charOffset="78-89" id="DBMI.pac124.s0.e0" origId="s0.e0" text="propranolol" type="Active ingredient"/>
		<entity charOffset="11-22" id="DBMI.pac124.s0.e1" origId="s0.e1" text="propafenone" type="Active ingredient"/>
		<pair e1="DBMI.pac124.s0.e0" e2="DBMI.pac124.s0.e1" id="DBMI.pac124.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propafenone" precipitant="propranolol"/>
		<pair e1="DBMI.pac124.s0.e1" e2="DBMI.pac124.s0.e0" id="DBMI.pac124.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac125" origId="pac125">
	<sentence id="DBMI.pac125.s0" origId="s0" text="The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.">
		<entity charOffset="65-74" id="DBMI.pac125.s0.e0" origId="s0.e0" text="quinidine" type="Active ingredient"/>
		<entity charOffset="18-29" id="DBMI.pac125.s0.e1" origId="s0.e1" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac125.s0.e0" e2="DBMI.pac125.s0.e1" id="DBMI.pac125.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol" precipitant="quinidine"/>
		<pair e1="DBMI.pac125.s0.e1" e2="DBMI.pac125.s0.e0" id="DBMI.pac125.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac126" origId="pac126">
	<sentence id="DBMI.pac126.s0" origId="s0" text="The mean Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.">
		<entity charOffset="104-115" id="DBMI.pac126.s0.e0" origId="s0.e0" text="propranolol" type="Active ingredient"/>
		<entity charOffset="25-35" id="DBMI.pac126.s0.e1" origId="s0.e1" text="nifedipine" type="Active ingredient"/>
		<pair e1="DBMI.pac126.s0.e0" e2="DBMI.pac126.s0.e1" id="DBMI.pac126.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="nifedipine" precipitant="propranolol"/>
		<pair e1="DBMI.pac126.s0.e1" e2="DBMI.pac126.s0.e0" id="DBMI.pac126.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac127" origId="pac127">
	<sentence id="DBMI.pac127.s0" origId="s0" text="Propranolol does not affect the pharmacokinetics of verapamil and norverapamil.">
		<entity charOffset="0-11" id="DBMI.pac127.s0.e0" origId="s0.e0" text="Propranolol" type="Active ingredient"/>
		<entity charOffset="52-61" id="DBMI.pac127.s0.e1" origId="s0.e1" text="verapamil" type="Active ingredient"/>
		<entity charOffset="66-78" id="DBMI.pac127.s0.e2" origId="s0.e2" text="norverapamil" type="Metabolite"/>
		<pair e1="DBMI.pac127.s0.e0" e2="DBMI.pac127.s0.e1" id="DBMI.pac127.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="verapamil" precipitant="Propranolol"/>
		<pair e1="DBMI.pac127.s0.e0" e2="DBMI.pac127.s0.e2" id="DBMI.pac127.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="norverapamil" precipitant="Propranolol"/>
		<pair e1="DBMI.pac127.s0.e1" e2="DBMI.pac127.s0.e0" id="DBMI.pac127.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.s0.e1" e2="DBMI.pac127.s0.e2" id="DBMI.pac127.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.s0.e2" e2="DBMI.pac127.s0.e0" id="DBMI.pac127.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.s0.e2" e2="DBMI.pac127.s0.e1" id="DBMI.pac127.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac127.s1" origId="s1" text="Verapamil does not affect the pharmacokinetics of propranolol.">
		<entity charOffset="80-89" id="DBMI.pac127.s1.e0" origId="s1.e0" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="130-141" id="DBMI.pac127.s1.e1" origId="s1.e1" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac127.s1.e0" e2="DBMI.pac127.s1.e1" id="DBMI.pac127.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol" precipitant="Verapamil"/>
		<pair e1="DBMI.pac127.s1.e1" e2="DBMI.pac127.s1.e0" id="DBMI.pac127.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac127.sp0" origId="sp0" text="Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol.">
		<entity charOffset="0-11" id="DBMI.pac127.sp0.e0" origId="sp0.e0" text="Propranolol" type="Active ingredient"/>
		<entity charOffset="52-61" id="DBMI.pac127.sp0.e1" origId="sp0.e1" text="verapamil" type="Active ingredient"/>
		<entity charOffset="66-78" id="DBMI.pac127.sp0.e2" origId="sp0.e2" text="norverapamil" type="Metabolite"/>
		<entity charOffset="80-89" id="DBMI.pac127.sp0.e3" origId="sp0.e3" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="130-141" id="DBMI.pac127.sp0.e4" origId="sp0.e4" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac127.sp0.e0" e2="DBMI.pac127.sp0.e1" id="DBMI.pac127.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="verapamil" precipitant="Propranolol"/>
		<pair e1="DBMI.pac127.sp0.e0" e2="DBMI.pac127.sp0.e2" id="DBMI.pac127.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="norverapamil" precipitant="Propranolol"/>
		<pair e1="DBMI.pac127.sp0.e0" e2="DBMI.pac127.sp0.e3" id="DBMI.pac127.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e0" e2="DBMI.pac127.sp0.e4" id="DBMI.pac127.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e1" e2="DBMI.pac127.sp0.e0" id="DBMI.pac127.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e1" e2="DBMI.pac127.sp0.e2" id="DBMI.pac127.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e1" e2="DBMI.pac127.sp0.e3" id="DBMI.pac127.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e1" e2="DBMI.pac127.sp0.e4" id="DBMI.pac127.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e2" e2="DBMI.pac127.sp0.e0" id="DBMI.pac127.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e2" e2="DBMI.pac127.sp0.e1" id="DBMI.pac127.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e2" e2="DBMI.pac127.sp0.e3" id="DBMI.pac127.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e2" e2="DBMI.pac127.sp0.e4" id="DBMI.pac127.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e3" e2="DBMI.pac127.sp0.e0" id="DBMI.pac127.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e3" e2="DBMI.pac127.sp0.e1" id="DBMI.pac127.sp0.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e3" e2="DBMI.pac127.sp0.e2" id="DBMI.pac127.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e3" e2="DBMI.pac127.sp0.e4" id="DBMI.pac127.sp0.p15" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol" precipitant="Verapamil"/>
		<pair e1="DBMI.pac127.sp0.e4" e2="DBMI.pac127.sp0.e0" id="DBMI.pac127.sp0.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e4" e2="DBMI.pac127.sp0.e1" id="DBMI.pac127.sp0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e4" e2="DBMI.pac127.sp0.e2" id="DBMI.pac127.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac127.sp0.e4" e2="DBMI.pac127.sp0.e3" id="DBMI.pac127.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac128" origId="pac128">
	<sentence id="DBMI.pac128.s0" origId="s0" text="Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites.">
		<entity charOffset="0-11" id="DBMI.pac128.s0.e0" origId="s0.e0" text="Propranolol" type="Active ingredient"/>
		<entity charOffset="42-50" id="DBMI.pac128.s0.e1" origId="s0.e1" text="diazepam" type="Active ingredient"/>
		<pair e1="DBMI.pac128.s0.e0" e2="DBMI.pac128.s0.e1" id="DBMI.pac128.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam" precipitant="Propranolol"/>
		<pair e1="DBMI.pac128.s0.e1" e2="DBMI.pac128.s0.e0" id="DBMI.pac128.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac128.s1" origId="s1" text="Diazepam does not alter the pharmacokinetics of propranolol.">
		<entity charOffset="123-131" id="DBMI.pac128.s1.e0" origId="s1.e0" text="Diazepam" type="Active ingredient"/>
		<entity charOffset="171-182" id="DBMI.pac128.s1.e1" origId="s1.e1" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac128.s1.e0" e2="DBMI.pac128.s1.e1" id="DBMI.pac128.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol" precipitant="Diazepam"/>
		<pair e1="DBMI.pac128.s1.e1" e2="DBMI.pac128.s1.e0" id="DBMI.pac128.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac128.sp0" origId="sp0" text="Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol.">
		<entity charOffset="0-11" id="DBMI.pac128.sp0.e0" origId="sp0.e0" text="Propranolol" type="Active ingredient"/>
		<entity charOffset="42-50" id="DBMI.pac128.sp0.e1" origId="sp0.e1" text="diazepam" type="Active ingredient"/>
		<entity charOffset="123-131" id="DBMI.pac128.sp0.e2" origId="sp0.e2" text="Diazepam" type="Active ingredient"/>
		<entity charOffset="171-182" id="DBMI.pac128.sp0.e3" origId="sp0.e3" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac128.sp0.e0" e2="DBMI.pac128.sp0.e1" id="DBMI.pac128.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam" precipitant="Propranolol"/>
		<pair e1="DBMI.pac128.sp0.e0" e2="DBMI.pac128.sp0.e2" id="DBMI.pac128.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e0" e2="DBMI.pac128.sp0.e3" id="DBMI.pac128.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e1" e2="DBMI.pac128.sp0.e0" id="DBMI.pac128.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e1" e2="DBMI.pac128.sp0.e2" id="DBMI.pac128.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e1" e2="DBMI.pac128.sp0.e3" id="DBMI.pac128.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e2" e2="DBMI.pac128.sp0.e0" id="DBMI.pac128.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e2" e2="DBMI.pac128.sp0.e1" id="DBMI.pac128.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e2" e2="DBMI.pac128.sp0.e3" id="DBMI.pac128.sp0.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol" precipitant="Diazepam"/>
		<pair e1="DBMI.pac128.sp0.e3" e2="DBMI.pac128.sp0.e0" id="DBMI.pac128.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e3" e2="DBMI.pac128.sp0.e1" id="DBMI.pac128.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac128.sp0.e3" e2="DBMI.pac128.sp0.e2" id="DBMI.pac128.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac129" origId="pac129">
	<sentence id="DBMI.pac129.s0" origId="s0" text="Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively.">
		<entity charOffset="38-48" id="DBMI.pac129.s0.e0" origId="s0.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="21-32" id="DBMI.pac129.s0.e1" origId="s0.e1" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac129.s0.e0" e2="DBMI.pac129.s0.e1" id="DBMI.pac129.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol" precipitant="cimetidine"/>
		<pair e1="DBMI.pac129.s0.e1" e2="DBMI.pac129.s0.e0" id="DBMI.pac129.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac129.s1" origId="s1" text="Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.">
		<entity charOffset="171-189" id="DBMI.pac129.s1.e0" origId="s1.e0" text="aluminum hydroxide" type="Active ingredient"/>
		<entity charOffset="232-243" id="DBMI.pac129.s1.e1" origId="s1.e1" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac129.s1.e0" e2="DBMI.pac129.s1.e1" id="DBMI.pac129.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol" precipitant="aluminum hydroxide"/>
		<pair e1="DBMI.pac129.s1.e1" e2="DBMI.pac129.s1.e0" id="DBMI.pac129.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac129.sp0" origId="sp0" text="Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively. Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.">
		<entity charOffset="171-189" id="DBMI.pac129.sp0.e0" origId="sp0.e0" text="aluminum hydroxide" type="Active ingredient"/>
		<entity charOffset="232-243" id="DBMI.pac129.sp0.e1" origId="sp0.e1" text="propranolol" type="Active ingredient"/>
		<entity charOffset="38-48" id="DBMI.pac129.sp0.e2" origId="sp0.e2" text="cimetidine" type="Active ingredient"/>
		<pair e1="DBMI.pac129.sp0.e0" e2="DBMI.pac129.sp0.e1" id="DBMI.pac129.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol" precipitant="aluminum hydroxide"/>
		<pair e1="DBMI.pac129.sp0.e0" e2="DBMI.pac129.sp0.e2" id="DBMI.pac129.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac129.sp0.e1" e2="DBMI.pac129.sp0.e0" id="DBMI.pac129.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac129.sp0.e1" e2="DBMI.pac129.sp0.e2" id="DBMI.pac129.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac129.sp0.e2" e2="DBMI.pac129.sp0.e0" id="DBMI.pac129.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac129.sp0.e2" e2="DBMI.pac129.sp0.e1" id="DBMI.pac129.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol" precipitant="cimetidine"/>
	</sentencespan>
</document>

<document id="DBMI.pac13" origId="pac13">
	<sentence id="DBMI.pac13.s0" origId="s0" text="In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium.">
		<entity charOffset="87-97" id="DBMI.pac13.s0.e0" origId="s0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="139-146" id="DBMI.pac13.s0.e1" origId="s0.e1" text="lithium" type="Active ingredient"/>
		<pair e1="DBMI.pac13.s0.e0" e2="DBMI.pac13.s0.e1" id="DBMI.pac13.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium" precipitant="sertraline"/>
		<pair e1="DBMI.pac13.s0.e1" e2="DBMI.pac13.s0.e0" id="DBMI.pac13.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac130" origId="pac130">
	<sentence id="DBMI.pac130.s0" origId="s0" text="Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolols pharmacokinetics.">
		<entity charOffset="21-35" id="DBMI.pac130.s0.e0" origId="s0.e0" text="metoclopramide" type="Active ingredient"/>
		<entity charOffset="57-68" id="DBMI.pac130.s0.e1" origId="s0.e1" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac130.s0.e0" e2="DBMI.pac130.s0.e1" id="DBMI.pac130.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol" precipitant="metoclopramide"/>
		<pair e1="DBMI.pac130.s0.e1" e2="DBMI.pac130.s0.e0" id="DBMI.pac130.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac131" origId="pac131">
	<sentence id="DBMI.pac131.s0" origId="s0" text="Co-administration of cholestyramine or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.">
		<entity charOffset="21-35" id="DBMI.pac131.s0.e0" origId="s0.e0" text="cholestyramine" type="Active ingredient"/>
		<entity charOffset="55-66" id="DBMI.pac131.s0.e1" origId="s0.e1" text="propranolol" type="Active ingredient"/>
		<entity charOffset="39-49" id="DBMI.pac131.s0.e2" origId="s0.e2" text="colestipol" type="Active ingredient"/>
		<pair e1="DBMI.pac131.s0.e0" e2="DBMI.pac131.s0.e1" id="DBMI.pac131.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol" precipitant="cholestyramine"/>
		<pair e1="DBMI.pac131.s0.e0" e2="DBMI.pac131.s0.e2" id="DBMI.pac131.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.s0.e1" e2="DBMI.pac131.s0.e0" id="DBMI.pac131.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.s0.e1" e2="DBMI.pac131.s0.e2" id="DBMI.pac131.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.s0.e2" e2="DBMI.pac131.s0.e0" id="DBMI.pac131.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac131.s0.e2" e2="DBMI.pac131.s0.e1" id="DBMI.pac131.s0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol" precipitant="colestipol"/>
	</sentence>
</document>

<document id="DBMI.pac132" origId="pac132">
	<sentence id="DBMI.pac132.s0" origId="s0" text="Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics.">
		<entity charOffset="21-32" id="DBMI.pac132.s0.e0" origId="s0.e0" text="propranolol" type="Active ingredient"/>
		<entity charOffset="38-48" id="DBMI.pac132.s0.e1" origId="s0.e1" text="lovastatin" type="Active ingredient"/>
		<entity charOffset="52-63" id="DBMI.pac132.s0.e2" origId="s0.e2" text="pravastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac132.s0.e0" e2="DBMI.pac132.s0.e1" id="DBMI.pac132.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="lovastatin" precipitant="propranolol"/>
		<pair e1="DBMI.pac132.s0.e0" e2="DBMI.pac132.s0.e2" id="DBMI.pac132.s0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pravastatin" precipitant="propranolol"/>
		<pair e1="DBMI.pac132.s0.e1" e2="DBMI.pac132.s0.e0" id="DBMI.pac132.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.s0.e1" e2="DBMI.pac132.s0.e2" id="DBMI.pac132.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.s0.e2" e2="DBMI.pac132.s0.e0" id="DBMI.pac132.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.s0.e2" e2="DBMI.pac132.s0.e1" id="DBMI.pac132.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac132.s1" origId="s1" text="Propranolol did not have an effect on the pharmacokinetics of fluvastatin.">
		<entity charOffset="145-156" id="DBMI.pac132.s1.e0" origId="s1.e0" text="Propranolol" type="Active ingredient"/>
		<entity charOffset="207-218" id="DBMI.pac132.s1.e1" origId="s1.e1" text="fluvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac132.s1.e0" e2="DBMI.pac132.s1.e1" id="DBMI.pac132.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin" precipitant="Propranolol"/>
		<pair e1="DBMI.pac132.s1.e1" e2="DBMI.pac132.s1.e0" id="DBMI.pac132.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac132.sp0" origId="sp0" text="Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Propranolol did not have an effect on the pharmacokinetics of fluvastatin.">
		<entity charOffset="145-156" id="DBMI.pac132.sp0.e0" origId="sp0.e0" text="Propranolol" type="Active ingredient"/>
		<entity charOffset="207-218" id="DBMI.pac132.sp0.e1" origId="sp0.e1" text="fluvastatin" type="Active ingredient"/>
		<entity charOffset="21-32" id="DBMI.pac132.sp0.e2" origId="sp0.e2" text="propranolol" type="Active ingredient"/>
		<entity charOffset="38-48" id="DBMI.pac132.sp0.e3" origId="sp0.e3" text="lovastatin" type="Active ingredient"/>
		<entity charOffset="52-63" id="DBMI.pac132.sp0.e4" origId="sp0.e4" text="pravastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac132.sp0.e0" e2="DBMI.pac132.sp0.e1" id="DBMI.pac132.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="fluvastatin" precipitant="Propranolol"/>
		<pair e1="DBMI.pac132.sp0.e0" e2="DBMI.pac132.sp0.e2" id="DBMI.pac132.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e0" e2="DBMI.pac132.sp0.e3" id="DBMI.pac132.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e0" e2="DBMI.pac132.sp0.e4" id="DBMI.pac132.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e1" e2="DBMI.pac132.sp0.e0" id="DBMI.pac132.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e1" e2="DBMI.pac132.sp0.e2" id="DBMI.pac132.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e1" e2="DBMI.pac132.sp0.e3" id="DBMI.pac132.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e1" e2="DBMI.pac132.sp0.e4" id="DBMI.pac132.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e2" e2="DBMI.pac132.sp0.e0" id="DBMI.pac132.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e2" e2="DBMI.pac132.sp0.e1" id="DBMI.pac132.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e2" e2="DBMI.pac132.sp0.e3" id="DBMI.pac132.sp0.p10" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="lovastatin" precipitant="propranolol"/>
		<pair e1="DBMI.pac132.sp0.e2" e2="DBMI.pac132.sp0.e4" id="DBMI.pac132.sp0.p11" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pravastatin" precipitant="propranolol"/>
		<pair e1="DBMI.pac132.sp0.e3" e2="DBMI.pac132.sp0.e0" id="DBMI.pac132.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e3" e2="DBMI.pac132.sp0.e1" id="DBMI.pac132.sp0.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e3" e2="DBMI.pac132.sp0.e2" id="DBMI.pac132.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e3" e2="DBMI.pac132.sp0.e4" id="DBMI.pac132.sp0.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e4" e2="DBMI.pac132.sp0.e0" id="DBMI.pac132.sp0.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e4" e2="DBMI.pac132.sp0.e1" id="DBMI.pac132.sp0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e4" e2="DBMI.pac132.sp0.e2" id="DBMI.pac132.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac132.sp0.e4" e2="DBMI.pac132.sp0.e3" id="DBMI.pac132.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac133" origId="pac133">
	<sentence id="DBMI.pac133.s0" origId="s0" text="Co-administration of long-acting propranolol at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.">
		<entity charOffset="33-44" id="DBMI.pac133.s0.e0" origId="s0.e0" text="propranolol" type="Active ingredient"/>
		<entity charOffset="112-124" id="DBMI.pac133.s0.e1" origId="s0.e1" text="thioridazine" type="Active ingredient"/>
		<entity charOffset="211-223" id="DBMI.pac133.s0.e2" origId="s0.e2" text="mesoridazine" type="Metabolite"/>
		<pair e1="DBMI.pac133.s0.e0" e2="DBMI.pac133.s0.e1" id="DBMI.pac133.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="thioridazine" precipitant="propranolol"/>
		<pair e1="DBMI.pac133.s0.e0" e2="DBMI.pac133.s0.e2" id="DBMI.pac133.s0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mesoridazine" precipitant="propranolol"/>
		<pair e1="DBMI.pac133.s0.e1" e2="DBMI.pac133.s0.e0" id="DBMI.pac133.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac133.s0.e1" e2="DBMI.pac133.s0.e2" id="DBMI.pac133.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac133.s0.e2" e2="DBMI.pac133.s0.e0" id="DBMI.pac133.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac133.s0.e2" e2="DBMI.pac133.s0.e1" id="DBMI.pac133.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac134" origId="pac134">
	<sentence id="DBMI.pac134.s0" origId="s0" text="Co-administration of chlorpromazine with propranolol resulted in a 70% increase in propranolol plasma level.">
		<entity charOffset="21-35" id="DBMI.pac134.s0.e0" origId="s0.e0" text="chlorpromazine" type="Active ingredient"/>
		<entity charOffset="41-52" id="DBMI.pac134.s0.e1" origId="s0.e1" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac134.s0.e0" e2="DBMI.pac134.s0.e1" id="DBMI.pac134.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="propranolol" precipitant="chlorpromazine"/>
		<pair e1="DBMI.pac134.s0.e1" e2="DBMI.pac134.s0.e0" id="DBMI.pac134.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac136" origId="pac136">
	<sentence id="DBMI.pac136.s0" origId="s0" text="In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.">
		<entity charOffset="194-203" id="DBMI.pac136.s0.e0" origId="s0.e0" text="ritonavir" type="Active ingredient"/>
		<entity charOffset="117-126" id="DBMI.pac136.s0.e1" origId="s0.e1" text="trazodone" type="Active ingredient"/>
		<entity charOffset="209-218" id="DBMI.pac136.s0.e2" origId="s0.e2" text="indinavir" type="Active ingredient"/>
		<pair e1="DBMI.pac136.s0.e0" e2="DBMI.pac136.s0.e1" id="DBMI.pac136.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="trazodone" precipitant="ritonavir"/>
		<pair e1="DBMI.pac136.s0.e0" e2="DBMI.pac136.s0.e2" id="DBMI.pac136.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.s0.e1" e2="DBMI.pac136.s0.e0" id="DBMI.pac136.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.s0.e1" e2="DBMI.pac136.s0.e2" id="DBMI.pac136.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.s0.e2" e2="DBMI.pac136.s0.e0" id="DBMI.pac136.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.s0.e2" e2="DBMI.pac136.s0.e1" id="DBMI.pac136.s0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="trazodone" precipitant="indinavir"/>
	</sentence>
	<sentence id="DBMI.pac136.s1" origId="s1" text="The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects.">
		<entity charOffset="263-272" id="DBMI.pac136.s1.e0" origId="s1.e0" text="ritonavir" type="Active ingredient"/>
		<entity charOffset="347-356" id="DBMI.pac136.s1.e1" origId="s1.e1" text="trazodone" type="Active ingredient"/>
		<pair e1="DBMI.pac136.s1.e0" e2="DBMI.pac136.s1.e1" id="DBMI.pac136.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="trazodone" precipitant="ritonavir"/>
		<pair e1="DBMI.pac136.s1.e1" e2="DBMI.pac136.s1.e0" id="DBMI.pac136.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac136.s2" origId="s2" text="The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%."/>
	<sentence id="DBMI.pac136.s3" origId="s3" text="Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were coadministered."/>
	<sentencespan id="DBMI.pac136.sp0" origId="sp0" text="In vitro drug metabolism studies reveal that trazodone is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and trazodone metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir. The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%.">
		<entity charOffset="194-203" id="DBMI.pac136.sp0.e0" origId="sp0.e0" text="ritonavir" type="Active ingredient"/>
		<entity charOffset="117-126" id="DBMI.pac136.sp0.e1" origId="sp0.e1" text="trazodone" type="Active ingredient"/>
		<entity charOffset="209-218" id="DBMI.pac136.sp0.e2" origId="sp0.e2" text="indinavir" type="Active ingredient"/>
		<pair e1="DBMI.pac136.sp0.e0" e2="DBMI.pac136.sp0.e1" id="DBMI.pac136.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="trazodone" precipitant="ritonavir"/>
		<pair e1="DBMI.pac136.sp0.e0" e2="DBMI.pac136.sp0.e1" id="DBMI.pac136.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="trazodone" precipitant="ritonavir"/>
		<pair e1="DBMI.pac136.sp0.e0" e2="DBMI.pac136.sp0.e2" id="DBMI.pac136.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.sp0.e1" e2="DBMI.pac136.sp0.e0" id="DBMI.pac136.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.sp0.e1" e2="DBMI.pac136.sp0.e2" id="DBMI.pac136.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.sp0.e2" e2="DBMI.pac136.sp0.e0" id="DBMI.pac136.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac136.sp0.e2" e2="DBMI.pac136.sp0.e1" id="DBMI.pac136.sp0.p6" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="trazodone" precipitant="indinavir"/>
	</sentencespan>
	<sentencespan id="DBMI.pac136.sp1" origId="sp1" text="Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were coadministered."/>
</document>

<document id="DBMI.pac137" origId="pac137">
	<sentence id="DBMI.pac137.s0" origId="s0" text="Carbamazepine induces CYP3A4."/>
	<sentence id="DBMI.pac137.s1" origId="s1" text="Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.">
		<entity charOffset="124-137" id="DBMI.pac137.s1.e0" origId="s1.e0" text="carbamazepine" type="Active ingredient"/>
		<entity charOffset="171-180" id="DBMI.pac137.s1.e1" origId="s1.e1" text="trazodone" type="Active ingredient"/>
		<entity charOffset="193-197" id="DBMI.pac137.s1.e2" origId="s1.e2" text="mCPP" type="Metabolite"/>
		<pair e1="DBMI.pac137.s1.e0" e2="DBMI.pac137.s1.e1" id="DBMI.pac137.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="trazodone" precipitant="carbamazepine"/>
		<pair e1="DBMI.pac137.s1.e0" e2="DBMI.pac137.s1.e2" id="DBMI.pac137.s1.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mCPP" precipitant="carbamazepine"/>
		<pair e1="DBMI.pac137.s1.e1" e2="DBMI.pac137.s1.e0" id="DBMI.pac137.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.s1.e1" e2="DBMI.pac137.s1.e2" id="DBMI.pac137.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.s1.e2" e2="DBMI.pac137.s1.e0" id="DBMI.pac137.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.s1.e2" e2="DBMI.pac137.s1.e1" id="DBMI.pac137.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac137.sp0" origId="sp0" text="Carbamazepine induces CYP3A4. Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.">
		<entity charOffset="124-137" id="DBMI.pac137.sp0.e0" origId="sp0.e0" text="carbamazepine" type="Active ingredient"/>
		<entity charOffset="171-180" id="DBMI.pac137.sp0.e1" origId="sp0.e1" text="trazodone" type="Active ingredient"/>
		<entity charOffset="193-197" id="DBMI.pac137.sp0.e2" origId="sp0.e2" text="mCPP" type="Metabolite"/>
		<pair e1="DBMI.pac137.sp0.e0" e2="DBMI.pac137.sp0.e1" id="DBMI.pac137.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="trazodone" precipitant="carbamazepine"/>
		<pair e1="DBMI.pac137.sp0.e0" e2="DBMI.pac137.sp0.e2" id="DBMI.pac137.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mCPP" precipitant="carbamazepine"/>
		<pair e1="DBMI.pac137.sp0.e1" e2="DBMI.pac137.sp0.e0" id="DBMI.pac137.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.sp0.e1" e2="DBMI.pac137.sp0.e2" id="DBMI.pac137.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.sp0.e2" e2="DBMI.pac137.sp0.e0" id="DBMI.pac137.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac137.sp0.e2" e2="DBMI.pac137.sp0.e1" id="DBMI.pac137.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac139" origId="pac139">
	<sentence id="DBMI.pac139.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 Antacids\n\nFexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids."/>
	<sentence id="DBMI.pac139.s1" origId="s1" text="In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2  60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox1) decreased fexofenadine AUC by 41% and Cmax by 43%.">
		<entity charOffset="273-281" id="DBMI.pac139.s1.e0" origId="s1.e0" text="aluminum" type="Active ingredient"/>
		<entity charOffset="202-214" id="DBMI.pac139.s1.e1" origId="s1.e1" text="fexofenadine" type="Active ingredient"/>
		<entity charOffset="286-295" id="DBMI.pac139.s1.e2" origId="s1.e2" text="magnesium" type="Active ingredient"/>
		<pair e1="DBMI.pac139.s1.e0" e2="DBMI.pac139.s1.e1" id="DBMI.pac139.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fexofenadine" precipitant="aluminum"/>
		<pair e1="DBMI.pac139.s1.e0" e2="DBMI.pac139.s1.e2" id="DBMI.pac139.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s1.e1" e2="DBMI.pac139.s1.e0" id="DBMI.pac139.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s1.e1" e2="DBMI.pac139.s1.e2" id="DBMI.pac139.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s1.e2" e2="DBMI.pac139.s1.e0" id="DBMI.pac139.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s1.e2" e2="DBMI.pac139.s1.e1" id="DBMI.pac139.s1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fexofenadine" precipitant="magnesium"/>
	</sentence>
	<sentence id="DBMI.pac139.s2" origId="s2" text="1 Maalox is a registered trademark of Novartis Consumer Healthcare."/>
	<sentence id="DBMI.pac139.s3" origId="s3" text="7.2 Erythromycin and Ketoconazole\n\nFexofenadine has been shown to exhibit minimal (ca."/>
	<sentence id="DBMI.pac139.s4" origId="s4" text="5%) metabolism."/>
	<sentence id="DBMI.pac139.s5" origId="s5" text="However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.">
		<entity charOffset="619-631" id="DBMI.pac139.s5.e0" origId="s5.e0" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="690-702" id="DBMI.pac139.s5.e1" origId="s5.e1" text="fexofenadine" type="Active ingredient"/>
		<entity charOffset="635-647" id="DBMI.pac139.s5.e2" origId="s5.e2" text="erythromycin" type="Active ingredient"/>
		<pair e1="DBMI.pac139.s5.e0" e2="DBMI.pac139.s5.e1" id="DBMI.pac139.s5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="ketoconazole"/>
		<pair e1="DBMI.pac139.s5.e0" e2="DBMI.pac139.s5.e2" id="DBMI.pac139.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s5.e1" e2="DBMI.pac139.s5.e0" id="DBMI.pac139.s5.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s5.e1" e2="DBMI.pac139.s5.e2" id="DBMI.pac139.s5.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s5.e2" e2="DBMI.pac139.s5.e0" id="DBMI.pac139.s5.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s5.e2" e2="DBMI.pac139.s5.e1" id="DBMI.pac139.s5.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="erythromycin"/>
		<pair e1="DBMI.pac139.s5.e2" e2="DBMI.pac139.s5.e1" id="DBMI.pac139.s5.p6" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="erythromycin"/>
	</sentence>
	<sentence id="DBMI.pac139.s6" origId="s6" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.">
		<entity charOffset="730-742" id="DBMI.pac139.s6.e0" origId="s6.e0" text="Fexofenadine" type="Active ingredient"/>
		<entity charOffset="791-803" id="DBMI.pac139.s6.e1" origId="s6.e1" text="erythromycin" type="Active ingredient"/>
		<entity charOffset="807-819" id="DBMI.pac139.s6.e2" origId="s6.e2" text="ketoconazole" type="Active ingredient"/>
		<pair e1="DBMI.pac139.s6.e0" e2="DBMI.pac139.s6.e1" id="DBMI.pac139.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin" precipitant="Fexofenadine"/>
		<pair e1="DBMI.pac139.s6.e0" e2="DBMI.pac139.s6.e2" id="DBMI.pac139.s6.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ketoconazole" precipitant="Fexofenadine"/>
		<pair e1="DBMI.pac139.s6.e1" e2="DBMI.pac139.s6.e0" id="DBMI.pac139.s6.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s6.e1" e2="DBMI.pac139.s6.e2" id="DBMI.pac139.s6.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s6.e2" e2="DBMI.pac139.s6.e0" id="DBMI.pac139.s6.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s6.e2" e2="DBMI.pac139.s6.e1" id="DBMI.pac139.s6.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac139.s7" origId="s7" text="In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study)."/>
	<sentence id="DBMI.pac139.s8" origId="s8" text="No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole."/>
	<sentence id="DBMI.pac139.s9" origId="s9" text="The findings of these studies are summarized in the following table:\n\nThe changes in plasma levels were within the range of plasma levels achieved in adequate and well controlled clinical trials."/>
	<sentence id="DBMI.pac139.s10" origId="s10" text="The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models."/>
	<sentence id="DBMI.pac139.s11" origId="s11" text="These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.">
		<entity charOffset="1638-1650" id="DBMI.pac139.s11.e0" origId="s11.e0" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="1693-1705" id="DBMI.pac139.s11.e1" origId="s11.e1" text="fexofenadine" type="Active ingredient"/>
		<entity charOffset="1654-1666" id="DBMI.pac139.s11.e2" origId="s11.e2" text="erythromycin" type="Active ingredient"/>
		<pair e1="DBMI.pac139.s11.e0" e2="DBMI.pac139.s11.e1" id="DBMI.pac139.s11.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="ketoconazole"/>
		<pair e1="DBMI.pac139.s11.e0" e2="DBMI.pac139.s11.e2" id="DBMI.pac139.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s11.e1" e2="DBMI.pac139.s11.e0" id="DBMI.pac139.s11.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s11.e1" e2="DBMI.pac139.s11.e2" id="DBMI.pac139.s11.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s11.e2" e2="DBMI.pac139.s11.e0" id="DBMI.pac139.s11.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.s11.e2" e2="DBMI.pac139.s11.e1" id="DBMI.pac139.s11.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="erythromycin"/>
	</sentence>
	<sentence id="DBMI.pac139.s12" origId="s12" text="This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein."/>
	<sentence id="DBMI.pac139.s13" origId="s13" text="In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion."/>
	<sentence id="DBMI.pac139.s14" origId="s14" text="7.3 Fruit Juices\n\nFruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine."/>
	<sentence id="DBMI.pac139.s15" origId="s15" text="This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis."/>
	<sentence id="DBMI.pac139.s16" origId="s16" text="The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water."/>
	<sentence id="DBMI.pac139.s17" origId="s17" text="Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice."/>
	<sentence id="DBMI.pac139.s18" origId="s18" text="The clinical significance of these observations is unknown."/>
	<sentence id="DBMI.pac139.s19" origId="s19" text="In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%."/>
	<sentence id="DBMI.pac139.s20" origId="s20" text="Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)]."/>
	<sentencespan id="DBMI.pac139.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 Antacids\n\nFexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids. In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2  60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox1) decreased fexofenadine AUC by 41% and Cmax by 43%. 1 Maalox is a registered trademark of Novartis Consumer Healthcare.">
		<entity charOffset="273-281" id="DBMI.pac139.sp0.e0" origId="sp0.e0" text="aluminum" type="Active ingredient"/>
		<entity charOffset="202-214" id="DBMI.pac139.sp0.e1" origId="sp0.e1" text="fexofenadine" type="Active ingredient"/>
		<entity charOffset="286-295" id="DBMI.pac139.sp0.e2" origId="sp0.e2" text="magnesium" type="Active ingredient"/>
		<pair e1="DBMI.pac139.sp0.e0" e2="DBMI.pac139.sp0.e1" id="DBMI.pac139.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fexofenadine" precipitant="aluminum"/>
		<pair e1="DBMI.pac139.sp0.e0" e2="DBMI.pac139.sp0.e2" id="DBMI.pac139.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp0.e1" e2="DBMI.pac139.sp0.e0" id="DBMI.pac139.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp0.e1" e2="DBMI.pac139.sp0.e2" id="DBMI.pac139.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp0.e2" e2="DBMI.pac139.sp0.e0" id="DBMI.pac139.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp0.e2" e2="DBMI.pac139.sp0.e1" id="DBMI.pac139.sp0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="fexofenadine" precipitant="magnesium"/>
	</sentencespan>
	<sentencespan id="DBMI.pac139.sp1" origId="sp1" text="7.2 Erythromycin and Ketoconazole\n\nFexofenadine has been shown to exhibit minimal (ca. 5%) metabolism. However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.">
		<entity charOffset="619-631" id="DBMI.pac139.sp1.e0" origId="sp1.e0" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="690-702" id="DBMI.pac139.sp1.e1" origId="sp1.e1" text="fexofenadine" type="Active ingredient"/>
		<entity charOffset="635-647" id="DBMI.pac139.sp1.e2" origId="sp1.e2" text="erythromycin" type="Active ingredient"/>
		<pair e1="DBMI.pac139.sp1.e0" e2="DBMI.pac139.sp1.e1" id="DBMI.pac139.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="ketoconazole"/>
		<pair e1="DBMI.pac139.sp1.e0" e2="DBMI.pac139.sp1.e2" id="DBMI.pac139.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp1.e1" e2="DBMI.pac139.sp1.e0" id="DBMI.pac139.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp1.e1" e2="DBMI.pac139.sp1.e2" id="DBMI.pac139.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp1.e2" e2="DBMI.pac139.sp1.e0" id="DBMI.pac139.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp1.e2" e2="DBMI.pac139.sp1.e1" id="DBMI.pac139.sp1.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="erythromycin"/>
		<pair e1="DBMI.pac139.sp1.e2" e2="DBMI.pac139.sp1.e1" id="DBMI.pac139.sp1.p6" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="erythromycin"/>
	</sentencespan>
	<sentencespan id="DBMI.pac139.sp2" origId="sp2" text="Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study). No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.">
		<entity charOffset="730-742" id="DBMI.pac139.sp2.e0" origId="sp2.e0" text="Fexofenadine" type="Active ingredient"/>
		<entity charOffset="791-803" id="DBMI.pac139.sp2.e1" origId="sp2.e1" text="erythromycin" type="Active ingredient"/>
		<entity charOffset="807-819" id="DBMI.pac139.sp2.e2" origId="sp2.e2" text="ketoconazole" type="Active ingredient"/>
		<pair e1="DBMI.pac139.sp2.e0" e2="DBMI.pac139.sp2.e1" id="DBMI.pac139.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin" precipitant="Fexofenadine"/>
		<pair e1="DBMI.pac139.sp2.e0" e2="DBMI.pac139.sp2.e2" id="DBMI.pac139.sp2.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ketoconazole" precipitant="Fexofenadine"/>
		<pair e1="DBMI.pac139.sp2.e1" e2="DBMI.pac139.sp2.e0" id="DBMI.pac139.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp2.e1" e2="DBMI.pac139.sp2.e2" id="DBMI.pac139.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp2.e2" e2="DBMI.pac139.sp2.e0" id="DBMI.pac139.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp2.e2" e2="DBMI.pac139.sp2.e1" id="DBMI.pac139.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac139.sp3" origId="sp3" text="The findings of these studies are summarized in the following table:\n\nThe changes in plasma levels were within the range of plasma levels achieved in adequate and well controlled clinical trials. The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models. These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.">
		<entity charOffset="1638-1650" id="DBMI.pac139.sp3.e0" origId="sp3.e0" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="1693-1705" id="DBMI.pac139.sp3.e1" origId="sp3.e1" text="fexofenadine" type="Active ingredient"/>
		<entity charOffset="1654-1666" id="DBMI.pac139.sp3.e2" origId="sp3.e2" text="erythromycin" type="Active ingredient"/>
		<pair e1="DBMI.pac139.sp3.e0" e2="DBMI.pac139.sp3.e1" id="DBMI.pac139.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="ketoconazole"/>
		<pair e1="DBMI.pac139.sp3.e0" e2="DBMI.pac139.sp3.e2" id="DBMI.pac139.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp3.e1" e2="DBMI.pac139.sp3.e0" id="DBMI.pac139.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp3.e1" e2="DBMI.pac139.sp3.e2" id="DBMI.pac139.sp3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp3.e2" e2="DBMI.pac139.sp3.e0" id="DBMI.pac139.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac139.sp3.e2" e2="DBMI.pac139.sp3.e1" id="DBMI.pac139.sp3.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="fexofenadine" precipitant="erythromycin"/>
	</sentencespan>
	<sentencespan id="DBMI.pac139.sp4" origId="sp4" text="This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion. 7.3 Fruit Juices\n\nFruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine."/>
	<sentencespan id="DBMI.pac139.sp5" origId="sp5" text="This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis. The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water. Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice."/>
	<sentencespan id="DBMI.pac139.sp6" origId="sp6" text="The clinical significance of these observations is unknown. In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%. Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)]."/>
</document>

<document id="DBMI.pac14" origId="pac14">
	<sentence id="DBMI.pac14.s0" origId="s0" text="In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%, but was not associated with any changes in EKG.">
		<entity charOffset="66-76" id="DBMI.pac14.s0.e0" origId="s0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="49-57" id="DBMI.pac14.s0.e1" origId="s0.e1" text="pimozide" type="Active ingredient"/>
		<pair e1="DBMI.pac14.s0.e0" e2="DBMI.pac14.s0.e1" id="DBMI.pac14.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pimozide" precipitant="sertraline"/>
		<pair e1="DBMI.pac14.s0.e1" e2="DBMI.pac14.s0.e0" id="DBMI.pac14.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac14.s1" origId="s1" text="Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known."/>
	<sentence id="DBMI.pac14.s2" origId="s2" text="While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline and pimozide should be contraindicated (see CONTRAINDICATIONS)."/>
	<sentencespan id="DBMI.pac14.sp0" origId="sp0" text="In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-adminis-tration to steady state was associated with a mean increase in pimozide AUC and C max of about 40%, but was not associated with any changes in EKG. Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline and pimozide should be contraindicated (see CONTRAINDICATIONS).">
		<entity charOffset="66-76" id="DBMI.pac14.sp0.e0" origId="sp0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="49-57" id="DBMI.pac14.sp0.e1" origId="sp0.e1" text="pimozide" type="Active ingredient"/>
		<pair e1="DBMI.pac14.sp0.e0" e2="DBMI.pac14.sp0.e1" id="DBMI.pac14.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="pimozide" precipitant="sertraline"/>
		<pair e1="DBMI.pac14.sp0.e1" e2="DBMI.pac14.sp0.e0" id="DBMI.pac14.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac141" origId="pac141">
	<sentence id="DBMI.pac141.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 In Vitro Data\n\nIn vitro data indicate that amlodipine besylate has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin."/>
	<sentence id="DBMI.pac141.s1" origId="s1" text="7.2 Cimetidine\n\nCoadministration of amlodipine besylate with cimetidine did not alter the pharmacokinetics of amlodipine besylate.">
		<entity charOffset="251-261" id="DBMI.pac141.s1.e0" origId="s1.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="226-236" id="DBMI.pac141.s1.e1" origId="s1.e1" text="amlodipine" type="Active ingredient"/>
		<pair e1="DBMI.pac141.s1.e0" e2="DBMI.pac141.s1.e1" id="DBMI.pac141.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine" precipitant="cimetidine"/>
		<pair e1="DBMI.pac141.s1.e1" e2="DBMI.pac141.s1.e0" id="DBMI.pac141.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s2" origId="s2" text="7.3 Grapefruit Juice\n\nCoadministration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine."/>
	<sentence id="DBMI.pac141.s3" origId="s3" text="7.4 Magnesium and Aluminum Hydroxide Antacid\n\nCoadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate.">
		<entity charOffset="594-603" id="DBMI.pac141.s3.e0" origId="s3.e0" text="magnesium" type="Active ingredient"/>
		<entity charOffset="657-667" id="DBMI.pac141.s3.e1" origId="s3.e1" text="amlodipine" type="Active ingredient"/>
		<entity charOffset="608-616" id="DBMI.pac141.s3.e2" origId="s3.e2" text="aluminum" type="Active ingredient"/>
		<pair e1="DBMI.pac141.s3.e0" e2="DBMI.pac141.s3.e1" id="DBMI.pac141.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine" precipitant="magnesium"/>
		<pair e1="DBMI.pac141.s3.e0" e2="DBMI.pac141.s3.e2" id="DBMI.pac141.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.s3.e1" e2="DBMI.pac141.s3.e0" id="DBMI.pac141.s3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.s3.e1" e2="DBMI.pac141.s3.e2" id="DBMI.pac141.s3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.s3.e2" e2="DBMI.pac141.s3.e0" id="DBMI.pac141.s3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.s3.e2" e2="DBMI.pac141.s3.e1" id="DBMI.pac141.s3.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine" precipitant="aluminum"/>
	</sentence>
	<sentence id="DBMI.pac141.s4" origId="s4" text="7.5 Sildenafil\n\nA single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine besylate.">
		<entity charOffset="792-802" id="DBMI.pac141.s4.e0" origId="s4.e0" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="894-904" id="DBMI.pac141.s4.e1" origId="s4.e1" text="amlodipine" type="Active ingredient"/>
		<pair e1="DBMI.pac141.s4.e0" e2="DBMI.pac141.s4.e1" id="DBMI.pac141.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine" precipitant="sildenafil"/>
		<pair e1="DBMI.pac141.s4.e1" e2="DBMI.pac141.s4.e0" id="DBMI.pac141.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s5" origId="s5" text="When amlodipine besylate and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect."/>
	<sentence id="DBMI.pac141.s6" origId="s6" text="7.6 Atorvastatin\n\nCoadministration of multiple 10 mg doses of amlodipine besylate with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.">
		<entity charOffset="1117-1127" id="DBMI.pac141.s6.e0" origId="s6.e0" text="amlodipine" type="Active ingredient"/>
		<entity charOffset="1151-1163" id="DBMI.pac141.s6.e1" origId="s6.e1" text="atorvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac141.s6.e0" e2="DBMI.pac141.s6.e1" id="DBMI.pac141.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin" precipitant="amlodipine"/>
		<pair e1="DBMI.pac141.s6.e1" e2="DBMI.pac141.s6.e0" id="DBMI.pac141.s6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s7" origId="s7" text="7.7 Digoxin\n\nCoadministration of amlodipine besylate with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.">
		<entity charOffset="1296-1306" id="DBMI.pac141.s7.e0" origId="s7.e0" text="amlodipine" type="Active ingredient"/>
		<entity charOffset="1321-1328" id="DBMI.pac141.s7.e1" origId="s7.e1" text="digoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac141.s7.e0" e2="DBMI.pac141.s7.e1" id="DBMI.pac141.s7.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin" precipitant="amlodipine"/>
		<pair e1="DBMI.pac141.s7.e1" e2="DBMI.pac141.s7.e0" id="DBMI.pac141.s7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s8" origId="s8" text="7.8 Ethanol (Alcohol)\n\nSingle and multiple 10 mg doses of amlodipine besylate had no significant effect on the pharmacokinetics of ethanol.">
		<entity charOffset="1473-1483" id="DBMI.pac141.s8.e0" origId="s8.e0" text="amlodipine" type="Active ingredient"/>
		<entity charOffset="1546-1553" id="DBMI.pac141.s8.e1" origId="s8.e1" text="ethanol" type="Active ingredient"/>
		<pair e1="DBMI.pac141.s8.e0" e2="DBMI.pac141.s8.e1" id="DBMI.pac141.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethanol" precipitant="amlodipine"/>
		<pair e1="DBMI.pac141.s8.e1" e2="DBMI.pac141.s8.e0" id="DBMI.pac141.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s9" origId="s9" text="7.9 Warfarin\n\nCoadministration of amlodipine besylate with warfarin did not change the warfarin prothrombin response time.">
		<entity charOffset="1590-1600" id="DBMI.pac141.s9.e0" origId="s9.e0" text="amlodipine" type="Active ingredient"/>
		<entity charOffset="1615-1623" id="DBMI.pac141.s9.e1" origId="s9.e1" text="warfarin" type="Active ingredient"/>
		<pair e1="DBMI.pac141.s9.e0" e2="DBMI.pac141.s9.e1" id="DBMI.pac141.s9.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="amlodipine"/>
		<pair e1="DBMI.pac141.s9.e1" e2="DBMI.pac141.s9.e0" id="DBMI.pac141.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac141.s10" origId="s10" text="7.10 Drug/Laboratory Test Interactions\n\nNone known."/>
	<sentencespan id="DBMI.pac141.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 In Vitro Data\n\nIn vitro data indicate that amlodipine besylate has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin. 7.2 Cimetidine\n\nCoadministration of amlodipine besylate with cimetidine did not alter the pharmacokinetics of amlodipine besylate. 7.3 Grapefruit Juice\n\nCoadministration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.">
		<entity charOffset="251-261" id="DBMI.pac141.sp0.e0" origId="sp0.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="226-236" id="DBMI.pac141.sp0.e1" origId="sp0.e1" text="amlodipine" type="Active ingredient"/>
		<pair e1="DBMI.pac141.sp0.e0" e2="DBMI.pac141.sp0.e1" id="DBMI.pac141.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine" precipitant="cimetidine"/>
		<pair e1="DBMI.pac141.sp0.e1" e2="DBMI.pac141.sp0.e0" id="DBMI.pac141.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac141.sp1" origId="sp1" text="7.4 Magnesium and Aluminum Hydroxide Antacid\n\nCoadministration of a magnesium and aluminum hydroxide antacid with a single dose of amlodipine besylate had no significant effect on the pharmacokinetics of amlodipine besylate. 7.5 Sildenafil\n\nA single 100 mg dose of sildenafil in subjects with essential hypertension had no effect on the pharmacokinetic parameters of amlodipine besylate. When amlodipine besylate and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.">
		<entity charOffset="594-603" id="DBMI.pac141.sp1.e0" origId="sp1.e0" text="magnesium" type="Active ingredient"/>
		<entity charOffset="657-667" id="DBMI.pac141.sp1.e1" origId="sp1.e1" text="amlodipine" type="Active ingredient"/>
		<entity charOffset="608-616" id="DBMI.pac141.sp1.e2" origId="sp1.e2" text="aluminum" type="Active ingredient"/>
		<entity charOffset="792-802" id="DBMI.pac141.sp1.e3" origId="sp1.e3" text="sildenafil" type="Active ingredient"/>
		<pair e1="DBMI.pac141.sp1.e0" e2="DBMI.pac141.sp1.e1" id="DBMI.pac141.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine" precipitant="magnesium"/>
		<pair e1="DBMI.pac141.sp1.e0" e2="DBMI.pac141.sp1.e2" id="DBMI.pac141.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e0" e2="DBMI.pac141.sp1.e3" id="DBMI.pac141.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e1" e2="DBMI.pac141.sp1.e0" id="DBMI.pac141.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e1" e2="DBMI.pac141.sp1.e2" id="DBMI.pac141.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e1" e2="DBMI.pac141.sp1.e3" id="DBMI.pac141.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e2" e2="DBMI.pac141.sp1.e0" id="DBMI.pac141.sp1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e2" e2="DBMI.pac141.sp1.e1" id="DBMI.pac141.sp1.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine" precipitant="aluminum"/>
		<pair e1="DBMI.pac141.sp1.e2" e2="DBMI.pac141.sp1.e3" id="DBMI.pac141.sp1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e3" e2="DBMI.pac141.sp1.e0" id="DBMI.pac141.sp1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp1.e3" e2="DBMI.pac141.sp1.e1" id="DBMI.pac141.sp1.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amlodipine" precipitant="sildenafil"/>
		<pair e1="DBMI.pac141.sp1.e3" e2="DBMI.pac141.sp1.e2" id="DBMI.pac141.sp1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac141.sp2" origId="sp2" text="7.6 Atorvastatin\n\nCoadministration of multiple 10 mg doses of amlodipine besylate with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin. 7.7 Digoxin\n\nCoadministration of amlodipine besylate with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers. 7.8 Ethanol (Alcohol)\n\nSingle and multiple 10 mg doses of amlodipine besylate had no significant effect on the pharmacokinetics of ethanol.">
		<entity charOffset="1117-1127" id="DBMI.pac141.sp2.e0" origId="sp2.e0" text="amlodipine" type="Active ingredient"/>
		<entity charOffset="1151-1163" id="DBMI.pac141.sp2.e1" origId="sp2.e1" text="atorvastatin" type="Active ingredient"/>
		<entity charOffset="1321-1328" id="DBMI.pac141.sp2.e2" origId="sp2.e2" text="digoxin" type="Active ingredient"/>
		<entity charOffset="1546-1553" id="DBMI.pac141.sp2.e3" origId="sp2.e3" text="ethanol" type="Active ingredient"/>
		<pair e1="DBMI.pac141.sp2.e0" e2="DBMI.pac141.sp2.e1" id="DBMI.pac141.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin" precipitant="amlodipine"/>
		<pair e1="DBMI.pac141.sp2.e0" e2="DBMI.pac141.sp2.e2" id="DBMI.pac141.sp2.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin" precipitant="amlodipine"/>
		<pair e1="DBMI.pac141.sp2.e0" e2="DBMI.pac141.sp2.e3" id="DBMI.pac141.sp2.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethanol" precipitant="amlodipine"/>
		<pair e1="DBMI.pac141.sp2.e1" e2="DBMI.pac141.sp2.e0" id="DBMI.pac141.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e1" e2="DBMI.pac141.sp2.e2" id="DBMI.pac141.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e1" e2="DBMI.pac141.sp2.e3" id="DBMI.pac141.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e2" e2="DBMI.pac141.sp2.e0" id="DBMI.pac141.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e2" e2="DBMI.pac141.sp2.e1" id="DBMI.pac141.sp2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e2" e2="DBMI.pac141.sp2.e3" id="DBMI.pac141.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e3" e2="DBMI.pac141.sp2.e0" id="DBMI.pac141.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e3" e2="DBMI.pac141.sp2.e1" id="DBMI.pac141.sp2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac141.sp2.e3" e2="DBMI.pac141.sp2.e2" id="DBMI.pac141.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac141.sp3" origId="sp3" text="7.9 Warfarin\n\nCoadministration of amlodipine besylate with warfarin did not change the warfarin prothrombin response time. 7.10 Drug/Laboratory Test Interactions\n\nNone known.">
		<entity charOffset="1590-1600" id="DBMI.pac141.sp3.e0" origId="sp3.e0" text="amlodipine" type="Active ingredient"/>
		<entity charOffset="1615-1623" id="DBMI.pac141.sp3.e1" origId="sp3.e1" text="warfarin" type="Active ingredient"/>
		<pair e1="DBMI.pac141.sp3.e0" e2="DBMI.pac141.sp3.e1" id="DBMI.pac141.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="amlodipine"/>
		<pair e1="DBMI.pac141.sp3.e1" e2="DBMI.pac141.sp3.e0" id="DBMI.pac141.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac145" origId="pac145">
	<sentence id="DBMI.pac145.s0" origId="s0" text="Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol at steady-state.">
		<entity charOffset="73-82" id="DBMI.pac145.s0.e0" origId="s0.e0" text="valproate" type="Active ingredient"/>
		<entity charOffset="103-111" id="DBMI.pac145.s0.e1" origId="s0.e1" text="Felbatol" type="Drug product"/>
		<pair e1="DBMI.pac145.s0.e0" e2="DBMI.pac145.s0.e1" id="DBMI.pac145.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Felbatol" precipitant="valproate"/>
		<pair e1="DBMI.pac145.s0.e1" e2="DBMI.pac145.s0.e0" id="DBMI.pac145.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac145.s1" origId="s1" text="Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol (felbamate) plasma concentrations.">
		<entity charOffset="157-166" id="DBMI.pac145.s1.e0" origId="s1.e0" text="valproate" type="Active ingredient"/>
		<entity charOffset="236-245" id="DBMI.pac145.s1.e1" origId="s1.e1" text="felbamate" type="Active ingredient"/>
		<pair e1="DBMI.pac145.s1.e0" e2="DBMI.pac145.s1.e1" id="DBMI.pac145.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="felbamate" precipitant="valproate"/>
		<pair e1="DBMI.pac145.s1.e1" e2="DBMI.pac145.s1.e0" id="DBMI.pac145.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac145.sp0" origId="sp0" text="Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol at steady-state. Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol (felbamate) plasma concentrations.">
		<entity charOffset="157-166" id="DBMI.pac145.sp0.e0" origId="sp0.e0" text="valproate" type="Active ingredient"/>
		<entity charOffset="236-245" id="DBMI.pac145.sp0.e1" origId="sp0.e1" text="felbamate" type="Active ingredient"/>
		<entity charOffset="103-111" id="DBMI.pac145.sp0.e2" origId="sp0.e2" text="Felbatol" type="Drug product"/>
		<pair e1="DBMI.pac145.sp0.e0" e2="DBMI.pac145.sp0.e1" id="DBMI.pac145.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="felbamate" precipitant="valproate"/>
		<pair e1="DBMI.pac145.sp0.e0" e2="DBMI.pac145.sp0.e2" id="DBMI.pac145.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="Felbatol" precipitant="valproate"/>
		<pair e1="DBMI.pac145.sp0.e1" e2="DBMI.pac145.sp0.e0" id="DBMI.pac145.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac145.sp0.e1" e2="DBMI.pac145.sp0.e2" id="DBMI.pac145.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac145.sp0.e2" e2="DBMI.pac145.sp0.e0" id="DBMI.pac145.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac145.sp0.e2" e2="DBMI.pac145.sp0.e1" id="DBMI.pac145.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac146" origId="pac146">
	<sentence id="DBMI.pac146.s0" origId="s0" text="Effects of Felbatol on Low-Dose Combination Oral Contraceptives:\nA group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 g ethinyl estradiol and 75 g gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles."/>
	<sentence id="DBMI.pac146.s1" origId="s1" text="Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.">
		<entity charOffset="370-379" id="DBMI.pac146.s1.e0" origId="s1.e0" text="Felbamate" type="Active ingredient"/>
		<entity charOffset="424-433" id="DBMI.pac146.s1.e1" origId="s1.e1" text="gestodene" type="Active ingredient"/>
		<entity charOffset="536-545" id="DBMI.pac146.s1.e2" origId="s1.e2" text="estradiol" type="Active ingredient"/>
		<pair e1="DBMI.pac146.s1.e0" e2="DBMI.pac146.s1.e1" id="DBMI.pac146.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="gestodene" precipitant="Felbamate"/>
		<pair e1="DBMI.pac146.s1.e0" e2="DBMI.pac146.s1.e2" id="DBMI.pac146.s1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="estradiol" precipitant="Felbamate"/>
		<pair e1="DBMI.pac146.s1.e1" e2="DBMI.pac146.s1.e0" id="DBMI.pac146.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.s1.e1" e2="DBMI.pac146.s1.e2" id="DBMI.pac146.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.s1.e2" e2="DBMI.pac146.s1.e0" id="DBMI.pac146.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.s1.e2" e2="DBMI.pac146.s1.e1" id="DBMI.pac146.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac146.s2" origId="s2" text="No volunteer showed hormonal evidence of ovulation, but one volunteer reported intermenstrual bleeding during felbamate treatment."/>
	<sentencespan id="DBMI.pac146.sp0" origId="sp0" text="Effects of Felbatol on Low-Dose Combination Oral Contraceptives:\nA group of 24 nonsmoking, healthy white female volunteers established on an oral contraceptive regimen containing 30 g ethinyl estradiol and 75 g gestodene for at least 3 months received 2400 mg/day of felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles. Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol. No volunteer showed hormonal evidence of ovulation, but one volunteer reported intermenstrual bleeding during felbamate treatment.">
		<entity charOffset="370-379" id="DBMI.pac146.sp0.e0" origId="sp0.e0" text="Felbamate" type="Active ingredient"/>
		<entity charOffset="424-433" id="DBMI.pac146.sp0.e1" origId="sp0.e1" text="gestodene" type="Active ingredient"/>
		<entity charOffset="536-545" id="DBMI.pac146.sp0.e2" origId="sp0.e2" text="estradiol" type="Active ingredient"/>
		<pair e1="DBMI.pac146.sp0.e0" e2="DBMI.pac146.sp0.e1" id="DBMI.pac146.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="gestodene" precipitant="Felbamate"/>
		<pair e1="DBMI.pac146.sp0.e0" e2="DBMI.pac146.sp0.e2" id="DBMI.pac146.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="estradiol" precipitant="Felbamate"/>
		<pair e1="DBMI.pac146.sp0.e1" e2="DBMI.pac146.sp0.e0" id="DBMI.pac146.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.sp0.e1" e2="DBMI.pac146.sp0.e2" id="DBMI.pac146.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.sp0.e2" e2="DBMI.pac146.sp0.e0" id="DBMI.pac146.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac146.sp0.e2" e2="DBMI.pac146.sp0.e1" id="DBMI.pac146.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac147" origId="pac147">
	<sentence id="DBMI.pac147.s0" origId="s0" text="Phenytoin: Felbatol causes an increase in steady-state phenytoin plasma concentrations.">
		<entity charOffset="11-19" id="DBMI.pac147.s0.e0" origId="s0.e0" text="Felbatol" type="Drug product"/>
		<entity charOffset="56-65" id="DBMI.pac147.s0.e1" origId="s0.e1" text="phenytoin" type="Active ingredient"/>
		<pair e1="DBMI.pac147.s0.e0" e2="DBMI.pac147.s0.e1" id="DBMI.pac147.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin" precipitant="Felbatol"/>
		<pair e1="DBMI.pac147.s0.e1" e2="DBMI.pac147.s0.e0" id="DBMI.pac147.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac147.s1" origId="s1" text="In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 175 micrograms/mL."/>
	<sentence id="DBMI.pac147.s2" origId="s2" text="The steady-state Cmin increased to 215 micrograms/mL when 1200 mg/day of felbamate was coadministered."/>
	<sentence id="DBMI.pac147.s3" origId="s3" text="Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 257 micrograms/mL.">
		<entity charOffset="362-371" id="DBMI.pac147.s3.e0" origId="s3.e0" text="felbamate" type="Active ingredient"/>
		<entity charOffset="444-453" id="DBMI.pac147.s3.e1" origId="s3.e1" text="phenytoin" type="Active ingredient"/>
		<pair e1="DBMI.pac147.s3.e0" e2="DBMI.pac147.s3.e1" id="DBMI.pac147.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin" precipitant="felbamate"/>
		<pair e1="DBMI.pac147.s3.e1" e2="DBMI.pac147.s3.e0" id="DBMI.pac147.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac147.s4" origId="s4" text="In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects."/>
	<sentence id="DBMI.pac147.s5" origId="s5" text="In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol therapy resulted in phenytoin levels comparable to those prior to Felbatol administration."/>
	<sentencespan id="DBMI.pac147.sp0" origId="sp0" text="Phenytoin: Felbatol causes an increase in steady-state phenytoin plasma concentrations. In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steady-state trough (Cmin) phenytoin plasma concentration was 175 micrograms/mL. The steady-state Cmin increased to 215 micrograms/mL when 1200 mg/day of felbamate was coadministered.">
		<entity charOffset="11-19" id="DBMI.pac147.sp0.e0" origId="sp0.e0" text="Felbatol" type="Drug product"/>
		<entity charOffset="56-65" id="DBMI.pac147.sp0.e1" origId="sp0.e1" text="phenytoin" type="Active ingredient"/>
		<pair e1="DBMI.pac147.sp0.e0" e2="DBMI.pac147.sp0.e1" id="DBMI.pac147.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin" precipitant="Felbatol"/>
		<pair e1="DBMI.pac147.sp0.e1" e2="DBMI.pac147.sp0.e0" id="DBMI.pac147.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac147.sp1" origId="sp1" text="Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 257 micrograms/mL. In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects. In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol therapy resulted in phenytoin levels comparable to those prior to Felbatol administration.">
		<entity charOffset="362-371" id="DBMI.pac147.sp1.e0" origId="sp1.e0" text="felbamate" type="Active ingredient"/>
		<entity charOffset="444-453" id="DBMI.pac147.sp1.e1" origId="sp1.e1" text="phenytoin" type="Active ingredient"/>
		<pair e1="DBMI.pac147.sp1.e0" e2="DBMI.pac147.sp1.e1" id="DBMI.pac147.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenytoin" precipitant="felbamate"/>
		<pair e1="DBMI.pac147.sp1.e1" e2="DBMI.pac147.sp1.e0" id="DBMI.pac147.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac148" origId="pac148">
	<sentence id="DBMI.pac148.s0" origId="s0" text="Carbamazepine: Felbatol causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.">
		<entity charOffset="15-23" id="DBMI.pac148.s0.e0" origId="s0.e0" text="Felbatol" type="Drug product"/>
		<entity charOffset="63-76" id="DBMI.pac148.s0.e1" origId="s0.e1" text="carbamazepine" type="Active ingredient"/>
		<entity charOffset="135-156" id="DBMI.pac148.s0.e2" origId="s0.e2" text="carbamazepine epoxide" type="Metabolite"/>
		<pair e1="DBMI.pac148.s0.e0" e2="DBMI.pac148.s0.e1" id="DBMI.pac148.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine" precipitant="Felbatol"/>
		<pair e1="DBMI.pac148.s0.e0" e2="DBMI.pac148.s0.e2" id="DBMI.pac148.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine epoxide" precipitant="Felbatol"/>
		<pair e1="DBMI.pac148.s0.e1" e2="DBMI.pac148.s0.e0" id="DBMI.pac148.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.s0.e1" e2="DBMI.pac148.s0.e2" id="DBMI.pac148.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.s0.e2" e2="DBMI.pac148.s0.e0" id="DBMI.pac148.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.s0.e2" e2="DBMI.pac148.s0.e1" id="DBMI.pac148.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac148.s1" origId="s1" text="In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 82 micrograms/mL."/>
	<sentence id="DBMI.pac148.s2" origId="s2" text="The carbamazepine steady-state Cmin decreased 31% to 51 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.">
		<entity charOffset="411-420" id="DBMI.pac148.s2.e0" origId="s2.e0" text="felbamate" type="Active ingredient"/>
		<entity charOffset="339-352" id="DBMI.pac148.s2.e1" origId="s2.e1" text="carbamazepine" type="Active ingredient"/>
		<pair e1="DBMI.pac148.s2.e0" e2="DBMI.pac148.s2.e1" id="DBMI.pac148.s2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="carbamazepine" precipitant="felbamate"/>
		<pair e1="DBMI.pac148.s2.e1" e2="DBMI.pac148.s2.e0" id="DBMI.pac148.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac148.s3" origId="s3" text="Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.00.3 to 1.60.4 micrograms/mL with the addition of felbamate.">
		<entity charOffset="609-618" id="DBMI.pac148.s3.e0" origId="s3.e0" text="felbamate" type="Active ingredient"/>
		<entity charOffset="481-502" id="DBMI.pac148.s3.e1" origId="s3.e1" text="Carbamazepine epoxide" type="Metabolite"/>
		<pair e1="DBMI.pac148.s3.e0" e2="DBMI.pac148.s3.e1" id="DBMI.pac148.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Carbamazepine epoxide" precipitant="felbamate"/>
		<pair e1="DBMI.pac148.s3.e1" e2="DBMI.pac148.s3.e0" id="DBMI.pac148.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac148.s4" origId="s4" text="In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen."/>
	<sentencespan id="DBMI.pac148.sp0" origId="sp0" text="Carbamazepine: Felbatol causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration. In nine otherwise healthy subjects with epilepsy ingesting carbamazepine, the steady-state trough (Cmin) carbamazepine concentration was 82 micrograms/mL. The carbamazepine steady-state Cmin decreased 31% to 51 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.">
		<entity charOffset="15-23" id="DBMI.pac148.sp0.e0" origId="sp0.e0" text="Felbatol" type="Drug product"/>
		<entity charOffset="63-76" id="DBMI.pac148.sp0.e1" origId="sp0.e1" text="carbamazepine" type="Active ingredient"/>
		<entity charOffset="135-156" id="DBMI.pac148.sp0.e2" origId="sp0.e2" text="carbamazepine epoxide" type="Metabolite"/>
		<entity charOffset="411-420" id="DBMI.pac148.sp0.e3" origId="sp0.e3" text="felbamate" type="Active ingredient"/>
		<pair e1="DBMI.pac148.sp0.e0" e2="DBMI.pac148.sp0.e1" id="DBMI.pac148.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine" precipitant="Felbatol"/>
		<pair e1="DBMI.pac148.sp0.e0" e2="DBMI.pac148.sp0.e2" id="DBMI.pac148.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine epoxide" precipitant="Felbatol"/>
		<pair e1="DBMI.pac148.sp0.e0" e2="DBMI.pac148.sp0.e3" id="DBMI.pac148.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e1" e2="DBMI.pac148.sp0.e0" id="DBMI.pac148.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e1" e2="DBMI.pac148.sp0.e2" id="DBMI.pac148.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e1" e2="DBMI.pac148.sp0.e3" id="DBMI.pac148.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e2" e2="DBMI.pac148.sp0.e0" id="DBMI.pac148.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e2" e2="DBMI.pac148.sp0.e1" id="DBMI.pac148.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e2" e2="DBMI.pac148.sp0.e3" id="DBMI.pac148.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e3" e2="DBMI.pac148.sp0.e0" id="DBMI.pac148.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac148.sp0.e3" e2="DBMI.pac148.sp0.e1" id="DBMI.pac148.sp0.p10" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="carbamazepine" precipitant="felbamate"/>
		<pair e1="DBMI.pac148.sp0.e3" e2="DBMI.pac148.sp0.e2" id="DBMI.pac148.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac148.sp1" origId="sp1" text="Carbamazepine epoxide steady-state Cmin concentrations increased 57% from 1.00.3 to 1.60.4 micrograms/mL with the addition of felbamate. In clinical trials, similar changes in carbamazepine and carbamazepine epoxide were seen.">
		<entity charOffset="609-618" id="DBMI.pac148.sp1.e0" origId="sp1.e0" text="felbamate" type="Active ingredient"/>
		<entity charOffset="481-502" id="DBMI.pac148.sp1.e1" origId="sp1.e1" text="Carbamazepine epoxide" type="Metabolite"/>
		<pair e1="DBMI.pac148.sp1.e0" e2="DBMI.pac148.sp1.e1" id="DBMI.pac148.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Carbamazepine epoxide" precipitant="felbamate"/>
		<pair e1="DBMI.pac148.sp1.e1" e2="DBMI.pac148.sp1.e0" id="DBMI.pac148.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac149" origId="pac149">
	<sentence id="DBMI.pac149.s0" origId="s0" text="Valproate: Felbatol causes an increase in steady-state valproate concentrations.">
		<entity charOffset="11-19" id="DBMI.pac149.s0.e0" origId="s0.e0" text="Felbatol" type="Drug product"/>
		<entity charOffset="56-65" id="DBMI.pac149.s0.e1" origId="s0.e1" text="valproate" type="Active ingredient"/>
		<pair e1="DBMI.pac149.s0.e0" e2="DBMI.pac149.s0.e1" id="DBMI.pac149.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="valproate" precipitant="Felbatol"/>
		<pair e1="DBMI.pac149.s0.e1" e2="DBMI.pac149.s0.e0" id="DBMI.pac149.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac149.s1" origId="s1" text="In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 6316 micrograms/mL."/>
	<sentence id="DBMI.pac149.s2" origId="s2" text="The steady-state Cmin increased to 7814 micrograms/mL when 1200 mg/day of felbamate was coadministered."/>
	<sentence id="DBMI.pac149.s3" origId="s3" text="Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 9625 micrograms/mL.">
		<entity charOffset="341-350" id="DBMI.pac149.s3.e0" origId="s3.e0" text="felbamate" type="Active ingredient"/>
		<entity charOffset="398-407" id="DBMI.pac149.s3.e1" origId="s3.e1" text="valproate" type="Active ingredient"/>
		<pair e1="DBMI.pac149.s3.e0" e2="DBMI.pac149.s3.e1" id="DBMI.pac149.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="valproate" precipitant="felbamate"/>
		<pair e1="DBMI.pac149.s3.e1" e2="DBMI.pac149.s3.e0" id="DBMI.pac149.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac149.s4" origId="s4" text="Corresponding values for free valproate Cmin concentrations were 73, 94, and 116 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol, respectively."/>
	<sentence id="DBMI.pac149.s5" origId="s5" text="The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol, respectively."/>
	<sentence id="DBMI.pac149.s6" origId="s6" text="This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol. ">
		<entity charOffset="881-889" id="DBMI.pac149.s6.e0" origId="s6.e0" text="Felbatol" type="Drug product"/>
		<entity charOffset="819-828" id="DBMI.pac149.s6.e1" origId="s6.e1" text="valproate" type="Active ingredient"/>
		<pair e1="DBMI.pac149.s6.e0" e2="DBMI.pac149.s6.e1" id="DBMI.pac149.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valproate" precipitant="Felbatol"/>
		<pair e1="DBMI.pac149.s6.e1" e2="DBMI.pac149.s6.e0" id="DBMI.pac149.s6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac149.sp0" origId="sp0" text="Valproate: Felbatol causes an increase in steady-state valproate concentrations. In four subjects with epilepsy ingesting valproate, the steady-state trough (Cmin) valproate plasma concentration was 6316 micrograms/mL. The steady-state Cmin increased to 7814 micrograms/mL when 1200 mg/day of felbamate was coadministered.">
		<entity charOffset="11-19" id="DBMI.pac149.sp0.e0" origId="sp0.e0" text="Felbatol" type="Drug product"/>
		<entity charOffset="56-65" id="DBMI.pac149.sp0.e1" origId="sp0.e1" text="valproate" type="Active ingredient"/>
		<pair e1="DBMI.pac149.sp0.e0" e2="DBMI.pac149.sp0.e1" id="DBMI.pac149.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="valproate" precipitant="Felbatol"/>
		<pair e1="DBMI.pac149.sp0.e1" e2="DBMI.pac149.sp0.e0" id="DBMI.pac149.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac149.sp1" origId="sp1" text="Increasing the felbamate dose to 2400 mg/day increased the steady-state valproate Cmin to 9625 micrograms/mL. Corresponding values for free valproate Cmin concentrations were 73, 94, and 116 micrograms/mL for 0, 1200, and 2400 mg/day Felbatol, respectively. The ratios of the AUCs of unbound valproate to the AUCs of the total valproate were 11.1%, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol, respectively.">
		<entity charOffset="341-350" id="DBMI.pac149.sp1.e0" origId="sp1.e0" text="felbamate" type="Active ingredient"/>
		<entity charOffset="398-407" id="DBMI.pac149.sp1.e1" origId="sp1.e1" text="valproate" type="Active ingredient"/>
		<pair e1="DBMI.pac149.sp1.e0" e2="DBMI.pac149.sp1.e1" id="DBMI.pac149.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="valproate" precipitant="felbamate"/>
		<pair e1="DBMI.pac149.sp1.e1" e2="DBMI.pac149.sp1.e0" id="DBMI.pac149.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac149.sp2" origId="sp2" text="This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol. ">
		<entity charOffset="881-889" id="DBMI.pac149.sp2.e0" origId="sp2.e0" text="Felbatol" type="Drug product"/>
		<entity charOffset="819-828" id="DBMI.pac149.sp2.e1" origId="sp2.e1" text="valproate" type="Active ingredient"/>
		<pair e1="DBMI.pac149.sp2.e0" e2="DBMI.pac149.sp2.e1" id="DBMI.pac149.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valproate" precipitant="Felbatol"/>
		<pair e1="DBMI.pac149.sp2.e1" e2="DBMI.pac149.sp2.e0" id="DBMI.pac149.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac15" origId="pac15">
	<sentence id="DBMI.pac15.s0" origId="s0" text="Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism.">
		<entity charOffset="98-108" id="DBMI.pac15.s0.e0" origId="s0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="172-181" id="DBMI.pac15.s0.e1" origId="s0.e1" text="phenytoin" type="Active ingredient"/>
		<pair e1="DBMI.pac15.s0.e0" e2="DBMI.pac15.s0.e1" id="DBMI.pac15.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin" precipitant="sertraline"/>
		<pair e1="DBMI.pac15.s0.e1" e2="DBMI.pac15.s0.e0" id="DBMI.pac15.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac15.s1" origId="s1" text="Nonetheless, at this time, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline therapy with appropriate adjustments to the phenytoin dose, particularly in patients with multiple underlying medical conditions and/or those receiving multiple concomitant medications."/>
	<sentencespan id="DBMI.pac15.sp0" origId="sp0" text="Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. Nonetheless, at this time, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline therapy with appropriate adjustments to the phenytoin dose, particularly in patients with multiple underlying medical conditions and/or those receiving multiple concomitant medications.">
		<entity charOffset="98-108" id="DBMI.pac15.sp0.e0" origId="sp0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="172-181" id="DBMI.pac15.sp0.e1" origId="sp0.e1" text="phenytoin" type="Active ingredient"/>
		<pair e1="DBMI.pac15.sp0.e0" e2="DBMI.pac15.sp0.e1" id="DBMI.pac15.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin" precipitant="sertraline"/>
		<pair e1="DBMI.pac15.sp0.e1" e2="DBMI.pac15.sp0.e0" id="DBMI.pac15.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac150" origId="pac150">
	<sentence id="DBMI.pac150.s0" origId="s0" text="Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations.">
		<entity charOffset="35-44" id="DBMI.pac150.s0.e0" origId="s0.e0" text="felbamate" type="Active ingredient"/>
		<entity charOffset="50-63" id="DBMI.pac150.s0.e1" origId="s0.e1" text="phenobarbital" type="Active ingredient"/>
		<pair e1="DBMI.pac150.s0.e0" e2="DBMI.pac150.s0.e1" id="DBMI.pac150.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenobarbital" precipitant="felbamate"/>
		<pair e1="DBMI.pac150.s0.e1" e2="DBMI.pac150.s0.e0" id="DBMI.pac150.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac150.s1" origId="s1" text="In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.">
		<entity charOffset="219-232" id="DBMI.pac150.s1.e0" origId="s1.e0" text="phenobarbital" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac150.s2" origId="s2" text="The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.">
		<entity charOffset="359-368" id="DBMI.pac150.s2.e0" origId="s2.e0" text="felbamate" type="Active ingredient"/>
	</sentence>
	<sentencespan id="DBMI.pac150.sp0" origId="sp0" text="Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations. In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL. The steady-state Cmin concentration increased to 17.8 micrograms/mL when 2400 mg/day of felbamate was coadministered for one week.">
		<entity charOffset="35-44" id="DBMI.pac150.sp0.e0" origId="sp0.e0" text="felbamate" type="Active ingredient"/>
		<entity charOffset="50-63" id="DBMI.pac150.sp0.e1" origId="sp0.e1" text="phenobarbital" type="Active ingredient"/>
		<pair e1="DBMI.pac150.sp0.e0" e2="DBMI.pac150.sp0.e1" id="DBMI.pac150.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenobarbital" precipitant="felbamate"/>
		<pair e1="DBMI.pac150.sp0.e0" e2="DBMI.pac150.sp0.e1" id="DBMI.pac150.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="phenobarbital" precipitant="felbamate"/>
		<pair e1="DBMI.pac150.sp0.e1" e2="DBMI.pac150.sp0.e0" id="DBMI.pac150.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac151" origId="pac151">
	<sentence id="DBMI.pac151.s0" origId="s0" text="Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady-state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.">
		<entity charOffset="11-20" id="DBMI.pac151.s0.e0" origId="s0.e0" text="Phenytoin" type="Active ingredient"/>
		<entity charOffset="83-92" id="DBMI.pac151.s0.e1" origId="s0.e1" text="felbamate" type="Active ingredient"/>
		<entity charOffset="142-151" id="DBMI.pac151.s0.e2" origId="s0.e2" text="phenytoin" type="Active ingredient"/>
		<entity charOffset="232-240" id="DBMI.pac151.s0.e3" origId="s0.e3" text="Felbatol" type="Drug product"/>
		<pair e1="DBMI.pac151.s0.e0" e2="DBMI.pac151.s0.e1" id="DBMI.pac151.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="felbamate" precipitant="Phenytoin"/>
		<pair e1="DBMI.pac151.s0.e0" e2="DBMI.pac151.s0.e2" id="DBMI.pac151.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e0" e2="DBMI.pac151.s0.e3" id="DBMI.pac151.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e1" e2="DBMI.pac151.s0.e0" id="DBMI.pac151.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e1" e2="DBMI.pac151.s0.e2" id="DBMI.pac151.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e1" e2="DBMI.pac151.s0.e3" id="DBMI.pac151.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e2" e2="DBMI.pac151.s0.e0" id="DBMI.pac151.s0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e2" e2="DBMI.pac151.s0.e1" id="DBMI.pac151.s0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e2" e2="DBMI.pac151.s0.e3" id="DBMI.pac151.s0.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Felbatol" precipitant="phenytoin"/>
		<pair e1="DBMI.pac151.s0.e3" e2="DBMI.pac151.s0.e0" id="DBMI.pac151.s0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e3" e2="DBMI.pac151.s0.e1" id="DBMI.pac151.s0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac151.s0.e3" e2="DBMI.pac151.s0.e2" id="DBMI.pac151.s0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac152" origId="pac152">
	<sentence id="DBMI.pac152.s0" origId="s0" text="Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol at steady-state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy. ">
		<entity charOffset="142-155" id="DBMI.pac152.s0.e0" origId="s0.e0" text="carbamazepine" type="Active ingredient"/>
		<entity charOffset="240-248" id="DBMI.pac152.s0.e1" origId="s0.e1" text="Felbatol" type="Drug product"/>
		<entity charOffset="15-28" id="DBMI.pac152.s0.e2" origId="s0.e2" text="Carbamazepine" type="Active ingredient"/>
		<pair e1="DBMI.pac152.s0.e0" e2="DBMI.pac152.s0.e1" id="DBMI.pac152.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Felbatol" precipitant="carbamazepine"/>
		<pair e1="DBMI.pac152.s0.e0" e2="DBMI.pac152.s0.e2" id="DBMI.pac152.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.s0.e1" e2="DBMI.pac152.s0.e0" id="DBMI.pac152.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.s0.e1" e2="DBMI.pac152.s0.e2" id="DBMI.pac152.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.s0.e2" e2="DBMI.pac152.s0.e0" id="DBMI.pac152.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac152.s0.e2" e2="DBMI.pac152.s0.e1" id="DBMI.pac152.s0.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="Felbatol" precipitant="Carbamazepine"/>
	</sentence>
</document>

<document id="DBMI.pac155" origId="pac155">
	<sentence id="DBMI.pac155.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSildenafil is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP."/>
	<sentence id="DBMI.pac155.s1" origId="s1" text="Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation."/>
	<sentence id="DBMI.pac155.s2" origId="s2" text="In patients with pulmonary hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation."/>
	<sentence id="DBMI.pac155.s3" origId="s3" text="Studies in vitro have shown that sildenafil is selective for PDE5."/>
	<sentence id="DBMI.pac155.s4" origId="s4" text="Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11)."/>
	<sentence id="DBMI.pac155.s5" origId="s5" text="The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility."/>
	<sentence id="DBMI.pac155.s6" origId="s6" text="Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina."/>
	<sentence id="DBMI.pac155.s7" origId="s7" text="This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels [see Clinical Pharmacology (12.2)]."/>
	<sentence id="DBMI.pac155.s8" origId="s8" text="In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE5 is also found in other tissues including vascular and visceral smooth muscle and in platelets."/>
	<sentence id="DBMI.pac155.s9" origId="s9" text="The inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed in vitro, and the mild peripheral arterial-venous dilatation in vivo."/>
	<sentence id="DBMI.pac155.s10" origId="s10" text="12.2 Pharmacodynamics\n\nEffects of REVATIO on Blood Pressure\n\nSingle oral doses of sildenafil 100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg)."/>
	<sentence id="DBMI.pac155.s11" origId="s11" text="The decrease in blood pressure was most notable approximately 12 hours after dosing, and was not different from placebo at 8 hours."/>
	<sentence id="DBMI.pac155.s12" origId="s12" text="Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range."/>
	<sentence id="DBMI.pac155.s13" origId="s13" text="Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)]."/>
	<sentence id="DBMI.pac155.s14" origId="s14" text="Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG."/>
	<sentence id="DBMI.pac155.s15" origId="s15" text="After chronic dosing of 80 mg TID to patients with pulmonary arterial hypertension, no clinically relevant effects on ECG were reported."/>
	<sentence id="DBMI.pac155.s16" origId="s16" text="After chronic dosing of 80 mg TID sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively."/>
	<sentence id="DBMI.pac155.s17" origId="s17" text="After chronic dosing of 80 mg TID sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively."/>
	<sentence id="DBMI.pac155.s18" origId="s18" text="After chronic dosing of 80 mg TID sildenafil to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg)."/>
	<sentence id="DBMI.pac155.s19" origId="s19" text="Effects of REVATIO on Vision\n\nAt single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels."/>
	<sentence id="DBMI.pac155.s20" origId="s20" text="This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina."/>
	<sentence id="DBMI.pac155.s21" origId="s21" text="An evaluation of visual function at doses up to 200 mg revealed no effects of REVATIO on visual acuity, intraocular pressure, or pupillometry."/>
	<sentence id="DBMI.pac155.s22" origId="s22" text="12.3 Pharmacokinetics\n\nAbsorption and Distribution\n\nREVATIO is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (2563%)."/>
	<sentence id="DBMI.pac155.s23" origId="s23" text="Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state."/>
	<sentence id="DBMI.pac155.s24" origId="s24" text="When REVATIO is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%."/>
	<sentence id="DBMI.pac155.s25" origId="s25" text="The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues."/>
	<sentence id="DBMI.pac155.s26" origId="s26" text="Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins."/>
	<sentence id="DBMI.pac155.s27" origId="s27" text="Protein binding is independent of total drug concentrations."/>
	<sentence id="DBMI.pac155.s28" origId="s28" text="Metabolism and Excretion\n\nSildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes."/>
	<sentence id="DBMI.pac155.s29" origId="s29" text="The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized."/>
	<sentence id="DBMI.pac155.s30" origId="s30" text="This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug."/>
	<sentence id="DBMI.pac155.s31" origId="s31" text="In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects."/>
	<sentence id="DBMI.pac155.s32" origId="s32" text="In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher."/>
	<sentence id="DBMI.pac155.s33" origId="s33" text="Both sildenafil and the active metabolite have terminal half-lives of about 4 hours."/>
	<sentence id="DBMI.pac155.s34" origId="s34" text="After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose)."/>
	<sentence id="DBMI.pac155.s35" origId="s35" text="REVATIO Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration."/>
	<sentence id="DBMI.pac155.s36" origId="s36" text="A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose."/>
	<sentence id="DBMI.pac155.s37" origId="s37" text="Population Pharmacokinetics\n\nAge, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH."/>
	<sentence id="DBMI.pac155.s38" origId="s38" text="The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function."/>
	<sentence id="DBMI.pac155.s39" origId="s39" text="None of these factors had a significant impact on sildenafil pharmacokinetics in patients with PAH."/>
	<sentence id="DBMI.pac155.s40" origId="s40" text="In patients with PAH, the average steady-state concentrations were 2050% higher when compared to those of healthy volunteers."/>
	<sentence id="DBMI.pac155.s41" origId="s41" text="There was also a doubling of Cmin levels compared to healthy volunteers."/>
	<sentence id="DBMI.pac155.s42" origId="s42" text="Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with pulmonary hypertension compared to healthy volunteers."/>
	<sentence id="DBMI.pac155.s43" origId="s43" text="Geriatric Patients\n\nHealthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (1845 years)."/>
	<sentence id="DBMI.pac155.s44" origId="s44" text="Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively."/>
	<sentence id="DBMI.pac155.s45" origId="s45" text="Renal Impairment\n\nIn volunteers with mild (CLcr = 5080 mL/min) and moderate (CLcr = 3049 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) was not altered."/>
	<sentence id="DBMI.pac155.s46" origId="s46" text="In volunteers with severe (CLcr &lt; 30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and Cmax compared to age-matched volunteers with no renal impairment."/>
	<sentence id="DBMI.pac155.s47" origId="s47" text="In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200 % and 79 %, respectively, in subjects with severe renal impairment compared to subjects with normal renal function."/>
	<sentence id="DBMI.pac155.s48" origId="s48" text="Hepatic Impairment\n\nIn volunteers with mild to moderate hepatic cirrhosis (Child-Pugh class A and B), sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment."/>
	<sentence id="DBMI.pac155.s49" origId="s49" text="Patients with severe hepatic impairment (Child-Pugh class C) have not been studied."/>
	<sentence id="DBMI.pac155.s50" origId="s50" text="Drug Interaction Studies\n\nSildenafil metabolism is principally mediated by the CYP3A (major route) and CYP2C9 (minor route) cytochrome P450 isoforms."/>
	<sentence id="DBMI.pac155.s51" origId="s51" text="Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance."/>
	<sentence id="DBMI.pac155.s52" origId="s52" text="Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 &gt;150 M)."/>
	<sentence id="DBMI.pac155.s53" origId="s53" text="Ritonavir and other CYP3A Inhibitors\n\nIn study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.">
		<entity charOffset="8627-8636" id="DBMI.pac155.s53.e0" origId="s53.e0" text="ritonavir" type="Active ingredient"/>
		<entity charOffset="8770-8780" id="DBMI.pac155.s53.e1" origId="s53.e1" text="sildenafil" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s53.e0" e2="DBMI.pac155.s53.e1" id="DBMI.pac155.s53.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="ritonavir"/>
		<pair e1="DBMI.pac155.s53.e0" e2="DBMI.pac155.s53.e1" id="DBMI.pac155.s53.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="ritonavir"/>
		<pair e1="DBMI.pac155.s53.e1" e2="DBMI.pac155.s53.e0" id="DBMI.pac155.s53.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s54" origId="s54" text="At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone.">
		<entity charOffset="8820-8830" id="DBMI.pac155.s54.e0" origId="s54.e0" text="sildenafil" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac155.s55" origId="s55" text="This is consistent with ritonavir's marked effects on a broad range of P450 substrates."/>
	<sentence id="DBMI.pac155.s56" origId="s56" text="Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.">
		<entity charOffset="9146-9156" id="DBMI.pac155.s56.e0" origId="s56.e0" text="saquinavir" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac155.s57" origId="s57" text="Population data from patients in clinical trials indicated a reduction in sildenafil clearance when it was co-administered with CYP3A inhibitors.">
		<entity charOffset="9238-9248" id="DBMI.pac155.s57.e0" origId="s57.e0" text="sildenafil" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac155.s58" origId="s58" text="Sildenafil exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID."/>
	<sentence id="DBMI.pac155.s59" origId="s59" text="This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir)."/>
	<sentence id="DBMI.pac155.s60" origId="s60" text="Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.">
		<entity charOffset="9791-9801" id="DBMI.pac155.s60.e0" origId="s60.e0" text="Cimetidine" type="Active ingredient"/>
		<entity charOffset="9873-9883" id="DBMI.pac155.s60.e1" origId="s60.e1" text="sildenafil" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s60.e0" e2="DBMI.pac155.s60.e1" id="DBMI.pac155.s60.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="Cimetidine"/>
		<pair e1="DBMI.pac155.s60.e1" e2="DBMI.pac155.s60.e0" id="DBMI.pac155.s60.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s61" origId="s61" text="When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).">
		<entity charOffset="10033-10045" id="DBMI.pac155.s61.e0" origId="s61.e0" text="erythromycin" type="Active ingredient"/>
		<entity charOffset="10136-10146" id="DBMI.pac155.s61.e1" origId="s61.e1" text="sildenafil" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s61.e0" e2="DBMI.pac155.s61.e1" id="DBMI.pac155.s61.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="erythromycin"/>
		<pair e1="DBMI.pac155.s61.e1" e2="DBMI.pac155.s61.e0" id="DBMI.pac155.s61.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s62" origId="s62" text="In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.">
		<entity charOffset="10265-10275" id="DBMI.pac155.s62.e0" origId="s62.e0" text="saquinavir" type="Active ingredient"/>
		<entity charOffset="10394-10404" id="DBMI.pac155.s62.e1" origId="s62.e1" text="sildenafil" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s62.e0" e2="DBMI.pac155.s62.e1" id="DBMI.pac155.s62.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="saquinavir"/>
		<pair e1="DBMI.pac155.s62.e0" e2="DBMI.pac155.s62.e1" id="DBMI.pac155.s62.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="saquinavir"/>
		<pair e1="DBMI.pac155.s62.e1" e2="DBMI.pac155.s62.e0" id="DBMI.pac155.s62.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s63" origId="s63" text="REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.">
		<entity charOffset="10433-10443" id="DBMI.pac155.s63.e0" origId="s63.e0" text="sildenafil" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac155.s64" origId="s64" text="Bosentan\n\nIn a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.">
		<entity charOffset="10714-10724" id="DBMI.pac155.s64.e0" origId="s64.e0" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="10758-10766" id="DBMI.pac155.s64.e1" origId="s64.e1" text="bosentan" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s64.e0" e2="DBMI.pac155.s64.e1" id="DBMI.pac155.s64.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="bosentan" precipitant="sildenafil"/>
		<pair e1="DBMI.pac155.s64.e1" e2="DBMI.pac155.s64.e0" id="DBMI.pac155.s64.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="bosentan"/>
		<pair e1="DBMI.pac155.s64.e1" e2="DBMI.pac155.s64.e0" id="DBMI.pac155.s64.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="bosentan"/>
	</sentence>
	<sentence id="DBMI.pac155.s65" origId="s65" text="Co-administration resulted in a 50% increase in AUC of bosentan.">
		<entity charOffset="10938-10948" id="DBMI.pac155.s65.e0" origId="s65.e0" text="sildenafil" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac155.s66" origId="s66" text="The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing).">
		<entity charOffset="11010-11018" id="DBMI.pac155.s66.e0" origId="s66.e0" text="bosentan" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac155.s67" origId="s67" text="Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil."/>
	<sentence id="DBMI.pac155.s68" origId="s68" text="Epoprostenol\n\nThe mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.">
		<entity charOffset="11364-11376" id="DBMI.pac155.s68.e0" origId="s68.e0" text="epoprostenol" type="Active ingredient"/>
		<entity charOffset="11297-11307" id="DBMI.pac155.s68.e1" origId="s68.e1" text="sildenafil" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s68.e0" e2="DBMI.pac155.s68.e1" id="DBMI.pac155.s68.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="epoprostenol"/>
		<pair e1="DBMI.pac155.s68.e1" e2="DBMI.pac155.s68.e0" id="DBMI.pac155.s68.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s69" origId="s69" text="Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant."/>
	<sentence id="DBMI.pac155.s70" origId="s70" text="The effect of sildenafil on epoprostenol pharmacokinetics is not known."/>
	<sentence id="DBMI.pac155.s71" origId="s71" text="CYP Substrates and Beta-blockers\n\nPopulation pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance or an increase of oral bioavailability when co-administered with CYP3A substrates and the combination of CYP3A substrates and beta-blockers."/>
	<sentence id="DBMI.pac155.s72" origId="s72" text="In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates.">
		<entity charOffset="11970-11980" id="DBMI.pac155.s72.e0" origId="s72.e0" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="12085-12094" id="DBMI.pac155.s72.e1" origId="s72.e1" text="ritonavir" type="Active ingredient"/>
		<entity charOffset="12070-12080" id="DBMI.pac155.s72.e2" origId="s72.e2" text="saquinavir" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s72.e0" e2="DBMI.pac155.s72.e1" id="DBMI.pac155.s72.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ritonavir" precipitant="sildenafil"/>
		<pair e1="DBMI.pac155.s72.e0" e2="DBMI.pac155.s72.e2" id="DBMI.pac155.s72.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="saquinavir" precipitant="sildenafil"/>
		<pair e1="DBMI.pac155.s72.e1" e2="DBMI.pac155.s72.e0" id="DBMI.pac155.s72.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s72.e1" e2="DBMI.pac155.s72.e2" id="DBMI.pac155.s72.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s72.e2" e2="DBMI.pac155.s72.e0" id="DBMI.pac155.s72.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s72.e2" e2="DBMI.pac155.s72.e1" id="DBMI.pac155.s72.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s73" origId="s73" text="No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9."/>
	<sentence id="DBMI.pac155.s74" origId="s74" text="Oral Contraceptives\n\nConcomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil.">
		<entity charOffset="12333-12350" id="DBMI.pac155.s74.e0" origId="s74.e0" text="ethinyl estradiol" type="Active ingredient"/>
		<entity charOffset="12362-12376" id="DBMI.pac155.s74.e1" origId="s74.e1" text="levonorgestrel" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s74.e0" e2="DBMI.pac155.s74.e1" id="DBMI.pac155.s74.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s74.e1" e2="DBMI.pac155.s74.e0" id="DBMI.pac155.s74.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s75" origId="s75" text="Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).">
		<entity charOffset="12425-12435" id="DBMI.pac155.s75.e0" origId="s75.e0" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="12437-12447" id="DBMI.pac155.s75.e1" origId="s75.e1" text="Sildenafil" type="Active ingredient"/>
		<entity charOffset="12507-12524" id="DBMI.pac155.s75.e2" origId="s75.e2" text="ethinyl estradiol" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s75.e0" e2="DBMI.pac155.s75.e1" id="DBMI.pac155.s75.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e0" e2="DBMI.pac155.s75.e2" id="DBMI.pac155.s75.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e1" e2="DBMI.pac155.s75.e0" id="DBMI.pac155.s75.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e1" e2="DBMI.pac155.s75.e2" id="DBMI.pac155.s75.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol" precipitant="Sildenafil"/>
		<pair e1="DBMI.pac155.s75.e2" e2="DBMI.pac155.s75.e0" id="DBMI.pac155.s75.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e2" e2="DBMI.pac155.s75.e1" id="DBMI.pac155.s75.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s76" origId="s76" text="Atorvastatin\n\nConcomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.">
		<entity charOffset="12536-12550" id="DBMI.pac155.s76.e0" origId="s76.e0" text="levonorgestrel" type="Active ingredient"/>
		<entity charOffset="12630-12640" id="DBMI.pac155.s76.e1" origId="s76.e1" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="12655-12667" id="DBMI.pac155.s76.e2" origId="s76.e2" text="atorvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s76.e0" e2="DBMI.pac155.s76.e1" id="DBMI.pac155.s76.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s76.e0" e2="DBMI.pac155.s76.e2" id="DBMI.pac155.s76.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s76.e1" e2="DBMI.pac155.s76.e0" id="DBMI.pac155.s76.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s76.e1" e2="DBMI.pac155.s76.e2" id="DBMI.pac155.s76.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin" precipitant="sildenafil"/>
		<pair e1="DBMI.pac155.s76.e2" e2="DBMI.pac155.s76.e0" id="DBMI.pac155.s76.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s76.e2" e2="DBMI.pac155.s76.e1" id="DBMI.pac155.s76.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil" precipitant="atorvastatin"/>
	</sentence>
	<sentence id="DBMI.pac155.s77" origId="s77" text="Antacids\n\nSingle doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.">
		<entity charOffset="12727-12739" id="DBMI.pac155.s77.e0" origId="s77.e0" text="atorvastatin" type="Active ingredient"/>
		<entity charOffset="12713-12723" id="DBMI.pac155.s77.e1" origId="s77.e1" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="12777-12796" id="DBMI.pac155.s77.e2" origId="s77.e2" text="magnesium hydroxide" type="Active ingredient"/>
		<entity charOffset="12797-12815" id="DBMI.pac155.s77.e3" origId="s77.e3" text="aluminum hydroxide" type="Active ingredient"/>
		<pair e1="DBMI.pac155.s77.e0" e2="DBMI.pac155.s77.e1" id="DBMI.pac155.s77.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e0" e2="DBMI.pac155.s77.e2" id="DBMI.pac155.s77.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e0" e2="DBMI.pac155.s77.e3" id="DBMI.pac155.s77.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e1" e2="DBMI.pac155.s77.e0" id="DBMI.pac155.s77.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e1" e2="DBMI.pac155.s77.e2" id="DBMI.pac155.s77.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e1" e2="DBMI.pac155.s77.e3" id="DBMI.pac155.s77.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e2" e2="DBMI.pac155.s77.e0" id="DBMI.pac155.s77.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e2" e2="DBMI.pac155.s77.e1" id="DBMI.pac155.s77.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil" precipitant="magnesium hydroxide"/>
		<pair e1="DBMI.pac155.s77.e2" e2="DBMI.pac155.s77.e3" id="DBMI.pac155.s77.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e3" e2="DBMI.pac155.s77.e0" id="DBMI.pac155.s77.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e3" e2="DBMI.pac155.s77.e1" id="DBMI.pac155.s77.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil" precipitant="aluminum hydroxide"/>
		<pair e1="DBMI.pac155.s77.e3" e2="DBMI.pac155.s77.e2" id="DBMI.pac155.s77.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s78" origId="s78" text="Aspirin\n\nSildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg).">
		<entity charOffset="12855-12865" id="DBMI.pac155.s78.e0" origId="s78.e0" text="sildenafil" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac155.s79" origId="s79" text="Alcohol\n\nSildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%."/>
	<sentencespan id="DBMI.pac155.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSildenafil is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation."/>
	<sentencespan id="DBMI.pac155.sp1" origId="sp1" text="Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility."/>
	<sentencespan id="DBMI.pac155.sp2" origId="sp2" text="Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels [see Clinical Pharmacology (12.2)]. In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE5 is also found in other tissues including vascular and visceral smooth muscle and in platelets."/>
	<sentencespan id="DBMI.pac155.sp3" origId="sp3" text="The inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed in vitro, and the mild peripheral arterial-venous dilatation in vivo. 12.2 Pharmacodynamics\n\nEffects of REVATIO on Blood Pressure\n\nSingle oral doses of sildenafil 100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg). The decrease in blood pressure was most notable approximately 12 hours after dosing, and was not different from placebo at 8 hours."/>
	<sentencespan id="DBMI.pac155.sp4" origId="sp4" text="Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)]. Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG."/>
	<sentencespan id="DBMI.pac155.sp5" origId="sp5" text="After chronic dosing of 80 mg TID to patients with pulmonary arterial hypertension, no clinically relevant effects on ECG were reported. After chronic dosing of 80 mg TID sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively. After chronic dosing of 80 mg TID sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively."/>
	<sentencespan id="DBMI.pac155.sp6" origId="sp6" text="After chronic dosing of 80 mg TID sildenafil to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg). Effects of REVATIO on Vision\n\nAt single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina."/>
	<sentencespan id="DBMI.pac155.sp7" origId="sp7" text="An evaluation of visual function at doses up to 200 mg revealed no effects of REVATIO on visual acuity, intraocular pressure, or pupillometry. 12.3 Pharmacokinetics\n\nAbsorption and Distribution\n\nREVATIO is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (2563%). Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state."/>
	<sentencespan id="DBMI.pac155.sp8" origId="sp8" text="When REVATIO is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins."/>
	<sentencespan id="DBMI.pac155.sp9" origId="sp9" text="Protein binding is independent of total drug concentrations. Metabolism and Excretion\n\nSildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized."/>
	<sentencespan id="DBMI.pac155.sp10" origId="sp10" text="This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects. In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher."/>
	<sentencespan id="DBMI.pac155.sp11" origId="sp11" text="Both sildenafil and the active metabolite have terminal half-lives of about 4 hours. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose). REVATIO Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration."/>
	<sentencespan id="DBMI.pac155.sp12" origId="sp12" text="A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose. Population Pharmacokinetics\n\nAge, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function."/>
	<sentencespan id="DBMI.pac155.sp13" origId="sp13" text="None of these factors had a significant impact on sildenafil pharmacokinetics in patients with PAH. In patients with PAH, the average steady-state concentrations were 2050% higher when compared to those of healthy volunteers. There was also a doubling of Cmin levels compared to healthy volunteers."/>
	<sentencespan id="DBMI.pac155.sp14" origId="sp14" text="Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with pulmonary hypertension compared to healthy volunteers. Geriatric Patients\n\nHealthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (1845 years). Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively."/>
	<sentencespan id="DBMI.pac155.sp15" origId="sp15" text="Renal Impairment\n\nIn volunteers with mild (CLcr = 5080 mL/min) and moderate (CLcr = 3049 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) was not altered. In volunteers with severe (CLcr &lt; 30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and Cmax compared to age-matched volunteers with no renal impairment. In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200 % and 79 %, respectively, in subjects with severe renal impairment compared to subjects with normal renal function."/>
	<sentencespan id="DBMI.pac155.sp16" origId="sp16" text="Hepatic Impairment\n\nIn volunteers with mild to moderate hepatic cirrhosis (Child-Pugh class A and B), sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment. Patients with severe hepatic impairment (Child-Pugh class C) have not been studied. Drug Interaction Studies\n\nSildenafil metabolism is principally mediated by the CYP3A (major route) and CYP2C9 (minor route) cytochrome P450 isoforms."/>
	<sentencespan id="DBMI.pac155.sp17" origId="sp17" text="Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 &gt;150 M). Ritonavir and other CYP3A Inhibitors\n\nIn study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.">
		<entity charOffset="8627-8636" id="DBMI.pac155.sp17.e0" origId="sp17.e0" text="ritonavir" type="Active ingredient"/>
		<entity charOffset="8770-8780" id="DBMI.pac155.sp17.e1" origId="sp17.e1" text="sildenafil" type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp17.e0" e2="DBMI.pac155.sp17.e1" id="DBMI.pac155.sp17.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="ritonavir"/>
		<pair e1="DBMI.pac155.sp17.e0" e2="DBMI.pac155.sp17.e1" id="DBMI.pac155.sp17.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="ritonavir"/>
		<pair e1="DBMI.pac155.sp17.e1" e2="DBMI.pac155.sp17.e0" id="DBMI.pac155.sp17.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp18" origId="sp18" text="At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.">
		<entity charOffset="9146-9156" id="DBMI.pac155.sp18.e0" origId="sp18.e0" text="saquinavir" type="Active ingredient"/>
		<entity charOffset="9238-9248" id="DBMI.pac155.sp18.e1" origId="sp18.e1" text="sildenafil" type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp18.e0" e2="DBMI.pac155.sp18.e1" id="DBMI.pac155.sp18.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="sildenafil" precipitant="saquinavir"/>
		<pair e1="DBMI.pac155.sp18.e1" e2="DBMI.pac155.sp18.e0" id="DBMI.pac155.sp18.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp19" origId="sp19" text="Population data from patients in clinical trials indicated a reduction in sildenafil clearance when it was co-administered with CYP3A inhibitors. Sildenafil exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir)."/>
	<sentencespan id="DBMI.pac155.sp20" origId="sp20" text="Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.">
		<entity charOffset="10033-10045" id="DBMI.pac155.sp20.e0" origId="sp20.e0" text="erythromycin" type="Active ingredient"/>
		<entity charOffset="10136-10146" id="DBMI.pac155.sp20.e1" origId="sp20.e1" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="10265-10275" id="DBMI.pac155.sp20.e2" origId="sp20.e2" text="saquinavir" type="Active ingredient"/>
		<entity charOffset="9791-9801" id="DBMI.pac155.sp20.e3" origId="sp20.e3" text="Cimetidine" type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp20.e0" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="erythromycin"/>
		<pair e1="DBMI.pac155.sp20.e0" e2="DBMI.pac155.sp20.e2" id="DBMI.pac155.sp20.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e0" e2="DBMI.pac155.sp20.e3" id="DBMI.pac155.sp20.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e1" e2="DBMI.pac155.sp20.e0" id="DBMI.pac155.sp20.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e1" e2="DBMI.pac155.sp20.e2" id="DBMI.pac155.sp20.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e1" e2="DBMI.pac155.sp20.e3" id="DBMI.pac155.sp20.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e0" id="DBMI.pac155.sp20.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p7" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="saquinavir"/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="saquinavir"/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e3" id="DBMI.pac155.sp20.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e3" e2="DBMI.pac155.sp20.e0" id="DBMI.pac155.sp20.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e3" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p11" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="Cimetidine"/>
		<pair e1="DBMI.pac155.sp20.e3" e2="DBMI.pac155.sp20.e2" id="DBMI.pac155.sp20.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp21" origId="sp21" text="REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration. Bosentan\n\nIn a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administration resulted in a 50% increase in AUC of bosentan.">
		<entity charOffset="10714-10724" id="DBMI.pac155.sp21.e0" origId="sp21.e0" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="10758-10766" id="DBMI.pac155.sp21.e1" origId="sp21.e1" text="bosentan" type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp21.e0" e2="DBMI.pac155.sp21.e1" id="DBMI.pac155.sp21.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="bosentan" precipitant="sildenafil"/>
		<pair e1="DBMI.pac155.sp21.e1" e2="DBMI.pac155.sp21.e0" id="DBMI.pac155.sp21.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="bosentan"/>
		<pair e1="DBMI.pac155.sp21.e1" e2="DBMI.pac155.sp21.e0" id="DBMI.pac155.sp21.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="bosentan"/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp22" origId="sp22" text="The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil. Epoprostenol\n\nThe mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.">
		<entity charOffset="11010-11018" id="DBMI.pac155.sp22.e0" origId="sp22.e0" text="bosentan" type="Active ingredient"/>
		<entity charOffset="11364-11376" id="DBMI.pac155.sp22.e1" origId="sp22.e1" text="epoprostenol" type="Active ingredient"/>
		<entity charOffset="11297-11307" id="DBMI.pac155.sp22.e2" origId="sp22.e2" text="sildenafil" type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp22.e0" e2="DBMI.pac155.sp22.e1" id="DBMI.pac155.sp22.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp22.e0" e2="DBMI.pac155.sp22.e2" id="DBMI.pac155.sp22.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp22.e1" e2="DBMI.pac155.sp22.e0" id="DBMI.pac155.sp22.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp22.e1" e2="DBMI.pac155.sp22.e2" id="DBMI.pac155.sp22.p3" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil" precipitant="epoprostenol"/>
		<pair e1="DBMI.pac155.sp22.e2" e2="DBMI.pac155.sp22.e0" id="DBMI.pac155.sp22.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp22.e2" e2="DBMI.pac155.sp22.e1" id="DBMI.pac155.sp22.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp23" origId="sp23" text="Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmacokinetics is not known. CYP Substrates and Beta-blockers\n\nPopulation pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance or an increase of oral bioavailability when co-administered with CYP3A substrates and the combination of CYP3A substrates and beta-blockers."/>
	<sentencespan id="DBMI.pac155.sp24" origId="sp24" text="In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates. No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9. Oral Contraceptives\n\nConcomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil.">
		<entity charOffset="11970-11980" id="DBMI.pac155.sp24.e0" origId="sp24.e0" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="12085-12094" id="DBMI.pac155.sp24.e1" origId="sp24.e1" text="ritonavir" type="Active ingredient"/>
		<entity charOffset="12070-12080" id="DBMI.pac155.sp24.e2" origId="sp24.e2" text="saquinavir" type="Active ingredient"/>
		<entity charOffset="12333-12350" id="DBMI.pac155.sp24.e3" origId="sp24.e3" text="ethinyl estradiol" type="Active ingredient"/>
		<entity charOffset="12362-12376" id="DBMI.pac155.sp24.e4" origId="sp24.e4" text="levonorgestrel" type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ritonavir" precipitant="sildenafil"/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="saquinavir" precipitant="sildenafil"/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil" precipitant="ethinyl estradiol"/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil" precipitant="levonorgestrel"/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp25" origId="sp25" text="Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg). Atorvastatin\n\nConcomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin. Antacids\n\nSingle doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.">
		<entity charOffset="12425-12435" id="DBMI.pac155.sp25.e0" origId="sp25.e0" text="sildenafil" type="Active ingredient"/>
		<entity charOffset="12437-12447" id="DBMI.pac155.sp25.e1" origId="sp25.e1" text="Sildenafil" type="Active ingredient"/>
		<entity charOffset="12536-12550" id="DBMI.pac155.sp25.e2" origId="sp25.e2" text="levonorgestrel" type="Active ingredient"/>
		<entity charOffset="12507-12524" id="DBMI.pac155.sp25.e3" origId="sp25.e3" text="ethinyl estradiol" type="Active ingredient"/>
		<entity charOffset="12727-12739" id="DBMI.pac155.sp25.e4" origId="sp25.e4" text="atorvastatin" type="Active ingredient"/>
		<entity charOffset="12777-12796" id="DBMI.pac155.sp25.e5" origId="sp25.e5" text="magnesium hydroxide" type="Active ingredient"/>
		<entity charOffset="12797-12815" id="DBMI.pac155.sp25.e6" origId="sp25.e6" text="aluminum hydroxide" type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin" precipitant="sildenafil"/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="levonorgestrel" precipitant="Sildenafil"/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol" precipitant="Sildenafil"/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p24" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil" precipitant="atorvastatin"/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p30" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil" precipitant="magnesium hydroxide"/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p36" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil" precipitant="aluminum hydroxide"/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp26" origId="sp26" text="Aspirin\n\nSildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). Alcohol\n\nSildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%.">
		<entity charOffset="12855-12865" id="DBMI.pac155.sp26.e0" origId="sp26.e0" text="sildenafil" type="Active ingredient"/>
	</sentencespan>
</document>

<document id="DBMI.pac156" origId="pac156">
	<sentence id="DBMI.pac156.s0" origId="s0" text="7  DRUG INTERACTIONS\n\n7.1 Effects of Other Drugs on Aliskiren\n\nBased on in vitro studies, aliskiren is metabolized by CYP 3A4."/>
	<sentence id="DBMI.pac156.s1" origId="s1" text="Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.">
		<entity charOffset="160-170" id="DBMI.pac156.s1.e0" origId="s1.e0" text="irbesartan" type="Active ingredient"/>
		<entity charOffset="179-188" id="DBMI.pac156.s1.e1" origId="s1.e1" text="aliskiren" type="Active ingredient"/>
		<pair e1="DBMI.pac156.s1.e0" e2="DBMI.pac156.s1.e1" id="DBMI.pac156.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="irbesartan"/>
		<pair e1="DBMI.pac156.s1.e1" e2="DBMI.pac156.s1.e0" id="DBMI.pac156.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s2" origId="s2" text="P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies."/>
	<sentence id="DBMI.pac156.s3" origId="s3" text="The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter."/>
	<sentence id="DBMI.pac156.s4" origId="s4" text="Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.">
		<entity charOffset="543-555" id="DBMI.pac156.s4.e0" origId="s4.e0" text="atorvastatin" type="Active ingredient"/>
		<entity charOffset="592-601" id="DBMI.pac156.s4.e1" origId="s4.e1" text="aliskiren" type="Active ingredient"/>
		<pair e1="DBMI.pac156.s4.e0" e2="DBMI.pac156.s4.e1" id="DBMI.pac156.s4.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="atorvastatin"/>
		<pair e1="DBMI.pac156.s4.e1" e2="DBMI.pac156.s4.e0" id="DBMI.pac156.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s5" origId="s5" text="Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.">
		<entity charOffset="692-704" id="DBMI.pac156.s5.e0" origId="s5.e0" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="710-719" id="DBMI.pac156.s5.e1" origId="s5.e1" text="aliskiren" type="Active ingredient"/>
		<pair e1="DBMI.pac156.s5.e0" e2="DBMI.pac156.s5.e1" id="DBMI.pac156.s5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="ketoconazole"/>
		<pair e1="DBMI.pac156.s5.e1" e2="DBMI.pac156.s5.e0" id="DBMI.pac156.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s6" origId="s6" text="A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further."/>
	<sentence id="DBMI.pac156.s7" origId="s7" text="Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren.">
		<entity charOffset="940-952" id="DBMI.pac156.s7.e0" origId="s7.e0" text="itraconazole" type="Active ingredient"/>
		<entity charOffset="965-974" id="DBMI.pac156.s7.e1" origId="s7.e1" text="aliskiren" type="Active ingredient"/>
		<pair e1="DBMI.pac156.s7.e0" e2="DBMI.pac156.s7.e1" id="DBMI.pac156.s7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="itraconazole"/>
		<pair e1="DBMI.pac156.s7.e1" e2="DBMI.pac156.s7.e0" id="DBMI.pac156.s7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s8" origId="s8" text="Concomitant use of aliskiren with itraconazole is not recommended."/>
	<sentence id="DBMI.pac156.s9" origId="s9" text="Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren.">
		<entity charOffset="1190-1202" id="DBMI.pac156.s9.e0" origId="s9.e0" text="cyclosporine" type="Active ingredient"/>
		<entity charOffset="1214-1223" id="DBMI.pac156.s9.e1" origId="s9.e1" text="aliskiren" type="Active ingredient"/>
		<pair e1="DBMI.pac156.s9.e0" e2="DBMI.pac156.s9.e1" id="DBMI.pac156.s9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="cyclosporine"/>
		<pair e1="DBMI.pac156.s9.e1" e2="DBMI.pac156.s9.e0" id="DBMI.pac156.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s10" origId="s10" text="Concomitant use of aliskiren with cyclosporine is not recommended."/>
	<sentence id="DBMI.pac156.s11" origId="s11" text="Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.">
		<entity charOffset="1430-1439" id="DBMI.pac156.s11.e0" origId="s11.e0" text="verapamil" type="Active ingredient"/>
		<entity charOffset="1452-1461" id="DBMI.pac156.s11.e1" origId="s11.e1" text="aliskiren" type="Active ingredient"/>
		<pair e1="DBMI.pac156.s11.e0" e2="DBMI.pac156.s11.e1" id="DBMI.pac156.s11.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="verapamil"/>
		<pair e1="DBMI.pac156.s11.e1" e2="DBMI.pac156.s11.e0" id="DBMI.pac156.s11.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s12" origId="s12" text="However, no dosage adjustment is necessary."/>
	<sentence id="DBMI.pac156.s13" origId="s13" text="Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.">
		<entity charOffset="1648-1658" id="DBMI.pac156.s13.e0" origId="s13.e0" text="lovastatin" type="Active ingredient"/>
		<entity charOffset="1833-1842" id="DBMI.pac156.s13.e1" origId="s13.e1" text="aliskiren" type="Active ingredient"/>
		<entity charOffset="1660-1668" id="DBMI.pac156.s13.e2" origId="s13.e2" text="atenolol" type="Active ingredient"/>
		<entity charOffset="1670-1678" id="DBMI.pac156.s13.e3" origId="s13.e3" text="warfarin" type="Active ingredient"/>
		<entity charOffset="1680-1690" id="DBMI.pac156.s13.e4" origId="s13.e4" text="furosemide" type="Active ingredient"/>
		<entity charOffset="1692-1699" id="DBMI.pac156.s13.e5" origId="s13.e5" text="digoxin" type="Active ingredient"/>
		<entity charOffset="1701-1710" id="DBMI.pac156.s13.e6" origId="s13.e6" text="celecoxib" type="Active ingredient"/>
		<entity charOffset="1712-1731" id="DBMI.pac156.s13.e7" origId="s13.e7" text="hydrochlorothiazide" type="Active ingredient"/>
		<entity charOffset="1733-1741" id="DBMI.pac156.s13.e8" origId="s13.e8" text="ramipril" type="Active ingredient"/>
		<entity charOffset="1743-1752" id="DBMI.pac156.s13.e9" origId="s13.e9" text="valsartan" type="Active ingredient"/>
		<entity charOffset="1754-1763" id="DBMI.pac156.s13.e10" origId="s13.e10" text="metformin" type="Active ingredient"/>
		<entity charOffset="1768-1778" id="DBMI.pac156.s13.e11" origId="s13.e11" text="amlodipine" type="Active ingredient"/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="lovastatin"/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e0" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e1" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p23" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="atenolol"/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e2" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p34" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="warfarin"/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e3" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p45" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="furosemide"/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e4" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p56" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="digoxin"/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p64" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e5" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p67" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="celecoxib"/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p74" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e6" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p78" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="hydrochlorothiazide"/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p79" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p80" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p81" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p82" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p83" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p84" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p85" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p86" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e7" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p87" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p88" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p89" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="ramipril"/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p90" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p91" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p92" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p93" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p94" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p95" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p96" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p97" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e8" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p98" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p99" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p100" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="valsartan"/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p101" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p102" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p103" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p104" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p105" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p106" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p107" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p108" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e9" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p109" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p110" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p111" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="metformin"/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p112" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p113" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p114" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p115" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p116" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p117" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p118" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p119" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e10" e2="DBMI.pac156.s13.e11" id="DBMI.pac156.s13.p120" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e0" id="DBMI.pac156.s13.p121" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e1" id="DBMI.pac156.s13.p122" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="amlodipine"/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e2" id="DBMI.pac156.s13.p123" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e3" id="DBMI.pac156.s13.p124" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e4" id="DBMI.pac156.s13.p125" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e5" id="DBMI.pac156.s13.p126" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e6" id="DBMI.pac156.s13.p127" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e7" id="DBMI.pac156.s13.p128" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e8" id="DBMI.pac156.s13.p129" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e9" id="DBMI.pac156.s13.p130" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s13.e11" e2="DBMI.pac156.s13.e10" id="DBMI.pac156.s13.p131" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s14" origId="s14" text="7.2 Effects of Aliskiren on Other Drugs\n\nAliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4."/>
	<sentence id="DBMI.pac156.s15" origId="s15" text="Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.">
		<entity charOffset="2024-2033" id="DBMI.pac156.s15.e0" origId="s15.e0" text="aliskiren" type="Active ingredient"/>
		<entity charOffset="2058-2068" id="DBMI.pac156.s15.e1" origId="s15.e1" text="furosemide" type="Active ingredient"/>
		<pair e1="DBMI.pac156.s15.e0" e2="DBMI.pac156.s15.e1" id="DBMI.pac156.s15.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="furosemide" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.s15.e1" e2="DBMI.pac156.s15.e0" id="DBMI.pac156.s15.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s16" origId="s16" text="Patients receiving furosemide could find its effect diminished after starting aliskiren."/>
	<sentence id="DBMI.pac156.s17" origId="s17" text="Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.">
		<entity charOffset="2306-2315" id="DBMI.pac156.s17.e0" origId="s17.e0" text="aliskiren" type="Active ingredient"/>
		<entity charOffset="2459-2467" id="DBMI.pac156.s17.e1" origId="s17.e1" text="ramipril" type="Active ingredient"/>
		<entity charOffset="2471-2490" id="DBMI.pac156.s17.e2" origId="s17.e2" text="hydrochlorothiazide" type="Active ingredient"/>
		<entity charOffset="2369-2379" id="DBMI.pac156.s17.e3" origId="s17.e3" text="lovastatin" type="Active ingredient"/>
		<entity charOffset="2381-2388" id="DBMI.pac156.s17.e4" origId="s17.e4" text="digoxin" type="Active ingredient"/>
		<entity charOffset="2390-2399" id="DBMI.pac156.s17.e5" origId="s17.e5" text="valsartan" type="Active ingredient"/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ramipril" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="hydrochlorothiazide" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lovastatin" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.s17.e0" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valsartan" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e1" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e2" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e3" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e4" e2="DBMI.pac156.s17.e5" id="DBMI.pac156.s17.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e0" id="DBMI.pac156.s17.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e1" id="DBMI.pac156.s17.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e2" id="DBMI.pac156.s17.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e3" id="DBMI.pac156.s17.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.s17.e5" e2="DBMI.pac156.s17.e4" id="DBMI.pac156.s17.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac156.s18" origId="s18" text="Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated."/>
	<sentencespan id="DBMI.pac156.sp0" origId="sp0" text="7  DRUG INTERACTIONS\n\n7.1 Effects of Other Drugs on Aliskiren\n\nBased on in vitro studies, aliskiren is metabolized by CYP 3A4. Irbesartan: Coadministration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing. P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major efflux system involved in absorption and disposition of aliskiren in preclinical studies.">
		<entity charOffset="160-170" id="DBMI.pac156.sp0.e0" origId="sp0.e0" text="irbesartan" type="Active ingredient"/>
		<entity charOffset="179-188" id="DBMI.pac156.sp0.e1" origId="sp0.e1" text="aliskiren" type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp0.e0" e2="DBMI.pac156.sp0.e1" id="DBMI.pac156.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="irbesartan"/>
		<pair e1="DBMI.pac156.sp0.e1" e2="DBMI.pac156.sp0.e0" id="DBMI.pac156.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp1" origId="sp1" text="The potential for drug interactions at the Pgp site will likely depend on the degree of inhibition of this transporter. Atorvastatin: Coadministration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing. Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.">
		<entity charOffset="543-555" id="DBMI.pac156.sp1.e0" origId="sp1.e0" text="atorvastatin" type="Active ingredient"/>
		<entity charOffset="592-601" id="DBMI.pac156.sp1.e1" origId="sp1.e1" text="aliskiren" type="Active ingredient"/>
		<entity charOffset="692-704" id="DBMI.pac156.sp1.e2" origId="sp1.e2" text="ketoconazole" type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp1.e0" e2="DBMI.pac156.sp1.e1" id="DBMI.pac156.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="atorvastatin"/>
		<pair e1="DBMI.pac156.sp1.e0" e2="DBMI.pac156.sp1.e2" id="DBMI.pac156.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp1.e1" e2="DBMI.pac156.sp1.e0" id="DBMI.pac156.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp1.e1" e2="DBMI.pac156.sp1.e2" id="DBMI.pac156.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp1.e2" e2="DBMI.pac156.sp1.e0" id="DBMI.pac156.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp1.e2" e2="DBMI.pac156.sp1.e1" id="DBMI.pac156.sp1.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="ketoconazole"/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp2" origId="sp2" text="A 400-mg once-daily dose was not studied but would be expected to increase aliskiren blood levels further. Itraconazole: Coadministration of 100 mg itraconazole with 150 mg aliskiren resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC of aliskiren. Concomitant use of aliskiren with itraconazole is not recommended.">
		<entity charOffset="940-952" id="DBMI.pac156.sp2.e0" origId="sp2.e0" text="itraconazole" type="Active ingredient"/>
		<entity charOffset="965-974" id="DBMI.pac156.sp2.e1" origId="sp2.e1" text="aliskiren" type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp2.e0" e2="DBMI.pac156.sp2.e1" id="DBMI.pac156.sp2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="itraconazole"/>
		<pair e1="DBMI.pac156.sp2.e1" e2="DBMI.pac156.sp2.e0" id="DBMI.pac156.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp3" origId="sp3" text="Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine with 75 mg aliskiren resulted in an approximately 2.5-fold increase in Cmax and 5-fold increase in AUC of aliskiren. Concomitant use of aliskiren with cyclosporine is not recommended. Verapamil: Coadministration of 240 mg of verapamil with 300 mg aliskiren resulted in an approximately 2-fold increase in Cmax and AUC of aliskiren.">
		<entity charOffset="1190-1202" id="DBMI.pac156.sp3.e0" origId="sp3.e0" text="cyclosporine" type="Active ingredient"/>
		<entity charOffset="1214-1223" id="DBMI.pac156.sp3.e1" origId="sp3.e1" text="aliskiren" type="Active ingredient"/>
		<entity charOffset="1430-1439" id="DBMI.pac156.sp3.e2" origId="sp3.e2" text="verapamil" type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp3.e0" e2="DBMI.pac156.sp3.e1" id="DBMI.pac156.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="cyclosporine"/>
		<pair e1="DBMI.pac156.sp3.e0" e2="DBMI.pac156.sp3.e2" id="DBMI.pac156.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp3.e1" e2="DBMI.pac156.sp3.e0" id="DBMI.pac156.sp3.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp3.e1" e2="DBMI.pac156.sp3.e2" id="DBMI.pac156.sp3.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp3.e2" e2="DBMI.pac156.sp3.e0" id="DBMI.pac156.sp3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp3.e2" e2="DBMI.pac156.sp3.e1" id="DBMI.pac156.sp3.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="aliskiren" precipitant="verapamil"/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp4" origId="sp4" text="However, no dosage adjustment is necessary. Drugs with no clinically significant effects: Coadministration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure. 7.2 Effects of Aliskiren on Other Drugs\n\nAliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A) or induce CYP 3A4.">
		<entity charOffset="1648-1658" id="DBMI.pac156.sp4.e0" origId="sp4.e0" text="lovastatin" type="Active ingredient"/>
		<entity charOffset="1833-1842" id="DBMI.pac156.sp4.e1" origId="sp4.e1" text="aliskiren" type="Active ingredient"/>
		<entity charOffset="1660-1668" id="DBMI.pac156.sp4.e2" origId="sp4.e2" text="atenolol" type="Active ingredient"/>
		<entity charOffset="1670-1678" id="DBMI.pac156.sp4.e3" origId="sp4.e3" text="warfarin" type="Active ingredient"/>
		<entity charOffset="1680-1690" id="DBMI.pac156.sp4.e4" origId="sp4.e4" text="furosemide" type="Active ingredient"/>
		<entity charOffset="1692-1699" id="DBMI.pac156.sp4.e5" origId="sp4.e5" text="digoxin" type="Active ingredient"/>
		<entity charOffset="1701-1710" id="DBMI.pac156.sp4.e6" origId="sp4.e6" text="celecoxib" type="Active ingredient"/>
		<entity charOffset="1712-1731" id="DBMI.pac156.sp4.e7" origId="sp4.e7" text="hydrochlorothiazide" type="Active ingredient"/>
		<entity charOffset="1733-1741" id="DBMI.pac156.sp4.e8" origId="sp4.e8" text="ramipril" type="Active ingredient"/>
		<entity charOffset="1743-1752" id="DBMI.pac156.sp4.e9" origId="sp4.e9" text="valsartan" type="Active ingredient"/>
		<entity charOffset="1754-1763" id="DBMI.pac156.sp4.e10" origId="sp4.e10" text="metformin" type="Active ingredient"/>
		<entity charOffset="1768-1778" id="DBMI.pac156.sp4.e11" origId="sp4.e11" text="amlodipine" type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="lovastatin"/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e0" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e1" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p23" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="atenolol"/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e2" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p34" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="warfarin"/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e3" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p45" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="furosemide"/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e4" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p56" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="digoxin"/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p64" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e5" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p67" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="celecoxib"/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p74" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e6" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p78" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="hydrochlorothiazide"/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p79" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p80" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p81" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p82" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p83" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p84" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p85" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p86" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e7" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p87" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p88" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p89" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="ramipril"/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p90" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p91" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p92" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p93" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p94" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p95" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p96" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p97" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e8" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p98" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p99" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p100" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="valsartan"/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p101" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p102" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p103" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p104" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p105" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p106" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p107" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p108" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e9" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p109" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p110" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p111" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="metformin"/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p112" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p113" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p114" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p115" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p116" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p117" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p118" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p119" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e10" e2="DBMI.pac156.sp4.e11" id="DBMI.pac156.sp4.p120" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e0" id="DBMI.pac156.sp4.p121" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e1" id="DBMI.pac156.sp4.p122" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="aliskiren" precipitant="amlodipine"/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e2" id="DBMI.pac156.sp4.p123" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e3" id="DBMI.pac156.sp4.p124" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e4" id="DBMI.pac156.sp4.p125" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e5" id="DBMI.pac156.sp4.p126" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e6" id="DBMI.pac156.sp4.p127" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e7" id="DBMI.pac156.sp4.p128" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e8" id="DBMI.pac156.sp4.p129" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e9" id="DBMI.pac156.sp4.p130" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp4.e11" e2="DBMI.pac156.sp4.e10" id="DBMI.pac156.sp4.p131" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp5" origId="sp5" text="Furosemide: When aliskiren was coadministered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively. Patients receiving furosemide could find its effect diminished after starting aliskiren. Drugs with no clinically significant effects: Coadministration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.">
		<entity charOffset="2024-2033" id="DBMI.pac156.sp5.e0" origId="sp5.e0" text="aliskiren" type="Active ingredient"/>
		<entity charOffset="2058-2068" id="DBMI.pac156.sp5.e1" origId="sp5.e1" text="furosemide" type="Active ingredient"/>
		<entity charOffset="2459-2467" id="DBMI.pac156.sp5.e2" origId="sp5.e2" text="ramipril" type="Active ingredient"/>
		<entity charOffset="2471-2490" id="DBMI.pac156.sp5.e3" origId="sp5.e3" text="hydrochlorothiazide" type="Active ingredient"/>
		<entity charOffset="2369-2379" id="DBMI.pac156.sp5.e4" origId="sp5.e4" text="lovastatin" type="Active ingredient"/>
		<entity charOffset="2381-2388" id="DBMI.pac156.sp5.e5" origId="sp5.e5" text="digoxin" type="Active ingredient"/>
		<entity charOffset="2390-2399" id="DBMI.pac156.sp5.e6" origId="sp5.e6" text="valsartan" type="Active ingredient"/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="furosemide" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ramipril" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="hydrochlorothiazide" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lovastatin" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.sp5.e0" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="valsartan" precipitant="aliskiren"/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e1" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e2" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e3" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e4" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e5" e2="DBMI.pac156.sp5.e6" id="DBMI.pac156.sp5.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e0" id="DBMI.pac156.sp5.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e1" id="DBMI.pac156.sp5.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e2" id="DBMI.pac156.sp5.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e3" id="DBMI.pac156.sp5.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e4" id="DBMI.pac156.sp5.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac156.sp5.e6" e2="DBMI.pac156.sp5.e5" id="DBMI.pac156.sp5.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac156.sp6" origId="sp6" text="Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not been evaluated."/>
</document>

<document id="DBMI.pac158" origId="pac158">
	<sentence id="DBMI.pac158.s0" origId="s0" text="Since mexiletine is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations."/>
	<sentence id="DBMI.pac158.s1" origId="s1" text="In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.">
		<entity charOffset="348-359" id="DBMI.pac158.s1.e0" origId="s1.e0" text="fluvoxamine" type="Active ingredient"/>
		<entity charOffset="282-292" id="DBMI.pac158.s1.e1" origId="s1.e1" text="mexiletine" type="Active ingredient"/>
		<pair e1="DBMI.pac158.s1.e0" e2="DBMI.pac158.s1.e1" id="DBMI.pac158.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mexiletine" precipitant="fluvoxamine"/>
		<pair e1="DBMI.pac158.s1.e1" e2="DBMI.pac158.s1.e0" id="DBMI.pac158.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac158.s2" origId="s2" text="In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.">
		<entity charOffset="486-497" id="DBMI.pac158.s2.e0" origId="s2.e0" text="propafenone" type="Active ingredient"/>
		<entity charOffset="528-538" id="DBMI.pac158.s2.e1" origId="s2.e1" text="mexiletine" type="Active ingredient"/>
		<pair e1="DBMI.pac158.s2.e0" e2="DBMI.pac158.s2.e1" id="DBMI.pac158.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="mexiletine" precipitant="propafenone"/>
		<pair e1="DBMI.pac158.s2.e0" e2="DBMI.pac158.s2.e1" id="DBMI.pac158.s2.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mexiletine" precipitant="propafenone"/>
		<pair e1="DBMI.pac158.s2.e1" e2="DBMI.pac158.s2.e0" id="DBMI.pac158.s2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac158.s3" origId="s3" text="However, the metabolic clearance of mexiletine in the extensive metabolizer phenotype decreased by about 70% making the poor and extensive metabolizer groups indistinguishable.">
		<entity charOffset="613-623" id="DBMI.pac158.s3.e0" origId="s3.e0" text="mexiletine" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac158.s4" origId="s4" text="In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine.">
		<entity charOffset="891-901" id="DBMI.pac158.s4.e0" origId="s4.e0" text="mexiletine" type="Active ingredient"/>
		<entity charOffset="816-827" id="DBMI.pac158.s4.e1" origId="s4.e1" text="propafenone" type="Active ingredient"/>
		<pair e1="DBMI.pac158.s4.e0" e2="DBMI.pac158.s4.e1" id="DBMI.pac158.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone" precipitant="mexiletine"/>
		<pair e1="DBMI.pac158.s4.e1" e2="DBMI.pac158.s4.e0" id="DBMI.pac158.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac158.s5" origId="s5" text="Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone."/>
	<sentence id="DBMI.pac158.s6" origId="s6" text="When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect."/>
	<sentencespan id="DBMI.pac158.sp0" origId="sp0" text="Since mexiletine is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations. In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.">
		<entity charOffset="348-359" id="DBMI.pac158.sp0.e0" origId="sp0.e0" text="fluvoxamine" type="Active ingredient"/>
		<entity charOffset="282-292" id="DBMI.pac158.sp0.e1" origId="sp0.e1" text="mexiletine" type="Active ingredient"/>
		<entity charOffset="486-497" id="DBMI.pac158.sp0.e2" origId="sp0.e2" text="propafenone" type="Active ingredient"/>
		<pair e1="DBMI.pac158.sp0.e0" e2="DBMI.pac158.sp0.e1" id="DBMI.pac158.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mexiletine" precipitant="fluvoxamine"/>
		<pair e1="DBMI.pac158.sp0.e0" e2="DBMI.pac158.sp0.e2" id="DBMI.pac158.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac158.sp0.e1" e2="DBMI.pac158.sp0.e0" id="DBMI.pac158.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac158.sp0.e1" e2="DBMI.pac158.sp0.e2" id="DBMI.pac158.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac158.sp0.e2" e2="DBMI.pac158.sp0.e0" id="DBMI.pac158.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac158.sp0.e2" e2="DBMI.pac158.sp0.e1" id="DBMI.pac158.sp0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="mexiletine" precipitant="propafenone"/>
		<pair e1="DBMI.pac158.sp0.e2" e2="DBMI.pac158.sp0.e1" id="DBMI.pac158.sp0.p6" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="mexiletine" precipitant="propafenone"/>
	</sentencespan>
	<sentencespan id="DBMI.pac158.sp1" origId="sp1" text="However, the metabolic clearance of mexiletine in the extensive metabolizer phenotype decreased by about 70% making the poor and extensive metabolizer groups indistinguishable. In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine. Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone.">
		<entity charOffset="613-623" id="DBMI.pac158.sp1.e0" origId="sp1.e0" text="mexiletine" type="Active ingredient"/>
		<entity charOffset="816-827" id="DBMI.pac158.sp1.e1" origId="sp1.e1" text="propafenone" type="Active ingredient"/>
		<pair e1="DBMI.pac158.sp1.e0" e2="DBMI.pac158.sp1.e1" id="DBMI.pac158.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propafenone" precipitant="mexiletine"/>
		<pair e1="DBMI.pac158.sp1.e1" e2="DBMI.pac158.sp1.e0" id="DBMI.pac158.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac158.sp2" origId="sp2" text="When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect."/>
</document>

<document id="DBMI.pac159" origId="pac159">
	<sentence id="DBMI.pac159.s0" origId="s0" text="Mexiletine does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to mexiletine hydrochloride USP capsules, has been reported to lower serum digoxin levels.">
		<entity charOffset="0-10" id="DBMI.pac159.s0.e0" origId="s0.e0" text="Mexiletine" type="Active ingredient"/>
		<entity charOffset="32-39" id="DBMI.pac159.s0.e1" origId="s0.e1" text="digoxin" type="Active ingredient"/>
		<entity charOffset="51-60" id="DBMI.pac159.s0.e2" origId="s0.e2" text="magnesium" type="Active ingredient"/>
		<entity charOffset="61-69" id="DBMI.pac159.s0.e3" origId="s0.e3" text="aluminum" type="Active ingredient"/>
		<pair e1="DBMI.pac159.s0.e0" e2="DBMI.pac159.s0.e1" id="DBMI.pac159.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin" precipitant="Mexiletine"/>
		<pair e1="DBMI.pac159.s0.e0" e2="DBMI.pac159.s0.e2" id="DBMI.pac159.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e0" e2="DBMI.pac159.s0.e3" id="DBMI.pac159.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e1" e2="DBMI.pac159.s0.e0" id="DBMI.pac159.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e1" e2="DBMI.pac159.s0.e2" id="DBMI.pac159.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e1" e2="DBMI.pac159.s0.e3" id="DBMI.pac159.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e2" e2="DBMI.pac159.s0.e0" id="DBMI.pac159.s0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e2" e2="DBMI.pac159.s0.e1" id="DBMI.pac159.s0.p7" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin" precipitant="magnesium"/>
		<pair e1="DBMI.pac159.s0.e2" e2="DBMI.pac159.s0.e3" id="DBMI.pac159.s0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e3" e2="DBMI.pac159.s0.e0" id="DBMI.pac159.s0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac159.s0.e3" e2="DBMI.pac159.s0.e1" id="DBMI.pac159.s0.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin" precipitant="aluminum"/>
		<pair e1="DBMI.pac159.s0.e3" e2="DBMI.pac159.s0.e2" id="DBMI.pac159.s0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac16" origId="pac16">
	<sentence id="DBMI.pac16.s0" origId="s0" text="In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions."/>
	<sentence id="DBMI.pac16.s1" origId="s1" text="The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.">
		<entity charOffset="231-241" id="DBMI.pac16.s1.e0" origId="s1.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="315-324" id="DBMI.pac16.s1.e1" origId="s1.e1" text="cisapride" type="Active ingredient"/>
		<entity charOffset="284-295" id="DBMI.pac16.s1.e2" origId="s1.e2" text="terfenadine" type="Active ingredient"/>
		<entity charOffset="297-310" id="DBMI.pac16.s1.e3" origId="s1.e3" text="carbamazepine" type="Active ingredient"/>
		<pair e1="DBMI.pac16.s1.e0" e2="DBMI.pac16.s1.e1" id="DBMI.pac16.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="cisapride" precipitant="sertraline"/>
		<pair e1="DBMI.pac16.s1.e0" e2="DBMI.pac16.s1.e2" id="DBMI.pac16.s1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="terfenadine" precipitant="sertraline"/>
		<pair e1="DBMI.pac16.s1.e0" e2="DBMI.pac16.s1.e3" id="DBMI.pac16.s1.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine" precipitant="sertraline"/>
		<pair e1="DBMI.pac16.s1.e1" e2="DBMI.pac16.s1.e0" id="DBMI.pac16.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e1" e2="DBMI.pac16.s1.e2" id="DBMI.pac16.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e1" e2="DBMI.pac16.s1.e3" id="DBMI.pac16.s1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e2" e2="DBMI.pac16.s1.e0" id="DBMI.pac16.s1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e2" e2="DBMI.pac16.s1.e1" id="DBMI.pac16.s1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e2" e2="DBMI.pac16.s1.e3" id="DBMI.pac16.s1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e3" e2="DBMI.pac16.s1.e0" id="DBMI.pac16.s1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e3" e2="DBMI.pac16.s1.e1" id="DBMI.pac16.s1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.s1.e3" e2="DBMI.pac16.s1.e2" id="DBMI.pac16.s1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac16.s2" origId="s2" text="These data indicate that sertralines extent of inhibition of P450 3A4 activity is not likely to be of clinical significance."/>
	<sentence id="DBMI.pac16.s3" origId="s3" text="Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).">
		<entity charOffset="514-524" id="DBMI.pac16.s3.e0" origId="s3.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="490-499" id="DBMI.pac16.s3.e1" origId="s3.e1" text="cisapride" type="Active ingredient"/>
		<pair e1="DBMI.pac16.s3.e0" e2="DBMI.pac16.s3.e1" id="DBMI.pac16.s3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="cisapride" precipitant="sertraline"/>
		<pair e1="DBMI.pac16.s3.e1" e2="DBMI.pac16.s3.e0" id="DBMI.pac16.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac16.sp0" origId="sp0" text="In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertralines extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.">
		<entity charOffset="231-241" id="DBMI.pac16.sp0.e0" origId="sp0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="315-324" id="DBMI.pac16.sp0.e1" origId="sp0.e1" text="cisapride" type="Active ingredient"/>
		<entity charOffset="284-295" id="DBMI.pac16.sp0.e2" origId="sp0.e2" text="terfenadine" type="Active ingredient"/>
		<entity charOffset="297-310" id="DBMI.pac16.sp0.e3" origId="sp0.e3" text="carbamazepine" type="Active ingredient"/>
		<pair e1="DBMI.pac16.sp0.e0" e2="DBMI.pac16.sp0.e1" id="DBMI.pac16.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="cisapride" precipitant="sertraline"/>
		<pair e1="DBMI.pac16.sp0.e0" e2="DBMI.pac16.sp0.e2" id="DBMI.pac16.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="terfenadine" precipitant="sertraline"/>
		<pair e1="DBMI.pac16.sp0.e0" e2="DBMI.pac16.sp0.e3" id="DBMI.pac16.sp0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine" precipitant="sertraline"/>
		<pair e1="DBMI.pac16.sp0.e1" e2="DBMI.pac16.sp0.e0" id="DBMI.pac16.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e1" e2="DBMI.pac16.sp0.e2" id="DBMI.pac16.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e1" e2="DBMI.pac16.sp0.e3" id="DBMI.pac16.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e2" e2="DBMI.pac16.sp0.e0" id="DBMI.pac16.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e2" e2="DBMI.pac16.sp0.e1" id="DBMI.pac16.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e2" e2="DBMI.pac16.sp0.e3" id="DBMI.pac16.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e3" e2="DBMI.pac16.sp0.e0" id="DBMI.pac16.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e3" e2="DBMI.pac16.sp0.e1" id="DBMI.pac16.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac16.sp0.e3" e2="DBMI.pac16.sp0.e2" id="DBMI.pac16.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac16.sp1" origId="sp1" text="Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).">
		<entity charOffset="514-524" id="DBMI.pac16.sp1.e0" origId="sp1.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="490-499" id="DBMI.pac16.sp1.e1" origId="sp1.e1" text="cisapride" type="Active ingredient"/>
		<pair e1="DBMI.pac16.sp1.e0" e2="DBMI.pac16.sp1.e1" id="DBMI.pac16.sp1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="cisapride" precipitant="sertraline"/>
		<pair e1="DBMI.pac16.sp1.e1" e2="DBMI.pac16.sp1.e0" id="DBMI.pac16.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac161" origId="pac161">
	<sentence id="DBMI.pac161.s0" origId="s0" text="Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations.">
		<entity charOffset="20-30" id="DBMI.pac161.s0.e0" origId="s0.e0" text="nelfinavir" type="Active ingredient"/>
		<entity charOffset="74-86" id="DBMI.pac161.s0.e1" origId="s0.e1" text="azithromycin" type="Active ingredient"/>
		<pair e1="DBMI.pac161.s0.e0" e2="DBMI.pac161.s0.e1" id="DBMI.pac161.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="azithromycin" precipitant="nelfinavir"/>
		<pair e1="DBMI.pac161.s0.e1" e2="DBMI.pac161.s0.e0" id="DBMI.pac161.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac161.s1" origId="s1" text="Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted (see ADVERSE REACTIONS)."/>
	<sentencespan id="DBMI.pac161.sp0" origId="sp0" text="Coadministration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted (see ADVERSE REACTIONS).">
		<entity charOffset="20-30" id="DBMI.pac161.sp0.e0" origId="sp0.e0" text="nelfinavir" type="Active ingredient"/>
		<entity charOffset="74-86" id="DBMI.pac161.sp0.e1" origId="sp0.e1" text="azithromycin" type="Active ingredient"/>
		<pair e1="DBMI.pac161.sp0.e0" e2="DBMI.pac161.sp0.e1" id="DBMI.pac161.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="azithromycin" precipitant="nelfinavir"/>
		<pair e1="DBMI.pac161.sp0.e1" e2="DBMI.pac161.sp0.e0" id="DBMI.pac161.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac163" origId="pac163">
	<sentence id="DBMI.pac163.s0" origId="s0" text="Acyclovir\n\nPlasma concentrations of meperidine and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.">
		<entity charOffset="102-111" id="DBMI.pac163.s0.e0" origId="s0.e0" text="acyclovir" type="Active ingredient"/>
		<entity charOffset="36-46" id="DBMI.pac163.s0.e1" origId="s0.e1" text="meperidine" type="Active ingredient"/>
		<entity charOffset="67-80" id="DBMI.pac163.s0.e2" origId="s0.e2" text="normeperidine" type="Metabolite"/>
		<pair e1="DBMI.pac163.s0.e0" e2="DBMI.pac163.s0.e1" id="DBMI.pac163.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="meperidine" precipitant="acyclovir"/>
		<pair e1="DBMI.pac163.s0.e0" e2="DBMI.pac163.s0.e2" id="DBMI.pac163.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="normeperidine" precipitant="acyclovir"/>
		<pair e1="DBMI.pac163.s0.e1" e2="DBMI.pac163.s0.e0" id="DBMI.pac163.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac163.s0.e1" e2="DBMI.pac163.s0.e2" id="DBMI.pac163.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac163.s0.e2" e2="DBMI.pac163.s0.e0" id="DBMI.pac163.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac163.s0.e2" e2="DBMI.pac163.s0.e1" id="DBMI.pac163.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac164" origId="pac164">
	<sentence id="DBMI.pac164.s0" origId="s0" text="Cimetidine\n\nCimetidine reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.">
		<entity charOffset="12-22" id="DBMI.pac164.s0.e0" origId="s0.e0" text="Cimetidine" type="Active ingredient"/>
		<entity charOffset="75-85" id="DBMI.pac164.s0.e1" origId="s0.e1" text="meperidine" type="Active ingredient"/>
		<entity charOffset="128-141" id="DBMI.pac164.s0.e2" origId="s0.e2" text="normeperidine" type="Metabolite"/>
		<pair e1="DBMI.pac164.s0.e0" e2="DBMI.pac164.s0.e1" id="DBMI.pac164.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="meperidine" precipitant="Cimetidine"/>
		<pair e1="DBMI.pac164.s0.e0" e2="DBMI.pac164.s0.e2" id="DBMI.pac164.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="normeperidine" precipitant="Cimetidine"/>
		<pair e1="DBMI.pac164.s0.e1" e2="DBMI.pac164.s0.e0" id="DBMI.pac164.s0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac164.s0.e1" e2="DBMI.pac164.s0.e2" id="DBMI.pac164.s0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac164.s0.e2" e2="DBMI.pac164.s0.e0" id="DBMI.pac164.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac164.s0.e2" e2="DBMI.pac164.s0.e1" id="DBMI.pac164.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
</document>

<document id="DBMI.pac166" origId="pac166">
	<sentence id="DBMI.pac166.s0" origId="s0" text="Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate.">
		<entity charOffset="0-10" id="DBMI.pac166.s0.e0" origId="s0.e0" text="Penicillin" type="Active ingredient"/>
		<entity charOffset="46-58" id="DBMI.pac166.s0.e1" origId="s0.e1" text="methotrexate" type="Active ingredient"/>
		<pair e1="DBMI.pac166.s0.e0" e2="DBMI.pac166.s0.e1" id="DBMI.pac166.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="methotrexate" precipitant="Penicillin"/>
		<pair e1="DBMI.pac166.s0.e1" e2="DBMI.pac166.s0.e0" id="DBMI.pac166.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac166.s1" origId="s1" text="Use of methotrexate with penicillins should be carefully monitored."/>
	<sentencespan id="DBMI.pac166.sp0" origId="sp0" text="Penicillins may reduce the renal clearance of methotrexate; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate. Use of methotrexate with penicillins should be carefully monitored.">
		<entity charOffset="0-10" id="DBMI.pac166.sp0.e0" origId="sp0.e0" text="Penicillin" type="Active ingredient"/>
		<entity charOffset="46-58" id="DBMI.pac166.sp0.e1" origId="sp0.e1" text="methotrexate" type="Active ingredient"/>
		<pair e1="DBMI.pac166.sp0.e0" e2="DBMI.pac166.sp0.e1" id="DBMI.pac166.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="methotrexate" precipitant="Penicillin"/>
		<pair e1="DBMI.pac166.sp0.e1" e2="DBMI.pac166.sp0.e0" id="DBMI.pac166.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac168" origId="pac168">
	<sentence id="DBMI.pac168.s0" origId="s0" text="Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital.">
		<entity charOffset="61-71" id="DBMI.pac168.s0.e0" origId="s0.e0" text="Clonazepam" type="Active ingredient"/>
		<entity charOffset="132-145" id="DBMI.pac168.s0.e1" origId="s0.e1" text="carbamazepine" type="Active ingredient"/>
		<entity charOffset="121-130" id="DBMI.pac168.s0.e2" origId="s0.e2" text="phenytoin" type="Active ingredient"/>
		<entity charOffset="149-162" id="DBMI.pac168.s0.e3" origId="s0.e3" text="phenobarbital" type="Active ingredient"/>
		<pair e1="DBMI.pac168.s0.e0" e2="DBMI.pac168.s0.e1" id="DBMI.pac168.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine" precipitant="Clonazepam"/>
		<pair e1="DBMI.pac168.s0.e0" e2="DBMI.pac168.s0.e1" id="DBMI.pac168.s0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine" precipitant="Clonazepam"/>
		<pair e1="DBMI.pac168.s0.e0" e2="DBMI.pac168.s0.e2" id="DBMI.pac168.s0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin" precipitant="Clonazepam"/>
		<pair e1="DBMI.pac168.s0.e0" e2="DBMI.pac168.s0.e3" id="DBMI.pac168.s0.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenobarbital" precipitant="Clonazepam"/>
		<pair e1="DBMI.pac168.s0.e1" e2="DBMI.pac168.s0.e0" id="DBMI.pac168.s0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e1" e2="DBMI.pac168.s0.e2" id="DBMI.pac168.s0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e1" e2="DBMI.pac168.s0.e3" id="DBMI.pac168.s0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e2" e2="DBMI.pac168.s0.e0" id="DBMI.pac168.s0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e2" e2="DBMI.pac168.s0.e1" id="DBMI.pac168.s0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e2" e2="DBMI.pac168.s0.e3" id="DBMI.pac168.s0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e3" e2="DBMI.pac168.s0.e0" id="DBMI.pac168.s0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e3" e2="DBMI.pac168.s0.e1" id="DBMI.pac168.s0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.s0.e3" e2="DBMI.pac168.s0.e2" id="DBMI.pac168.s0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac168.s1" origId="s1" text="The effect of clonazepam on the metabolism of other drugs has not been investigated."/>
	<sentencespan id="DBMI.pac168.sp0" origId="sp0" text="Effect Of Clonazepam On The Pharmacokinetics Of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine or phenobarbital. The effect of clonazepam on the metabolism of other drugs has not been investigated.">
		<entity charOffset="61-71" id="DBMI.pac168.sp0.e0" origId="sp0.e0" text="Clonazepam" type="Active ingredient"/>
		<entity charOffset="132-145" id="DBMI.pac168.sp0.e1" origId="sp0.e1" text="carbamazepine" type="Active ingredient"/>
		<entity charOffset="121-130" id="DBMI.pac168.sp0.e2" origId="sp0.e2" text="phenytoin" type="Active ingredient"/>
		<entity charOffset="149-162" id="DBMI.pac168.sp0.e3" origId="sp0.e3" text="phenobarbital" type="Active ingredient"/>
		<pair e1="DBMI.pac168.sp0.e0" e2="DBMI.pac168.sp0.e1" id="DBMI.pac168.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine" precipitant="Clonazepam"/>
		<pair e1="DBMI.pac168.sp0.e0" e2="DBMI.pac168.sp0.e1" id="DBMI.pac168.sp0.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="carbamazepine" precipitant="Clonazepam"/>
		<pair e1="DBMI.pac168.sp0.e0" e2="DBMI.pac168.sp0.e2" id="DBMI.pac168.sp0.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin" precipitant="Clonazepam"/>
		<pair e1="DBMI.pac168.sp0.e0" e2="DBMI.pac168.sp0.e3" id="DBMI.pac168.sp0.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenobarbital" precipitant="Clonazepam"/>
		<pair e1="DBMI.pac168.sp0.e1" e2="DBMI.pac168.sp0.e0" id="DBMI.pac168.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e1" e2="DBMI.pac168.sp0.e2" id="DBMI.pac168.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e1" e2="DBMI.pac168.sp0.e3" id="DBMI.pac168.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e2" e2="DBMI.pac168.sp0.e0" id="DBMI.pac168.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e2" e2="DBMI.pac168.sp0.e1" id="DBMI.pac168.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e2" e2="DBMI.pac168.sp0.e3" id="DBMI.pac168.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e3" e2="DBMI.pac168.sp0.e0" id="DBMI.pac168.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e3" e2="DBMI.pac168.sp0.e1" id="DBMI.pac168.sp0.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac168.sp0.e3" e2="DBMI.pac168.sp0.e2" id="DBMI.pac168.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac17" origId="pac17">
	<sentence id="DBMI.pac17.s0" origId="s0" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose.">
		<entity charOffset="70-80" id="DBMI.pac17.s0.e0" origId="s0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="220-231" id="DBMI.pac17.s0.e1" origId="s0.e1" text="tolbutamide" type="Active ingredient"/>
		<pair e1="DBMI.pac17.s0.e0" e2="DBMI.pac17.s0.e1" id="DBMI.pac17.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tolbutamide" precipitant="sertraline"/>
		<pair e1="DBMI.pac17.s0.e1" e2="DBMI.pac17.s0.e0" id="DBMI.pac17.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac17.s1" origId="s1" text="Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug."/>
	<sentence id="DBMI.pac17.s2" origId="s2" text="The clinical significance of this decrease in tolbutamide clearance is unknown."/>
	<sentencespan id="DBMI.pac17.sp0" origId="sp0" text="In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.">
		<entity charOffset="70-80" id="DBMI.pac17.sp0.e0" origId="sp0.e0" text="sertraline" type="Active ingredient"/>
		<entity charOffset="220-231" id="DBMI.pac17.sp0.e1" origId="sp0.e1" text="tolbutamide" type="Active ingredient"/>
		<pair e1="DBMI.pac17.sp0.e0" e2="DBMI.pac17.sp0.e1" id="DBMI.pac17.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tolbutamide" precipitant="sertraline"/>
		<pair e1="DBMI.pac17.sp0.e1" e2="DBMI.pac17.sp0.e0" id="DBMI.pac17.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac170" origId="pac170">
	<sentence id="DBMI.pac170.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nIrbesartan\n\nNo significant drug-drug interactions have been reported with irbesartan."/>
	<sentence id="DBMI.pac170.s1" origId="s1" text="[See Clinical Pharmacology (12.3).]"/>
	<sentence id="DBMI.pac170.s2" origId="s2" text="Hydrochlorothiazide\n\nWhen administered concurrently the following drugs may interact with thiazide diuretics:\n\nAlcohol, Barbiturates, or Narcotics: potentiation of orthostatic hypotension may occur."/>
	<sentence id="DBMI.pac170.s3" origId="s3" text="Antidiabetic Drugs (oral agents and insulin): dosage adjustment of the antidiabetic drug may be required."/>
	<sentence id="DBMI.pac170.s4" origId="s4" text="Other Antihypertensive Drugs: additive effect or potentiation."/>
	<sentence id="DBMI.pac170.s5" origId="s5" text="Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins."/>
	<sentence id="DBMI.pac170.s6" origId="s6" text="Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.">
		<entity charOffset="666-680" id="DBMI.pac170.s6.e0" origId="s6.e0" text="cholestyramine" type="Active ingredient"/>
		<entity charOffset="711-730" id="DBMI.pac170.s6.e1" origId="s6.e1" text="hydrochlorothiazide" type="Active ingredient"/>
		<entity charOffset="684-694" id="DBMI.pac170.s6.e2" origId="s6.e2" text="colestipol" type="Active ingredient"/>
		<pair e1="DBMI.pac170.s6.e0" e2="DBMI.pac170.s6.e1" id="DBMI.pac170.s6.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="hydrochlorothiazide" precipitant="cholestyramine"/>
		<pair e1="DBMI.pac170.s6.e0" e2="DBMI.pac170.s6.e2" id="DBMI.pac170.s6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.s6.e1" e2="DBMI.pac170.s6.e0" id="DBMI.pac170.s6.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.s6.e1" e2="DBMI.pac170.s6.e2" id="DBMI.pac170.s6.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.s6.e2" e2="DBMI.pac170.s6.e0" id="DBMI.pac170.s6.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.s6.e2" e2="DBMI.pac170.s6.e1" id="DBMI.pac170.s6.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="hydrochlorothiazide" precipitant="colestipol"/>
	</sentence>
	<sentence id="DBMI.pac170.s7" origId="s7" text="Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia."/>
	<sentence id="DBMI.pac170.s8" origId="s8" text="Pressor Amines (e.g., Norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use."/>
	<sentence id="DBMI.pac170.s9" origId="s9" text="Skeletal Muscle Relaxants, Nondepolarizing (e.g., Tubocurarine): possible increased responsiveness to the muscle relaxant."/>
	<sentence id="DBMI.pac170.s10" origId="s10" text="Lithium: should not generally be given with diuretics."/>
	<sentence id="DBMI.pac170.s11" origId="s11" text="Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.">
		<entity charOffset="1264-1271" id="DBMI.pac170.s11.e0" origId="s11.e0" text="lithium" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac170.s12" origId="s12" text="Refer to the package insert for lithium preparations before use of such preparations with AVALIDE.">
		<entity charOffset="1403-1410" id="DBMI.pac170.s12.e0" origId="s12.e0" text="AVALIDE" type="Drug product"/>
	</sentence>
	<sentence id="DBMI.pac170.s13" origId="s13" text="[See Warnings and Precautions (5.5).]"/>
	<sentence id="DBMI.pac170.s14" origId="s14" text="Non-steroidal Anti-inflammatory Drugs: in some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics."/>
	<sentence id="DBMI.pac170.s15" origId="s15" text="Therefore, when AVALIDE (irbesartan-hydrochlorothiazide) Tablets and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."/>
	<sentencespan id="DBMI.pac170.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nIrbesartan\n\nNo significant drug-drug interactions have been reported with irbesartan. [See Clinical Pharmacology (12.3).] Hydrochlorothiazide\n\nWhen administered concurrently the following drugs may interact with thiazide diuretics:\n\nAlcohol, Barbiturates, or Narcotics: potentiation of orthostatic hypotension may occur."/>
	<sentencespan id="DBMI.pac170.sp1" origId="sp1" text="Antidiabetic Drugs (oral agents and insulin): dosage adjustment of the antidiabetic drug may be required. Other Antihypertensive Drugs: additive effect or potentiation. Cholestyramine and Colestipol Resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins."/>
	<sentencespan id="DBMI.pac170.sp2" origId="sp2" text="Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. Corticosteroids, ACTH: intensified electrolyte depletion, particularly hypokalemia. Pressor Amines (e.g., Norepinephrine): possible decreased response to pressor amines but not sufficient to preclude their use.">
		<entity charOffset="666-680" id="DBMI.pac170.sp2.e0" origId="sp2.e0" text="cholestyramine" type="Active ingredient"/>
		<entity charOffset="711-730" id="DBMI.pac170.sp2.e1" origId="sp2.e1" text="hydrochlorothiazide" type="Active ingredient"/>
		<entity charOffset="684-694" id="DBMI.pac170.sp2.e2" origId="sp2.e2" text="colestipol" type="Active ingredient"/>
		<pair e1="DBMI.pac170.sp2.e0" e2="DBMI.pac170.sp2.e1" id="DBMI.pac170.sp2.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="hydrochlorothiazide" precipitant="cholestyramine"/>
		<pair e1="DBMI.pac170.sp2.e0" e2="DBMI.pac170.sp2.e2" id="DBMI.pac170.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.sp2.e1" e2="DBMI.pac170.sp2.e0" id="DBMI.pac170.sp2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.sp2.e1" e2="DBMI.pac170.sp2.e2" id="DBMI.pac170.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.sp2.e2" e2="DBMI.pac170.sp2.e0" id="DBMI.pac170.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac170.sp2.e2" e2="DBMI.pac170.sp2.e1" id="DBMI.pac170.sp2.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="hydrochlorothiazide" precipitant="colestipol"/>
	</sentencespan>
	<sentencespan id="DBMI.pac170.sp3" origId="sp3" text="Skeletal Muscle Relaxants, Nondepolarizing (e.g., Tubocurarine): possible increased responsiveness to the muscle relaxant. Lithium: should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.">
		<entity charOffset="1264-1271" id="DBMI.pac170.sp3.e0" origId="sp3.e0" text="lithium" type="Active ingredient"/>
	</sentencespan>
	<sentencespan id="DBMI.pac170.sp4" origId="sp4" text="Refer to the package insert for lithium preparations before use of such preparations with AVALIDE. [See Warnings and Precautions (5.5).] Non-steroidal Anti-inflammatory Drugs: in some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.">
		<entity charOffset="1403-1410" id="DBMI.pac170.sp4.e0" origId="sp4.e0" text="AVALIDE" type="Drug product"/>
	</sentencespan>
	<sentencespan id="DBMI.pac170.sp5" origId="sp5" text="Therefore, when AVALIDE (irbesartan-hydrochlorothiazide) Tablets and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained."/>
</document>

<document id="DBMI.pac171" origId="pac171">
	<sentence id="DBMI.pac171.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nIrbesartan\n\nAngiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II)."/>
	<sentence id="DBMI.pac171.s1" origId="s1" text="Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth."/>
	<sentence id="DBMI.pac171.s2" origId="s2" text="Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor."/>
	<sentence id="DBMI.pac171.s3" origId="s3" text="There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis."/>
	<sentence id="DBMI.pac171.s4" origId="s4" text="Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity."/>
	<sentence id="DBMI.pac171.s5" origId="s5" text="Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure."/>
	<sentence id="DBMI.pac171.s6" origId="s6" text="Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis."/>
	<sentence id="DBMI.pac171.s7" origId="s7" text="Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known."/>
	<sentence id="DBMI.pac171.s8" origId="s8" text="Hydrochlorothiazide\n\nHydrochlorothiazide is a thiazide diuretic."/>
	<sentence id="DBMI.pac171.s9" origId="s9" text="Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts."/>
	<sentence id="DBMI.pac171.s10" origId="s10" text="Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium."/>
	<sentence id="DBMI.pac171.s11" origId="s11" text="The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics."/>
	<sentence id="DBMI.pac171.s12" origId="s12" text="The mechanism of the antihypertensive effect of thiazides is not fully understood."/>
	<sentence id="DBMI.pac171.s13" origId="s13" text="12.2 Pharmacodynamics\n\nIrbesartan\n\nIn healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions."/>
	<sentence id="DBMI.pac171.s14" origId="s14" text="Inhibition was complete (100%) 4 hours following oral doses of 150 mg or 300 mg and partial inhibition was sustained for 24 hours (60% and 40% at 300 mg and 150 mg, respectively)."/>
	<sentence id="DBMI.pac171.s15" origId="s15" text="In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels."/>
	<sentence id="DBMI.pac171.s16" origId="s16" text="Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses."/>
	<sentence id="DBMI.pac171.s17" origId="s17" text="In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction."/>
	<sentence id="DBMI.pac171.s18" origId="s18" text="In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations."/>
	<sentence id="DBMI.pac171.s19" origId="s19" text="There was no effect on serum uric acid during chronic oral administration and no uricosuric effect."/>
	<sentence id="DBMI.pac171.s20" origId="s20" text="Hydrochlorothiazide\n\nAfter oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours."/>
	<sentence id="DBMI.pac171.s21" origId="s21" text="12.3 Pharmacokinetics\n\nIrbesartan\n\nIrbesartan is an orally active agent that does not require biotransformation into an active form."/>
	<sentence id="DBMI.pac171.s22" origId="s22" text="The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%."/>
	<sentence id="DBMI.pac171.s23" origId="s23" text="Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing."/>
	<sentence id="DBMI.pac171.s24" origId="s24" text="Food does not affect the bioavailability of irbesartan."/>
	<sentence id="DBMI.pac171.s25" origId="s25" text="Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range."/>
	<sentence id="DBMI.pac171.s26" origId="s26" text="The terminal elimination half-life of irbesartan averaged 11 to 15 hours."/>
	<sentence id="DBMI.pac171.s27" origId="s27" text="Steady-state concentrations are achieved within 3 days."/>
	<sentence id="DBMI.pac171.s28" origId="s28" text="Limited accumulation of irbesartan (&lt;20%) is observed in plasma upon repeated once-daily dosing."/>
	<sentence id="DBMI.pac171.s29" origId="s29" text="Hydrochlorothiazide\n\nWhen plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours."/>
	<sentence id="DBMI.pac171.s30" origId="s30" text="Metabolism and Elimination\n\nIrbesartan\n\nIrbesartan is metabolized via glucuronide conjugation and oxidation."/>
	<sentence id="DBMI.pac171.s31" origId="s31" text="Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan."/>
	<sentence id="DBMI.pac171.s32" origId="s32" text="The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%)."/>
	<sentence id="DBMI.pac171.s33" origId="s33" text="The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity."/>
	<sentence id="DBMI.pac171.s34" origId="s34" text="Irbesartan and its metabolites are excreted by both biliary and renal routes."/>
	<sentence id="DBMI.pac171.s35" origId="s35" text="Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide."/>
	<sentence id="DBMI.pac171.s36" origId="s36" text="In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible."/>
	<sentence id="DBMI.pac171.s37" origId="s37" text="Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1)."/>
	<sentence id="DBMI.pac171.s38" origId="s38" text="There was no induction or inhibition of 3A4."/>
	<sentence id="DBMI.pac171.s39" origId="s39" text="Hydrochlorothiazide\n\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney."/>
	<sentence id="DBMI.pac171.s40" origId="s40" text="At least 61% of the oral dose is eliminated unchanged within 24 hours."/>
	<sentence id="DBMI.pac171.s41" origId="s41" text="Distribution\n\nIrbesartan\n\nIrbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood."/>
	<sentence id="DBMI.pac171.s42" origId="s42" text="The average volume of distribution is 53 to 93 liters."/>
	<sentence id="DBMI.pac171.s43" origId="s43" text="Total plasma and renal clearances are in the range of 157 to 176 mL/min and 3.0 to 3.5 mL/min, respectively."/>
	<sentence id="DBMI.pac171.s44" origId="s44" text="With repetitive dosing, irbesartan accumulates to no clinically relevant extent."/>
	<sentence id="DBMI.pac171.s45" origId="s45" text="Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta."/>
	<sentence id="DBMI.pac171.s46" origId="s46" text="Irbesartan is excreted in the milk of lactating rats."/>
	<sentence id="DBMI.pac171.s47" origId="s47" text="Hydrochlorothiazide\n\nHydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk."/>
	<sentence id="DBMI.pac171.s48" origId="s48" text="Pediatric\n\nIrbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients &lt;18 years of age."/>
	<sentence id="DBMI.pac171.s49" origId="s49" text="Gender\n\nNo gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects."/>
	<sentence id="DBMI.pac171.s50" origId="s50" text="In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%)."/>
	<sentence id="DBMI.pac171.s51" origId="s51" text="No gender-related dosage adjustment is necessary."/>
	<sentence id="DBMI.pac171.s52" origId="s52" text="Geriatric\n\nIn elderly subjects (age 65 to 80 years), irbesartan elimination half-life was not significantly altered, but AUC and Cmax values were about 20% to 50% greater than those of young subjects (age 18 to 40 years)."/>
	<sentence id="DBMI.pac171.s53" origId="s53" text="No dosage adjustment is necessary in the elderly."/>
	<sentence id="DBMI.pac171.s54" origId="s54" text="Race\n\nIn healthy black subjects, irbesartan AUC values were approximately 25% greater than whites; there were no differences in Cmax values."/>
	<sentence id="DBMI.pac171.s55" origId="s55" text="Renal Insufficiency\n\nThe pharmacokinetics of irbesartan were not altered in patients with renal impairment or in patients on hemodialysis."/>
	<sentence id="DBMI.pac171.s56" origId="s56" text="Irbesartan is not removed by hemodialysis."/>
	<sentence id="DBMI.pac171.s57" origId="s57" text="No dosage adjustment is necessary in patients with mild to severe renal impairment unless a patient with renal impairment is also volume depleted."/>
	<sentence id="DBMI.pac171.s58" origId="s58" text="[See Warnings and Precautions (5.2).]"/>
	<sentence id="DBMI.pac171.s59" origId="s59" text="Hepatic Insufficiency\n\nThe pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver."/>
	<sentence id="DBMI.pac171.s60" origId="s60" text="No dosage adjustment is necessary in patients with hepatic insufficiency."/>
	<sentence id="DBMI.pac171.s61" origId="s61" text="Drug-Drug Interactions\n\nNo significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine."/>
	<sentence id="DBMI.pac171.s62" origId="s62" text="In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine."/>
	<sentence id="DBMI.pac171.s63" origId="s63" text="However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible."/>
	<sentence id="DBMI.pac171.s64" origId="s64" text="Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics.">
		<entity charOffset="8604-8614" id="DBMI.pac171.s64.e0" origId="s64.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="8618-8637" id="DBMI.pac171.s64.e1" origId="s64.e1" text="hydrochlorothiazide" type="Active ingredient"/>
		<pair e1="DBMI.pac171.s64.e0" e2="DBMI.pac171.s64.e1" id="DBMI.pac171.s64.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s64.e1" e2="DBMI.pac171.s64.e0" id="DBMI.pac171.s64.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac171.s65" origId="s65" text="Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.">
		<entity charOffset="8655-8665" id="DBMI.pac171.s65.e0" origId="s65.e0" text="irbesartan" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac171.s66" origId="s66" text="In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.">
		<entity charOffset="8959-8969" id="DBMI.pac171.s66.e0" origId="s66.e0" text="irbesartan" type="Active ingredient"/>
		<entity charOffset="8916-8924" id="DBMI.pac171.s66.e1" origId="s66.e1" text="warfarin" type="Active ingredient"/>
		<entity charOffset="8950-8957" id="DBMI.pac171.s66.e2" origId="s66.e2" text="digoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac171.s66.e0" e2="DBMI.pac171.s66.e1" id="DBMI.pac171.s66.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="irbesartan"/>
		<pair e1="DBMI.pac171.s66.e0" e2="DBMI.pac171.s66.e2" id="DBMI.pac171.s66.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin" precipitant="irbesartan"/>
		<pair e1="DBMI.pac171.s66.e1" e2="DBMI.pac171.s66.e0" id="DBMI.pac171.s66.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s66.e1" e2="DBMI.pac171.s66.e2" id="DBMI.pac171.s66.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s66.e2" e2="DBMI.pac171.s66.e0" id="DBMI.pac171.s66.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.s66.e2" e2="DBMI.pac171.s66.e1" id="DBMI.pac171.s66.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac171.s67" origId="s67" text="The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.">
		<entity charOffset="9177-9187" id="DBMI.pac171.s67.e0" origId="s67.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="9125-9135" id="DBMI.pac171.s67.e1" origId="s67.e1" text="irbesartan" type="Active ingredient"/>
		<pair e1="DBMI.pac171.s67.e0" e2="DBMI.pac171.s67.e1" id="DBMI.pac171.s67.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan" precipitant="nifedipine"/>
		<pair e1="DBMI.pac171.s67.e1" e2="DBMI.pac171.s67.e0" id="DBMI.pac171.s67.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac171.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nIrbesartan\n\nAngiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the RAS and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor."/>
	<sentencespan id="DBMI.pac171.sp1" origId="sp1" text="There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor, and no agonist activity. Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure."/>
	<sentencespan id="DBMI.pac171.sp2" origId="sp2" text="Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis. Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known. Hydrochlorothiazide\n\nHydrochlorothiazide is a thiazide diuretic."/>
	<sentencespan id="DBMI.pac171.sp3" origId="sp3" text="Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics."/>
	<sentencespan id="DBMI.pac171.sp4" origId="sp4" text="The mechanism of the antihypertensive effect of thiazides is not fully understood. 12.2 Pharmacodynamics\n\nIrbesartan\n\nIn healthy subjects, single oral irbesartan doses of up to 300 mg produced dose-dependent inhibition of the pressor effect of angiotensin II infusions. Inhibition was complete (100%) 4 hours following oral doses of 150 mg or 300 mg and partial inhibition was sustained for 24 hours (60% and 40% at 300 mg and 150 mg, respectively)."/>
	<sentencespan id="DBMI.pac171.sp5" origId="sp5" text="In hypertensive patients, angiotensin II receptor inhibition following chronic administration of irbesartan causes a 1.5- to 2-fold rise in angiotensin II plasma concentration and a 2- to 3-fold increase in plasma renin levels. Aldosterone plasma concentrations generally decline following irbesartan administration, but serum potassium levels are not significantly affected at recommended doses. In hypertensive patients, chronic oral doses of irbesartan (up to 300 mg) had no effect on glomerular filtration rate, renal plasma flow or filtration fraction."/>
	<sentencespan id="DBMI.pac171.sp6" origId="sp6" text="In multiple dose studies in hypertensive patients, there were no clinically important effects on fasting triglycerides, total cholesterol, HDL-cholesterol, or fasting glucose concentrations. There was no effect on serum uric acid during chronic oral administration and no uricosuric effect. Hydrochlorothiazide\n\nAfter oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours."/>
	<sentencespan id="DBMI.pac171.sp7" origId="sp7" text="12.3 Pharmacokinetics\n\nIrbesartan\n\nIrbesartan is an orally active agent that does not require biotransformation into an active form. The oral absorption of irbesartan is rapid and complete with an average absolute bioavailability of 60% to 80%. Following oral administration of irbesartan, peak plasma concentrations of irbesartan are attained at 1.5 to 2 hours after dosing."/>
	<sentencespan id="DBMI.pac171.sp8" origId="sp8" text="Food does not affect the bioavailability of irbesartan. Irbesartan exhibits linear pharmacokinetics over the therapeutic dose range. The terminal elimination half-life of irbesartan averaged 11 to 15 hours."/>
	<sentencespan id="DBMI.pac171.sp9" origId="sp9" text="Steady-state concentrations are achieved within 3 days. Limited accumulation of irbesartan (&lt;20%) is observed in plasma upon repeated once-daily dosing. Hydrochlorothiazide\n\nWhen plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours."/>
	<sentencespan id="DBMI.pac171.sp10" origId="sp10" text="Metabolism and Elimination\n\nIrbesartan\n\nIrbesartan is metabolized via glucuronide conjugation and oxidation. Following oral or intravenous administration of 14C-labeled irbesartan, more than 80% of the circulating plasma radioactivity is attributable to unchanged irbesartan. The primary circulating metabolite is the inactive irbesartan glucuronide conjugate (approximately 6%)."/>
	<sentencespan id="DBMI.pac171.sp11" origId="sp11" text="The remaining oxidative metabolites do not add appreciably to irbesartans pharmacologic activity. Irbesartan and its metabolites are excreted by both biliary and renal routes. Following either oral or intravenous administration of 14C-labeled irbesartan, about 20% of radioactivity is recovered in the urine and the remainder in the feces, as irbesartan or irbesartan glucuronide."/>
	<sentencespan id="DBMI.pac171.sp12" origId="sp12" text="In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible. Irbesartan was neither metabolized by, nor did it substantially induce or inhibit, isoenzymes commonly associated with drug metabolism (1A1, 1A2, 2A6, 2B6, 2D6, 2E1). There was no induction or inhibition of 3A4."/>
	<sentencespan id="DBMI.pac171.sp13" origId="sp13" text="Hydrochlorothiazide\n\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated unchanged within 24 hours. Distribution\n\nIrbesartan\n\nIrbesartan is 90% bound to serum proteins (primarily albumin and 1-acid glycoprotein) with negligible binding to cellular components of blood."/>
	<sentencespan id="DBMI.pac171.sp14" origId="sp14" text="The average volume of distribution is 53 to 93 liters. Total plasma and renal clearances are in the range of 157 to 176 mL/min and 3.0 to 3.5 mL/min, respectively. With repetitive dosing, irbesartan accumulates to no clinically relevant extent."/>
	<sentencespan id="DBMI.pac171.sp15" origId="sp15" text="Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta. Irbesartan is excreted in the milk of lactating rats. Hydrochlorothiazide\n\nHydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk."/>
	<sentencespan id="DBMI.pac171.sp16" origId="sp16" text="Pediatric\n\nIrbesartan-hydrochlorothiazide pharmacokinetics have not been investigated in patients &lt;18 years of age. Gender\n\nNo gender-related differences in pharmacokinetics were observed in healthy elderly (age 65 to 80 years) or in healthy young (age 18 to 40 years) subjects. In studies of hypertensive patients, there was no gender difference in half-life or accumulation, but somewhat higher plasma concentrations of irbesartan were observed in females (11% to 44%)."/>
	<sentencespan id="DBMI.pac171.sp17" origId="sp17" text="No gender-related dosage adjustment is necessary. Geriatric\n\nIn elderly subjects (age 65 to 80 years), irbesartan elimination half-life was not significantly altered, but AUC and Cmax values were about 20% to 50% greater than those of young subjects (age 18 to 40 years). No dosage adjustment is necessary in the elderly."/>
	<sentencespan id="DBMI.pac171.sp18" origId="sp18" text="Race\n\nIn healthy black subjects, irbesartan AUC values were approximately 25% greater than whites; there were no differences in Cmax values. Renal Insufficiency\n\nThe pharmacokinetics of irbesartan were not altered in patients with renal impairment or in patients on hemodialysis. Irbesartan is not removed by hemodialysis."/>
	<sentencespan id="DBMI.pac171.sp19" origId="sp19" text="No dosage adjustment is necessary in patients with mild to severe renal impairment unless a patient with renal impairment is also volume depleted. [See Warnings and Precautions (5.2).] Hepatic Insufficiency\n\nThe pharmacokinetics of irbesartan following repeated oral administration were not significantly affected in patients with mild to moderate cirrhosis of the liver."/>
	<sentencespan id="DBMI.pac171.sp20" origId="sp20" text="No dosage adjustment is necessary in patients with hepatic insufficiency. Drug-Drug Interactions\n\nNo significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine. In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine."/>
	<sentencespan id="DBMI.pac171.sp21" origId="sp21" text="However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible. Concomitant nifedipine or hydrochlorothiazide had no effect on irbesartan pharmacokinetics. Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isoenzymes 1A1, 1A2, 2A6, 2B6, 2D6, 2E1, or 3A4.">
		<entity charOffset="8604-8614" id="DBMI.pac171.sp21.e0" origId="sp21.e0" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="8655-8665" id="DBMI.pac171.sp21.e1" origId="sp21.e1" text="irbesartan" type="Active ingredient"/>
		<entity charOffset="8618-8637" id="DBMI.pac171.sp21.e2" origId="sp21.e2" text="hydrochlorothiazide" type="Active ingredient"/>
		<pair e1="DBMI.pac171.sp21.e0" e2="DBMI.pac171.sp21.e1" id="DBMI.pac171.sp21.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan" precipitant="nifedipine"/>
		<pair e1="DBMI.pac171.sp21.e0" e2="DBMI.pac171.sp21.e2" id="DBMI.pac171.sp21.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e1" e2="DBMI.pac171.sp21.e0" id="DBMI.pac171.sp21.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e1" e2="DBMI.pac171.sp21.e2" id="DBMI.pac171.sp21.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e2" e2="DBMI.pac171.sp21.e0" id="DBMI.pac171.sp21.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp21.e2" e2="DBMI.pac171.sp21.e1" id="DBMI.pac171.sp21.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan" precipitant="hydrochlorothiazide"/>
	</sentencespan>
	<sentencespan id="DBMI.pac171.sp22" origId="sp22" text="In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin. The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.">
		<entity charOffset="8959-8969" id="DBMI.pac171.sp22.e0" origId="sp22.e0" text="irbesartan" type="Active ingredient"/>
		<entity charOffset="8916-8924" id="DBMI.pac171.sp22.e1" origId="sp22.e1" text="warfarin" type="Active ingredient"/>
		<entity charOffset="8950-8957" id="DBMI.pac171.sp22.e2" origId="sp22.e2" text="digoxin" type="Active ingredient"/>
		<entity charOffset="9177-9187" id="DBMI.pac171.sp22.e3" origId="sp22.e3" text="nifedipine" type="Active ingredient"/>
		<entity charOffset="9191-9210" id="DBMI.pac171.sp22.e4" origId="sp22.e4" text="hydrochlorothiazide" type="Active ingredient"/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="irbesartan"/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="digoxin" precipitant="irbesartan"/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e0" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e1" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e2" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan" precipitant="nifedipine"/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e3" e2="DBMI.pac171.sp22.e4" id="DBMI.pac171.sp22.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e0" id="DBMI.pac171.sp22.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="irbesartan" precipitant="hydrochlorothiazide"/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e1" id="DBMI.pac171.sp22.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e2" id="DBMI.pac171.sp22.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac171.sp22.e4" e2="DBMI.pac171.sp22.e3" id="DBMI.pac171.sp22.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac172" origId="pac172">
	<sentence id="DBMI.pac172.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nThe risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see Warnings and Precautions, Skeletal Muscle (5.1) and Clinical Pharmacology (12.3)]."/>
	<sentence id="DBMI.pac172.s1" origId="s1" text="7.1 Strong Inhibitors of CYP 3A4\n\nLIPITOR is metabolized by cytochrome P450 3A4."/>
	<sentence id="DBMI.pac172.s2" origId="s2" text="Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin."/>
	<sentence id="DBMI.pac172.s3" origId="s3" text="The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4."/>
	<sentence id="DBMI.pac172.s4" origId="s4" text="Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].">
		<entity charOffset="816-830" id="DBMI.pac172.s4.e0" origId="s4.e0" text="clarithromycin" type="Active ingredient"/>
		<entity charOffset="797-804" id="DBMI.pac172.s4.e1" origId="s4.e1" text="LIPITOR" type="Drug product"/>
		<entity charOffset="717-729" id="DBMI.pac172.s4.e2" origId="s4.e2" text="Atorvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac172.s4.e0" e2="DBMI.pac172.s4.e1" id="DBMI.pac172.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="clarithromycin"/>
		<pair e1="DBMI.pac172.s4.e0" e2="DBMI.pac172.s4.e2" id="DBMI.pac172.s4.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="clarithromycin"/>
		<pair e1="DBMI.pac172.s4.e1" e2="DBMI.pac172.s4.e0" id="DBMI.pac172.s4.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s4.e1" e2="DBMI.pac172.s4.e2" id="DBMI.pac172.s4.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s4.e2" e2="DBMI.pac172.s4.e0" id="DBMI.pac172.s4.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s4.e2" e2="DBMI.pac172.s4.e1" id="DBMI.pac172.s4.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s5" origId="s5" text="Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]."/>
	<sentence id="DBMI.pac172.s6" origId="s6" text="Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].">
		<entity charOffset="1260-1269" id="DBMI.pac172.s6.e0" origId="s6.e0" text="ritonavir" type="Active ingredient"/>
		<entity charOffset="1241-1248" id="DBMI.pac172.s6.e1" origId="s6.e1" text="LIPITOR" type="Drug product"/>
		<entity charOffset="1161-1173" id="DBMI.pac172.s6.e2" origId="s6.e2" text="Atorvastatin" type="Active ingredient"/>
		<entity charOffset="1275-1285" id="DBMI.pac172.s6.e3" origId="s6.e3" text="saquinavir" type="Active ingredient"/>
		<entity charOffset="1329-1338" id="DBMI.pac172.s6.e4" origId="s6.e4" text="lopinavir" type="Active ingredient"/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e1" id="DBMI.pac172.s6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="ritonavir"/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="ritonavir"/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="ritonavir"/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e3" id="DBMI.pac172.s6.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e0" e2="DBMI.pac172.s6.e4" id="DBMI.pac172.s6.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e1" e2="DBMI.pac172.s6.e0" id="DBMI.pac172.s6.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e1" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e1" e2="DBMI.pac172.s6.e3" id="DBMI.pac172.s6.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e1" e2="DBMI.pac172.s6.e4" id="DBMI.pac172.s6.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e2" e2="DBMI.pac172.s6.e0" id="DBMI.pac172.s6.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e2" e2="DBMI.pac172.s6.e1" id="DBMI.pac172.s6.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e2" e2="DBMI.pac172.s6.e3" id="DBMI.pac172.s6.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e2" e2="DBMI.pac172.s6.e4" id="DBMI.pac172.s6.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e3" e2="DBMI.pac172.s6.e0" id="DBMI.pac172.s6.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e3" e2="DBMI.pac172.s6.e1" id="DBMI.pac172.s6.p14" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="saquinavir"/>
		<pair e1="DBMI.pac172.s6.e3" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p15" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="saquinavir"/>
		<pair e1="DBMI.pac172.s6.e3" e2="DBMI.pac172.s6.e4" id="DBMI.pac172.s6.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e4" e2="DBMI.pac172.s6.e0" id="DBMI.pac172.s6.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s6.e4" e2="DBMI.pac172.s6.e1" id="DBMI.pac172.s6.p18" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="lopinavir"/>
		<pair e1="DBMI.pac172.s6.e4" e2="DBMI.pac172.s6.e2" id="DBMI.pac172.s6.p19" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="lopinavir"/>
		<pair e1="DBMI.pac172.s6.e4" e2="DBMI.pac172.s6.e3" id="DBMI.pac172.s6.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s7" origId="s7" text="Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]."/>
	<sentence id="DBMI.pac172.s8" origId="s8" text="Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].">
		<entity charOffset="1778-1790" id="DBMI.pac172.s8.e0" origId="s8.e0" text="itraconazole" type="Active ingredient"/>
		<entity charOffset="1680-1692" id="DBMI.pac172.s8.e1" origId="s8.e1" text="Atorvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac172.s8.e0" e2="DBMI.pac172.s8.e1" id="DBMI.pac172.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="itraconazole"/>
		<pair e1="DBMI.pac172.s8.e1" e2="DBMI.pac172.s8.e0" id="DBMI.pac172.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s9" origId="s9" text="Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]."/>
	<sentence id="DBMI.pac172.s10" origId="s10" text="7.2 Grapefruit Juice\n\nContains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day)."/>
	<sentence id="DBMI.pac172.s11" origId="s11" text="7.3 Cyclosporine\n\nAtorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter."/>
	<sentence id="DBMI.pac172.s12" origId="s12" text="Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin."/>
	<sentence id="DBMI.pac172.s13" origId="s13" text="Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)].">
		<entity charOffset="2537-2549" id="DBMI.pac172.s13.e0" origId="s13.e0" text="cyclosporine" type="Active ingredient"/>
		<entity charOffset="2439-2451" id="DBMI.pac172.s13.e1" origId="s13.e1" text="Atorvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac172.s13.e0" e2="DBMI.pac172.s13.e1" id="DBMI.pac172.s13.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="cyclosporine"/>
		<pair e1="DBMI.pac172.s13.e1" e2="DBMI.pac172.s13.e0" id="DBMI.pac172.s13.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s14" origId="s14" text="In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)]."/>
	<sentence id="DBMI.pac172.s15" origId="s15" text="7.4 Rifampin or other Inducers of Cytochrome P450 3A4\n\nConcomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.">
		<entity charOffset="2947-2956" id="DBMI.pac172.s15.e0" origId="s15.e0" text="efavirenz" type="Active ingredient"/>
		<entity charOffset="2895-2902" id="DBMI.pac172.s15.e1" origId="s15.e1" text="LIPITOR" type="Drug product"/>
		<entity charOffset="2958-2966" id="DBMI.pac172.s15.e2" origId="s15.e2" text="rifampin" type="Active ingredient"/>
		<pair e1="DBMI.pac172.s15.e0" e2="DBMI.pac172.s15.e1" id="DBMI.pac172.s15.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="efavirenz"/>
		<pair e1="DBMI.pac172.s15.e0" e2="DBMI.pac172.s15.e2" id="DBMI.pac172.s15.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s15.e1" e2="DBMI.pac172.s15.e0" id="DBMI.pac172.s15.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s15.e1" e2="DBMI.pac172.s15.e2" id="DBMI.pac172.s15.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s15.e2" e2="DBMI.pac172.s15.e0" id="DBMI.pac172.s15.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s15.e2" e2="DBMI.pac172.s15.e1" id="DBMI.pac172.s15.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="rifampin"/>
	</sentence>
	<sentence id="DBMI.pac172.s16" origId="s16" text="Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.">
		<entity charOffset="3226-3234" id="DBMI.pac172.s16.e0" origId="s16.e0" text="rifampin" type="Active ingredient"/>
		<entity charOffset="3287-3299" id="DBMI.pac172.s16.e1" origId="s16.e1" text="atorvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac172.s16.e0" e2="DBMI.pac172.s16.e1" id="DBMI.pac172.s16.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atorvastatin" precipitant="rifampin"/>
		<pair e1="DBMI.pac172.s16.e1" e2="DBMI.pac172.s16.e0" id="DBMI.pac172.s16.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s17" origId="s17" text="7.5 Digoxin\n\nWhen multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.">
		<entity charOffset="3360-3367" id="DBMI.pac172.s17.e0" origId="s17.e0" text="LIPITOR" type="Drug product"/>
		<entity charOffset="3372-3379" id="DBMI.pac172.s17.e1" origId="s17.e1" text="digoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac172.s17.e0" e2="DBMI.pac172.s17.e1" id="DBMI.pac172.s17.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin" precipitant="LIPITOR"/>
		<pair e1="DBMI.pac172.s17.e0" e2="DBMI.pac172.s17.e1" id="DBMI.pac172.s17.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin" precipitant="LIPITOR"/>
		<pair e1="DBMI.pac172.s17.e1" e2="DBMI.pac172.s17.e0" id="DBMI.pac172.s17.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s18" origId="s18" text="Patients taking digoxin should be monitored appropriately."/>
	<sentence id="DBMI.pac172.s19" origId="s19" text="7.6 Oral Contraceptives\n\nCo-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)].">
		<entity charOffset="3582-3589" id="DBMI.pac172.s19.e0" origId="s19.e0" text="LIPITOR" type="Drug product"/>
		<entity charOffset="3641-3654" id="DBMI.pac172.s19.e1" origId="s19.e1" text="norethindrone" type="Active ingredient"/>
		<entity charOffset="3659-3676" id="DBMI.pac172.s19.e2" origId="s19.e2" text="ethinyl estradiol" type="Active ingredient"/>
		<pair e1="DBMI.pac172.s19.e0" e2="DBMI.pac172.s19.e1" id="DBMI.pac172.s19.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="norethindrone" precipitant="LIPITOR"/>
		<pair e1="DBMI.pac172.s19.e0" e2="DBMI.pac172.s19.e2" id="DBMI.pac172.s19.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethinyl estradiol" precipitant="LIPITOR"/>
		<pair e1="DBMI.pac172.s19.e1" e2="DBMI.pac172.s19.e0" id="DBMI.pac172.s19.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s19.e1" e2="DBMI.pac172.s19.e2" id="DBMI.pac172.s19.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s19.e2" e2="DBMI.pac172.s19.e0" id="DBMI.pac172.s19.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.s19.e2" e2="DBMI.pac172.s19.e1" id="DBMI.pac172.s19.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac172.s20" origId="s20" text="These increases should be considered when selecting an oral contraceptive for a woman taking LIPITOR."/>
	<sentence id="DBMI.pac172.s21" origId="s21" text="7.7 Warfarin\n\nLIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment. "/>
	<sentencespan id="DBMI.pac172.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nThe risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see Warnings and Precautions, Skeletal Muscle (5.1) and Clinical Pharmacology (12.3)]. 7.1 Strong Inhibitors of CYP 3A4\n\nLIPITOR is metabolized by cytochrome P450 3A4. Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin."/>
	<sentencespan id="DBMI.pac172.sp1" origId="sp1" text="The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4. Clarithromycin: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)].">
		<entity charOffset="816-830" id="DBMI.pac172.sp1.e0" origId="sp1.e0" text="clarithromycin" type="Active ingredient"/>
		<entity charOffset="797-804" id="DBMI.pac172.sp1.e1" origId="sp1.e1" text="LIPITOR" type="Drug product"/>
		<entity charOffset="717-729" id="DBMI.pac172.sp1.e2" origId="sp1.e2" text="Atorvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp1.e0" e2="DBMI.pac172.sp1.e1" id="DBMI.pac172.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="clarithromycin"/>
		<pair e1="DBMI.pac172.sp1.e0" e2="DBMI.pac172.sp1.e2" id="DBMI.pac172.sp1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="clarithromycin"/>
		<pair e1="DBMI.pac172.sp1.e1" e2="DBMI.pac172.sp1.e0" id="DBMI.pac172.sp1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp1.e1" e2="DBMI.pac172.sp1.e2" id="DBMI.pac172.sp1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp1.e2" e2="DBMI.pac172.sp1.e0" id="DBMI.pac172.sp1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp1.e2" e2="DBMI.pac172.sp1.e1" id="DBMI.pac172.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp2" origId="sp2" text="Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg with ritonavir plus saquinavir (400 mg twice daily) or LIPITOR 20 mg with lopinavir plus ritonavir (400 mg + 100 mg twice daily) compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. Therefore, in patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]. Itraconazole: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg [see Clinical Pharmacology (12.3)].">
		<entity charOffset="1260-1269" id="DBMI.pac172.sp2.e0" origId="sp2.e0" text="ritonavir" type="Active ingredient"/>
		<entity charOffset="1241-1248" id="DBMI.pac172.sp2.e1" origId="sp2.e1" text="LIPITOR" type="Drug product"/>
		<entity charOffset="1161-1173" id="DBMI.pac172.sp2.e2" origId="sp2.e2" text="Atorvastatin" type="Active ingredient"/>
		<entity charOffset="1275-1285" id="DBMI.pac172.sp2.e3" origId="sp2.e3" text="saquinavir" type="Active ingredient"/>
		<entity charOffset="1329-1338" id="DBMI.pac172.sp2.e4" origId="sp2.e4" text="lopinavir" type="Active ingredient"/>
		<entity charOffset="1778-1790" id="DBMI.pac172.sp2.e5" origId="sp2.e5" text="itraconazole" type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="ritonavir"/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="ritonavir"/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="ritonavir"/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e0" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e1" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e2" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="saquinavir"/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p18" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="saquinavir"/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e3" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p22" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="lopinavir"/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p23" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="lopinavir"/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e4" e2="DBMI.pac172.sp2.e5" id="DBMI.pac172.sp2.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e0" id="DBMI.pac172.sp2.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e1" id="DBMI.pac172.sp2.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e2" id="DBMI.pac172.sp2.p28" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="itraconazole"/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e3" id="DBMI.pac172.sp2.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp2.e5" e2="DBMI.pac172.sp2.e4" id="DBMI.pac172.sp2.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp3" origId="sp3" text="Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg [see Warnings and Precautions, Skeletal Muscle (5.1) and Dosage and Administration (2.6)]. 7.2 Grapefruit Juice\n\nContains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day). 7.3 Cyclosporine\n\nAtorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter."/>
	<sentencespan id="DBMI.pac172.sp4" origId="sp4" text="Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone [see Clinical Pharmacology (12.3)]. In cases where co-administration of LIPITOR with cyclosporine is necessary, the dose of LIPITOR should not exceed 10 mg [see Warnings and Precautions, Skeletal Muscle (5.1)].">
		<entity charOffset="2537-2549" id="DBMI.pac172.sp4.e0" origId="sp4.e0" text="cyclosporine" type="Active ingredient"/>
		<entity charOffset="2439-2451" id="DBMI.pac172.sp4.e1" origId="sp4.e1" text="Atorvastatin" type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp4.e0" e2="DBMI.pac172.sp4.e1" id="DBMI.pac172.sp4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="Atorvastatin" precipitant="cyclosporine"/>
		<pair e1="DBMI.pac172.sp4.e1" e2="DBMI.pac172.sp4.e0" id="DBMI.pac172.sp4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp5" origId="sp5" text="7.4 Rifampin or other Inducers of Cytochrome P450 3A4\n\nConcomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. 7.5 Digoxin\n\nWhen multiple doses of LIPITOR and digoxin were coadministered, steady state plasma digoxin concentrations increased by approximately 20%.">
		<entity charOffset="2947-2956" id="DBMI.pac172.sp5.e0" origId="sp5.e0" text="efavirenz" type="Active ingredient"/>
		<entity charOffset="2895-2902" id="DBMI.pac172.sp5.e1" origId="sp5.e1" text="LIPITOR" type="Drug product"/>
		<entity charOffset="2958-2966" id="DBMI.pac172.sp5.e2" origId="sp5.e2" text="rifampin" type="Active ingredient"/>
		<entity charOffset="3287-3299" id="DBMI.pac172.sp5.e3" origId="sp5.e3" text="atorvastatin" type="Active ingredient"/>
		<entity charOffset="3372-3379" id="DBMI.pac172.sp5.e4" origId="sp5.e4" text="digoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp5.e0" e2="DBMI.pac172.sp5.e1" id="DBMI.pac172.sp5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="efavirenz"/>
		<pair e1="DBMI.pac172.sp5.e0" e2="DBMI.pac172.sp5.e2" id="DBMI.pac172.sp5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e0" e2="DBMI.pac172.sp5.e3" id="DBMI.pac172.sp5.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e0" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e0" id="DBMI.pac172.sp5.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e2" id="DBMI.pac172.sp5.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e3" id="DBMI.pac172.sp5.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p7" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin" precipitant="LIPITOR"/>
		<pair e1="DBMI.pac172.sp5.e1" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin" precipitant="LIPITOR"/>
		<pair e1="DBMI.pac172.sp5.e2" e2="DBMI.pac172.sp5.e0" id="DBMI.pac172.sp5.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e2" e2="DBMI.pac172.sp5.e1" id="DBMI.pac172.sp5.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="LIPITOR" precipitant="rifampin"/>
		<pair e1="DBMI.pac172.sp5.e2" e2="DBMI.pac172.sp5.e3" id="DBMI.pac172.sp5.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atorvastatin" precipitant="rifampin"/>
		<pair e1="DBMI.pac172.sp5.e2" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e3" e2="DBMI.pac172.sp5.e0" id="DBMI.pac172.sp5.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e3" e2="DBMI.pac172.sp5.e1" id="DBMI.pac172.sp5.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e3" e2="DBMI.pac172.sp5.e2" id="DBMI.pac172.sp5.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e3" e2="DBMI.pac172.sp5.e4" id="DBMI.pac172.sp5.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e4" e2="DBMI.pac172.sp5.e0" id="DBMI.pac172.sp5.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e4" e2="DBMI.pac172.sp5.e1" id="DBMI.pac172.sp5.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e4" e2="DBMI.pac172.sp5.e2" id="DBMI.pac172.sp5.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp5.e4" e2="DBMI.pac172.sp5.e3" id="DBMI.pac172.sp5.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp6" origId="sp6" text="Patients taking digoxin should be monitored appropriately. 7.6 Oral Contraceptives\n\nCo-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see Clinical Pharmacology (12.3)]. These increases should be considered when selecting an oral contraceptive for a woman taking LIPITOR.">
		<entity charOffset="3582-3589" id="DBMI.pac172.sp6.e0" origId="sp6.e0" text="LIPITOR" type="Drug product"/>
		<entity charOffset="3641-3654" id="DBMI.pac172.sp6.e1" origId="sp6.e1" text="norethindrone" type="Active ingredient"/>
		<entity charOffset="3659-3676" id="DBMI.pac172.sp6.e2" origId="sp6.e2" text="ethinyl estradiol" type="Active ingredient"/>
		<pair e1="DBMI.pac172.sp6.e0" e2="DBMI.pac172.sp6.e1" id="DBMI.pac172.sp6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="norethindrone" precipitant="LIPITOR"/>
		<pair e1="DBMI.pac172.sp6.e0" e2="DBMI.pac172.sp6.e2" id="DBMI.pac172.sp6.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethinyl estradiol" precipitant="LIPITOR"/>
		<pair e1="DBMI.pac172.sp6.e1" e2="DBMI.pac172.sp6.e0" id="DBMI.pac172.sp6.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp6.e1" e2="DBMI.pac172.sp6.e2" id="DBMI.pac172.sp6.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp6.e2" e2="DBMI.pac172.sp6.e0" id="DBMI.pac172.sp6.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac172.sp6.e2" e2="DBMI.pac172.sp6.e1" id="DBMI.pac172.sp6.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac172.sp7" origId="sp7" text="7.7 Warfarin\n\nLIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment. "/>
</document>

<document id="DBMI.pac174" origId="pac174">
	<sentence id="DBMI.pac174.s0" origId="s0" text="In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (146% vs. 73%) was observed with concomitant rifampin administration (600 mg).">
		<entity charOffset="140-148" id="DBMI.pac174.s0.e0" origId="s0.e0" text="rifampin" type="Active ingredient"/>
		<entity charOffset="61-71" id="DBMI.pac174.s0.e1" origId="s0.e1" text="tacrolimus" type="Active ingredient"/>
		<pair e1="DBMI.pac174.s0.e0" e2="DBMI.pac174.s0.e1" id="DBMI.pac174.s0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrolimus" precipitant="rifampin"/>
		<pair e1="DBMI.pac174.s0.e1" e2="DBMI.pac174.s0.e0" id="DBMI.pac174.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac174.s1" origId="s1" text="In addition, there was a significant increase in tacrolimus clearance (0.0360.008 L/hr/kg vs. 0.0530.010 L/hr/kg) with concomitant rifampin administration.">
		<entity charOffset="307-315" id="DBMI.pac174.s1.e0" origId="s1.e0" text="rifampin" type="Active ingredient"/>
		<entity charOffset="223-233" id="DBMI.pac174.s1.e1" origId="s1.e1" text="tacrolimus" type="Active ingredient"/>
		<pair e1="DBMI.pac174.s1.e0" e2="DBMI.pac174.s1.e1" id="DBMI.pac174.s1.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrolimus" precipitant="rifampin"/>
		<pair e1="DBMI.pac174.s1.e1" e2="DBMI.pac174.s1.e0" id="DBMI.pac174.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac174.sp0" origId="sp0" text="In a study of 6 normal volunteers, a significant decrease in tacrolimus oral bioavailability (146% vs. 73%) was observed with concomitant rifampin administration (600 mg). In addition, there was a significant increase in tacrolimus clearance (0.0360.008 L/hr/kg vs. 0.0530.010 L/hr/kg) with concomitant rifampin administration.">
		<entity charOffset="140-148" id="DBMI.pac174.sp0.e0" origId="sp0.e0" text="rifampin" type="Active ingredient"/>
		<entity charOffset="61-71" id="DBMI.pac174.sp0.e1" origId="sp0.e1" text="tacrolimus" type="Active ingredient"/>
		<pair e1="DBMI.pac174.sp0.e0" e2="DBMI.pac174.sp0.e1" id="DBMI.pac174.sp0.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrolimus" precipitant="rifampin"/>
		<pair e1="DBMI.pac174.sp0.e0" e2="DBMI.pac174.sp0.e1" id="DBMI.pac174.sp0.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="tacrolimus" precipitant="rifampin"/>
		<pair e1="DBMI.pac174.sp0.e1" e2="DBMI.pac174.sp0.e0" id="DBMI.pac174.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac175" origId="pac175">
	<sentence id="DBMI.pac175.s0" origId="s0" text="Interaction studies with drugs used in HIV therapy have not been conducted."/>
	<sentence id="DBMI.pac175.s1" origId="s1" text="However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus."/>
	<sentence id="DBMI.pac175.s2" origId="s2" text="Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL.">
		<entity charOffset="369-379" id="DBMI.pac175.s2.e0" origId="s2.e0" text="nelfinavir" type="Active ingredient"/>
		<entity charOffset="353-363" id="DBMI.pac175.s2.e1" origId="s2.e1" text="tacrolimus" type="Active ingredient"/>
		<pair e1="DBMI.pac175.s2.e0" e2="DBMI.pac175.s2.e1" id="DBMI.pac175.s2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus" precipitant="nelfinavir"/>
		<pair e1="DBMI.pac175.s2.e1" e2="DBMI.pac175.s2.e0" id="DBMI.pac175.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac175.s3" origId="s3" text="Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly."/>
	<sentence id="DBMI.pac175.s4" origId="s4" text="Tacrolimus may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration.">
		<entity charOffset="747-757" id="DBMI.pac175.s4.e0" origId="s4.e0" text="Tacrolimus" type="Active ingredient"/>
		<entity charOffset="812-821" id="DBMI.pac175.s4.e1" origId="s4.e1" text="phenytoin" type="Active ingredient"/>
		<pair e1="DBMI.pac175.s4.e0" e2="DBMI.pac175.s4.e1" id="DBMI.pac175.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="phenytoin" precipitant="Tacrolimus"/>
		<pair e1="DBMI.pac175.s4.e1" e2="DBMI.pac175.s4.e0" id="DBMI.pac175.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac175.s5" origId="s5" text="Grapefruit juice affects CYP3A-mediated metabolism and should be avoided (see DOSAGE AND ADMINISTRATION)."/>
	<sentencespan id="DBMI.pac175.sp0" origId="sp0" text="Interaction studies with drugs used in HIV therapy have not been conducted. However, care should be exercised when drugs that are nephrotoxic (e.g., ganciclovir) or that are metabolized by CYP3A (e.g., nelfinavir, ritonavir) are administered concomitantly with tacrolimus. Based on a clinical study of 5 liver transplant recipients, coadministration of tacrolimus with nelfinavir increased blood concentrations of tacrolimus significantly and, as a result, a reduction in the tacrolimus dose by an average of 16-fold was needed to maintain mean trough tacrolimus blood concentrations of 9.7 ng/mL.">
		<entity charOffset="369-379" id="DBMI.pac175.sp0.e0" origId="sp0.e0" text="nelfinavir" type="Active ingredient"/>
		<entity charOffset="353-363" id="DBMI.pac175.sp0.e1" origId="sp0.e1" text="tacrolimus" type="Active ingredient"/>
		<pair e1="DBMI.pac175.sp0.e0" e2="DBMI.pac175.sp0.e1" id="DBMI.pac175.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus" precipitant="nelfinavir"/>
		<pair e1="DBMI.pac175.sp0.e1" e2="DBMI.pac175.sp0.e0" id="DBMI.pac175.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac175.sp1" origId="sp1" text="Thus, frequent monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are essential when nelfinavir is used concomitantly. Tacrolimus may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration. Grapefruit juice affects CYP3A-mediated metabolism and should be avoided (see DOSAGE AND ADMINISTRATION).">
		<entity charOffset="747-757" id="DBMI.pac175.sp1.e0" origId="sp1.e0" text="Tacrolimus" type="Active ingredient"/>
		<entity charOffset="812-821" id="DBMI.pac175.sp1.e1" origId="sp1.e1" text="phenytoin" type="Active ingredient"/>
		<pair e1="DBMI.pac175.sp1.e0" e2="DBMI.pac175.sp1.e1" id="DBMI.pac175.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="phenytoin" precipitant="Tacrolimus"/>
		<pair e1="DBMI.pac175.sp1.e1" e2="DBMI.pac175.sp1.e0" id="DBMI.pac175.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac177" origId="pac177">
	<sentence id="DBMI.pac177.s0" origId="s0" text="There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19)."/>
	<sentence id="DBMI.pac177.s1" origId="s1" text="Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation.">
		<entity charOffset="226-234" id="DBMI.pac177.s1.e0" origId="s1.e0" text="diazepam" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac177.s2" origId="s2" text="At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.">
		<entity charOffset="334-344" id="DBMI.pac177.s2.e0" origId="s2.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="346-358" id="DBMI.pac177.s2.e1" origId="s2.e1" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="360-371" id="DBMI.pac177.s2.e2" origId="s2.e2" text="fluvoxamine" type="Active ingredient"/>
		<entity charOffset="373-383" id="DBMI.pac177.s2.e3" origId="s2.e3" text="fluoxetine" type="Active ingredient"/>
		<entity charOffset="389-399" id="DBMI.pac177.s2.e4" origId="s2.e4" text="omeprazole" type="Active ingredient"/>
		<pair e1="DBMI.pac177.s2.e0" e2="DBMI.pac177.s2.e1" id="DBMI.pac177.s2.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e0" e2="DBMI.pac177.s2.e2" id="DBMI.pac177.s2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e0" e2="DBMI.pac177.s2.e3" id="DBMI.pac177.s2.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e0" e2="DBMI.pac177.s2.e4" id="DBMI.pac177.s2.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e1" e2="DBMI.pac177.s2.e0" id="DBMI.pac177.s2.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e1" e2="DBMI.pac177.s2.e2" id="DBMI.pac177.s2.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e1" e2="DBMI.pac177.s2.e3" id="DBMI.pac177.s2.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e1" e2="DBMI.pac177.s2.e4" id="DBMI.pac177.s2.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e2" e2="DBMI.pac177.s2.e0" id="DBMI.pac177.s2.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e2" e2="DBMI.pac177.s2.e1" id="DBMI.pac177.s2.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e2" e2="DBMI.pac177.s2.e3" id="DBMI.pac177.s2.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e2" e2="DBMI.pac177.s2.e4" id="DBMI.pac177.s2.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e3" e2="DBMI.pac177.s2.e0" id="DBMI.pac177.s2.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e3" e2="DBMI.pac177.s2.e1" id="DBMI.pac177.s2.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e3" e2="DBMI.pac177.s2.e2" id="DBMI.pac177.s2.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e3" e2="DBMI.pac177.s2.e4" id="DBMI.pac177.s2.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e4" e2="DBMI.pac177.s2.e0" id="DBMI.pac177.s2.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e4" e2="DBMI.pac177.s2.e1" id="DBMI.pac177.s2.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e4" e2="DBMI.pac177.s2.e2" id="DBMI.pac177.s2.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.s2.e4" e2="DBMI.pac177.s2.e3" id="DBMI.pac177.s2.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac177.sp0" origId="sp0" text="There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19). Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged sedation. At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.">
		<entity charOffset="334-344" id="DBMI.pac177.sp0.e0" origId="sp0.e0" text="cimetidine" type="Active ingredient"/>
		<entity charOffset="226-234" id="DBMI.pac177.sp0.e1" origId="sp0.e1" text="diazepam" type="Active ingredient"/>
		<entity charOffset="346-358" id="DBMI.pac177.sp0.e2" origId="sp0.e2" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="360-371" id="DBMI.pac177.sp0.e3" origId="sp0.e3" text="fluvoxamine" type="Active ingredient"/>
		<entity charOffset="373-383" id="DBMI.pac177.sp0.e4" origId="sp0.e4" text="fluoxetine" type="Active ingredient"/>
		<entity charOffset="389-399" id="DBMI.pac177.sp0.e5" origId="sp0.e5" text="omeprazole" type="Active ingredient"/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam" precipitant="cimetidine"/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e0" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e1" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p11" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam" precipitant="ketoconazole"/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e2" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p16" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam" precipitant="fluvoxamine"/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e3" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p21" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam" precipitant="fluoxetine"/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e4" e2="DBMI.pac177.sp0.e5" id="DBMI.pac177.sp0.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e0" id="DBMI.pac177.sp0.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e1" id="DBMI.pac177.sp0.p26" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="diazepam" precipitant="omeprazole"/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e2" id="DBMI.pac177.sp0.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e3" id="DBMI.pac177.sp0.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac177.sp0.e5" e2="DBMI.pac177.sp0.e4" id="DBMI.pac177.sp0.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac179" origId="pac179">
	<sentence id="DBMI.pac179.s0" origId="s0" text="Carbamazepine\n\nIsoniazid is known to slow the metabolism of carbamazepine and increase its serum levels.">
		<entity charOffset="15-24" id="DBMI.pac179.s0.e0" origId="s0.e0" text="Isoniazid" type="Active ingredient"/>
		<entity charOffset="60-73" id="DBMI.pac179.s0.e1" origId="s0.e1" text="carbamazepine" type="Active ingredient"/>
		<pair e1="DBMI.pac179.s0.e0" e2="DBMI.pac179.s0.e1" id="DBMI.pac179.s0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine" precipitant="Isoniazid"/>
		<pair e1="DBMI.pac179.s0.e1" e2="DBMI.pac179.s0.e0" id="DBMI.pac179.s0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac179.s1" origId="s1" text="Carbamazepine levels should be determined prior to concurrent administration with isonia-\n\nzid, signs and symptoms of carbamazepine toxicity should be monitored closely, and ap- propriate dosage adjustment of the anticonvulsant should be made3."/>
	<sentencespan id="DBMI.pac179.sp0" origId="sp0" text="Carbamazepine\n\nIsoniazid is known to slow the metabolism of carbamazepine and increase its serum levels. Carbamazepine levels should be determined prior to concurrent administration with isonia-\n\nzid, signs and symptoms of carbamazepine toxicity should be monitored closely, and ap- propriate dosage adjustment of the anticonvulsant should be made3.">
		<entity charOffset="15-24" id="DBMI.pac179.sp0.e0" origId="sp0.e0" text="Isoniazid" type="Active ingredient"/>
		<entity charOffset="60-73" id="DBMI.pac179.sp0.e1" origId="sp0.e1" text="carbamazepine" type="Active ingredient"/>
		<pair e1="DBMI.pac179.sp0.e0" e2="DBMI.pac179.sp0.e1" id="DBMI.pac179.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine" precipitant="Isoniazid"/>
		<pair e1="DBMI.pac179.sp0.e1" e2="DBMI.pac179.sp0.e0" id="DBMI.pac179.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac181" origId="pac181">
	<sentence id="DBMI.pac181.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A4 Inhibitors and Inducers\n\nIn vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C."/>
	<sentence id="DBMI.pac181.s1" origId="s1" text="Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil.">
		<entity charOffset="257-269" id="DBMI.pac181.s1.e0" origId="s1.e0" text="erythromycin" type="Active ingredient"/>
		<entity charOffset="320-329" id="DBMI.pac181.s1.e1" origId="s1.e1" text="verapamil" type="Active ingredient"/>
		<entity charOffset="271-280" id="DBMI.pac181.s1.e2" origId="s1.e2" text="ritonavir" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s1.e0" e2="DBMI.pac181.s1.e1" id="DBMI.pac181.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="erythromycin"/>
		<pair e1="DBMI.pac181.s1.e0" e2="DBMI.pac181.s1.e2" id="DBMI.pac181.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s1.e1" e2="DBMI.pac181.s1.e0" id="DBMI.pac181.s1.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s1.e1" e2="DBMI.pac181.s1.e2" id="DBMI.pac181.s1.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s1.e2" e2="DBMI.pac181.s1.e0" id="DBMI.pac181.s1.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s1.e2" e2="DBMI.pac181.s1.e1" id="DBMI.pac181.s1.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="ritonavir"/>
	</sentence>
	<sentence id="DBMI.pac181.s2" origId="s2" text="Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics."/>
	<sentence id="DBMI.pac181.s3" origId="s3" text="Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil.">
		<entity charOffset="527-535" id="DBMI.pac181.s3.e0" origId="s3.e0" text="rifampin" type="Active ingredient"/>
		<entity charOffset="580-589" id="DBMI.pac181.s3.e1" origId="s3.e1" text="verapamil" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s3.e0" e2="DBMI.pac181.s3.e1" id="DBMI.pac181.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="rifampin"/>
		<pair e1="DBMI.pac181.s3.e1" e2="DBMI.pac181.s3.e0" id="DBMI.pac181.s3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s4" origId="s4" text="7.2 Grapefruit Juice\n\nGrapefruit juice may significantly increase concentrations of verapamil."/>
	<sentence id="DBMI.pac181.s5" origId="s5" text="Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively."/>
	<sentence id="DBMI.pac181.s6" origId="s6" text="Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control."/>
	<sentence id="DBMI.pac181.s7" origId="s7" text="Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively."/>
	<sentence id="DBMI.pac181.s8" origId="s8" text="Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control."/>
	<sentence id="DBMI.pac181.s9" origId="s9" text="Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil."/>
	<sentence id="DBMI.pac181.s10" origId="s10" text="This increase in verapamil plasma concentration is not expected to have any clinical consequences."/>
	<sentence id="DBMI.pac181.s11" origId="s11" text="7.3 Beta-Blockers\n\nConcomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility."/>
	<sentence id="DBMI.pac181.s12" origId="s12" text="The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied."/>
	<sentence id="DBMI.pac181.s13" origId="s13" text="However, there have been reports of excess bradycardia and AV block, including complete heart block, when the combination has been used for the treatment of hypertension."/>
	<sentence id="DBMI.pac181.s14" origId="s14" text="For hypertensive patients, the risk of combined therapy may outweigh the potential benefits."/>
	<sentence id="DBMI.pac181.s15" origId="s15" text="The combination should be used only with caution and close monitoring."/>
	<sentence id="DBMI.pac181.s16" origId="s16" text="Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil."/>
	<sentence id="DBMI.pac181.s17" origId="s17" text="A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.">
		<entity charOffset="2278-2287" id="DBMI.pac181.s17.e0" origId="s17.e0" text="verapamil" type="Active ingredient"/>
		<entity charOffset="2171-2181" id="DBMI.pac181.s17.e1" origId="s17.e1" text="metoprolol" type="Active ingredient"/>
		<entity charOffset="2186-2197" id="DBMI.pac181.s17.e2" origId="s17.e2" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s17.e0" e2="DBMI.pac181.s17.e1" id="DBMI.pac181.s17.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.s17.e0" e2="DBMI.pac181.s17.e2" id="DBMI.pac181.s17.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.s17.e1" e2="DBMI.pac181.s17.e0" id="DBMI.pac181.s17.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s17.e1" e2="DBMI.pac181.s17.e2" id="DBMI.pac181.s17.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s17.e2" e2="DBMI.pac181.s17.e0" id="DBMI.pac181.s17.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s17.e2" e2="DBMI.pac181.s17.e1" id="DBMI.pac181.s17.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s18" origId="s18" text="A variable effect has been seen when verapamil and atenolol were given together."/>
	<sentence id="DBMI.pac181.s19" origId="s19" text="7.4 Digitalis\n\nConsider reducing digoxin dose when verapamil and digoxin are to be given together."/>
	<sentence id="DBMI.pac181.s20" origId="s20" text="Monitor digoxin level periodically during therapy."/>
	<sentence id="DBMI.pac181.s21" origId="s21" text="Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity.">
		<entity charOffset="2529-2538" id="DBMI.pac181.s21.e0" origId="s21.e0" text="verapamil" type="Active ingredient"/>
		<entity charOffset="2568-2575" id="DBMI.pac181.s21.e1" origId="s21.e1" text="digoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s21.e0" e2="DBMI.pac181.s21.e1" id="DBMI.pac181.s21.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.s21.e1" e2="DBMI.pac181.s21.e0" id="DBMI.pac181.s21.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s22" origId="s22" text="In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified."/>
	<sentence id="DBMI.pac181.s23" origId="s23" text="Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.">
		<entity charOffset="2778-2787" id="DBMI.pac181.s23.e0" origId="s23.e0" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="2848-2857" id="DBMI.pac181.s23.e1" origId="s23.e1" text="digitoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s23.e0" e2="DBMI.pac181.s23.e1" id="DBMI.pac181.s23.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digitoxin" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.s23.e1" e2="DBMI.pac181.s23.e0" id="DBMI.pac181.s23.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s24" origId="s24" text="If digoxin toxicity is suspected, suspend or discontinue digoxin therapy."/>
	<sentence id="DBMI.pac181.s25" origId="s25" text="In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients."/>
	<sentence id="DBMI.pac181.s26" origId="s26" text="7.5 Alcohol\n\nVerapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.">
		<entity charOffset="3285-3294" id="DBMI.pac181.s26.e0" origId="s26.e0" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="3335-3342" id="DBMI.pac181.s26.e1" origId="s26.e1" text="ethanol" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s26.e0" e2="DBMI.pac181.s26.e1" id="DBMI.pac181.s26.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethanol" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.s26.e1" e2="DBMI.pac181.s26.e0" id="DBMI.pac181.s26.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s27" origId="s27" text="7.6 Clonidine\n\nSinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil."/>
	<sentence id="DBMI.pac181.s28" origId="s28" text="Monitor heart rate in patients receiving concomitant verapamil and clonidine."/>
	<sentence id="DBMI.pac181.s29" origId="s29" text="7.7 Telithromycin\n\nHypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics."/>
	<sentence id="DBMI.pac181.s30" origId="s30" text="7.8 Antineoplastic Agents\n\nVerapamil can increase doxorubicin levels.">
		<entity charOffset="3930-3939" id="DBMI.pac181.s30.e0" origId="s30.e0" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="3953-3964" id="DBMI.pac181.s30.e1" origId="s30.e1" text="doxorubicin" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s30.e0" e2="DBMI.pac181.s30.e1" id="DBMI.pac181.s30.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="doxorubicin" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.s30.e1" e2="DBMI.pac181.s30.e0" id="DBMI.pac181.s30.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s31" origId="s31" text="The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens.">
		<entity charOffset="4023-4039" id="DBMI.pac181.s31.e0" origId="s31.e0" text="cyclophosphamide" type="Active ingredient"/>
		<entity charOffset="3991-4000" id="DBMI.pac181.s31.e1" origId="s31.e1" text="verapamil" type="Active ingredient"/>
		<entity charOffset="4041-4048" id="DBMI.pac181.s31.e2" origId="s31.e2" text="oncovin" type="Drug product"/>
		<entity charOffset="4050-4062" id="DBMI.pac181.s31.e3" origId="s31.e3" text="procarbazine" type="Active ingredient"/>
		<entity charOffset="4064-4074" id="DBMI.pac181.s31.e4" origId="s31.e4" text="prednisone" type="Active ingredient"/>
		<entity charOffset="4090-4099" id="DBMI.pac181.s31.e5" origId="s31.e5" text="vindesine" type="Active ingredient"/>
		<entity charOffset="4101-4111" id="DBMI.pac181.s31.e6" origId="s31.e6" text="adriamycin" type="Drug product"/>
		<entity charOffset="4113-4122" id="DBMI.pac181.s31.e7" origId="s31.e7" text="cisplatin" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="cyclophosphamide"/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e0" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e1" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p15" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="oncovin"/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p16" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="oncovin"/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e2" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p23" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="procarbazine"/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e3" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p30" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="prednisone"/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e4" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p37" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="vindesine"/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e5" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p44" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="adriamycin"/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p45" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="adriamycin"/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e6" e2="DBMI.pac181.s31.e7" id="DBMI.pac181.s31.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e0" id="DBMI.pac181.s31.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e1" id="DBMI.pac181.s31.p52" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="cisplatin"/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e2" id="DBMI.pac181.s31.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e3" id="DBMI.pac181.s31.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e4" id="DBMI.pac181.s31.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e5" id="DBMI.pac181.s31.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s31.e7" e2="DBMI.pac181.s31.e6" id="DBMI.pac181.s31.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s32" origId="s32" text="Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.">
		<entity charOffset="4186-4195" id="DBMI.pac181.s32.e0" origId="s32.e0" text="verapamil" type="Active ingredient"/>
		<entity charOffset="4226-4236" id="DBMI.pac181.s32.e1" origId="s32.e1" text="paclitaxel" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s32.e0" e2="DBMI.pac181.s32.e1" id="DBMI.pac181.s32.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="paclitaxel" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.s32.e1" e2="DBMI.pac181.s32.e0" id="DBMI.pac181.s32.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s33" origId="s33" text="7.9 Quinidine\n\nIn a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension."/>
	<sentence id="DBMI.pac181.s34" origId="s34" text="Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy."/>
	<sentence id="DBMI.pac181.s35" origId="s35" text="The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients."/>
	<sentence id="DBMI.pac181.s36" origId="s36" text="Verapamil significantly counteracted the effects of quinidine on AV conduction."/>
	<sentence id="DBMI.pac181.s37" origId="s37" text="There has been a report of increased quinidine levels during verapamil therapy.">
		<entity charOffset="4778-4787" id="DBMI.pac181.s37.e0" origId="s37.e0" text="verapamil" type="Active ingredient"/>
		<entity charOffset="4754-4763" id="DBMI.pac181.s37.e1" origId="s37.e1" text="quinidine" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s37.e0" e2="DBMI.pac181.s37.e1" id="DBMI.pac181.s37.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="quinidine" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.s37.e1" e2="DBMI.pac181.s37.e0" id="DBMI.pac181.s37.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s38" origId="s38" text="7.10 Aspirin\n\nIn a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone."/>
	<sentence id="DBMI.pac181.s39" origId="s39" text="7.11 Antihypertensive agents\n\nVerapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure."/>
	<sentence id="DBMI.pac181.s40" origId="s40" text="Monitor patients receiving these combinations appropriately."/>
	<sentence id="DBMI.pac181.s41" origId="s41" text="Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients."/>
	<sentence id="DBMI.pac181.s42" origId="s42" text="Such an effect was observed in one study following the concomitant administration of verapamil and prazosin."/>
	<sentence id="DBMI.pac181.s43" origId="s43" text="7.12 Disopyramide\n\nUntil data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration."/>
	<sentence id="DBMI.pac181.s44" origId="s44" text="7.13 Flecainide\n\nA study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization."/>
	<sentence id="DBMI.pac181.s45" origId="s45" text="Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction."/>
	<sentence id="DBMI.pac181.s46" origId="s46" text="7.14 Carbamazepine\n\nVerapamil therapy may increase carbamazepine concentrations during combined therapy.">
		<entity charOffset="6125-6134" id="DBMI.pac181.s46.e0" origId="s46.e0" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="6156-6169" id="DBMI.pac181.s46.e1" origId="s46.e1" text="carbamazepine" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s46.e0" e2="DBMI.pac181.s46.e1" id="DBMI.pac181.s46.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.s46.e1" e2="DBMI.pac181.s46.e0" id="DBMI.pac181.s46.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s47" origId="s47" text="This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness."/>
	<sentence id="DBMI.pac181.s48" origId="s48" text="7.15 Cyclosporine\n\nVerapamil therapy may increase serum levels of cyclosporine.">
		<entity charOffset="6323-6332" id="DBMI.pac181.s48.e0" origId="s48.e0" text="Verapamil" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac181.s49" origId="s49" text="7.16 Lithium\n\nIncreased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels.">
		<entity charOffset="6370-6382" id="DBMI.pac181.s49.e0" origId="s49.e0" text="cyclosporine" type="Active ingredient"/>
		<entity charOffset="6500-6509" id="DBMI.pac181.s49.e1" origId="s49.e1" text="verapamil" type="Active ingredient"/>
		<entity charOffset="6510-6517" id="DBMI.pac181.s49.e2" origId="s49.e2" text="lithium" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s49.e0" e2="DBMI.pac181.s49.e1" id="DBMI.pac181.s49.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s49.e0" e2="DBMI.pac181.s49.e2" id="DBMI.pac181.s49.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s49.e1" e2="DBMI.pac181.s49.e0" id="DBMI.pac181.s49.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s49.e1" e2="DBMI.pac181.s49.e2" id="DBMI.pac181.s49.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.s49.e1" e2="DBMI.pac181.s49.e2" id="DBMI.pac181.s49.p4" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.s49.e2" e2="DBMI.pac181.s49.e0" id="DBMI.pac181.s49.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s49.e2" e2="DBMI.pac181.s49.e1" id="DBMI.pac181.s49.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s50" origId="s50" text="However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.">
		<entity charOffset="6572-6579" id="DBMI.pac181.s50.e0" origId="s50.e0" text="lithium" type="Active ingredient"/>
		<entity charOffset="6613-6622" id="DBMI.pac181.s50.e1" origId="s50.e1" text="verapamil" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s50.e0" e2="DBMI.pac181.s50.e1" id="DBMI.pac181.s50.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s50.e1" e2="DBMI.pac181.s50.e0" id="DBMI.pac181.s50.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium" precipitant="verapamil"/>
	</sentence>
	<sentence id="DBMI.pac181.s51" origId="s51" text="Patients receiving both drugs must be monitored carefully."/>
	<sentence id="DBMI.pac181.s52" origId="s52" text="7.17 Inhalation Anesthetics\n\nAnimal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions."/>
	<sentence id="DBMI.pac181.s53" origId="s53" text="When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression."/>
	<sentence id="DBMI.pac181.s54" origId="s54" text="7.18 Neuromuscular Blocking Agents\n\nClinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing)."/>
	<sentence id="DBMI.pac181.s55" origId="s55" text="It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly."/>
	<sentence id="DBMI.pac181.s56" origId="s56" text="7.19 Phenobarbital\n\nPhenobarbital therapy may increase verapamil clearance.">
		<entity charOffset="7467-7480" id="DBMI.pac181.s56.e0" origId="s56.e0" text="Phenobarbital" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac181.s57" origId="s57" text="7.20 Rifampin\n\nTherapy with rifampin may markedly reduce oral verapamil bioavailability.">
		<entity charOffset="7502-7511" id="DBMI.pac181.s57.e0" origId="s57.e0" text="verapamil" type="Active ingredient"/>
		<entity charOffset="7552-7560" id="DBMI.pac181.s57.e1" origId="s57.e1" text="rifampin" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s57.e0" e2="DBMI.pac181.s57.e1" id="DBMI.pac181.s57.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s57.e1" e2="DBMI.pac181.s57.e0" id="DBMI.pac181.s57.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="rifampin"/>
	</sentence>
	<sentence id="DBMI.pac181.s58" origId="s58" text="7.21 Theophylline\n\nVerapamil may inhibit the clearance and increase the plasma levels of theophylline.">
		<entity charOffset="7633-7642" id="DBMI.pac181.s58.e0" origId="s58.e0" text="Verapamil" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac181.s59" origId="s59" text="7.22 Cimetidine\n\nThe interaction between cimetidine and chronically administered verapamil has not been studied.">
		<entity charOffset="7703-7715" id="DBMI.pac181.s59.e0" origId="s59.e0" text="theophylline" type="Active ingredient"/>
		<entity charOffset="7759-7769" id="DBMI.pac181.s59.e1" origId="s59.e1" text="cimetidine" type="Active ingredient"/>
		<pair e1="DBMI.pac181.s59.e0" e2="DBMI.pac181.s59.e1" id="DBMI.pac181.s59.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.s59.e1" e2="DBMI.pac181.s59.e0" id="DBMI.pac181.s59.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac181.s60" origId="s60" text="Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged.">
		<entity charOffset="7933-7942" id="DBMI.pac181.s60.e0" origId="s60.e0" text="verapamil" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac181.s61" origId="s61" text="7.23 Nitrates\n\nVerapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions."/>
	<sentence id="DBMI.pac181.s62" origId="s62" text="The pharmacologic profile of both drugs and the clinical experience suggest beneficial interactions."/>
	<sentencespan id="DBMI.pac181.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CYP3A4 Inhibitors and Inducers\n\nIn vitro metabolic studies indicate that verapamil is metabolized by cytochrome P450 CYP3A4, CYPlA2 and CYP2C. Clinically significant interactions have been reported with inhibitors of CYP3A4 (e.g.,  erythromycin, ritonavir) causing elevation of plasma levels of verapamil. Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telithromycin, an antibiotic in the ketolide class of antibiotics.">
		<entity charOffset="257-269" id="DBMI.pac181.sp0.e0" origId="sp0.e0" text="erythromycin" type="Active ingredient"/>
		<entity charOffset="320-329" id="DBMI.pac181.sp0.e1" origId="sp0.e1" text="verapamil" type="Active ingredient"/>
		<entity charOffset="271-280" id="DBMI.pac181.sp0.e2" origId="sp0.e2" text="ritonavir" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp0.e0" e2="DBMI.pac181.sp0.e1" id="DBMI.pac181.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="erythromycin"/>
		<pair e1="DBMI.pac181.sp0.e0" e2="DBMI.pac181.sp0.e2" id="DBMI.pac181.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp0.e1" e2="DBMI.pac181.sp0.e0" id="DBMI.pac181.sp0.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp0.e1" e2="DBMI.pac181.sp0.e2" id="DBMI.pac181.sp0.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp0.e2" e2="DBMI.pac181.sp0.e0" id="DBMI.pac181.sp0.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp0.e2" e2="DBMI.pac181.sp0.e1" id="DBMI.pac181.sp0.p5" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="ritonavir"/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp1" origId="sp1" text="Inducers of CYP3A4 (e.g.,  rifampin) have caused a lowering of plasma levels of verapamil. 7.2 Grapefruit Juice\n\nGrapefruit juice may significantly increase concentrations of verapamil. Grapefruit juice given to nine healthy volunteers increased S- and R-verapamil AUC0-12 by 36% and 28%, respectively.">
		<entity charOffset="527-535" id="DBMI.pac181.sp1.e0" origId="sp1.e0" text="rifampin" type="Active ingredient"/>
		<entity charOffset="580-589" id="DBMI.pac181.sp1.e1" origId="sp1.e1" text="verapamil" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp1.e0" e2="DBMI.pac181.sp1.e1" id="DBMI.pac181.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="rifampin"/>
		<pair e1="DBMI.pac181.sp1.e1" e2="DBMI.pac181.sp1.e0" id="DBMI.pac181.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp2" origId="sp2" text="Steady-state Cmax and Cmin, of S-verapamil increased by 57% and 16.7%, respectively with grapefruit juice compared to control. Similarly, Cmax and Cmin, of R-verapamil increased by 40% and 13%, respectively. Grapefruit juice did not affect half-life, nor was there a significant change in AUC0-12 ratio R/S compared to control."/>
	<sentencespan id="DBMI.pac181.sp3" origId="sp3" text="Grapefruit juice did not cause a significant difference in the pharmacokinetics of norverapamil. This increase in verapamil plasma concentration is not expected to have any clinical consequences. 7.3 Beta-Blockers\n\nConcomitant therapy with beta-adrenergic blockers and verapamil may result in additive negative effects on heart rate, atrioventricular conduction and/or cardiac contractility."/>
	<sentencespan id="DBMI.pac181.sp4" origId="sp4" text="The combination of extended-release verapamil and beta-adrenergic blocking agents has not been studied. However, there have been reports of excess bradycardia and AV block, including complete heart block, when the combination has been used for the treatment of hypertension. For hypertensive patients, the risk of combined therapy may outweigh the potential benefits."/>
	<sentencespan id="DBMI.pac181.sp5" origId="sp5" text="The combination should be used only with caution and close monitoring. Asymptomatic bradycardia (36 beats/min) with a wandering atrial pacemaker has been observed in a patient receiving concomitant timolol (a beta-adrenergic blocker) eyedrops and oral verapamil. A decrease in metoprolol and propranolol clearance has been observed when either drug is administered concomitantly with verapamil.">
		<entity charOffset="2278-2287" id="DBMI.pac181.sp5.e0" origId="sp5.e0" text="verapamil" type="Active ingredient"/>
		<entity charOffset="2171-2181" id="DBMI.pac181.sp5.e1" origId="sp5.e1" text="metoprolol" type="Active ingredient"/>
		<entity charOffset="2186-2197" id="DBMI.pac181.sp5.e2" origId="sp5.e2" text="propranolol" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp5.e0" e2="DBMI.pac181.sp5.e1" id="DBMI.pac181.sp5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="metoprolol" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.sp5.e0" e2="DBMI.pac181.sp5.e2" id="DBMI.pac181.sp5.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="propranolol" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.sp5.e1" e2="DBMI.pac181.sp5.e0" id="DBMI.pac181.sp5.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp5.e1" e2="DBMI.pac181.sp5.e2" id="DBMI.pac181.sp5.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp5.e2" e2="DBMI.pac181.sp5.e0" id="DBMI.pac181.sp5.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp5.e2" e2="DBMI.pac181.sp5.e1" id="DBMI.pac181.sp5.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp6" origId="sp6" text="A variable effect has been seen when verapamil and atenolol were given together. 7.4 Digitalis\n\nConsider reducing digoxin dose when verapamil and digoxin are to be given together. Monitor digoxin level periodically during therapy."/>
	<sentencespan id="DBMI.pac181.sp7" origId="sp7" text="Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively.">
		<entity charOffset="2529-2538" id="DBMI.pac181.sp7.e0" origId="sp7.e0" text="verapamil" type="Active ingredient"/>
		<entity charOffset="2568-2575" id="DBMI.pac181.sp7.e1" origId="sp7.e1" text="digoxin" type="Active ingredient"/>
		<entity charOffset="2778-2787" id="DBMI.pac181.sp7.e2" origId="sp7.e2" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="2848-2857" id="DBMI.pac181.sp7.e3" origId="sp7.e3" text="digitoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp7.e0" e2="DBMI.pac181.sp7.e1" id="DBMI.pac181.sp7.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.sp7.e0" e2="DBMI.pac181.sp7.e2" id="DBMI.pac181.sp7.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e0" e2="DBMI.pac181.sp7.e3" id="DBMI.pac181.sp7.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e1" e2="DBMI.pac181.sp7.e0" id="DBMI.pac181.sp7.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e1" e2="DBMI.pac181.sp7.e2" id="DBMI.pac181.sp7.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e1" e2="DBMI.pac181.sp7.e3" id="DBMI.pac181.sp7.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e2" e2="DBMI.pac181.sp7.e0" id="DBMI.pac181.sp7.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e2" e2="DBMI.pac181.sp7.e1" id="DBMI.pac181.sp7.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e2" e2="DBMI.pac181.sp7.e3" id="DBMI.pac181.sp7.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digitoxin" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.sp7.e3" e2="DBMI.pac181.sp7.e0" id="DBMI.pac181.sp7.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e3" e2="DBMI.pac181.sp7.e1" id="DBMI.pac181.sp7.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp7.e3" e2="DBMI.pac181.sp7.e2" id="DBMI.pac181.sp7.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp8" origId="sp8" text="If digoxin toxicity is suspected, suspend or discontinue digoxin therapy. In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients. 7.5 Alcohol\n\nVerapamil has been found to significantly inhibit ethanol elimination resulting in elevated blood ethanol concentrations that may prolong the intoxicating effects of alcohol.">
		<entity charOffset="3285-3294" id="DBMI.pac181.sp8.e0" origId="sp8.e0" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="3335-3342" id="DBMI.pac181.sp8.e1" origId="sp8.e1" text="ethanol" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp8.e0" e2="DBMI.pac181.sp8.e1" id="DBMI.pac181.sp8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ethanol" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.sp8.e1" e2="DBMI.pac181.sp8.e0" id="DBMI.pac181.sp8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp9" origId="sp9" text="7.6 Clonidine\n\nSinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. Monitor heart rate in patients receiving concomitant verapamil and clonidine. 7.7 Telithromycin\n\nHypotension, bradyarrhythmias and lactic acidosis have been observed in patients receiving concurrent telethromycin, an antibiotic in the ketolide class of antibiotics."/>
	<sentencespan id="DBMI.pac181.sp10" origId="sp10" text="7.8 Antineoplastic Agents\n\nVerapamil can increase doxorubicin levels. The absorption of verapamil can be reduced by the cyclophosphamide, oncovin, procarbazine, prednisone (COPP) and the vindesine, adriamycin, cisplatin (VAC) cytotoxic drug regimens. Concomitant administration of R-verapamil can decrease the clearance of paclitaxel.">
		<entity charOffset="3930-3939" id="DBMI.pac181.sp10.e0" origId="sp10.e0" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="3953-3964" id="DBMI.pac181.sp10.e1" origId="sp10.e1" text="doxorubicin" type="Active ingredient"/>
		<entity charOffset="4023-4039" id="DBMI.pac181.sp10.e2" origId="sp10.e2" text="cyclophosphamide" type="Active ingredient"/>
		<entity charOffset="3991-4000" id="DBMI.pac181.sp10.e3" origId="sp10.e3" text="verapamil" type="Active ingredient"/>
		<entity charOffset="4041-4048" id="DBMI.pac181.sp10.e4" origId="sp10.e4" text="oncovin" type="Drug product"/>
		<entity charOffset="4050-4062" id="DBMI.pac181.sp10.e5" origId="sp10.e5" text="procarbazine" type="Active ingredient"/>
		<entity charOffset="4064-4074" id="DBMI.pac181.sp10.e6" origId="sp10.e6" text="prednisone" type="Active ingredient"/>
		<entity charOffset="4090-4099" id="DBMI.pac181.sp10.e7" origId="sp10.e7" text="vindesine" type="Active ingredient"/>
		<entity charOffset="4101-4111" id="DBMI.pac181.sp10.e8" origId="sp10.e8" text="adriamycin" type="Drug product"/>
		<entity charOffset="4113-4122" id="DBMI.pac181.sp10.e9" origId="sp10.e9" text="cisplatin" type="Active ingredient"/>
		<entity charOffset="4226-4236" id="DBMI.pac181.sp10.e10" origId="sp10.e10" text="paclitaxel" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="doxorubicin" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e0" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e1" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p22" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="cyclophosphamide"/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e2" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e3" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p39" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="paclitaxel" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p43" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="oncovin"/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p44" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="oncovin"/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e4" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p54" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="procarbazine"/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e5" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p64" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="prednisone"/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p67" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e6" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p74" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="vindesine"/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p78" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p79" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e7" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p80" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p81" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p82" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p83" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p84" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="adriamycin"/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p85" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="adriamycin"/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p86" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p87" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p88" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p89" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p90" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e8" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p91" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p92" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p93" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p94" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p95" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="cisplatin"/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p96" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p97" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p98" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p99" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p100" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e9" e2="DBMI.pac181.sp10.e10" id="DBMI.pac181.sp10.p101" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e0" id="DBMI.pac181.sp10.p102" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e1" id="DBMI.pac181.sp10.p103" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e2" id="DBMI.pac181.sp10.p104" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e3" id="DBMI.pac181.sp10.p105" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e4" id="DBMI.pac181.sp10.p106" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e5" id="DBMI.pac181.sp10.p107" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e6" id="DBMI.pac181.sp10.p108" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e7" id="DBMI.pac181.sp10.p109" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e8" id="DBMI.pac181.sp10.p110" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp10.e10" e2="DBMI.pac181.sp10.e9" id="DBMI.pac181.sp10.p111" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp11" origId="sp11" text="7.9 Quinidine\n\nIn a small number of patients with hypertrophic cardiomyopathy, concomitant use of verapamil and quinidine resulted in significant hypotension. Until further data are obtained, avoid combined therapy of verapamil and quinidine in patients with hypertrophic cardiomyopathy. The electrophysiological effects of quinidine and verapamil on AV conduction were studied in eight patients."/>
	<sentencespan id="DBMI.pac181.sp12" origId="sp12" text="Verapamil significantly counteracted the effects of quinidine on AV conduction. There has been a report of increased quinidine levels during verapamil therapy. 7.10 Aspirin\n\nIn a few reported cases, coadministration of verapamil with aspirin has led to increased bleeding times greater than observed with aspirin alone.">
		<entity charOffset="4778-4787" id="DBMI.pac181.sp12.e0" origId="sp12.e0" text="verapamil" type="Active ingredient"/>
		<entity charOffset="4754-4763" id="DBMI.pac181.sp12.e1" origId="sp12.e1" text="quinidine" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp12.e0" e2="DBMI.pac181.sp12.e1" id="DBMI.pac181.sp12.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="quinidine" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.sp12.e1" e2="DBMI.pac181.sp12.e0" id="DBMI.pac181.sp12.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp13" origId="sp13" text="7.11 Antihypertensive agents\n\nVerapamil administered concomitantly with oral antihypertensive agents (e.g.,  vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta-blockers) will usually have an additive effect on lowering blood pressure. Monitor patients receiving these combinations appropriately. Concomitant use of agents that attenuate alpha-adrenergic function with verapamil may result in reduction in blood pressure that is excessive in some patients."/>
	<sentencespan id="DBMI.pac181.sp14" origId="sp14" text="Such an effect was observed in one study following the concomitant administration of verapamil and prazosin. 7.12 Disopyramide\n\nUntil data on possible interactions between verapamil and disopyramide are obtained, do not administer disopyramide within 48 hours before or 24 hours after verapamil administration. 7.13 Flecainide\n\nA study in healthy volunteers showed that the concomitant administration of flecainide and verapamil may have additive effects on myocardial contractility, AV conduction and repolarization."/>
	<sentencespan id="DBMI.pac181.sp15" origId="sp15" text="Concomitant therapy with flecainide and verapamil may result in additive negative inotropic effect and prolongation of atrioventricular conduction. 7.14 Carbamazepine\n\nVerapamil therapy may increase carbamazepine concentrations during combined therapy. This may produce carbamazepine side effects such as diplopia, headache, ataxia or dizziness.">
		<entity charOffset="6125-6134" id="DBMI.pac181.sp15.e0" origId="sp15.e0" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="6156-6169" id="DBMI.pac181.sp15.e1" origId="sp15.e1" text="carbamazepine" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp15.e0" e2="DBMI.pac181.sp15.e1" id="DBMI.pac181.sp15.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="carbamazepine" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.sp15.e1" e2="DBMI.pac181.sp15.e0" id="DBMI.pac181.sp15.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp16" origId="sp16" text="7.15 Cyclosporine\n\nVerapamil therapy may increase serum levels of cyclosporine. 7.16 Lithium\n\nIncreased sensitivity to the effects of lithium (neurotoxicity) has been reported during concomitant verapamil-lithium therapy with either no change or an increase in serum lithium levels. However, the addition of verapamil has also resulted in the lowering of serum lithium levels in patients receiving chronic stable oral lithium.">
		<entity charOffset="6323-6332" id="DBMI.pac181.sp16.e0" origId="sp16.e0" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="6370-6382" id="DBMI.pac181.sp16.e1" origId="sp16.e1" text="cyclosporine" type="Active ingredient"/>
		<entity charOffset="6500-6509" id="DBMI.pac181.sp16.e2" origId="sp16.e2" text="verapamil" type="Active ingredient"/>
		<entity charOffset="6510-6517" id="DBMI.pac181.sp16.e3" origId="sp16.e3" text="lithium" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp16.e0" e2="DBMI.pac181.sp16.e1" id="DBMI.pac181.sp16.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="cyclosporine" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.sp16.e0" e2="DBMI.pac181.sp16.e2" id="DBMI.pac181.sp16.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e0" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e1" e2="DBMI.pac181.sp16.e0" id="DBMI.pac181.sp16.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e1" e2="DBMI.pac181.sp16.e2" id="DBMI.pac181.sp16.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e1" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e0" id="DBMI.pac181.sp16.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e1" id="DBMI.pac181.sp16.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="lithium" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p9" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.sp16.e2" e2="DBMI.pac181.sp16.e3" id="DBMI.pac181.sp16.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="lithium" precipitant="verapamil"/>
		<pair e1="DBMI.pac181.sp16.e3" e2="DBMI.pac181.sp16.e0" id="DBMI.pac181.sp16.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e3" e2="DBMI.pac181.sp16.e1" id="DBMI.pac181.sp16.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp16.e3" e2="DBMI.pac181.sp16.e2" id="DBMI.pac181.sp16.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp17" origId="sp17" text="Patients receiving both drugs must be monitored carefully. 7.17 Inhalation Anesthetics\n\nAnimal experiments have shown that inhalation anesthetics depress cardiovascular activity by decreasing the inward movement of calcium ions. When used concomitantly, inhalation anesthetics and calcium antagonists, such as verapamil, titrate slowly to avoid excessive cardiovascular depression."/>
	<sentencespan id="DBMI.pac181.sp18" origId="sp18" text="7.18 Neuromuscular Blocking Agents\n\nClinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). It may be necessary to decrease the dose of verapamil and/or the dose of the neuromuscular blocking agent when the drugs are used concomitantly. 7.19 Phenobarbital\n\nPhenobarbital therapy may increase verapamil clearance.">
		<entity charOffset="7467-7480" id="DBMI.pac181.sp18.e0" origId="sp18.e0" text="Phenobarbital" type="Active ingredient"/>
		<entity charOffset="7502-7511" id="DBMI.pac181.sp18.e1" origId="sp18.e1" text="verapamil" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp18.e0" e2="DBMI.pac181.sp18.e1" id="DBMI.pac181.sp18.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="Phenobarbital"/>
		<pair e1="DBMI.pac181.sp18.e1" e2="DBMI.pac181.sp18.e0" id="DBMI.pac181.sp18.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp19" origId="sp19" text="7.20 Rifampin\n\nTherapy with rifampin may markedly reduce oral verapamil bioavailability. 7.21 Theophylline\n\nVerapamil may inhibit the clearance and increase the plasma levels of theophylline. 7.22 Cimetidine\n\nThe interaction between cimetidine and chronically administered verapamil has not been studied.">
		<entity charOffset="7552-7560" id="DBMI.pac181.sp19.e0" origId="sp19.e0" text="rifampin" type="Active ingredient"/>
		<entity charOffset="7586-7595" id="DBMI.pac181.sp19.e1" origId="sp19.e1" text="verapamil" type="Active ingredient"/>
		<entity charOffset="7633-7642" id="DBMI.pac181.sp19.e2" origId="sp19.e2" text="Verapamil" type="Active ingredient"/>
		<entity charOffset="7703-7715" id="DBMI.pac181.sp19.e3" origId="sp19.e3" text="theophylline" type="Active ingredient"/>
		<entity charOffset="7759-7769" id="DBMI.pac181.sp19.e4" origId="sp19.e4" text="cimetidine" type="Active ingredient"/>
		<pair e1="DBMI.pac181.sp19.e0" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="rifampin"/>
		<pair e1="DBMI.pac181.sp19.e0" e2="DBMI.pac181.sp19.e2" id="DBMI.pac181.sp19.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e0" e2="DBMI.pac181.sp19.e3" id="DBMI.pac181.sp19.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e0" e2="DBMI.pac181.sp19.e4" id="DBMI.pac181.sp19.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e1" e2="DBMI.pac181.sp19.e0" id="DBMI.pac181.sp19.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e1" e2="DBMI.pac181.sp19.e2" id="DBMI.pac181.sp19.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e1" e2="DBMI.pac181.sp19.e3" id="DBMI.pac181.sp19.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e1" e2="DBMI.pac181.sp19.e4" id="DBMI.pac181.sp19.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e2" e2="DBMI.pac181.sp19.e0" id="DBMI.pac181.sp19.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e2" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e2" e2="DBMI.pac181.sp19.e3" id="DBMI.pac181.sp19.p10" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="theophylline" precipitant="Verapamil"/>
		<pair e1="DBMI.pac181.sp19.e2" e2="DBMI.pac181.sp19.e4" id="DBMI.pac181.sp19.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e3" e2="DBMI.pac181.sp19.e0" id="DBMI.pac181.sp19.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e3" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e3" e2="DBMI.pac181.sp19.e2" id="DBMI.pac181.sp19.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e3" e2="DBMI.pac181.sp19.e4" id="DBMI.pac181.sp19.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e0" id="DBMI.pac181.sp19.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p17" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="verapamil" precipitant="cimetidine"/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e1" id="DBMI.pac181.sp19.p18" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="verapamil" precipitant="cimetidine"/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e2" id="DBMI.pac181.sp19.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac181.sp19.e4" e2="DBMI.pac181.sp19.e3" id="DBMI.pac181.sp19.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac181.sp20" origId="sp20" text="Variable results on clearance have been obtained in acute studies of healthy volunteers; clearance of verapamil was either reduced or unchanged. 7.23 Nitrates\n\nVerapamil has been given concomitantly with short- and long-acting nitrates without any undesirable drug interactions. The pharmacologic profile of both drugs and the clinical experience suggest beneficial interactions.">
		<entity charOffset="7933-7942" id="DBMI.pac181.sp20.e0" origId="sp20.e0" text="verapamil" type="Active ingredient"/>
	</sentencespan>
</document>

<document id="DBMI.pac183" origId="pac183">
	<sentence id="DBMI.pac183.s0" origId="s0" text="7 DRUG INTERACTIONS\n\nDrugs with pH-Dependent Absorption Kinetics\n\nLansoprazole delayed-release capsules causes long-lasting inhibition of gastric acid secretion."/>
	<sentence id="DBMI.pac183.s1" origId="s1" text="Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.">
		<entity charOffset="162-174" id="DBMI.pac183.s1.e0" origId="s1.e0" text="Lansoprazole" type="Active ingredient"/>
		<entity charOffset="310-320" id="DBMI.pac183.s1.e1" origId="s1.e1" text="atazanavir" type="Active ingredient"/>
		<pair e1="DBMI.pac183.s1.e0" e2="DBMI.pac183.s1.e1" id="DBMI.pac183.s1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir" precipitant="Lansoprazole"/>
		<pair e1="DBMI.pac183.s1.e1" e2="DBMI.pac183.s1.e0" id="DBMI.pac183.s1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s2" origId="s2" text="Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir."/>
	<sentence id="DBMI.pac183.s3" origId="s3" text="[See Clinical Pharmacology (12.5)]\n\nIt is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole).">
		<entity charOffset="672-684" id="DBMI.pac183.s3.e0" origId="s3.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="890-902" id="DBMI.pac183.s3.e1" origId="s3.e1" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="878-882" id="DBMI.pac183.s3.e2" origId="s3.e2" text="iron" type="Active ingredient"/>
		<entity charOffset="850-860" id="DBMI.pac183.s3.e3" origId="s3.e3" text="ampicillin" type="Active ingredient"/>
		<entity charOffset="869-876" id="DBMI.pac183.s3.e4" origId="s3.e4" text="digoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac183.s3.e0" e2="DBMI.pac183.s3.e1" id="DBMI.pac183.s3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.s3.e0" e2="DBMI.pac183.s3.e2" id="DBMI.pac183.s3.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="iron" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.s3.e0" e2="DBMI.pac183.s3.e3" id="DBMI.pac183.s3.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.s3.e0" e2="DBMI.pac183.s3.e4" id="DBMI.pac183.s3.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.s3.e1" e2="DBMI.pac183.s3.e0" id="DBMI.pac183.s3.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e1" e2="DBMI.pac183.s3.e2" id="DBMI.pac183.s3.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e1" e2="DBMI.pac183.s3.e3" id="DBMI.pac183.s3.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e1" e2="DBMI.pac183.s3.e4" id="DBMI.pac183.s3.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e2" e2="DBMI.pac183.s3.e0" id="DBMI.pac183.s3.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e2" e2="DBMI.pac183.s3.e1" id="DBMI.pac183.s3.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e2" e2="DBMI.pac183.s3.e3" id="DBMI.pac183.s3.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e2" e2="DBMI.pac183.s3.e4" id="DBMI.pac183.s3.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e3" e2="DBMI.pac183.s3.e0" id="DBMI.pac183.s3.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e3" e2="DBMI.pac183.s3.e1" id="DBMI.pac183.s3.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e3" e2="DBMI.pac183.s3.e2" id="DBMI.pac183.s3.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e3" e2="DBMI.pac183.s3.e4" id="DBMI.pac183.s3.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e4" e2="DBMI.pac183.s3.e0" id="DBMI.pac183.s3.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e4" e2="DBMI.pac183.s3.e1" id="DBMI.pac183.s3.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e4" e2="DBMI.pac183.s3.e2" id="DBMI.pac183.s3.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.s3.e4" e2="DBMI.pac183.s3.e3" id="DBMI.pac183.s3.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s4" origId="s4" text="[See Clinical Pharmacology (12.5)]\n\nWarfarin\n\nIn a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5).">
		<entity charOffset="1038-1050" id="DBMI.pac183.s4.e0" origId="s4.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="1128-1136" id="DBMI.pac183.s4.e1" origId="s4.e1" text="warfarin" type="Active ingredient"/>
		<pair e1="DBMI.pac183.s4.e0" e2="DBMI.pac183.s4.e1" id="DBMI.pac183.s4.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.s4.e1" e2="DBMI.pac183.s4.e0" id="DBMI.pac183.s4.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s5" origId="s5" text="However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly."/>
	<sentence id="DBMI.pac183.s6" origId="s6" text="Increases in INR and prothrombin time may lead to abnormal bleeding and even death."/>
	<sentence id="DBMI.pac183.s7" origId="s7" text="Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time."/>
	<sentence id="DBMI.pac183.s8" origId="s8" text="[See Clinical Pharmacology (12.5)]\n\nTacrolimus\n\nConcomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.">
		<entity charOffset="1603-1615" id="DBMI.pac183.s8.e0" origId="s8.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="1620-1630" id="DBMI.pac183.s8.e1" origId="s8.e1" text="tacrolimus" type="Active ingredient"/>
		<pair e1="DBMI.pac183.s8.e0" e2="DBMI.pac183.s8.e1" id="DBMI.pac183.s8.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.s8.e1" e2="DBMI.pac183.s8.e0" id="DBMI.pac183.s8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s9" origId="s9" text="Theophylline\n\nA minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline.">
		<entity charOffset="1882-1894" id="DBMI.pac183.s9.e0" origId="s9.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="1824-1836" id="DBMI.pac183.s9.e1" origId="s9.e1" text="theophylline" type="Active ingredient"/>
		<pair e1="DBMI.pac183.s9.e0" e2="DBMI.pac183.s9.e1" id="DBMI.pac183.s9.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="theophylline" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.s9.e1" e2="DBMI.pac183.s9.e0" id="DBMI.pac183.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac183.s10" origId="s10" text="Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels."/>
	<sentence id="DBMI.pac183.s11" origId="s11" text="[See Clinical Pharmacology (12.5)]\n\nFor information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections."/>
	<sentencespan id="DBMI.pac183.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\nDrugs with pH-Dependent Absorption Kinetics\n\nLansoprazole delayed-release capsules causes long-lasting inhibition of gastric acid secretion. Lansoprazole delayed-release capsules and other PPIs are likely to substantially decrease the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, lansoprazole delayed-release capsules and other PPIs should not be co-administered with atazanavir.">
		<entity charOffset="162-174" id="DBMI.pac183.sp0.e0" origId="sp0.e0" text="Lansoprazole" type="Active ingredient"/>
		<entity charOffset="310-320" id="DBMI.pac183.sp0.e1" origId="sp0.e1" text="atazanavir" type="Active ingredient"/>
		<pair e1="DBMI.pac183.sp0.e0" e2="DBMI.pac183.sp0.e1" id="DBMI.pac183.sp0.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir" precipitant="Lansoprazole"/>
		<pair e1="DBMI.pac183.sp0.e1" e2="DBMI.pac183.sp0.e0" id="DBMI.pac183.sp0.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac183.sp1" origId="sp1" text="[See Clinical Pharmacology (12.5)]\n\nIt is theoretically possible that lansoprazole delayed-release capsules and other PPIs may interfere with the absorption of other drugs where gastric pH is an important determinant of oral bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). [See Clinical Pharmacology (12.5)]\n\nWarfarin\n\nIn a study of healthy subjects, co-administration of single or multiple 60 mg doses of lansoprazole delayed-release capsules and warfarin did not affect the pharmacokinetics of warfarin nor prothrombin time (see Clinical Pharmacology (12.5). However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly.">
		<entity charOffset="1038-1050" id="DBMI.pac183.sp1.e0" origId="sp1.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="1128-1136" id="DBMI.pac183.sp1.e1" origId="sp1.e1" text="warfarin" type="Active ingredient"/>
		<entity charOffset="890-902" id="DBMI.pac183.sp1.e2" origId="sp1.e2" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="878-882" id="DBMI.pac183.sp1.e3" origId="sp1.e3" text="iron" type="Active ingredient"/>
		<entity charOffset="850-860" id="DBMI.pac183.sp1.e4" origId="sp1.e4" text="ampicillin" type="Active ingredient"/>
		<entity charOffset="869-876" id="DBMI.pac183.sp1.e5" origId="sp1.e5" text="digoxin" type="Active ingredient"/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="iron" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.sp1.e0" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p4" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e1" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e2" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e3" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e4" e2="DBMI.pac183.sp1.e5" id="DBMI.pac183.sp1.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e0" id="DBMI.pac183.sp1.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e1" id="DBMI.pac183.sp1.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e2" id="DBMI.pac183.sp1.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e3" id="DBMI.pac183.sp1.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac183.sp1.e5" e2="DBMI.pac183.sp1.e4" id="DBMI.pac183.sp1.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac183.sp2" origId="sp2" text="Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. [See Clinical Pharmacology (12.5)]\n\nTacrolimus\n\nConcomitant administration of lansoprazole and tacrolimus may increase whole blood levels of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.">
		<entity charOffset="1603-1615" id="DBMI.pac183.sp2.e0" origId="sp2.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="1620-1630" id="DBMI.pac183.sp2.e1" origId="sp2.e1" text="tacrolimus" type="Active ingredient"/>
		<pair e1="DBMI.pac183.sp2.e0" e2="DBMI.pac183.sp2.e1" id="DBMI.pac183.sp2.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="tacrolimus" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.sp2.e1" e2="DBMI.pac183.sp2.e0" id="DBMI.pac183.sp2.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac183.sp3" origId="sp3" text="Theophylline\n\nA minor increase (10%) in the clearance of theophylline was observed following the administration of lansoprazole delayed-release capsules concomitantly with theophylline. Although the magnitude of the effect on theophylline clearance is small, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels. [See Clinical Pharmacology (12.5)]\n\nFor information on drug interactions for amoxicillin or clarithromycin, refer to their full prescribing information, DRUG INTERACTIONS sections.">
		<entity charOffset="1882-1894" id="DBMI.pac183.sp3.e0" origId="sp3.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="1824-1836" id="DBMI.pac183.sp3.e1" origId="sp3.e1" text="theophylline" type="Active ingredient"/>
		<pair e1="DBMI.pac183.sp3.e0" e2="DBMI.pac183.sp3.e1" id="DBMI.pac183.sp3.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="theophylline" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac183.sp3.e1" e2="DBMI.pac183.sp3.e0" id="DBMI.pac183.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>

<document id="DBMI.pac184" origId="pac184">
	<sentence id="DBMI.pac184.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nLansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell."/>
	<sentence id="DBMI.pac184.s1" origId="s1" text="Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production."/>
	<sentence id="DBMI.pac184.s2" origId="s2" text="This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus."/>
	<sentence id="DBMI.pac184.s3" origId="s3" text="Lansoprazole does not exhibit anticholinergic or histamine type-2 antagonist activity."/>
	<sentence id="DBMI.pac184.s4" origId="s4" text="12.2 Pharmacodynamics\n\nAntisecretory Activity: After oral administration, lansoprazole was shown to significantly decrease the basal acid output and significantly increase the mean gastric pH and percent of time the gastric pH was greater than 3 and greater than 4."/>
	<sentence id="DBMI.pac184.s5" origId="s5" text="Lansoprazole also significantly reduced meal-stimulated gastric acid output and secretion volume, as well as pentagastrin-stimulated acid output."/>
	<sentence id="DBMI.pac184.s6" origId="s6" text="In patients with hypersecretion of acid, lansoprazole significantly reduced basal and pentagastrin-stimulated gastric acid secretion."/>
	<sentence id="DBMI.pac184.s7" origId="s7" text="Lansoprazole inhibited the normal increases in secretion volume, acidity and acid output induced by insulin."/>
	<sentence id="DBMI.pac184.s8" origId="s8" text="The intragastric pH results of a five-day, pharmacodynamic, crossover study of 15 mg and 30 mg of once daily lansoprazole are presented in Table 4:\n\nAfter the initial dose in this study, increased gastric pH was seen within 1 to 2 hours with 30 mg of lansoprazole and 2 to 3 hours with 15 mg of lansoprazole."/>
	<sentence id="DBMI.pac184.s9" origId="s9" text="After multiple daily dosing, increased gastric pH was seen within the first hour post-dosing with 30 mg of lansoprazole and within 1 to 2 hours post-dosing with 15 mg of lansoprazole."/>
	<sentence id="DBMI.pac184.s10" origId="s10" text="Acid suppression may enhance the effect of antimicrobials in eradicating Helicobacter pylori (H. pylori)."/>
	<sentence id="DBMI.pac184.s11" origId="s11" text="The percentage of time gastric pH was elevated above 5 and 6 was evaluated in a crossover study of lansoprazole delayed-release capsules given daily, twice daily and three times daily (Table 5)."/>
	<sentence id="DBMI.pac184.s12" origId="s12" text="The inhibition of gastric acid secretion as measured by intragastric pH gradually returned to normal over two to four days after multiple doses."/>
	<sentence id="DBMI.pac184.s13" origId="s13" text="There was no indication of rebound gastric acidity."/>
	<sentence id="DBMI.pac184.s14" origId="s14" text="Enterochromaffin-like (ECL) Cell Effects\n\nDuring lifetime exposure of rats with up to 150 mg/kg/day of lansoprazole dosed seven days per week, marked hypergastrinemia was observed followed by ECL cell proliferation and formation of carcinoid tumors, especially in female rats."/>
	<sentence id="DBMI.pac184.s15" origId="s15" text="Gastric biopsy specimens from the body of the stomach from approximately 150 patients treated continuously with lansoprazole for at least one year did not show evidence of ECL cell effects similar to those seen in rat studies."/>
	<sentence id="DBMI.pac184.s16" origId="s16" text="Longer term data are needed to rule out the possibility of an increased risk of the development of gastric tumors in patients receiving long-term therapy with lansoprazole."/>
	<sentence id="DBMI.pac184.s17" origId="s17" text="[See Nonclinical Toxicology (13.1)]\n\nOther Gastric Effects in Humans\n\nLansoprazole did not significantly affect mucosal blood flow in the fundus of the stomach."/>
	<sentence id="DBMI.pac184.s18" origId="s18" text="Due to the normal physiologic effect caused by the inhibition of gastric acid secretion, a decrease of about 17% in blood flow in the antrum, pylorus, and duodenal bulb was seen."/>
	<sentence id="DBMI.pac184.s19" origId="s19" text="Lansoprazole significantly slowed the gastric emptying of digestible solids."/>
	<sentence id="DBMI.pac184.s20" origId="s20" text="Lansoprazole increased serum pepsinogen levels and decreased pepsin activity under basal conditions and in response to meal stimulation or insulin injection."/>
	<sentence id="DBMI.pac184.s21" origId="s21" text="As with other agents that elevate intragastric pH, increases in gastric pH were associated with increases in nitrate-reducing bacteria and elevation of nitrite concentration in gastric juice in patients with gastric ulcer."/>
	<sentence id="DBMI.pac184.s22" origId="s22" text="No significant increase in nitrosamine concentrations was observed."/>
	<sentence id="DBMI.pac184.s23" origId="s23" text="Serum Gastrin Effects\n\nIn over 2100 patients, median fasting serum gastrin levels increased 50% to 100% from baseline but remained within normal range after treatment with 15 to 60 mg of oral lansoprazole."/>
	<sentence id="DBMI.pac184.s24" origId="s24" text="These elevations reached a plateau within two months of therapy and returned to pretreatment levels within four weeks after discontinuation of therapy."/>
	<sentence id="DBMI.pac184.s25" origId="s25" text="Endocrine Effects\n\nHuman studies for up to one year have not detected any clinically significant effects on the endocrine system."/>
	<sentence id="DBMI.pac184.s26" origId="s26" text="Hormones studied include testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEA-S), prolactin, cortisol, estradiol, insulin, aldosterone, parathormone, glucagon, thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and somatotropic hormone (STH)."/>
	<sentence id="DBMI.pac184.s27" origId="s27" text="Lansoprazole in oral doses of 15 to 60 mg for up to one year had no clinically significant effect on sexual function."/>
	<sentence id="DBMI.pac184.s28" origId="s28" text="In addition, lansoprazole in oral doses of 15 to 60 mg for two to eight weeks had no clinically significant effect on thyroid function."/>
	<sentence id="DBMI.pac184.s29" origId="s29" text="In 24-month carcinogenicity studies in Sprague-Dawley rats with daily lansoprazole dosages up to 150 mg/kg, proliferative changes in the Leydig cells of the testes, including benign neoplasm, were increased compared to control rats."/>
	<sentence id="DBMI.pac184.s30" origId="s30" text="Other Effects\n\nNo systemic effects of lansoprazole on the central nervous system, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems have been found in humans."/>
	<sentence id="DBMI.pac184.s31" origId="s31" text="Among 56 patients who had extensive baseline eye evaluations, no visual toxicity was observed after lansoprazole treatment (up to 180 mg/day) for up to 58 months."/>
	<sentence id="DBMI.pac184.s32" origId="s32" text="After lifetime lansoprazole exposure in rats, focal pancreatic atrophy, diffuse lymphoid hyperplasia in the thymus, and spontaneous retinal atrophy were seen."/>
	<sentence id="DBMI.pac184.s33" origId="s33" text="Microbiology\n\nLansoprazole, clarithromycin and/or amoxicillin have been shown to be active against most strains of Helicobacter pylori in vitro and in clinical infections as described in the INDICATIONS AND USAGE section."/>
	<sentence id="DBMI.pac184.s34" origId="s34" text="[SeeIndications and Usage (1.2)]  \n\nHelicobacter pylori Pretreatment Resistance\n\nClarithromycin pretreatment resistance (2.0 mcg/mL) was 9.5% (91/960) by E-test and 11.3% (12/106) by agar dilution in the dual and triple therapy clinical trials (M93-125, M93-130, M93-131, M95-392, and M95-399)."/>
	<sentence id="DBMI.pac184.s35" origId="s35" text="Amoxicillin pretreatment susceptible isolates (0.25 mcg/mL) occurred in 97.8% (936/957) and 98 % (98/100) of the patients in the dual and triple therapy clinical trials by E-test and agar dilution, respectively."/>
	<sentence id="DBMI.pac184.s36" origId="s36" text="Twenty-one of 957 patients (2.2%) by E-test and 2 of 100 patients (2%) by agar dilution had amoxicillin pretreatment MICs of greater than 0.25 mcg/mL."/>
	<sentence id="DBMI.pac184.s37" origId="s37" text="One patient on the 14-day triple therapy regimen had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of greater than 256 mcg/mL by E-test and the patient was eradicated of H. pylori (Table 6)."/>
	<sentence id="DBMI.pac184.s38" origId="s38" text="Patients not eradicated of H. pylori following lansoprazole/amoxicillin/clarithromycin triple therapy will likely have clarithromycin resistant H. pylori."/>
	<sentence id="DBMI.pac184.s39" origId="s39" text="Therefore, for those patients who fail therapy, clarithromycin susceptibility testing should be done when possible."/>
	<sentence id="DBMI.pac184.s40" origId="s40" text="Patients with clarithromycin resistant H. pylori should not be treated withlansoprazole/amoxicillin/clarithromycin triple therapy or with regimens which include clarithromycin as the sole antimicrobial agent."/>
	<sentence id="DBMI.pac184.s41" origId="s41" text="Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes: In the dual and triple therapy clinical trials, 82.6% (195/236) of the patients that had pretreatment amoxicillin susceptible MICs (0.25 mcg/mL) were eradicated of H. pylori."/>
	<sentence id="DBMI.pac184.s42" origId="s42" text="Of those with pretreatment amoxicillin MICs of greater than 0.25 mcg/mL, three of six had the H. pylori eradicated."/>
	<sentence id="DBMI.pac184.s43" origId="s43" text="A total of 30% (21/70) of the patients failed lansoprazole 30 mg three times daily /amoxicillin 1 gm three times daily dual therapy and a total of 12.8% (22/172) of the patients failed the 10 and 14 day triple therapy regimens."/>
	<sentence id="DBMI.pac184.s44" origId="s44" text="Post-treatment susceptibility results were not obtained on 11 of the patients who failed therapy."/>
	<sentence id="DBMI.pac184.s45" origId="s45" text="Nine of the 11 patients with amoxicillin post-treatment MICs that failed the triple therapy regimen also had clarithromycin resistant H. pylori isolates."/>
	<sentence id="DBMI.pac184.s46" origId="s46" text="Susceptibility Test for Helicobacter pylori: The reference methodology for susceptibility testing of H. pylori is agar dilution MICs.1 One to three microliters of an inoculum equivalent to a No."/>
	<sentence id="DBMI.pac184.s47" origId="s47" text="2 McFarland standard (1 x 107 to 1 x 108 CFU/mL for H. pylori) are inoculated directly onto freshly prepared antimicrobial-containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood (2 weeks old)."/>
	<sentence id="DBMI.pac184.s48" origId="s48" text="The agar dilution plates are incubated at 35C in a microaerobic environment produced by a gas generating system suitable for campylobacters."/>
	<sentence id="DBMI.pac184.s49" origId="s49" text="After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism."/>
	<sentence id="DBMI.pac184.s50" origId="s50" text="The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria (Table 7):\n\nStandardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures."/>
	<sentence id="DBMI.pac184.s51" origId="s51" text="Standard clarithromycin and amoxicillin powders should provide the following MIC values (Table 8):\n\n12.3 Pharmacokinetics\n\nLansoprazole delayed-release capsules contain an enteric-coated granule formulation of lansoprazole."/>
	<sentence id="DBMI.pac184.s52" origId="s52" text="Absorption of lansoprazole begins only after the granules leave the stomach."/>
	<sentence id="DBMI.pac184.s53" origId="s53" text="Absorption is rapid, with mean peak plasma levels of lansoprazole occurring after approximately 1.7 hours."/>
	<sentence id="DBMI.pac184.s54" origId="s54" text="After a single-dose administration of 15 mg to 60 mg of oral lansoprazole, the peak plasma concentrations (Cmax) of lansoprazole and the area under the plasma concentration curves (AUCs) of lansoprazole were approximately proportional to the administered dose."/>
	<sentence id="DBMI.pac184.s55" origId="s55" text="Lansoprazole does not accumulate and its pharmacokinetics are unaltered by multiple dosing."/>
	<sentence id="DBMI.pac184.s56" origId="s56" text="Absorption: The absorption of lansoprazole is rapid, with the mean Cmax occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%."/>
	<sentence id="DBMI.pac184.s57" origId="s57" text="In healthy subjects, the mean (SD) plasma half-life was 1.5 (1.0) hours."/>
	<sentence id="DBMI.pac184.s58" origId="s58" text="Both the Cmax and AUC are diminished by about 50% to 70% if lansoprazole is given 30 minutes after food, compared to the fasting condition."/>
	<sentence id="DBMI.pac184.s59" origId="s59" text="There is no significant food effect if lansoprazole is given before meals."/>
	<sentence id="DBMI.pac184.s60" origId="s60" text="Distribution: Lansoprazole is 97% bound to plasma proteins."/>
	<sentence id="DBMI.pac184.s61" origId="s61" text="Plasma protein binding is constant over the concentration range of 0.05 to 5.0 mcg/mL."/>
	<sentence id="DBMI.pac184.s62" origId="s62" text="Metabolism: Lansoprazole is extensively metabolized in the liver."/>
	<sentence id="DBMI.pac184.s63" origId="s63" text="Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole)."/>
	<sentence id="DBMI.pac184.s64" origId="s64" text="These metabolites have very little or no antisecretory activity."/>
	<sentence id="DBMI.pac184.s65" origId="s65" text="Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by blocking the proton pump [(H+, K+)-ATPase enzyme system] at the secretory surface of the gastric parietal cell."/>
	<sentence id="DBMI.pac184.s66" origId="s66" text="The two active species are not present in the systemic circulation."/>
	<sentence id="DBMI.pac184.s67" origId="s67" text="The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours."/>
	<sentence id="DBMI.pac184.s68" origId="s68" text="Therefore, the plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion."/>
	<sentence id="DBMI.pac184.s69" origId="s69" text="Elimination: Following single-dose oral administration of lansoprazole delayed-release capsules, virtually no unchanged lansoprazole was excreted in the urine."/>
	<sentence id="DBMI.pac184.s70" origId="s70" text="In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces."/>
	<sentence id="DBMI.pac184.s71" origId="s71" text="This implies a significant biliary excretion of the lansoprazole metabolites."/>
	<sentence id="DBMI.pac184.s72" origId="s72" text="12.4 Specific Populations\n\nPediatric Use:\n\nOne to 17 years of age\n\nThe pharmacokinetics of lansoprazole were studied in pediatric patients with GERD aged 1 to 11 years and 12 to 17 years in two separate clinical studies."/>
	<sentence id="DBMI.pac184.s73" origId="s73" text="In children aged 1 to 11 years, lansoprazole was dosed 15 mg daily for subjects weighing  30 kg and 30 mg daily for subjects weighing greater than 30 kg."/>
	<sentence id="DBMI.pac184.s74" origId="s74" text="Mean Cmax and AUC values observed on Day 5 of dosing were similar between the two dose groups and were not affected by weight or age within each weight-adjusted dose group used in the study."/>
	<sentence id="DBMI.pac184.s75" origId="s75" text="In adolescent subjects aged 12 to 17 years, subjects were randomized to receive lansoprazole at 15 mg or 30 mg daily."/>
	<sentence id="DBMI.pac184.s76" origId="s76" text="Mean Cmax and AUC values of lansoprazole were not affected by body weight or age; and nearly dose-proportional increases in mean Cmax and AUC values were observed between the two dose groups in the study."/>
	<sentence id="DBMI.pac184.s77" origId="s77" text="Overall, lansoprazole pharmacokinetics in pediatric patients aged 1 to 17 years were similar to those observed in healthy adult subjects."/>
	<sentence id="DBMI.pac184.s78" origId="s78" text="Geriatric Use: The clearance of lansoprazole is decreased in the elderly, with elimination half-life increased approximately 50% to 100%."/>
	<sentence id="DBMI.pac184.s79" origId="s79" text="Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole."/>
	<sentence id="DBMI.pac184.s80" origId="s80" text="Peak plasma levels were not increased in the elderly."/>
	<sentence id="DBMI.pac184.s81" origId="s81" text="No dosage adjustment is necessary in the elderly [See Use in Specific Populations (8.5)]."/>
	<sentence id="DBMI.pac184.s82" origId="s82" text="Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1% to 1.5% after administration of 60 mg of lansoprazole."/>
	<sentence id="DBMI.pac184.s83" origId="s83" text="Patients with renal impairment had a shortened elimination half-life and decreased total AUC (free and bound)."/>
	<sentence id="DBMI.pac184.s84" origId="s84" text="The AUC for free lansoprazole in plasma, however, was not related to the degree of renal impairment; and the Cmax and tmax (time to reach the maximum concentration) were not different than the Cmax and tmax from subjects with normal renal function."/>
	<sentence id="DBMI.pac184.s85" origId="s85" text="No dosage adjustment is necessary in patients with renal impairment [See Use in Specific Populations (8.6])."/>
	<sentence id="DBMI.pac184.s86" origId="s86" text="Hepatic Impairment: In patients with various degrees of chronic hepatic impairment, the mean plasma half-life of lansoprazole was prolonged from 1.5 hours to 3.2 to 7.2 hours."/>
	<sentence id="DBMI.pac184.s87" origId="s87" text="An increase in the mean AUC of up to 500% was observed at steady state in hepatically-impaired patients compared to healthy subjects."/>
	<sentence id="DBMI.pac184.s88" origId="s88" text="Consider dose reduction in patients with severe hepatic impairment [See Use in Specific Populations (8.7)]."/>
	<sentence id="DBMI.pac184.s89" origId="s89" text="Gender: In a study comparing 12 male and 6 female human subjects who received lansoprazole, no gender differences were found in pharmacokinetics and intragastric pH results [See Use in Specific Populations (8.5)]."/>
	<sentence id="DBMI.pac184.s90" origId="s90" text="12.5 Drug-Drug Interactions\n\nIt is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin).">
		<entity charOffset="14590-14602" id="DBMI.pac184.s90.e0" origId="s90.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="14723-14735" id="DBMI.pac184.s90.e1" origId="s90.e1" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="14737-14747" id="DBMI.pac184.s90.e2" origId="s90.e2" text="ampicillin" type="Active ingredient"/>
		<pair e1="DBMI.pac184.s90.e0" e2="DBMI.pac184.s90.e1" id="DBMI.pac184.s90.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s90.e0" e2="DBMI.pac184.s90.e2" id="DBMI.pac184.s90.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s90.e1" e2="DBMI.pac184.s90.e0" id="DBMI.pac184.s90.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e1" e2="DBMI.pac184.s90.e2" id="DBMI.pac184.s90.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e2" e2="DBMI.pac184.s90.e0" id="DBMI.pac184.s90.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s90.e2" e2="DBMI.pac184.s90.e1" id="DBMI.pac184.s90.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s91" origId="s91" text="Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes.">
		<entity charOffset="14768-14775" id="DBMI.pac184.s91.e0" origId="s91.e0" text="digoxin" type="Active ingredient"/>
		<entity charOffset="14756-14760" id="DBMI.pac184.s91.e1" origId="s91.e1" text="iron" type="Active ingredient"/>
		<pair e1="DBMI.pac184.s91.e0" e2="DBMI.pac184.s91.e1" id="DBMI.pac184.s91.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s91.e1" e2="DBMI.pac184.s91.e0" id="DBMI.pac184.s91.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s92" origId="s92" text="Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.">
		<entity charOffset="14920-14932" id="DBMI.pac184.s92.e0" origId="s92.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="15134-15142" id="DBMI.pac184.s92.e1" origId="s92.e1" text="diazepam" type="Active ingredient"/>
		<entity charOffset="15122-15132" id="DBMI.pac184.s92.e2" origId="s92.e2" text="prednisone" type="Active ingredient"/>
		<entity charOffset="15061-15071" id="DBMI.pac184.s92.e3" origId="s92.e3" text="antipyrine" type="Active ingredient"/>
		<entity charOffset="15109-15120" id="DBMI.pac184.s92.e4" origId="s92.e4" text="propranolol" type="Active ingredient"/>
		<entity charOffset="15087-15096" id="DBMI.pac184.s92.e5" origId="s92.e5" text="ibuprofen" type="Active ingredient"/>
		<entity charOffset="15098-15107" id="DBMI.pac184.s92.e6" origId="s92.e6" text="phenytoin" type="Active ingredient"/>
		<entity charOffset="15051-15059" id="DBMI.pac184.s92.e7" origId="s92.e7" text="warfarin" type="Active ingredient"/>
		<entity charOffset="15073-15085" id="DBMI.pac184.s92.e8" origId="s92.e8" text="indomethacin" type="Active ingredient"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p2" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="prednisone" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="prednisone" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="antipyrine" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="antipyrine" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p6" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ibuprofen" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p9" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ibuprofen" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p11" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p13" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e0" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p14" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="indomethacin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e1" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e2" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e3" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e4" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e5" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e6" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p64" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p67" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e7" e2="DBMI.pac184.s92.e8" id="DBMI.pac184.s92.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e0" id="DBMI.pac184.s92.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e1" id="DBMI.pac184.s92.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e2" id="DBMI.pac184.s92.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e3" id="DBMI.pac184.s92.p74" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e4" id="DBMI.pac184.s92.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e5" id="DBMI.pac184.s92.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e6" id="DBMI.pac184.s92.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s92.e8" e2="DBMI.pac184.s92.e7" id="DBMI.pac184.s92.p78" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s93" origId="s93" text="These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.">
		<entity charOffset="15147-15161" id="DBMI.pac184.s93.e0" origId="s93.e0" text="clarithromycin" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac184.s94" origId="s94" text="Atazanavir: Lansoprazole delayed-release capsules causes long-lasting inhibition of gastric acid secretion. lansoprazole delayed-release capsules substantially decreases the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance.">
		<entity charOffset="15419-15431" id="DBMI.pac184.s94.e0" origId="s94.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="15539-15549" id="DBMI.pac184.s94.e1" origId="s94.e1" text="atazanavir" type="Active ingredient"/>
		<pair e1="DBMI.pac184.s94.e0" e2="DBMI.pac184.s94.e1" id="DBMI.pac184.s94.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s94.e1" e2="DBMI.pac184.s94.e0" id="DBMI.pac184.s94.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s95" origId="s95" text="Therefore, lansoprazole delayed-release capsules, or other proton pump inhibitors, should not be co-administered with atazanavir."/>
	<sentence id="DBMI.pac184.s96" origId="s96" text="Theophylline: When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.">
		<entity charOffset="15870-15882" id="DBMI.pac184.s96.e0" origId="s96.e0" text="lansoprazole" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac184.s97" origId="s97" text="Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern.">
		<entity charOffset="16018-16030" id="DBMI.pac184.s97.e0" origId="s97.e0" text="theophylline" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac184.s98" origId="s98" text="Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels."/>
	<sentence id="DBMI.pac184.s99" origId="s99" text="Warfarin: In a study of healthy subjects neither the pharmacokinetics of warfarin enantiomers nor prothrombin time were affected following single or multiple 60 mg doses of lansoprazole.">
		<entity charOffset="16466-16474" id="DBMI.pac184.s99.e0" origId="s99.e0" text="warfarin" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac184.s100" origId="s100" text="However, there have been reports of increased International Normalized Ratio (INR) and prothrombin time in patients receiving proton pump inhibitors, including lansoprazole delayed-release capsules, and warfarin concomitantly.">
		<entity charOffset="16566-16578" id="DBMI.pac184.s100.e0" origId="s100.e0" text="lansoprazole" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac184.s101" origId="s101" text="Increases in INR and prothrombin time may lead to abnormal bleeding and even death."/>
	<sentence id="DBMI.pac184.s102" origId="s102" text="Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time."/>
	<sentence id="DBMI.pac184.s103" origId="s103" text="Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate.">
		<entity charOffset="17280-17288" id="DBMI.pac184.s103.e0" origId="s103.e0" text="naproxen" type="Active ingredient"/>
		<entity charOffset="17312-17324" id="DBMI.pac184.s103.e1" origId="s103.e1" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="17224-17236" id="DBMI.pac184.s103.e2" origId="s103.e2" text="methotrexate" type="Active ingredient"/>
		<pair e1="DBMI.pac184.s103.e0" e2="DBMI.pac184.s103.e1" id="DBMI.pac184.s103.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e0" e2="DBMI.pac184.s103.e2" id="DBMI.pac184.s103.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate" precipitant="naproxen"/>
		<pair e1="DBMI.pac184.s103.e1" e2="DBMI.pac184.s103.e0" id="DBMI.pac184.s103.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e1" e2="DBMI.pac184.s103.e2" id="DBMI.pac184.s103.p3" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s103.e1" e2="DBMI.pac184.s103.e2" id="DBMI.pac184.s103.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.s103.e2" e2="DBMI.pac184.s103.e0" id="DBMI.pac184.s103.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s103.e2" e2="DBMI.pac184.s103.e1" id="DBMI.pac184.s103.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s104" origId="s104" text="While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.">
		<entity charOffset="17403-17415" id="DBMI.pac184.s104.e0" origId="s104.e0" text="methotrexate" type="Active ingredient"/>
		<entity charOffset="17420-17441" id="DBMI.pac184.s104.e1" origId="s104.e1" text="7-hydroxymethotrexate" type="Metabolite"/>
		<pair e1="DBMI.pac184.s104.e0" e2="DBMI.pac184.s104.e1" id="DBMI.pac184.s104.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s104.e1" e2="DBMI.pac184.s104.e0" id="DBMI.pac184.s104.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s105" origId="s105" text="Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin.">
		<entity charOffset="17581-17593" id="DBMI.pac184.s105.e0" origId="s105.e0" text="Lansoprazole" type="Active ingredient"/>
	</sentence>
	<sentence id="DBMI.pac184.s106" origId="s106" text="Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.">
		<entity charOffset="17690-17701" id="DBMI.pac184.s106.e0" origId="s106.e0" text="amoxicillin" type="Active ingredient"/>
		<entity charOffset="17871-17881" id="DBMI.pac184.s106.e1" origId="s106.e1" text="sucralfate" type="Active ingredient"/>
		<entity charOffset="17759-17771" id="DBMI.pac184.s106.e2" origId="s106.e2" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="17807-17817" id="DBMI.pac184.s106.e3" origId="s106.e3" text="omeprazole" type="Active ingredient"/>
		<pair e1="DBMI.pac184.s106.e0" e2="DBMI.pac184.s106.e1" id="DBMI.pac184.s106.p0" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e0" e2="DBMI.pac184.s106.e2" id="DBMI.pac184.s106.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e0" e2="DBMI.pac184.s106.e3" id="DBMI.pac184.s106.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e1" e2="DBMI.pac184.s106.e0" id="DBMI.pac184.s106.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e1" e2="DBMI.pac184.s106.e2" id="DBMI.pac184.s106.p4" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="lansoprazole" precipitant="sucralfate"/>
		<pair e1="DBMI.pac184.s106.e1" e2="DBMI.pac184.s106.e3" id="DBMI.pac184.s106.p5" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole" precipitant="sucralfate"/>
		<pair e1="DBMI.pac184.s106.e2" e2="DBMI.pac184.s106.e0" id="DBMI.pac184.s106.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e2" e2="DBMI.pac184.s106.e1" id="DBMI.pac184.s106.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e2" e2="DBMI.pac184.s106.e3" id="DBMI.pac184.s106.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e3" e2="DBMI.pac184.s106.e0" id="DBMI.pac184.s106.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e3" e2="DBMI.pac184.s106.e1" id="DBMI.pac184.s106.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.s106.e3" e2="DBMI.pac184.s106.e2" id="DBMI.pac184.s106.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac184.s107" origId="s107" text="Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate."/>
	<sentence id="DBMI.pac184.s108" origId="s108" text="In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules and there was no evidence of a change in the efficacy of lansoprazole delayed-release capsules."/>
	<sentencespan id="DBMI.pac184.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nLansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus."/>
	<sentencespan id="DBMI.pac184.sp1" origId="sp1" text="Lansoprazole does not exhibit anticholinergic or histamine type-2 antagonist activity. 12.2 Pharmacodynamics\n\nAntisecretory Activity: After oral administration, lansoprazole was shown to significantly decrease the basal acid output and significantly increase the mean gastric pH and percent of time the gastric pH was greater than 3 and greater than 4. Lansoprazole also significantly reduced meal-stimulated gastric acid output and secretion volume, as well as pentagastrin-stimulated acid output."/>
	<sentencespan id="DBMI.pac184.sp2" origId="sp2" text="In patients with hypersecretion of acid, lansoprazole significantly reduced basal and pentagastrin-stimulated gastric acid secretion. Lansoprazole inhibited the normal increases in secretion volume, acidity and acid output induced by insulin. The intragastric pH results of a five-day, pharmacodynamic, crossover study of 15 mg and 30 mg of once daily lansoprazole are presented in Table 4:\n\nAfter the initial dose in this study, increased gastric pH was seen within 1 to 2 hours with 30 mg of lansoprazole and 2 to 3 hours with 15 mg of lansoprazole."/>
	<sentencespan id="DBMI.pac184.sp3" origId="sp3" text="After multiple daily dosing, increased gastric pH was seen within the first hour post-dosing with 30 mg of lansoprazole and within 1 to 2 hours post-dosing with 15 mg of lansoprazole. Acid suppression may enhance the effect of antimicrobials in eradicating Helicobacter pylori (H. pylori). The percentage of time gastric pH was elevated above 5 and 6 was evaluated in a crossover study of lansoprazole delayed-release capsules given daily, twice daily and three times daily (Table 5)."/>
	<sentencespan id="DBMI.pac184.sp4" origId="sp4" text="The inhibition of gastric acid secretion as measured by intragastric pH gradually returned to normal over two to four days after multiple doses. There was no indication of rebound gastric acidity. Enterochromaffin-like (ECL) Cell Effects\n\nDuring lifetime exposure of rats with up to 150 mg/kg/day of lansoprazole dosed seven days per week, marked hypergastrinemia was observed followed by ECL cell proliferation and formation of carcinoid tumors, especially in female rats."/>
	<sentencespan id="DBMI.pac184.sp5" origId="sp5" text="Gastric biopsy specimens from the body of the stomach from approximately 150 patients treated continuously with lansoprazole for at least one year did not show evidence of ECL cell effects similar to those seen in rat studies. Longer term data are needed to rule out the possibility of an increased risk of the development of gastric tumors in patients receiving long-term therapy with lansoprazole. [See Nonclinical Toxicology (13.1)]\n\nOther Gastric Effects in Humans\n\nLansoprazole did not significantly affect mucosal blood flow in the fundus of the stomach."/>
	<sentencespan id="DBMI.pac184.sp6" origId="sp6" text="Due to the normal physiologic effect caused by the inhibition of gastric acid secretion, a decrease of about 17% in blood flow in the antrum, pylorus, and duodenal bulb was seen. Lansoprazole significantly slowed the gastric emptying of digestible solids. Lansoprazole increased serum pepsinogen levels and decreased pepsin activity under basal conditions and in response to meal stimulation or insulin injection."/>
	<sentencespan id="DBMI.pac184.sp7" origId="sp7" text="As with other agents that elevate intragastric pH, increases in gastric pH were associated with increases in nitrate-reducing bacteria and elevation of nitrite concentration in gastric juice in patients with gastric ulcer. No significant increase in nitrosamine concentrations was observed. Serum Gastrin Effects\n\nIn over 2100 patients, median fasting serum gastrin levels increased 50% to 100% from baseline but remained within normal range after treatment with 15 to 60 mg of oral lansoprazole."/>
	<sentencespan id="DBMI.pac184.sp8" origId="sp8" text="These elevations reached a plateau within two months of therapy and returned to pretreatment levels within four weeks after discontinuation of therapy. Endocrine Effects\n\nHuman studies for up to one year have not detected any clinically significant effects on the endocrine system. Hormones studied include testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEA-S), prolactin, cortisol, estradiol, insulin, aldosterone, parathormone, glucagon, thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and somatotropic hormone (STH)."/>
	<sentencespan id="DBMI.pac184.sp9" origId="sp9" text="Lansoprazole in oral doses of 15 to 60 mg for up to one year had no clinically significant effect on sexual function. In addition, lansoprazole in oral doses of 15 to 60 mg for two to eight weeks had no clinically significant effect on thyroid function. In 24-month carcinogenicity studies in Sprague-Dawley rats with daily lansoprazole dosages up to 150 mg/kg, proliferative changes in the Leydig cells of the testes, including benign neoplasm, were increased compared to control rats."/>
	<sentencespan id="DBMI.pac184.sp10" origId="sp10" text="Other Effects\n\nNo systemic effects of lansoprazole on the central nervous system, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems have been found in humans. Among 56 patients who had extensive baseline eye evaluations, no visual toxicity was observed after lansoprazole treatment (up to 180 mg/day) for up to 58 months. After lifetime lansoprazole exposure in rats, focal pancreatic atrophy, diffuse lymphoid hyperplasia in the thymus, and spontaneous retinal atrophy were seen."/>
	<sentencespan id="DBMI.pac184.sp11" origId="sp11" text="Microbiology\n\nLansoprazole, clarithromycin and/or amoxicillin have been shown to be active against most strains of Helicobacter pylori in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. [SeeIndications and Usage (1.2)]  \n\nHelicobacter pylori Pretreatment Resistance\n\nClarithromycin pretreatment resistance (2.0 mcg/mL) was 9.5% (91/960) by E-test and 11.3% (12/106) by agar dilution in the dual and triple therapy clinical trials (M93-125, M93-130, M93-131, M95-392, and M95-399). Amoxicillin pretreatment susceptible isolates (0.25 mcg/mL) occurred in 97.8% (936/957) and 98 % (98/100) of the patients in the dual and triple therapy clinical trials by E-test and agar dilution, respectively."/>
	<sentencespan id="DBMI.pac184.sp12" origId="sp12" text="Twenty-one of 957 patients (2.2%) by E-test and 2 of 100 patients (2%) by agar dilution had amoxicillin pretreatment MICs of greater than 0.25 mcg/mL. One patient on the 14-day triple therapy regimen had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of greater than 256 mcg/mL by E-test and the patient was eradicated of H. pylori (Table 6). Patients not eradicated of H. pylori following lansoprazole/amoxicillin/clarithromycin triple therapy will likely have clarithromycin resistant H. pylori."/>
	<sentencespan id="DBMI.pac184.sp13" origId="sp13" text="Therefore, for those patients who fail therapy, clarithromycin susceptibility testing should be done when possible. Patients with clarithromycin resistant H. pylori should not be treated withlansoprazole/amoxicillin/clarithromycin triple therapy or with regimens which include clarithromycin as the sole antimicrobial agent. Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes: In the dual and triple therapy clinical trials, 82.6% (195/236) of the patients that had pretreatment amoxicillin susceptible MICs (0.25 mcg/mL) were eradicated of H. pylori."/>
	<sentencespan id="DBMI.pac184.sp14" origId="sp14" text="Of those with pretreatment amoxicillin MICs of greater than 0.25 mcg/mL, three of six had the H. pylori eradicated. A total of 30% (21/70) of the patients failed lansoprazole 30 mg three times daily /amoxicillin 1 gm three times daily dual therapy and a total of 12.8% (22/172) of the patients failed the 10 and 14 day triple therapy regimens. Post-treatment susceptibility results were not obtained on 11 of the patients who failed therapy."/>
	<sentencespan id="DBMI.pac184.sp15" origId="sp15" text="Nine of the 11 patients with amoxicillin post-treatment MICs that failed the triple therapy regimen also had clarithromycin resistant H. pylori isolates. Susceptibility Test for Helicobacter pylori: The reference methodology for susceptibility testing of H. pylori is agar dilution MICs.1 One to three microliters of an inoculum equivalent to a No. 2 McFarland standard (1 x 107 to 1 x 108 CFU/mL for H. pylori) are inoculated directly onto freshly prepared antimicrobial-containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood (2 weeks old)."/>
	<sentencespan id="DBMI.pac184.sp16" origId="sp16" text="The agar dilution plates are incubated at 35C in a microaerobic environment produced by a gas generating system suitable for campylobacters. After 3 days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism. The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria (Table 7):\n\nStandardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures."/>
	<sentencespan id="DBMI.pac184.sp17" origId="sp17" text="Standard clarithromycin and amoxicillin powders should provide the following MIC values (Table 8):\n\n12.3 Pharmacokinetics\n\nLansoprazole delayed-release capsules contain an enteric-coated granule formulation of lansoprazole. Absorption of lansoprazole begins only after the granules leave the stomach. Absorption is rapid, with mean peak plasma levels of lansoprazole occurring after approximately 1.7 hours."/>
	<sentencespan id="DBMI.pac184.sp18" origId="sp18" text="After a single-dose administration of 15 mg to 60 mg of oral lansoprazole, the peak plasma concentrations (Cmax) of lansoprazole and the area under the plasma concentration curves (AUCs) of lansoprazole were approximately proportional to the administered dose. Lansoprazole does not accumulate and its pharmacokinetics are unaltered by multiple dosing. Absorption: The absorption of lansoprazole is rapid, with the mean Cmax occurring approximately 1.7 hours after oral dosing, and the absolute bioavailability is over 80%."/>
	<sentencespan id="DBMI.pac184.sp19" origId="sp19" text="In healthy subjects, the mean (SD) plasma half-life was 1.5 (1.0) hours. Both the Cmax and AUC are diminished by about 50% to 70% if lansoprazole is given 30 minutes after food, compared to the fasting condition. There is no significant food effect if lansoprazole is given before meals."/>
	<sentencespan id="DBMI.pac184.sp20" origId="sp20" text="Distribution: Lansoprazole is 97% bound to plasma proteins. Plasma protein binding is constant over the concentration range of 0.05 to 5.0 mcg/mL. Metabolism: Lansoprazole is extensively metabolized in the liver."/>
	<sentencespan id="DBMI.pac184.sp21" origId="sp21" text="Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by blocking the proton pump [(H+, K+)-ATPase enzyme system] at the secretory surface of the gastric parietal cell."/>
	<sentencespan id="DBMI.pac184.sp22" origId="sp22" text="The two active species are not present in the systemic circulation. The plasma elimination half-life of lansoprazole is less than 2 hours while the acid inhibitory effect lasts more than 24 hours. Therefore, the plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion."/>
	<sentencespan id="DBMI.pac184.sp23" origId="sp23" text="Elimination: Following single-dose oral administration of lansoprazole delayed-release capsules, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites."/>
	<sentencespan id="DBMI.pac184.sp24" origId="sp24" text="12.4 Specific Populations\n\nPediatric Use:\n\nOne to 17 years of age\n\nThe pharmacokinetics of lansoprazole were studied in pediatric patients with GERD aged 1 to 11 years and 12 to 17 years in two separate clinical studies. In children aged 1 to 11 years, lansoprazole was dosed 15 mg daily for subjects weighing  30 kg and 30 mg daily for subjects weighing greater than 30 kg. Mean Cmax and AUC values observed on Day 5 of dosing were similar between the two dose groups and were not affected by weight or age within each weight-adjusted dose group used in the study."/>
	<sentencespan id="DBMI.pac184.sp25" origId="sp25" text="In adolescent subjects aged 12 to 17 years, subjects were randomized to receive lansoprazole at 15 mg or 30 mg daily. Mean Cmax and AUC values of lansoprazole were not affected by body weight or age; and nearly dose-proportional increases in mean Cmax and AUC values were observed between the two dose groups in the study. Overall, lansoprazole pharmacokinetics in pediatric patients aged 1 to 17 years were similar to those observed in healthy adult subjects."/>
	<sentencespan id="DBMI.pac184.sp26" origId="sp26" text="Geriatric Use: The clearance of lansoprazole is decreased in the elderly, with elimination half-life increased approximately 50% to 100%. Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole. Peak plasma levels were not increased in the elderly."/>
	<sentencespan id="DBMI.pac184.sp27" origId="sp27" text="No dosage adjustment is necessary in the elderly [See Use in Specific Populations (8.5)]. Renal Impairment: In patients with severe renal impairment, plasma protein binding decreased by 1% to 1.5% after administration of 60 mg of lansoprazole. Patients with renal impairment had a shortened elimination half-life and decreased total AUC (free and bound)."/>
	<sentencespan id="DBMI.pac184.sp28" origId="sp28" text="The AUC for free lansoprazole in plasma, however, was not related to the degree of renal impairment; and the Cmax and tmax (time to reach the maximum concentration) were not different than the Cmax and tmax from subjects with normal renal function. No dosage adjustment is necessary in patients with renal impairment [See Use in Specific Populations (8.6]). Hepatic Impairment: In patients with various degrees of chronic hepatic impairment, the mean plasma half-life of lansoprazole was prolonged from 1.5 hours to 3.2 to 7.2 hours."/>
	<sentencespan id="DBMI.pac184.sp29" origId="sp29" text="An increase in the mean AUC of up to 500% was observed at steady state in hepatically-impaired patients compared to healthy subjects. Consider dose reduction in patients with severe hepatic impairment [See Use in Specific Populations (8.7)]. Gender: In a study comparing 12 male and 6 female human subjects who received lansoprazole, no gender differences were found in pharmacokinetics and intragastric pH results [See Use in Specific Populations (8.5)]."/>
	<sentencespan id="DBMI.pac184.sp30" origId="sp30" text="12.5 Drug-Drug Interactions\n\nIt is theoretically possible that lansoprazole may interfere with the absorption of other drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, ampicillin esters, iron salts, digoxin). Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects.">
		<entity charOffset="14590-14602" id="DBMI.pac184.sp30.e0" origId="sp30.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="14768-14775" id="DBMI.pac184.sp30.e1" origId="sp30.e1" text="digoxin" type="Active ingredient"/>
		<entity charOffset="14756-14760" id="DBMI.pac184.sp30.e2" origId="sp30.e2" text="iron" type="Active ingredient"/>
		<entity charOffset="14723-14735" id="DBMI.pac184.sp30.e3" origId="sp30.e3" text="ketoconazole" type="Active ingredient"/>
		<entity charOffset="14737-14747" id="DBMI.pac184.sp30.e4" origId="sp30.e4" text="ampicillin" type="Active ingredient"/>
		<entity charOffset="15134-15142" id="DBMI.pac184.sp30.e5" origId="sp30.e5" text="diazepam" type="Active ingredient"/>
		<entity charOffset="15122-15132" id="DBMI.pac184.sp30.e6" origId="sp30.e6" text="prednisone" type="Active ingredient"/>
		<entity charOffset="15147-15161" id="DBMI.pac184.sp30.e7" origId="sp30.e7" text="clarithromycin" type="Active ingredient"/>
		<entity charOffset="15061-15071" id="DBMI.pac184.sp30.e8" origId="sp30.e8" text="antipyrine" type="Active ingredient"/>
		<entity charOffset="15109-15120" id="DBMI.pac184.sp30.e9" origId="sp30.e9" text="propranolol" type="Active ingredient"/>
		<entity charOffset="15087-15096" id="DBMI.pac184.sp30.e10" origId="sp30.e10" text="ibuprofen" type="Active ingredient"/>
		<entity charOffset="15098-15107" id="DBMI.pac184.sp30.e11" origId="sp30.e11" text="phenytoin" type="Active ingredient"/>
		<entity charOffset="15051-15059" id="DBMI.pac184.sp30.e12" origId="sp30.e12" text="warfarin" type="Active ingredient"/>
		<entity charOffset="15073-15085" id="DBMI.pac184.sp30.e13" origId="sp30.e13" text="indomethacin" type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="digoxin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p1" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="iron" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p2" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ketoconazole" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p3" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="ampicillin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p4" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="diazepam" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p6" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="prednisone" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p7" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="prednisone" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p8" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="clarithromycin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p9" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="clarithromycin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="antipyrine" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p11" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="antipyrine" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p13" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="propranolol" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p14" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ibuprofen" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p15" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ibuprofen" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p17" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="phenytoin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p18" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p19" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e0" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p20" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="indomethacin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p21" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p27" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e1" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p33" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p39" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p42" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p43" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p44" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p45" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e2" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p46" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p47" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p48" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p49" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p50" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p51" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p52" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p53" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p54" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p55" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p56" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p57" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p58" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e3" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p59" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p60" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p61" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p62" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p63" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p64" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p65" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p66" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p67" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p68" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p69" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p70" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p71" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e4" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p72" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p73" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p74" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p75" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p76" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p77" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p78" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p79" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p80" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p81" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p82" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p83" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p84" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e5" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p85" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p86" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p87" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p88" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p89" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p90" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p91" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p92" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p93" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p94" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p95" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p96" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p97" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e6" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p98" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p99" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p100" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p101" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p102" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p103" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p104" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p105" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p106" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p107" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p108" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p109" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p110" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e7" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p111" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p112" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p113" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p114" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p115" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p116" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p117" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p118" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p119" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p120" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p121" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p122" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p123" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e8" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p124" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p125" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p126" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p127" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p128" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p129" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p130" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p131" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p132" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p133" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p134" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p135" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p136" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e9" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p137" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p138" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p139" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p140" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p141" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p142" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p143" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p144" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p145" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p146" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p147" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p148" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p149" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e10" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p150" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p151" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p152" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p153" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p154" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p155" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p156" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p157" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p158" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p159" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p160" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p161" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p162" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e11" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p163" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p164" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p165" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p166" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p167" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p168" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p169" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p170" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p171" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p172" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p173" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p174" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p175" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e12" e2="DBMI.pac184.sp30.e13" id="DBMI.pac184.sp30.p176" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e0" id="DBMI.pac184.sp30.p177" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e1" id="DBMI.pac184.sp30.p178" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e2" id="DBMI.pac184.sp30.p179" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e3" id="DBMI.pac184.sp30.p180" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e4" id="DBMI.pac184.sp30.p181" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e5" id="DBMI.pac184.sp30.p182" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e6" id="DBMI.pac184.sp30.p183" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e7" id="DBMI.pac184.sp30.p184" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e8" id="DBMI.pac184.sp30.p185" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e9" id="DBMI.pac184.sp30.p186" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e10" id="DBMI.pac184.sp30.p187" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e11" id="DBMI.pac184.sp30.p188" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp30.e13" e2="DBMI.pac184.sp30.e12" id="DBMI.pac184.sp30.p189" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp31" origId="sp31" text="These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A. Atazanavir: Lansoprazole delayed-release capsules causes long-lasting inhibition of gastric acid secretion. lansoprazole delayed-release capsules substantially decreases the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, lansoprazole delayed-release capsules, or other proton pump inhibitors, should not be co-administered with atazanavir.">
		<entity charOffset="15419-15431" id="DBMI.pac184.sp31.e0" origId="sp31.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="15539-15549" id="DBMI.pac184.sp31.e1" origId="sp31.e1" text="atazanavir" type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp31.e0" e2="DBMI.pac184.sp31.e1" id="DBMI.pac184.sp31.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="atazanavir" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp31.e1" e2="DBMI.pac184.sp31.e0" id="DBMI.pac184.sp31.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp32" origId="sp32" text="Theophylline: When lansoprazole delayed-release capsules were administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern. Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole delayed-release capsules is started or stopped to ensure clinically effective blood levels.">
		<entity charOffset="15870-15882" id="DBMI.pac184.sp32.e0" origId="sp32.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="16018-16030" id="DBMI.pac184.sp32.e1" origId="sp32.e1" text="theophylline" type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp32.e0" e2="DBMI.pac184.sp32.e1" id="DBMI.pac184.sp32.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="theophylline" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp32.e1" e2="DBMI.pac184.sp32.e0" id="DBMI.pac184.sp32.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp33" origId="sp33" text="Warfarin: In a study of healthy subjects neither the pharmacokinetics of warfarin enantiomers nor prothrombin time were affected following single or multiple 60 mg doses of lansoprazole. However, there have been reports of increased International Normalized Ratio (INR) and prothrombin time in patients receiving proton pump inhibitors, including lansoprazole delayed-release capsules, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.">
		<entity charOffset="16566-16578" id="DBMI.pac184.sp33.e0" origId="sp33.e0" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="16466-16474" id="DBMI.pac184.sp33.e1" origId="sp33.e1" text="warfarin" type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp33.e0" e2="DBMI.pac184.sp33.e1" id="DBMI.pac184.sp33.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="warfarin" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp33.e1" e2="DBMI.pac184.sp33.e0" id="DBMI.pac184.sp33.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp34" origId="sp34" text="Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time. Methotrexate and 7-hydromethotrexate: In an open-label, single-arm, eight-day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of 7 days of naproxen 500 mg twice daily and lansoprazole delayed-release capsules 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted.">
		<entity charOffset="17280-17288" id="DBMI.pac184.sp34.e0" origId="sp34.e0" text="naproxen" type="Active ingredient"/>
		<entity charOffset="17403-17415" id="DBMI.pac184.sp34.e1" origId="sp34.e1" text="methotrexate" type="Active ingredient"/>
		<entity charOffset="17420-17441" id="DBMI.pac184.sp34.e2" origId="sp34.e2" text="7-hydroxymethotrexate" type="Metabolite"/>
		<entity charOffset="17312-17324" id="DBMI.pac184.sp34.e3" origId="sp34.e3" text="lansoprazole" type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp34.e0" e2="DBMI.pac184.sp34.e1" id="DBMI.pac184.sp34.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate" precipitant="naproxen"/>
		<pair e1="DBMI.pac184.sp34.e0" e2="DBMI.pac184.sp34.e2" id="DBMI.pac184.sp34.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="7-hydroxymethotrexate" precipitant="naproxen"/>
		<pair e1="DBMI.pac184.sp34.e0" e2="DBMI.pac184.sp34.e3" id="DBMI.pac184.sp34.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e1" e2="DBMI.pac184.sp34.e0" id="DBMI.pac184.sp34.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e1" e2="DBMI.pac184.sp34.e2" id="DBMI.pac184.sp34.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e1" e2="DBMI.pac184.sp34.e3" id="DBMI.pac184.sp34.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e2" e2="DBMI.pac184.sp34.e0" id="DBMI.pac184.sp34.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e2" e2="DBMI.pac184.sp34.e1" id="DBMI.pac184.sp34.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e2" e2="DBMI.pac184.sp34.e3" id="DBMI.pac184.sp34.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e3" e2="DBMI.pac184.sp34.e0" id="DBMI.pac184.sp34.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp34.e3" e2="DBMI.pac184.sp34.e1" id="DBMI.pac184.sp34.p10" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp34.e3" e2="DBMI.pac184.sp34.e1" id="DBMI.pac184.sp34.p11" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="methotrexate" precipitant="lansoprazole"/>
		<pair e1="DBMI.pac184.sp34.e3" e2="DBMI.pac184.sp34.e2" id="DBMI.pac184.sp34.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="7-hydroxymethotrexate" precipitant="lansoprazole"/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp35" origId="sp35" text="Amoxicillin: Lansoprazole delayed-release capsules has also been shown to have no clinically significant interaction with amoxicillin. Sucralfate: In a single-dose crossover study examining lansoprazole delayed-release capsules 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate. Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.">
		<entity charOffset="17581-17593" id="DBMI.pac184.sp35.e0" origId="sp35.e0" text="Lansoprazole" type="Active ingredient"/>
		<entity charOffset="17690-17701" id="DBMI.pac184.sp35.e1" origId="sp35.e1" text="amoxicillin" type="Active ingredient"/>
		<entity charOffset="17871-17881" id="DBMI.pac184.sp35.e2" origId="sp35.e2" text="sucralfate" type="Active ingredient"/>
		<entity charOffset="17759-17771" id="DBMI.pac184.sp35.e3" origId="sp35.e3" text="lansoprazole" type="Active ingredient"/>
		<entity charOffset="17807-17817" id="DBMI.pac184.sp35.e4" origId="sp35.e4" text="omeprazole" type="Active ingredient"/>
		<pair e1="DBMI.pac184.sp35.e0" e2="DBMI.pac184.sp35.e1" id="DBMI.pac184.sp35.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="amoxicillin" precipitant="Lansoprazole"/>
		<pair e1="DBMI.pac184.sp35.e0" e2="DBMI.pac184.sp35.e2" id="DBMI.pac184.sp35.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e0" e2="DBMI.pac184.sp35.e3" id="DBMI.pac184.sp35.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e0" e2="DBMI.pac184.sp35.e4" id="DBMI.pac184.sp35.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e1" e2="DBMI.pac184.sp35.e0" id="DBMI.pac184.sp35.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e1" e2="DBMI.pac184.sp35.e2" id="DBMI.pac184.sp35.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e1" e2="DBMI.pac184.sp35.e3" id="DBMI.pac184.sp35.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e1" e2="DBMI.pac184.sp35.e4" id="DBMI.pac184.sp35.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e2" e2="DBMI.pac184.sp35.e0" id="DBMI.pac184.sp35.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e2" e2="DBMI.pac184.sp35.e1" id="DBMI.pac184.sp35.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e2" e2="DBMI.pac184.sp35.e3" id="DBMI.pac184.sp35.p10" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="lansoprazole" precipitant="sucralfate"/>
		<pair e1="DBMI.pac184.sp35.e2" e2="DBMI.pac184.sp35.e4" id="DBMI.pac184.sp35.p11" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="omeprazole" precipitant="sucralfate"/>
		<pair e1="DBMI.pac184.sp35.e3" e2="DBMI.pac184.sp35.e0" id="DBMI.pac184.sp35.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e3" e2="DBMI.pac184.sp35.e1" id="DBMI.pac184.sp35.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e3" e2="DBMI.pac184.sp35.e2" id="DBMI.pac184.sp35.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e3" e2="DBMI.pac184.sp35.e4" id="DBMI.pac184.sp35.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e4" e2="DBMI.pac184.sp35.e0" id="DBMI.pac184.sp35.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e4" e2="DBMI.pac184.sp35.e1" id="DBMI.pac184.sp35.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e4" e2="DBMI.pac184.sp35.e2" id="DBMI.pac184.sp35.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac184.sp35.e4" e2="DBMI.pac184.sp35.e3" id="DBMI.pac184.sp35.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac184.sp36" origId="sp36" text="In clinical trials, antacids were administered concomitantly with lansoprazole delayed-release capsules and there was no evidence of a change in the efficacy of lansoprazole delayed-release capsules."/>
</document>
